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  ABSTRACT 
Angela Liu Mazul: Single Nucleotide Polymorphisms In Vitamin A, Folate And Choline Related 
Genes And Interaction With Maternal Vitamin Intake And Neuroblastoma  
(Under the direction of Andrew Olshan) 
 
Previous epidemiologic studies suggest maternal vitamin supplementation during 
pregnancy reduces the risk of neuroblastoma. We hypothesize offspring and maternal genetic 
variants in vitamin A, folate and choline-related genes are associated with neuroblastoma and are 
modified  by maternal intake of vitamin A, folate, and choline 
The Neuroblastoma Epidemiology in North America (NENA) study recruited 563 
affected child-parent sets through the Children’s Oncology Group’s (COG) Childhood Cancer 
Research Network. We ascertained pre-pregnancy supplementation and estimated usual maternal 
dietary intake with questionnaires and genotyped genetic variants related to folate, choline and 
vitamin A pathways from DNA extracted from saliva. A log-linear model was employed to 
estimate additive offspring and maternal risk ratios and stratum-specific risk ratios by COG 
prognostic risk-classification and age at diagnosis and for gene-environment interactions.  For 
replication for the offspring main effects, we used a genome-wide offspring case-control study 
from Children’s Hospital of Philadelphia (CHOP). 
Overall, no offspring genotypic results met criteria for a false discovery rate (FDR) Q-
value<0.2 for variants related to vitamin A, folate, and choline.  We found one maternal FDR-
corrected maternal inverse association for a vitamin A-related SNP and neuroblastoma overall.
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We found nine SNPs in/near 4 folate-related genes that were FDR-corrected significantly 
associated with intermediate-risk neuroblastoma but none replicated in the CHOP replication. 
FDR-corrected significant maternal results were found within the high-risk neuroblastoma strata 
and offspring age of diagnosis < 1 year with rs6776706 and rs11103603, respectively. No 
significant gene-environment interaction was found for pre-pregnancy vitamin supplementation.  
However from diet, we found a maternal rs729147-vitamin A interaction when vitamin A was 
dichotomized at the Recommended Dietary Allowance.  Gene-choline interactions were found 
for offspring SNPs located in MTHFD1L and TYMS.   
Our results suggest that some genetic variants involved in vitamin A and choline may be 
associated with neuroblastoma.  The significant maternal variants and their joint effects with 
maternal vitamin A intake suggest a relationship between neuroblastoma and vitamin A.  We 
also found variants related to one-carbon metabolism are not strongly associated with 
neuroblastoma, but some choline-related variants may play a role. However the functional 
consequences of these variants are unknown and require independent replication. 
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CHAPTER 1. BACKGROUND AND LITERATURE REVIEW 
1.1 Dissertation Aims 
Neuroblastoma is an embryonic tumor arising from a malignancy within cells of the 
neural crest.1,2 While 7.2% of all childhood cancers are neuroblastomas, it disproportionately 
accounts for 15% of all childhood cancer-related deaths.3,4  It is the most common cancer in 
infancy and is thought to occur by either environmental or genetic disruption of normal 
embryonic development.5  Familial cases of neuroblastoma have been associated with specific 
mutations in the PHOX2B and ALK genes. Among non-familial cases, recent genome-wide 
association (GWA) studies have identified several common variants of interest.6-9   
Previous epidemiologic studies have found evidence of an inverse association between 
maternal prenatal vitamin use and neuroblastoma,10,11 suggesting that maternal pregnancy 
vitamin status may play a role in neuroblastoma development.  Thus, for this study we focused 
on three vitamins with biologic plausibility: vitamin A, folate and choline.  
Vitamin A is required for many growth and developmental processes including 
embryonic neuronal differentiation and development.12,13  When cultured neuroblastoma cells are 
treated with retinoic acid, a metabolite of vitamin A, they exhibit decreased proliferation and 
improved differentiation.14,15 Folate is essential for one-carbon metabolism and is important in 
cell proliferation and differentiation of neural crest cells.16,17  Choline is also involved in one-
carbon metabolism and an essential building block for membrane development.18  
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Since maternal pre-pregnancy vitamin use has been previously associated with 
neuroblastoma and the biologic plausibility of these vitamins,10  we are interested in common 
single nucleotide polymorphism in genes involved in vitamin A, folate and choline metabolism 
and transport pathways as well as interactions with maternal pregnancy vitamin intake from diet 
and vitamin supplementation. 
Neuroblastoma Epidemiology in North America (NENA) is a case-parent triad study. 
NENA recruited families with cases of neuroblastoma under 6 years of age from the Childhood 
Cancer Research Network (CCRN), a registry of childhood cancer treated in Children’s 
Oncology Group’s (COG) hospitals in North America. Buccal DNA was collected from the child 
and both biologic parents. If the child was deceased, then banked samples were requested from 
COG.  A self-administered questionnaire was mailed to the biologic mother to assess vitamin 
intake through diet and supplements pre-pregnancy and during pregnancy.  It also asked for 
demographic data and other lifestyle factors including tobacco and alcohol use, medication use 
and family history.  NENA recruited a total 626 parent-child trios or dyads. 
Genetic effects for the offspring genotype and the maternal genotype was evaluated using 
log-linear models.19 20 Additional analyses was carried out within strata defined by offspring age 
of diagnosis and neuroblastoma prognostic risk-classification as defined by the COG.  The log-
linear models was extended to test for gene-environment interactions between both the offspring 
and the maternal genotype and maternal early-pregnancy vitamin status.21 
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The specific aims of this project are: 
Aim 1.  Evaluate the association between maternal and offspring single nucleotide 
polymorphisms (SNPs) in genes involved in vitamin A related pathways with the risk of 
neuroblastoma 
      Aim 1a. Evaluate effects of offspring variants and maternal variants on the risk of 
neuroblastoma stratified by offspring age at diagnosis and neuroblastoma Children’s Oncology 
group (COG) risk-classification. 
      Aim 1b. Describe the gene-environment interactions of maternal vitamin A intake during 
pregnancy with the offspring genotype for SNPs in the vitamin A pathway on the risk of 
neuroblastoma. 
      Aim 1c. Describe the gene-environment interactions of maternal vitamin A intake during 
pregnancy with the maternal genotype for SNPs in the vitamin A pathway on the risk of 
neuroblastoma in the offspring. 
Aim 2.  Evaluate the association between maternal and offspring SNPs in genes involved in 
folate and choline related pathways with the risk of neuroblastoma. 
      Aim 2a. Evaluate these offspring and maternal variants on the risk of neuroblastoma markers 
stratified by age at diagnosis and neuroblastoma risk-classification as defined by COG 
guidelines. 
      Aim 2b. Describe the gene-environment interactions of maternal folate and choline intake 
during pregnancy with the offspring genotype in folate and choline related pathway on the risk of 
neuroblastoma. 
      Aim 2c. Describe the gene-environment interactions of maternal folate and choline intake 
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during pregnancy with the maternal genotype in folate and choline related pathway on the risk of 
neuroblastoma in the offspring.  
1.2 Neuroblastoma Overview 
1.2.1 Biologic Characteristics 
Neuroblastoma is an embryonic tumor of the sympathetic nervous system arising in the 
neural crest with embryonic origins.1,2  Neurulation is a complicated folding process during 
embryogensis that transforms the neural plate into the neural tube.  As the plate folds, the neural 
plate borders join and become the neural crest. As the neural tube closes, the neural crest is 
disconnected from the ectoderm.  A neural tube closes, the neural crest cells migrate.22  As these 
neural crest cells migrate, they further differentiate into the sympathetic nervous system.  
Neuroblastoma tumors are thought to derive from stem cells in the sympathetic nervous system 
that did not properly differentiate. 
Neuroblastoma is a heterogeneous malignancy with variable site of origin, clinical 
presentation and cellular composition.1  These tumors have been categorized into four basic 
morphologic categories: 
1. Neuroblastoma (Schwannian stroma-poor) 
2. Ganglioneuroblastoma, intermixed (Schwannian stroma-rich) 
3. Ganglioneuroblastoma, nodular (composite Schwannian stroma-rich/stroma-
dominant and stroma-poor) 
4. Ganglioneuroma (Schwannian stroma-dominant)23 
These neuroblastic tumors consist of two main cell populations, neuroblasts and Schwann 
cells. Since these Schwannian cells are non-malignant, these cells are likely to have been 
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recruited by the malignant neuroblasts.24  Schwann cells in the tumors produce anti-proliferative 
and differentiation-inducing factors, thus indicating less aggressive disease.23 
Neuroblastoma tumors are less differentiated than are ganglioneuroblastoma tumors.  
Ganglioneuromas arise spontaneously from maturation of neuroblastic tumors (i.e. all 
Ganglioneuromas were once neuroblastomas in an earlier phase).  Ganglioneuroblastoma falls in 
between neuroblastoma and ganglioneuromas in terms of differentiation.23 In addition to 
spontaneous differentiation, neuroblastoma undergoes spontaneous regression more than any 
other cancer type, which most likely related to apoptosis of undifferentiated cells.4  Although 
most clinically diagnosed neuroblastic tumors do not undergo spontaneous maturation or 
spontaneous regression after detection,23 it is estimated that over 10% of cases of neuroblastoma 
are missed due to spontaneous regression.25 
1.2.2 Clinical Characteristics 
Neuroblastoma can arise anywhere in the sympathetic nervous system, but about 65% 
arises in the abdomen and over half of these in the adrenal glands.  Location of the primary 
tumor varies by age.  Children younger than 1 year of age tend to have more primary tumors in 
the mediastinum (the central compartment in the thoracic cavity) and children older than 1 year 
tend have their primary site in the central and autonomic nervous system.26 (Figure 1)  
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Figure 1. Distribution of the Location of Primary Tumor by Age of Diagnosis 
 
Reproduced from “Sympathetic Nervous System Tumors: SEER Pediatric Monograph” by M. Goodman 
et al., 2008.26 
Symptoms vary depending on the location of the tumor.  Approximately 50% of patients 
have localized or regional disease, 35% have regional lymph node spread at the time of diagnosis 
and the rest have widespread disease.3  Patients with localized disease are typically 
asymptomatic and are often diagnosed when testing for unassociated conditions. Some 
symptoms include Horner’s syndrome caused by primary tumors in the neck27 and neurological 
impairments caused by tumors on the spinal cord.28  However, localized tumors tend to be 
encapsulated and can be surgically removed.  By contrast, children with metastatic disease tend 
to have extreme tumor burden and are very ill at diagnosis.  Higher stage tumors often infiltrate 
to local organ systems and surround critical nerves and blood vessels, making them harder to 
remove.4 
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The current staging for neuroblastoma was defined by the International Neuroblastoma 
Staging System (INSS) and criteria are based on clinical features.29  
 Stage 1 tumors are localized, do not involve vital structures, are confined to one 
body compartment and lymph nodes do not contain tumor cells. 
 Stage 2A tumors are also localized and confined to one side of the body, but cannot 
be completely removed. Lymph nodes do not contain tumor cells. 
 Stage 2B tumors are localized, but nearby lymph nodes show tumor cells.  Lymph 
nodes on the other side of the body can be enlarged but do not contain cancer cells. 
 Stage 3 tumors can fall into two categories.  Either the tumor crosses the midline of 
the body and cannot be surgically removed, or the tumor is restricted to one side of 
the body, but there are enlarged lymph nodes on the opposite side of the body that 
contain cancer cells. 
 Stage 4 tumors have spread further than stage 3 to distant lymph nodes, bone, bone 
marrow, liver, skin, and/or other organs.   
 Stage 4S tumors tend to regress without any treatment.  The criteria for these tumors 
are: the child is younger than 1 year of age and a localized primary tumor has only 
spread to the skin, lymph nodes or liver, although very small amounts may be seen 
in the bone marrow.  
In addition to clinical characteristics, age is a very strong predictor of neuroblastoma 
prognosis.  Children who are older than 12 months at diagnosis have lower survival rates than 
children who are younger than 12 months, regardless of the stage of the disease.30  According to 
SEER data from 1985 to 1994, the 5-year survival for infants less than 1 year of age at diagnosis 
is 83%, while 5-year survival in those diagnosed from 1 to 4 years is 55%.26 
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1.2.3 Molecular Characteristics 
There are many genetic aberrations commonly found in neuroblastoma tumors that are 
highly correlated with survival and prognosis. The genetic aberration most commonly associated 
with poor neuroblastoma outcomes is the amplification of the proto-oncogene MYCN. 31  MYCN 
amplification of 50 to 100-fold occurs in about 20% of primary tumors and is strongly correlated 
with advanced disease.32,33  Somatic DNA sequence mutations have not been found in MYCN, 
suggesting that the wild-type protein is contributing to tumorigenesis or to pathogenicity of the 
tumor.34 Additionally, transgenic mice that are genetically engineered to overexpress MYCN in 
the neural crest develop neuroblastoma several months after birth, suggesting MYCN can initiate 
tumorigenesis.35 
The number of copies of chromosomes in a tumor cell, or ploidy, can be an important 
prognostic factor in children under the age of 2.36,37  Patients with lower grade of disease tend to 
be hyperdiploid or near-triploid (three sets of chromosomes), while patients with a higher grade 
of disease are nearly diploid. 38  This is likely because whole chromosome gains and losses are 
associated with a defect in mitosis, leading to tumor cell death and more favorable outcomes, 
while more malignant tumors have a defect in chromosomal stability, resulting in chromosomal 
rearrangements.  
Allelic loss in tumors is commonly seen in many locations and is also predictive of 
outcome. Allelic loss of the chromosome 11q is present in 35–45% of neuroblastoma tumors and 
is rarely seen in MYCN amplified tumors.39,40  These aberrations are highly associated with many 
high risk features and prognosis independent of MYCN status.41  
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Recently with DNA sequencing, additional somatic changes have been identified. In one 
study, somatic mutations were identified in ARID1A and ARID1B in 11% of the samples and 
were associated with early treatment failure and decreased survival.42 In a sample of 240 “high-
risk” cases, ALK, PTPN11, ATRX, MYCN and NRAS were found to be somatically altered.7 
These studies revealed that high-risk neuroblastoma has markedly fewer somatic mutations than 
adult solid tumors, which has a stronger environmental contribution than childhood tumors. This 
suggests germline variants, copy number variants and epigenetic modifications drive high-risk 
neuroblastoma.7,42 
1.2.4 Neuroblastoma Risk-Classifications 
The Children’s Oncology Group (COG) separated neuroblastoma into three prognostic 
risk-classifications defined by International Neuroblastoma Staging System (INSS), age at 
diagnosis, MYCN oncogene status, International Neuroblastoma Pathologic Classification 
(INPC), and DNA ploidy index.43  The INPC risk-classification is based on tumor classifications, 
grade of neuroblastic differentiation and mitosis-karyorrhexis index (MKI) (Table 1).  There are 
three COG prognostic risk-classifications: low-risk, intermediate-risk and high-risk (Table 2). 
Although these categories are prognostic, there is little evidence that favorable tumors progress 
to unfavorable tumors, suggesting they may be etiologically distinct.44 Brodeur et al. 
demonstrated that 60 patients without MCYN amplification did not change MCYN status.45  
However the relationship of these prognostic risk-classifications with tumorigenesis remains 
unclear.   
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Table 1. International Neuroblastoma Pathologic Classification 
Morphologic categories  Age Pathology Classification Prognostic Category 
Neuroblastoma  < 1.5 yrs Poorly differentiated or differentiating 
& low or intermediate MKI tumor 
Favorable 
1.5–5 yrs Differentiating & low MKI tumor  
< 1.5 yrs Undifferentiated tumor or high MKI 
tumor 
Unfavorable 
1.5–5 yrs Undifferentiated or poorly 
differentiated tumor or intermediate or 
high MKI tumor 
 
≥5 yrs All Tumors  
Ganglioneuroblastoma, intermixed  Any Any Favorable 
Ganglioneuroma Any Any Favorable 
Ganglioneuroma, nodular  Any Any Unfavorable 
Yrs: Years; MKI: Mitosis-karyorrhexis index 
Table 2. Children Oncology Group risk-classification 
Risk INSS Stage Age MYCN INPC 
Classification 
DNA 
ploidy 
Low risk 1 Any Any Any Any 
 2A/2B <12 mos Any Any Any 
  ≥12 mos Non-Amplified Any - 
  >12 mos Amplified Favorable - 
 4S < 12 mos Non-Amplified Favorable >1 
Intermediate 
Risk 
3 < 12 mos Non-Amplified Any Any 
 ≥12 mos Non-Amplified Favorable - 
 4 < 18 mos Non-Amplified Any Any 
 4S < 12 mos Non-Amplified Any =1 
  < 12 mos Non-Amplified Unfavorable Any 
High Risk 2A/2B ≥12 mos Amplified Unfavorable - 
 3 < 12 mos Amplified Any Any 
  ≥12 mos Non-Amplified Unfavorable - 
  ≥12 mos Amplified Any - 
 4 <12 mos Amplified Any Any 
  ≥18 mos Any Any - 
 4S <12 mos Amplified Any Any 
INSS: International Neuroblastoma Staging System; INPC: International Neuroblastoma 
Pathological Classification; Mos: Months; -: Not Applicable 
Treatment is dependent on prognostic category of the neuroblastoma. Treatment for low-
risk neuroblastoma is generally only surgery. Intermediate neuroblastoma is usually surgically 
removed followed with low-dosage chemotherapy.  High-risk neuroblastoma has intensive 
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treatment of surgery, radiation and chemotherapy followed preventative medication (usually 13-
cis-retinoic acid) for a year. 
1.3 Neuroblastoma Descriptive Epidemiology 
1.3.1 Incidence and Mortality in the United States 
Each year approximately 1,500 cases in Europe, 700 cases in the United States (U.S.), 
and 70 cases in Canada are diagnosed with neuroblastoma.2,46,47 The overall age-standardized 
incidence rate according to Surveillance, Epidemiology, and End Results (SEER) from 2006 to 
2010 is 7.83 per million. However, the neuroblastoma incidence rate is higher among younger 
children.  The average annual age-standardized incidence rate of neuroblastoma is 54.1 per 
million person-years for children less than 1 year old, 18.8 per million person-years for children 
1 to 4 years old and 3.0 per million person-years for children 5 to 9 years old.  Incidence of 
neuroblastoma is slightly higher in males than in females (7.7 per million vs 6.9 per million).48 
The difference in incidence by gender is greatest in infants under 1 year of age.26  There are also 
racial/ethnic trends in incidence.  European Americans have a higher rate of infant 
neuroblastoma than African Americans, but this trend does not persist in older children aged 1 to 
14 years old and could be due to differences in detection.26,48  
Most neuroblastoma cases fall into the COG high-risk prognostic classification. In a 
COG clinical cohort, 34% of neuroblastomas were low-risk, 20% were intermediate-risk and 
46% were high-risk.49 There was a higher proportion of high-risk neuroblastoma in African 
Americans (54%) and Native Americans (68%) than European Americans (44%).  In this cohort, 
Asian Americans and Hispanic populations had a lower proportion of high-risk neuroblastoma 
than African Americans.  However, the number of cases was small and solid conclusions cannot 
be drawn. 49  
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Although the five-year survival rate for all neuroblastoma is 69%, this is highly variable 
by COG risk-classification. The five-year survival for high-risk neuroblastoma is about 20%.1,50 
Both low-risk and intermediate-risk neuroblastoma have a good survival rate of about 90% to 
95%.4  Because of the difference in proportion of high-risk neuroblastoma by race, 5 year overall 
survival and 5 year event-free survival is highly correlated with race.49  Figure 2 shows the 
survival curves stratified by risk-group over enrollment in COG from 1986 to 2001.  This figure 
shows that high-risk neuroblastoma has very poor survival that plateaus around 5 years after 
enrollment in COG. 
Figure 2. Neuroblastoma survival curves stratified by risk type 
 
Produced from “Neuroblastoma” by J. Maris, M. et al., 2007, Lancet, 369: 2111.4 
Aside from mortality, neuroblastoma also presents with life-long sequelae.  About 50% to 
60% of high-risk neuroblastoma cases relapse.1 Treatment for neuroblastoma can lead to lasting 
effects in the survivors such as growth and developmental delays and loss of function in related 
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organs.51-53 Neuroblastoma and its sequelae have been shown to cause strain on the family unit 
and contribute to learning and psychological distress. The 20-year incidence of chronic health 
conditions in survivors of neuroblastoma is 41%.2 These lasting effects, along with the high 
mortality, emphasize the need to improve prevention of neuroblastoma. 
1.3.2 Time Trends in the United States 
The incidence of neuroblastoma in the United States has not changed in recent years. In a 
study from SEER, the annual percent change from 1994 to 2004 was not statistically 
significantly different from 0 [Annual percent change = -0.6 (95% confidence interval: -2.2, 
3.5)].48 Figure 3 displays the changes in incidence rate of neuroblastoma in SEER from 1984 to 
2006 in five year increments, which also shows no change in the incidence of neuroblastoma, 
even after folic acid supplementation of foods in the U.S. in 1997.54   There also have not been 
changes in neuroblastoma incidence by race or gender.48  Although a study from the Greater 
Delaware Valley Pediatric Tumor Registry showed a rise in neuroblastoma incidence over from 
the 1970 to the 1989, 55  this rise is most likely due to changes in imaging technology and 
increased awareness. 
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Figure 3. Incidence rate in millions of person-years of neuroblastoma from 1975 to 2006 directly 
standardized to the 2000 population 
 
Adapted from “Incidence, Survival, and Prevalence of Neuroendocrine Tumors Versus Neuroblastoma in Children 
and Young Adults: Nine Standard SEER Registries, 1975-2006” by Navalkele et al., 2007, Pediatrics Blood & 
Cancer, 56. 54 
Overall survival has been improving for neuroblastoma in the United States.56 From 1975 
to 2006, mortality over all ages has declined from 75% to 40%. Since infants have more 
favorable outcomes, survival for infants with neuroblastoma has been relatively stable since the 
mid-1970’s with five year survival ranging from 87% to 95%. Although older children tend to 
have less favorable outcomes, 5-year survival rates have improved from 35% in the 1970s to 
65% in 2002 possibly due to better treatment options.57 
1.3.3 International Incidence and Time Trends 
Neuroblastoma incidence varies widely around the world.  Higher-income countries tend 
to have higher incidence of neuroblastoma than middle-income or lower-income countries.58  In 
a report for the World Health Organization, Asia (with the exception of Japan and Hong Kong) 
and Sub-Saharan Africa have the lowest rates of neuroblastoma.59 Countries with lower 
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standards of medical care and technology are less likely to incidentally diagnose neuroblastoma 
that does not present clinically.  Similarly, survival in neuroblastoma has seen dramatic 
improvement from the 1980’s in higher-income countries, while lower income countries have 
improved at a slower rate. 60,61 
Incidence rates have been increasing in Europe, but this trend is most likely due to better 
diagnostic tools and improving ability to differentiate neuroblastoma from other types of 
cancer.62  Neuroblastoma screening has been implemented city-wide or country-wide in many 
countries including Japan, Germany and Canada.63,64  As expected, these regions have 
experienced an increased incidence of neuroblastoma.65 However, these programs did not lower 
the number of high-risk tumors or deaths related to neuroblastoma and were all abandoned.63,64 
These screening programs were most likely detecting low risk cases that would not have been 
previously clinically detected and regressed without treatment.   
1.4 Neuroblastoma Risk Factors 
1.4.1 Genetic Basis for Neuroblastoma 
Neuroblastoma is both genetically and clinically heterogeneous.  Cases of neuroblastoma 
can present with conditions associated with the sympathetic nervous system such as congenital 
central hypoventilation syndrome, Hirschsprung disease, pheochromocytoma, and 
neurofibromatosis, which suggests a shared underlying genetic cause.9,66,67 In the 1970s, 
Knudson and Strong proposed that the two-stage neuroblastoma mutation model, in which two 
events need to occur for cancer initiation.68  This hypothesis suggests if the first mutational event 
is in germline cells and the second event in somatic cells, familial cases will have an earlier age 
at diagnosis and be more likely to have multiple primary sites. This two-hit hypothesis has been 
expanded to the multiple-hit hypothesis that proposes a minimum genetic mutation  threshold for 
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the development of disease and malignant transformation is modified by environmental 
exposures.1 Common germline mutations contribute to this minimum genetic threshold, but other 
events must also occur for malignant transformation.  
To further support this theory, the fetal environment for the tumor is very different from 
the infant environment.  During development, humans create more cells than necessary.69,70  As 
the embryo grows, the cells will go through stages of differentiation and apoptosis.  In order for 
neuroblastoma to be clinically detected, the tumors that arise prenatally must maintain the ability 
for uninhibited replication in both the fetal environment and the environment after birth. To 
maintain this unabated replication, somatic mutations must occur early in development and again 
after birth.71  In autopsies of infants whose cause of death was not cancer, the incidence of 
neuroblast pre-cancer is higher than the incidence of neuroblastoma.25  These tumors that regress 
after birth likely did not acquire the necessary hits to lose the ability to respond to apoptotic 
signals after birth.  
1.4.1.1 Familial Neuroblastoma 
About 1% of cases present with a positive family history of neuroblastoma, which 
implies that neuroblastoma is highly heritable.9 Based on the pedigree of the families, it is 
inherited in an autosomal dominant inheritance pattern with incomplete penetrance.72 This 
incomplete penetrance could be due to the spontaneous regression of the tumor and/or to 
protective genetic or environmental factors.  Consistent with Knudson and Strong, familial 
patients are often diagnosed at an earlier age and with multiple primary sites.68  Familial 
neuroblastoma also has a heterogeneous presentation across affected families ranging from 
benign disease to widely disseminated disease within the same family,73 suggesting that both 
genetic and environmental factors modify the presentation of disease. 
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In a small subset of patients neuroblastoma also present with other sympathetic nervous 
systems conditions.9  Genes involved in these comorbid conditions have been studied in relation 
to neuroblastoma. A loss of function in paired-like homeobox 2b (PHOX2B), a gene related to 
congenital central hypoventilation syndrome,74 has been observed in 6.4% of familial 
neuroblastoma cases and almost exclusively in cases of neuroblastoma with associated 
conditions of the neural crest.75   
Given the rarity and the incomplete penetrance of familial neuroblastoma, identifying 
underlying genetic causes based on multi-case families has been difficult. Linkage analysis 
found a significant peak at 16p12–13 in seven families, but subsequent association analysis did 
not map a gene to this region.76  Mossé et al. identified anaplastic lymphoma kinase (ALK) as a 
major familial neuroblastoma gene in a significant linkage peak on the short arm of chromosome 
2 (2p23–p24) in 20 neuroblastoma families.  Resequencing of coding exons revealed three 
distinct germline mutations (Table 3). Families that did not have an ALK mutation harbored a 
PHOX2B mutation, suggesting that either mutations in ALK or PHOX2B causes familial 
neuroblastoma.77 
1.4.1.2 Spontaneous Neuroblastoma 
Spontaneous, or non-familial, neuroblastoma has been associated with common as well as rare 
germline variants. Recent genome-wide association (GWA) studies have identified common 
(minor allele frequency greater than 5%) genetic single nucleotide polymorphisms (SNPs) 
associated with neuroblastoma mostly in Europeans and European Americans.6 Whole genome 
and exome sequencing have also identified rare (minor allele frequency less than 5%) germline 
variants.7 
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Common polymorphisms  
In a GWA study of 1,032 European American cases of neuroblastoma registered in COG 
and 2,043 European American disease-free control subjects from the Children’s Hospital of 
Philadelphia Health Care Network, Maris and colleagues identified three common SNPs 
(rs6939340, rs4712653, and rs9295536) at 6p22 within the predicted gene cancer susceptibility 
candidate 15 (CASC15).6,78 These three SNPs are in high linkage disequilibrium (LD; r2 = 0.731-
0.873) and yield allelic odds ratios that range from 1.39 to 1.40. These three SNPs were also 
significant in two replication series, one of high-risk cases in COG and another from the United 
Kingdom. When stratified by risk type, these SNPs were overrepresented in high-risk cases and 
among cases with aggressive disease. Two SNPs at chromosome 20p11 (rs3790171 and 
rs7272481 within SLC24A3) were also genome wide significant, but did not retain significance 
after adjustment for population substructure.6 
A second GWA study was conducted limiting the cases to the 397 high-risk cases and the 
same 2,043 controls.  In this subset, the previously identified SNPs remained significant and an 
additional six common intronic SNPs (rs3768716, rs17487792, rs7587476, rs6712055, 
rs6435862, and rs6715570) in BARD1 (BRCA1-associated RING domain-1) were also 
significant in both the discovery and replication sets.79 These six SNPs, located in the 2q35 locus 
and are in relatively high LD (r2 =0.47–0.96).  The odds ratios for these SNPs ranged from 1.59 
to 1.63 in the discovery set. Genome wide significant associations were not seen between these 
SNPs in BARD1 and low-risk or intermediate-risk neuroblastoma. BARD1 has also been 
implicated with other cancers since it is closely related to BRCA1 (Breast cancer 1, early onset), 
a tumor suppressor gene that is associated with increased risk for breast, ovarian and prostate 
cancer. 79  BARD1 heterodimerizes with BRCA1 and is thought to be necessary for the tumor 
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suppression function of BRCA1.  There is no interaction observed between the most significant 
SNPs in the 6p22 locus and the 2q35 locus in this study. 
Researchers have also identified a common germline copy number variant (CNV) 
associated with neuroblastoma in the same case-control study.80  The deletion polymorphism 
spans less than 145 kb at 1q21.1 located within neuroblastoma breakpoint family member 17, 
pseudogene (NBPF17P).  Expression of this transcript is associated with the underlying CNV 
genotype in neuroblastoma tumors and with expression in fetal brain and sympathetic nervous 
systems in normal tissue.  There were no significant interactions of this CNV with previously 
associated 6p22 risk alleles.  
Another GWA study was conducted with the original case group expanded to 1,627 and 
the original controls to 3,254.  This study replicated the previous two loci and discovered two 
additional SNPs, rs4758051 and rs110419, with moderate LD (r2=27) within LMO1 (LIM 
domain only 1) at 11p15.4.  The additive odds ratios combined across the discovery and all 
replication sets are 1.28 (95% Confidence Interval (CI):1.19, 1.37) and 1.34 (95% CI: 1.25, 0.44) 
for rs4758051 and rs110419, respectively.  Similar to the SNPs in the 2q35 and 6p22 locus these 
SNPs are also significantly associated with offspring age at diagnosis older than 1 and high-risk 
neuroblastoma. 81  Additionally, the authors found that the LMO1 locus is also aberrant through a 
duplication event in 12.4% of the tumors.  LMO1 encodes a transcriptional regulator and has 
been previous associated with acute lymphoblastic T-cell leukemia. 82 Germline SNPs and 
somatic copy number gains are associated with increased expression of LMO1, suggesting a role 
in tumorigenesis. 
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Nguyen and colleagues developed a gene-centric method to analyze the association of 
15,885 genes annotated in UCSC Genome Browser with neuroblastoma in the expanded GWA 
study of 1,627 cases and 3,254 controls.83 In addition to identifying previously significant genes, 
the dual-specificity phosphatase 12 gene (DUSP12) at chromosome band 1q23.3 was also 
associated.  When the sample was restricted to a subset of 574 low-risk cases and 1,722 matched 
control subjects, DUSP12 along with three genes in two chromosome bands (5q11.2 and 
11p11.2) were significant. DDX4 (DEAD (Asp-Glu-Ala-Asp) box polypeptide 4 isoform) and 
IL31RA (interleukin-31 receptor A precursor) are located in 5q11.2. HSD17B12 (hydroxysteroid 
(17-beta) dehydrogenase 12) is located at chromosome band 11p11.2.  DUSP12 contains 1 SNP 
and HSD17B12 contains 3 SNPs that were genome-wide significant, while IL31RA and DDX4 
did not include any SNPs that were genome-wide significant.  There was no significant 
interaction among these three loci (p-value ranges from 0.45–0.91). 
The GWA study was further expanded to 2,101 neuroblastoma cases from the COG in 
North America and 4,202 control subjects of European ancestry.  Two additional loci, one at 
chromosome 4p16 with 1 SNP (rs4696715) and another at 6q16 with 2 SNPs (rs4336470 and 
rs9404576), were discovered.  However, SNPs in high LD with the SNP at chromosome 4p16 
were not associated with neuroblastoma.  Upon closer examination of 6q16, 4 additional SNPs 
were associated with neuroblastoma (rs4079063, rs2499663, rs2499667, and rs17065417). 
Rs4336470 is located within the HACE1 gene (encoding HECT domain–and ankyrin) and is in 
moderate LD with 3 additional SNPs (rs4079063, rs2499663, and rs2499667). Rs17065417 is 
located within an intron of the LIN28B gene (encoding lin-28 homolog B repeat–containing E3 
ubiquitin protein ligase 1).  Low HACE1 expression and high LIN2B expression are both 
associated with worse overall survival.8 
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Another candidate gene analysis based on imputed genotypes was conducted with the 
TP53 locus with the same 2,101 cases and 4,202 controls of European ancestry.  Two imputed 
rare variants rs35850753 and rs78378222 (minor allele frequency= 3.0% and 1.0%, respectively) 
were significant at a genome-wide level.  In 176 case patients, the imputed SNPs were genotyped 
and there was 96% concordance between the measured and imputed genotypes at those loci.  
Additionally, these results were replicated in an African ancestry cohort with 365 cases and 2491 
controls through imputation.  PCR genotyping was performed on 351 neuroblastoma case 
patients and 780 control subjects in an Italian cohort.  The effect estimate was in the same 
direction and statistically significant.  When pooled across the replication sets the estimated OR 
for rs35850753 was 2.7 (95% CI: 2.0,3.6) and for rs78378222 was 2.3 (95% CI: 1.8,2.9).84  
Two small candidate SNP studies were conducted on Brazil.  The first was a case-control 
study that evaluated folate-related SNPD (MTHFR C677T and A1298C, MTR A2756G, TYMS 
2R/3R and SLC19A1 G80A) in 31 Brazilian cases and 92 controls.  MTHFR C677T, MTR 
A2756G and TYMS 2R/3R trended in a positively, but were non-significant.  SLC19A1 G80A 
was significantly associated with neuroblastoma (5.17; 95% CI: 1.45, 18.43).85  Another case-
mother dyad of 64 case-mother pairs and 222 control-mother pairs investigated associations with 
MTHFR C677T and SLC19A1 G80A.  Null maternal and offspring associations were seen for 
MTHFR C677T, but positive associations were seen for both maternal (G/A OR: 3.09; 95% CI: 
1.02, 9.31; A/A OR: 3.16; 95% CI: 0.93, 10.67) and offspring (G/A OR: 2.48; 95% CI 1.13, 
5.44); A/A OR: 3.46; 95% CI: 1.45, 8.24) associations of SLC19A1 G80A.86 These offspring and 
maternal associations are not mutually adjusted for and thus the offspring associations could be 
confounded by the maternal associations. 
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Sequencing results 
Recently whole genome and exome sequencing completed on tumors and whole blood 
from neuroblastoma patients to investigated germline variants associated with neuroblastoma. 
Genes that harbored clinically annotated variants from the ClinVar database and loss-of-function 
variants in cancer genes were identified in the 222 cases compared to the 1,974 adult European 
American controls from the Exome Sequencing Project,.7  Five candidate genes were nominated 
as having putative germline pathogenic variants: ALK, CHEK2, PINK1, TP53, and BARD1.7  
Two genes, BARD1 and ALK, were previously identified in GWA studies.77,79  CHEK2 is has 
been previously linked with breast and prostate cancer.87,88 TP53 is associated with Li-Fraumeni 
syndrome, which greatly increases the risk of cancer and has been reported in neuroblastoma 
families.89 PINK1 has been previously associated with early-onset Parkinson’s disease90.  
Summary.   
Knudson and Strong proposed that early life cancers have a genetic basis and that familial 
cases present earlier and with multiple primary sites, as seen in neuroblastoma.  Numerous 
studies suggest that there are common variants that are associated with neuroblastoma. Because 
of the changing fetal environment, there is evidence that neuroblastoma has an underlying 
genetic basis that is modified by the environment. Table 3 provides a summary of all the studies 
and the variants that have been associated with neuroblastoma. Although these studies did not 
find an association between variants within vitamin pathways and neuroblastoma, these studies 
are genome-wide and may not be adequately powered to find small effects in a few genes due to 
correction for multiple testing. In addition to genetic factors, neuroblastoma can be influenced by 
environmental factors, such as the fetal environment.2 Current studies have not looked at 
maternal genetic effects and interactions with the maternal environment. 
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Table 3. A summary of genes related to neuroblastoma predisposition from Familial and GWA Studies 
Gene Variants Neuroblastoma 
Subtype 
Cytoband OR (95% CI) for SNP 
or most significant SNP 
Gene Function from NCBI gene78 Ref 
PHOX2B Rare Mutation Familial 4p13 __ Promotes the development of neuronal 
development and differentiation in the neural 
crest 
75 
ALK Rare Mutation Familial 2p23.1-.2 __ Regulates the proliferation of nerve cells 77 
CASC15 rs6939340 
rs4712653 
rs9295536 
High-risk 6p22 1.37 (1.27–1.49)a 
1.35 (1.24–1.46)a 
1.32 (1.22–1.43)a 
 6 
BARD1 rs3768716 
rs17487792 
rs7587476 
rs6712055 
rs6435862 
rs6715570 
High-Risk 2q35 1.68 (1.48–1.91) 
1.68 (1.47–1.92) 
1.61 (1.41–1.84) 
1.56 (1.37–1.78) 
1.68 (1.49–1.90) 
1.58 (1.39–1.79) 
Control cell growth and proliferation and 
involved with BRCA1 repairing DNA 
79 
NBPF17P CNV  1q21.1 2.23 (1.77–2.82) Duplicated gene associated with development 80 
LMO1 rs4758051 
rs110419 
High-Risk  1.28 (1.19–1.37) 
1.34 (1.25–1.44) 
Transcriptional regulator potentially involved 
in neural crest cells 
81 
DDX4/IL31RA Gene-centric Low-Risk 5q11.2 1.49 (1.23–1.81)b DDX4 alters of RNA secondary structure 
IL31RA  is involved in IL-31 activation  
83 
DUSP12 Gene-centric Low-Risk 1q23.3 2.01 (1.47–2.79)c Regulates members of the mitogen-activated 
protein (MAP) kinase superfamily 
83 
HSD17B12 Gene-centric Low-Risk 11p11.2 1.674 (1.35–2.08)d Converts estrone into estradiol in ovarian 
tissue 
83 
HACE1 rs4336470 
rs9404576 
rs4079063 
rs2499663 
rs2499667 
 6q16 1.26 (1.18–1.35) 
1.27 (1.18–1.36) 
1.20 (1.12–1.29) 
1.21 (1.13–1.29) 
1.21 (1.13–1.29) 
Involved in Golgi membrane fusion and 
regulation of small GTPases 
8 
LIN28B rs17065417  6q16 1.38 (1.23–1.54) Suppressor of microRNA (miRNA) 
biogenesis 
8 
TP53 rs35850753 
rs78378222 
 17p13.1 2.7 (2.0–3.6)e Tumor suppressor protein 84 
SLC19A1 rs1051266   2.51 (1.24–5.08)f Involved in the regulation of intracellular 
concentrations of folate 
86 
aOR for all neuroblastoma subtype  brs10055201 c rs1027702 d rs11037575 ers35850753 fDominant Offspring OR
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1.4.2 Environmental Exposures 
1.4.2.1 Vitamin supplementation 
Studies have shown that folic acid supplementation during the preconception period 
lowers the risk of neural tube defects as well as several childhood cancers including 
neuroblastoma.48,91-93  Neural tube defects occur when the neural tube does not close fully. Since 
neural tube defects occur within close proximity to the neural crest, it is possible that both can 
arise from related errors in signaling.71 Although the United States food supply was fortified with 
folic acid at the beginning of 1998,94 women of reproductive age from 2003 to 2006 in NHANES 
still are estimated to have daily folic acid intake levels lower than the recommended level of 400 
μg for women of childbearing age.95,96 From 1999-2006 NHANES, 74% of women reported 
taking folic acid containing multivitamin/multimineral supplements at one point in pregnancy. 
The percentage of women taking supplements also differs by trimester. Only 63% of mothers 
reported taking vitamins in the 1st trimester, 80% in the 2nd trimester and 90% in the 3rd 
trimester.97 Since the neural crest migration and differentiation usually begins at around 5 weeks, 
this usage pattern suggests that many women may not be taking supplements during the most 
crucial time of fetal neuronal development. In addition to lower folic acid intake, less than 3% of 
the US population has folic acid consumption above the tolerable upper intake level 
(1000µg/day), above which there may be adverse health events as set by the Institute of 
Medicine.98  
Most of the epidemiological data suggests an inverse association between neuroblastoma 
and maternal pregnancy vitamin intake.10,11,99  The first study to report this association included 
183 neuroblastoma cases from the New York Cancer registry from 1976 to 1987.  Controls were 
age and race matched from the New York State live birth certificate registry (N=372).  The 
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response rate for both cases and controls were very high (85% and 87%, respectively). Since the 
purpose of the study was to describe the role of prenatal medication usage in neuroblastoma, no 
specific question about prenatal vitamin use.  The prenatal vitamin data was collected from 
mothers who answered an open-ended question about other medications prescribed by doctors 
during the pregnancy.  The reported unadjusted odds ratio was 0.5 (95% CI: 0.3, 0.7) for self-
reported vitamin use versus no vitamin use.  Due to the open-ended question used, these results 
may not be an accurate reflection of vitamin use.11  In a study where neuroblastoma cases were 
recruited at St. Jude in the same time period, about 90% of the mothers took prescription 
vitamins while 3.7% of the mothers took non-prescription vitamins,100 suggesting that most of 
the women taking vitamins were by prescription. 
These results were replicated in the largest case-control study (530 cases and 500 
controls) to date with maternal vitamin supplementation information.   Cases were enrolled from 
COG from 1992–1994 and 73% provided interviews. Controls were recruited with random digit 
dialing (72% were interviewed) and matched on date of birth with the cases.  Mothers were 
specifically asked whether vitamin or mineral supplements were used during the pregnancy with 
neuroblastoma by trimester. The odds ratio for daily vitamin use during the pregnancy or 1 
month before pregnancy versus no vitamin use during the pregnancy or 1 month before 
pregnancy was 0.6 (95% CI: 0.4, 1.0), adjusted for age at diagnosis, mother's race and education.  
Less than daily and daily vitamin use in the first trimester had an inverse association versus no 
vitamin use in the first trimester [OR = 0.6 (95% CI: 0.4, 0.9) and 0.7 (95% CI: 0.5, 1.0), 
respectively].  Similar results were seen in the 2nd and 3rd trimester, but only daily vitamin use 
was statistically significant.10  Trimester-specific data are difficult to interpret since the women 
who took vitamins in the 1st trimester were very likely to continue the next trimester.10  However, 
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this study clearly points to an inverse association between prenatal vitamins during pregnancy 
and neuroblastoma. 
A small German study reported a positive association between maternal vitamin use and 
neuroblastoma. It was conducted from 1992 to 1994 in West Germany with cases from the 
German Childhood Registry (N=158). Controls were randomly sampled from the local resident 
registration offices and matched on community and age.  This study looked at multiple childhood 
cancers and the authors used all controls for this analysis (2,057 controls).  A questionnaire 
assessed whether the mother took vitamin, folate, or iron supplements during pregnancy. The 
results were adjusted for the matching factors and sex, age, year of birth, degree of urbanization, 
and socioeconomic status.  Mothers who took vitamin, folate, or iron supplements were 1.5 (95% 
CI: 1.06, 2.13) times as likely to have a child with neuroblastoma as mothers who did not take 
supplements. However, the proportion of vitamin supplementation among controls in this study 
are much lower than in other studies in the US10,11 and Germany in 1998.101 Additionally, this 
study recruited cases from West Germany, while the other studies are North American, which 
could explain the different vitamin supplementation pattern. 
A negative association was also suggested by surveillance data in Ontario, Canada with a 
60% decrease in the incidence of neuroblastoma after food fortification with folic acid began in 
January 1997.  The incidence of neuroblastoma decreased from 1.58 per 10,000 births to 0.88 per 
10,000 births.  The incidence rate ratio adjusted for age at diagnosis is 0.53 (95% CI: 0.37, 
0.76).99  However, these results failed to replicate with SEER data in United States after food 
fortification, which began in 1998.48  The age-adjusted incidence rate to the 2000 US Standard 
Population was 30 per million person-years pre-fortification and 29.5 per million person-years 
post-fortification.  The incidence rate ratio is 0.98 (95% CI: 0.87, 1.11). The SEER analysis 
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excluded cases that occurred from 1995 to 1999, while the Canadian study includes these years, 
allowing for potential misclassification of the exposure.  Additionally, there were few cases of 
neuroblastoma post-fortification in the Canadian study. As with all ecologic studies the results 
are affected by other changing factors such as variation in patterns of personal vitamin 
supplementation during pregnancy.  
Summary 
 Lowering the incidence of neural tube defects has been attributed to folic acid 
supplementation in food and is considered one of public health’s biggest successes.  Although an 
effect of maternal prenatal vitamins and dietary vitamin intake on neuroblastoma has not been 
well established, there is clear suggestive evidence for a protective association.  The studies that 
have been done are small, but the largest suggest that there is a negative association. The 
inconsistent results could be due to gene-environment interactions and different environmental 
exposure patterns.  However, case-control could be biased due to selection bias, since it would be 
difficult for the cases, who are usually recruited from a large registry, and the controls to arise 
from the same population.  The controls could also fail to be representative of the sample 
population by either self-selection in sampling, or differential recall of the exposure variable.   
1.4.2.2 Other possible risk factors 
There are a few other exposures, such as maternal alcohol consumption, paternal 
occupational exposures, maternal use of diuretics, pain medication or codeine and low birth 
weight that show a positive association in multiple studies.  Maternal vitamin and folic acid 
supplementation and history of asthma have shown a negative association in some studies.  More 
detailed descriptions of these exposures are summarized in Table 4. 
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Table 4. Summary of possible risk factors of neuroblastoma 
Exposure Comments References 
Maternal Alcohol Use 
Most studies report a positive association with daily or binge drinking pre-pregnancy or pre-pregnancy. Two studies 
reported a null association 
100,102-104 
Electromagnetic Field 
Studies have found an association or elevated odds ratio with paternal occupations that have exposures to 
electromagnetic fields such as those involved with power plants. One study found a null association. 
105-110 
Pesticides 
Studies of associations with paternal or maternal occupations that work with pesticides pesticide use have been 
mixed with both positive and null results.  A meta-analysis also found null result as well. 
103,105-107,109,111-116 
Other occupational 
exposures 
Maternal exposures to hair dye or maternal occupation of hairdresser or barber either before pregnancy or during 
pregnancy was associated with neuroblastoma.  Maternal exposures to acetone, lead, petroleum, occupation in 
service retail and paternal exposures creosote, dioxin, lead, petroleum, occupation materials handling have also been 
associated with neuroblastoma in one study. 
102,106,112,117 
Use of Diuretics 
Three studies have identified an imprecise, but positive association with diuretics.  Another study found a positive 
association with diuretics and antihypertensive drugs. 
100,102,118,119 
Use of Pain 
Medications or 
Codeine 
Three studies have found a positive association with non-prescription pain relievers and codeine during pregnancy. 
No association was found with drugs taken for fever during pregnancy New York State study and any type of pain 
medication in a German study.    
11,100,118,120 
Birth weight 
Most studies have found a suggestive positive association with low and high birth weight.  However, only a few 
studies have adjusted for gestational age, but there is a suggestive relationship with small for gestational age babies. 
Studies suggest a U-shape curve in which both low birth weight and high birth weight at associated.  Additionally a 
meta-analysis found associations with both low birth weight and high birth weight. 
103,121-132 
History of Asthma or 
Allergies 
Studies have identified an inverse association between childhood allergies and later development of neuroblastoma. 
In one study, family history of asthma has also been associated, but in another maternal history of asthma is not. 
103,133 
Parental 
Demographics 
No clear association has been seen in maternal age. There is suggestive evidence of low or high maternal age 
associated with neuroblastoma.  However, there are many studies showing null effects.  Fewer studies have looked at 
paternal age, but there is one study that found an association with higher paternal age.  
103,106,121,122,124-
126,128-131,133,134 
Tobacco Use 
Most studies did not find an association with maternal tobacco use.  One reported a weak positive association with 
maternal smoking pre-conception and during pregnancy, while a couple reported non-significant elevated odds ratios. 
Paternal smoking has been less studied and yielded mostly null results.  
100,102-104,122,127,134-
136 
Maternal 
Recreational Drug 
Use 
A positive association with a broadly defined recreational drug use was seen in two studies.  In one study, marijuana 
use in the first trimester had the strongest association.  Another study did not find an association, but other cancer 
cases served as the controls. 
127,137 
Sex Hormones 
Two studies identified a positive association, especially in stage 1 or 2 cases.  However, one study with subjects 
reporting exposure was very small.  These results failed to replicate in 3 other studies. 
11,100,102,103,138 
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1.5 Literature on Vitamin Pathways 
Epidemiologic studies have suggested that the prenatal environment is important for the 
risk of neuroblastoma.  Maternal vitamin intake has been consistently associated with decreased 
risk of neuroblastoma and likely modifies the risk of mutational “hits” occurring.  There are 3 
vitamins that could potentially be of importance with neuroblastoma.  Vitamin A is essential to 
the differentiation and development of neuronal cells.  Since both excess vitamin A and 
deficiency are associated with teratogenicity, cellular levels must be kept at equilibrium to 
prevent birth defects.  Folate and folic acid have been associated with decreased incidence of 
neural tube defects.  Additionally folate and choline are essential to DNA and RNA repair, 
synthesis and methylation. Low levels of choline and folate have been associated with DNA 
errors that could lead to somatic changes in the tumor. 
1.5.1 Vitamin A 
1.5.1.1 Biologic literature 
Retinoic acid (RA) is a lipophilic molecule derived from retinoids (chemical compounds 
related to vitamin A).  RA is required for many different biologic processes including normal 
growth and development and is especially important in embryonic neuronal differentiation and 
development.12,13  RA concentrations must be within a very narrow range in order to avoid 
teratogenic effects.13  In animal models, severe maternal vitamin A deficiency can cause 
embryonic death. Less severe deficiencies in fetal developmental malformations include heart 
defects, cleft lip or palate and malformation of forelimbs.13,139  Vitamin A excess during 
development also results in major embryonic defects that overlap with those in vitamin A 
deficiency.140,141  In a study of women who underwent screening for vitamin A, high levels of 
vitamin A intake during pregnancy have been associated with birth defects of the cranio-neural-
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crest tissue.142  Excessive vitamin A intake during pregnancy occurs from supplementation.143 
Figure 4 summarizes genes and metabolites involved in vitamin A metabolism and transport. 
The body does not manufacture retinoids and so they must be acquired through the diet.  
Vitamin A is taken into the system either in the form animal products as retinyl esters, retinol, or 
RA or from fruits and vegetables as beta-carotene.144  Dietary retinol can be directly taken up in 
the intestine.  However retinyl ester must first be converted to retinol by retinyl ester hydrolases 
(REHs) such as carboxyl ester lipase (CEL), and pancreatic lipase-related protein 2 
(PNLIPRP2).145,146 Beta-carotene is broken down into retinal by Beta-carotene 15,15'-
monooxygenase (BCMO1).  When absorbed, all retinoids are converted to retinyl esters by 
lecithin retinol acyltransferase (LRAT) and is stored in the liver.147 
When needed, retinyl esters are hydrolyzed to retinol by REHs in the liver.  There is a 
large family of  REHs and the enzyme varies based on location, but in the liver CEL and 
carboxylesterase (CES) are mostly responsible.145  The retinol is bound by retinol binding protein 
(RBP) to be secreted into the bloodstream and made available to all cells including embryonic 
cells by maternal transfer across the placenta.144 However, research shows that there must be 
undiscovered placental transfer methods for vitamin A that are not RBP dependent, because 
homozygous RBP null mutant mice are viable.148  There is evidence that blood retinyl esters can 
be hydrolyzed by lipoprotein lipase (LPL) in the blood and can be transferred into cells.149 Blood 
levels of Retinol-RBP are very stable, except in extreme cases of insufficient intake of vitamin 
A, protein, calories, or zinc.144 
The cellular uptake of vitamin A from Retinol-RBP is mediated by the transmembrane 
protein Stimulated by retinoic acid 6 (STRA6).150  Retinol is then reversibly oxidized to 
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retinaldehyde by several alcohol dehydrogenases (ADH) and retinol dehydrogenases (RDH).  
Retinaldehyde is then oxidized to RA by retinaldehyde dehydrogenases (RALDH).151  To keep a 
balance of RA in a cell, RA can be degraded to 4-hydroxy-RA or 4-oxo-RA, which are believed 
to be non-transcriptionally active 152,153 by three cytochrome p450 enzymes.154 Since retinoids 
are lipid molecules, they must be bound to proteins within cells.155 Several binding proteins have 
been identified including cellular retinol-binding proteins (CRBP), cellular retinaldehyde–
binding protein (CRalBP) and cellular retinoic acid-binding protein (CRABPI).155 CRBPI has 
been proposed to facilitate the conversion of retinol to retinyl esters for storage and the oxidation 
of retinol to retinaldehyde by RDHs.156 
RA is the biologically active form and it functions as a ligand for specific nuclear 
receptors, retinoic acid receptor (RAR) or retinoid X receptor (RXR), which together regulate 
more than 500 genes.157 All-trans-RA, the most abundant form of RA, binds to RAR, while 9-
cis-RA binds to RXR.158  Additionally, RAR binds with RXR to form a heterodimer, suggesting 
RXR is most likely a scaffold protein to facilitate DNA binding.159  In vivo studies have 
demonstrated that binding to RAR is sufficient for rescuing a lethal defect in RA synthesis, while 
binding to RXR is not.160 These RAR-RXR heterodimers interact with retinoic acid response 
elements (RARE) in the promoter region of target genes.161 
Animal models have demonstrated the importance of vitamin A metabolism and transport 
in fetal development.  Mice that have mutations in Rdh10 have serious defects in embryonic RA 
signaling resulting in embryonic death, while mice knocked out in Adh4 and Rdh1 do not display 
RA signaling alterations.162,163   Loss of Adh3 impairs post-natal survival, but Adh3 has low 
activity for retinol oxidation, suggesting the effects may not be due to RA signaling.164  Mice that 
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lack Crbp1 have decreased stores of retinyl esters and are sensitive to vitamin A deficiency, but 
do not have decreased RA synthesis. 165 
Mice that are null for Cyp26a1, a gene encoding cytochrome P450 enzyme, have lethal 
morphogenetic phenotypes.  These mice can be phenotypically rescued by disruption of Aldh1a2, 
suggesting that excess retinoic acid exposure induces these phenotypes.166 Double null mutations 
in Rar in mice impair survival in utero or shortly after birth and lead to numerous vitamin A 
deficiency abnormalities.167  Similar results are seen in mice with null mutations in RAR and 
RXR.  These results showed that Rxr-α is the main Rxr involved in developmental signaling.168   
When cultured neuroblastoma cells are treated with RA, they exhibit decreased 
proliferation and MYCN expression and differentiation.14,15 Although survival after RA as a 
treatment for neuroblastoma was low,16913-cis-RA is used to prevent the recurrence of disease 
after treatment for high-risk neuroblastoma.170,171  The differentiation of neuroblasts induced by 
retinoic acid suggests that levels of RA within the child could have an effect on the development 
of neuroblastoma.  
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Figure 4. Vitamin A transport and metabolism 
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1.5.1.2 Epidemiologic literature  
Fetal RA level needs to be maintained at a proper concentration. Two studies have found 
that fetal RA has no correlation with fetal retinol levels, suggesting the variation in fetal RA 
levels reflects fetal generation and degradation of RA.172,173 Common variants in ALDH1A2 and 
CRABP2 have been associated with higher cord blood retinoic acid levels in 145 healthy full-
term infants.172  A genome wide association study identified common variants near TTR and 
RBP4 as associated with blood retinol levels in adult males.174  Another GWA study failed to 
find an association with blood retinol levels, but found that rs6564851, a variant near BMCO1, 
was associated with higher blood β-carotene levels.175  Similarly, three polymorphisms, 
including rs6564851 in BMCO1 were also associated with lower catalytic activity in 28 
females.176 
Common variants within genes involved in the vitamin A pathway have been associated 
with neural tube defects. A case-parent triad study of 329 case-parent trios and 281 mother-child 
or father-child dyads found SNPs within RARA, RARB, and RARG to be negatively associated 
with meningomyelocele, a severe form of a neural tube defect.177  Another study with 230 case-
parent triads and 68 one-parent dyads found associations with 3 SNPs in ALDH1A2 and 
meningomyelocele.178  Multiple studies have found linkage in the region containing RARA with 
cleft lip/palate, suggesting these loci may harbor variants.179-181   
Adult cancers have also been associated with variants located in the vitamin A pathway. 
Childhood cancer survivors are at higher risk of adult cancers.  However, the reason for this 
increased risk is unknown since it is unclear if increased risk is due to a general genetic 
predisposition, to effects of the treatment, or to the original cancer.182,183  Variants within or near 
the alcohol dehydrogenases have been associated with upper aerodigestive tract cancer, gastric 
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cancer and ovarian cancer. 184-187  Colorectal cancer, pancreatic cancer, and non-Hodgkin’s 
lymphoma have been associated with variants in the RXR genes.188-190  These associations could 
suggest that variation within these genes could be involved in malignant transformation. 
1.5.2 Folate 
1.5.2.1 Biologic literature 
Folate is an essential B vitamin naturally found in foods and is available as folic acid in 
supplements and food fortification.  Food folate has a reduced pteridine ring and a polyglutamate 
polypeptide that must be hydrolyzed in the intestinal lumen to a monoglutamate form before 
being absorbed by the intestinal cell and metabolized.  Folic acid, which is synthetically 
produced to fortify foods, contains only a single glutamate and once converted to 
tetrahydrofolate (THF) by dihydrofolate reductase (DHFR) is identical to those from food 
folates.191  Bioavailability of food folate depends on many factors such as the type of food, 
cooking methods of the food and genetics of the host. Studies have shown that food folate has 
30% to 98% of the bioavailability of folic acid.192,193 
Folate is necessary in one-carbon metabolism, which is involved in DNA and RNA 
methylation and DNA synthesis and maintenance.194  Deficiencies in folate while pregnant have 
been associated with birth defects such as neural tube defects,93,195 low birth weight,196,197 and 
preterm birth.196  Due to its association with neural tube defects, mandatory folic acid 
fortification of cereal products has been in place in the United States since 1997 and in Canada 
since 1998.93,198 
5-methyltetrahydrofolate (5-MeTHF) monoglutamate is the main form of folate 
circulated throughout the body.199  These folates are taken into the cell by folate receptors or 
reduced folate carriers.200  Once in the cell, folylpolyglutamate synthase (FPGS) links multiple 
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glutamate residuals.  These polyglutamated folates cannot be transported out of the cell, so they 
accumulate in the cell to keep proper cellular folate levels.201  
One-carbon metabolism is involved in the biosynthesis of many important 
macromolecules such as proteins, lipids, and nucleic acids involved in cells proliferation.16 One-
carbon metabolism refers to the metabolic system that uses THF to donate or accept carbon units 
for cellular biosynthetic reactions and occurs in the cytoplasm, mitochondria and nucleus.202  
Figure 5 describes the one-carbon pathway in greater detail.  
Briefly, during one-carbon metabolism, three major reactions occur in the cytoplasm. 202 
1. 10-formyltetrahydrofolate is the one-carbon unit involved in the synthesis of the purine 
ring by phosphoribosylglycinamide formyltransferase (GART) and 5-aminoimidazole-4-
carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase (ATIC).  
2. Thymidylate synthetase (TYMS) uses 5,10-methylene tetrahydrofolate as the one-carbon 
unit for the conversion of deoxyuridine monophosphate (dUMP) to deoxythymidine 
monophosphate (dTMP).  
3. 5-methyltetrahydrofolate is used in for the remethylation of homocysteine to methionine 
by 5-methyltetrahydrofolate-homocysteine methyltransferase (MTR) and 5-
methyltetrahydrofolate-homocysteine methyltransferase reductase (MTRR).   
Methionine can be converted to S-adenosylmethionine (AdoMet) by methionine 
adenosyltransferase, encoded by and MAT1A and MAT2B, which serves as a cofactor for 
methylation reactions.  The primary role of mitochondrial one-carbon metabolism is to generate 
serine and formate for one-carbon metabolism in the cytoplasm or formylate MET-tRNA for 
mitochondrial protein synthesis.16,203  Small amounts of thymidylate synthesis occur in the 
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nucleus. About 10% cellular folate is present in the nucleus and both TYMS and serine 
hydroxymethyltransferase (SHMT) have been localized in the nucleus.204 
The regulation of cellular folate concentration is complex since it is influenced by uptake, 
polyglutamylation, export, and catabolism.  The folate receptor Folbp1 shows localized patterns 
of expression in the embryo and is highly expressed in the yolk sac, suggesting this receptor is 
important for maternal-to-fetal transport of folate.205  Additionally, mice that are null for Folbp1 
present with the same birth defects as mice with folate deficiencies.206,207 During pregnancy, the 
need for folate increases due to the growth of the fetus, the placenta, and maternal tissues as well 
as a requirement for more red blood cells due to uterine enlargement and expansion of blood 
volume.  Although there is an increased need for folate in the mother, newborns have higher red 
blood cell folate levels compared to maternal levels, 208,209 suggesting the importance of folate to 
fetal development. 
Folate transfer and polyglutamylation are critical to maintain a proper concentration of 
folate, and disruption of either leads to impaired folate accumulation. Folate monoglutamates can 
also be transferred to into mitochondria by a specific reduced folate carrier 210,211  and then 
converted to polyglutamated folates.212 Because of this transfer and conversion, folate 
concentrations in the cytoplasm are not in equilibrium with folate concentration in the 
mitochondria.191  
10-FormylTHF synthetase (FTHFS encoded by MTHFD1) and SHMT provide the 
primary entry point for one-carbon units into the network.  However, one-carbon units generated 
by FTHFS are preferentially utilized in homocysteine remethylation and purine synthesis, while 
SHMT one-carbons are preferentially directed to thymidylate biosynthesis.  When folate levels 
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are low, dUMP levels tend to accumulate, which leads to increased rates of uracil nucleotide 
incorporation into DNA and been associated with strand breaks and chromosomal instability.213  
Similarly, an insufficient rate of homocysteine remethylation results in an elevated plasma 
homocysteine, decrease in AdoMet and increase in S-adenosoylhomocysteine (AdoHcy).  This 
leads to a decreased cellular conversion of AdoMet to AdoHcy, which is crucial for cellular 
methylation and results in decreased levels of 5-methylcytosine, the methylated form of cytosine, 
in DNA.214,215 
Since folic acid is crucial for DNA synthesis, excess folic acid can exacerbate pre-
existing cancers. Excess folic acid has also been suggestively associated with the etiology of 
certain cancers.  In a randomized control trial in Norway, folic acid treatments in patients with 
ischemic heart disease was reported to increase the risk of cancer.216 Experimental data suggest 
that folic acid may stimulate growth in pre-existing cancerous lesions.217  There is likely a U-
shaped curve in which both low and high levels of folic acid are important to the risk of birth 
defects and childhood cancer. 
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Figure 5. Folate metabolism and one-carbon pathway within a cell 
 
THF: Tetrahydrofolate; AdoMet: S-Adenosyl methionine; AdoHcy: S-Adenosylhomocysteine ; dTMP: Thymidine monophosphate; dUMP: deoxyuridine 
monophosphate 
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1.5.2.2 Epidemiologic literature 
Because of the association of folate with neural tube defects, variants within the one-
carbon pathway have been highly studied with respect to birth defects and childhood cancer.  
Variants within genes involved in the one-carbon pathway have been associated with both adult 
and childhood cancers as well as certain birth defects.  
MTHFR 
The most studied gene within the one-carbon metabolism pathway is 
methylenetetrahydrofolate reductase (MTHFR), which has two common exonic variants, C677T 
and A1298C. MTHFR regulation is critical for AdoMet dependent reactions and regulation of 
homocysteine levels in the cell.  The MTHFR reaction is not reversible and commits one-carbon 
units to methionine biosynthesis.218  Studies have shown the low MTHFR activity may reduce 
DNA methylation,215 but may enhance synthesis of thymidylate.219  
One exonic C677T SNP (rsid: rs1801133) is one of the most common SNPs associated 
with MTHFR deficiency affecting 5 to 20% of North Americans.220,221 This SNP has been 
associated with increased plasma homocysteine and decreased plasma and red blood cell folate 
levels, especially in those with low folate levels.222-225  Another exonic variant A1298C (rsid: 
rs1801131) has also been associated with decreased enzymatic activity of MTHFR but to a lower 
extent than the C667T variant.226 Individuals with this polymorphism exhibit increased red blood 
cell folate levels and homocysteine levels. 
MTHFR variants has been studied in relation to birth defects and childhood cancers, 
including neuroblastoma.  The relationship between variants in MTHFR and neuroblastoma was 
previously described.  A meta-analysis found that the C677T variant is positively associated with 
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neural tube defects.  Although there is evidence of between-study heterogeneity, all the studies 
have a positive trend. One study did not find an independent association with the MTHFR 
A1298C variant with neural tube defects.227  One meta-analysis of cleft lip/palate found a 
positive association with maternal C677T, a suggestive association with infant C677T and null 
associations with A1298C.228  Another meta-analysis found a positive association with infant 
C677T and cleft lip/palate in Asian populations,229 which was replicated with a newer meta-
analysis which found both a maternal and child associations with C677T.230 Additionally, this 
variant has been associated with increased risk of embryonal central nervous system tumors 
based on a small study of Thai children.231 
Meta-analyses have found the C677T variant to be associated with decreased risk of 
pediatric acute lymphoblastic leukemia, but results were null for the A1298C variant.232,233  In 
addition to childhood cancers and birth defects, MTHFR variants have been associated with adult 
cancers. Although meta-analyses of adult cancers have been largely inconsistent, associations 
have been found with colon cancer234-236 and ovarian cancer237 among Caucasians, and primary 
brain tumors 238 among Asians with MTHFR C677T.  One meta-analysis pooled all cancer 
studies together and found that MTHFR C677T was positively associated with cancer in the 
aggregate, especially in esophageal and stomach cancer and among Asians. 239 
Other Genes in one-carbon metabolism  
Many other genes within the one-carbon pathway have been associated with blood folate 
and homocysteine levels.  One exonic SNP in reduced folate carrier 1 encoded by gene 
SLC19A1, G80A (rsid: rs1051266), has been associated with decreased levels of intracellular 
folate through decreased efficiency of cellular uptake, but with no impact on homocysteine 
levels, especially in women.240,241 Folate hydrolase 1 (FOLH1) C1561T (rsid: rs61886492) and 
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serine hydroxymethyltransferase 1 (SHMT1) C1420T genotype (rsid: rs1979277) have been 
associated with increased folate levels, but not with homocysteine levels. 222,242 243 Decreased 
homocysteine levels 244-246 and increased plasma folate levels have been associated with MTR 
A2756G (Rsid: rs1805087).247  A 19-bp deletion in DHFR have been associated with decreased 
homocysteine levels.248 These studies show that individual folate and homocysteine levels are 
highly dependent on genes within the one-carbon pathway. 
Since these genes can alter folate stores, they have also been associated with many birth 
defects.  Two meta-analyses found a null, but suggestive positive association with neural tube 
defects and SLC19A1 G80A, but the individual contributing studies were small and might be 
underpowered to detect small effects.227,249   The meta-analysis performed by Zhang et al. did not 
find an association between neural tube defects and MTR A2756G or MTRR A66G. 227  Further 
studies have implicated SNPs within cystathionine-β-synthase (CBS),250 MTHFD1,251 
methylenetetrahydrofolate dehydrogenase 2, methenyltetrahydrofolate cyclohydrolase 
(MTHFD2),250 SHMT1, 250,252 methylenetetrahydrofolate dehydrogenase 1-like (MTHFD1L) 253 
and TYMS 250 with neural tube defects. 
Only a few studies investigated these variants in relation to childhood cancer.  The 
neuroblastoma study was detailed previously. One study found that SLC19A1 G80A was 
negatively associated with pediatric acute lymphoblastic leukemia in Brazilian children254 and 
another found a positive association in Eastern European children.255  Using a Bayesian 
approach, another study found an association between SNPs in MTRR and MTHFD1 and acute 
lymphoblastic leukemia.256   
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The inconsistencies in results within these genes could be due to modification of genetic 
effects by folate levels. Some studies suggest that variants within the one-carbon pathway tend to 
have stronger effects among those with lower maternal folate intake.  One study found that 
variants within MTHFD1, MTHFR, SHMT1, and TYMS were associated with neural tube defects, 
but only among children whose mothers had low folate levels.252  Variants within MTHFR and 
TYMS have also been associated with conotruncal heart defects, but only among women in the 
lowest quartile of folate intake. 257,258  
In addition to the offspring genotype, the mother’s genotype could also play a role in 
disease risk through the maternal metabolism of folate.  A maternal C699T variant in CBS has 
been associated with cleft lip/palate independent of folate status.259 One study found a positive 
association of unilateral retinoblastoma in the offspring and a maternal 19bp deletion in DHFR, 
even after adjustment of the offspring genotype.  Interestingly, this effect is stronger among 
mothers who look folic acid in their first trimester.260  Children born to mothers with variants in 
MTR pre-fortification are more likely to have acute lymphoblastic leukemia than children born 
post-fortification.261   
Adult cancers have also been associated with genes within the one-carbon pathway. A 
meta-analysis found weak but significantly positive associations between MTR A2756G and 
SHMT1 C1420T and prostate cancer.262  An inverse association for a variant in MTR A2756G 
was seen with breast cancer in Caucasians, but not East Asians in two meta-analyses, while one 
meta-analysis found a null association.263-265  Central nervous system cancers such as 
meningioma has been inversely associated with MTRR A66G (rsid: rs1801394) in a case control 
study with 631 meningioma cases, and 1,101 controls from the United Kingdom.266  SLC19A1 
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G80A has been associated with many adults cancers including colorectal cancer,267,268 and 
gastroesophageal cancer.269 
1.5.3 Choline 
1.5.3.1 Biologic literature 
Choline is an essential nutrient for normal function of all cells and is critical during fetal 
development when it influences cell proliferation and apoptosis.270 Although it can be 
synthesized de novo by phosphatidylethanolamine N-methyltransferase (PEMT), choline also 
must be consumed through the diet for normal biologic functions.271 Choline is found in both 
free and esterified form in many foods. However, the foods with the highest choline levels 
include liver, eggs, and wheat germ.272 Choline deficiency in adults can lead to liver and muscle 
damage.273 
Choline is closely related to the one-carbon-pathway through a metabolite, betaine. Thus, 
choline is also necessary for neural tube closure. In mice, inhibition of choline leads to defects in 
the neural tube and face.274  In humans, women in the lowest quartile for dietary choline, betaine, 
and methionine intake had almost six times the risk of having a baby with a neural tube defect 
compared to those in the highest quartile of intake.275  Similar to phenotypes seen with folate 
deficiency, in mice choline deficiency leads to decreased stem cell proliferation and apoptosis in 
the brain.276 
Pre-menopausal women tend to have fewer complications from a low choline diet than 
males and postmenopausal women.277  This is due to their enhanced capacity for de novo choline 
synthesis to maintain choline stores during times of high demand for choline, such as pregnancy 
and lactation, 278 when cholines stores tend to be depleted.279 Additionally, Pemt−/− mice abort 
pregnancies at around 9−10 days gestation unless fed supplemental choline.280  
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Choline is a major source of methyl groups since betaine participates in the methylation 
of homocysteine to methionine, as seen in Figure 6.281  Choline dehydrogenase, encoded by 
CHDH, catalyzes the oxidization of choline into betaine aldehyde and then to betaine within the 
mitochondria primarily in the liver and kidney.280  In addition to MTR, betaine homocysteine 
methyltransferase (BHMT) can also convert homocysteine to methionine by using betaine as 
methyl donor.282 MTR is present in all tissues, while BHMT is mainly present in the liver.283 
Choline is also used for the synthesis of the most abundant membrane phospholipid, 
phosphatidylcholine.284 There are two pathways for this conversion. In one, choline is 
phosphorylated by choline kinase A or choline kinase B and then converted to cytidine 
diphosphocholine (CDP-choline) by phosphate cytidylyltransferase 1. CDP-choline is catalyzed 
by choline phosphotransferase (CHPT1) to form phosphatidylcholine and cytidine 
monophosphate.  In the other pathway, phosphatidylethanolamine is sequentially methylated to 
form phosphatidylcholine by phosphatidylethanolamine N-methyltransferase, using AdoMet as 
the methyl donor.280 
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Figure 6. Choline metabolism and relationship with one-carbon pathway 
 
AdoMet: S-Adenosyl methionine; AdoHcy: S-Adenosylhomocysteine
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1.5.3.2 Epidemiologic literature 
Dietary choline requirements for premenopausal women differ from postmenopausal 
women and men.280 Premenopausal women who were carriers of MTHFD1 G1958A (rsid: 
rs2236225) were 15 times as likely as non-carriers to develop signs of choline deficiency when 
on a low-choline diet.285  Since PEMT is involved with choline synthesis, one SNP in PEMT 
G939C (rsid: rs12325817) was associated with choline deficiency in women.286   A SNP within 
CHDH, rs12676, was positively associated with choline deficiency. CHDH A119C (rsid: rs9001) 
was inversely associated with choline deficiency286 and homocysteine in an Indian population.287 
Since one-carbon metabolism and choline are intertwined, SNPs within choline genes 
have also been associated with neural tube defects. One study found that one SNP within choline 
kinase A (CHKA), rs7928739, was associated with decreased risk of spina bifida, while rs939883 
in phosphate cytidylyltransferase 1, choline (PCYT1A) was positively associated.  This same 
study did not find effect modification with maternal periconceptional choline intake.288  Two 
exonic variants, rs897453 and rs7946, within PEMT have been shown to have a joint inverse 
association.289 A variant within BHMT has been positively associated with neural tube defects.250 
Another study found that BHMT was significantly associated with neural tube defects when 
mothers were receiving pre-conception folic acid supplementation.290    
Gene-gene interactions with folate-related genes were found between MTHFR 
(rs1801133), MTR (rs1805087), and PEMT (rs4646406) and non-syndromic isolated cleft lip 
with or without cleft palate.291  Maternal gene-gene interactions have been found with BHMT2 
(rs673752), PEMT (rs12325817), and PCYT1A (rs712012) with non-syndromic isolated cleft lip 
with or without cleft palate susceptibility.292 
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Adult cancers have been associated with variants within these pathways as well. PEMT 
G774GC (rsid: rs12325817) and CHDH G432T (rsid: rs12676) were found to be associated with 
increased breast cancer risk in the Long Island Breast Cancer Study Project.  The same study 
found a significant interaction between dietary betaine intake and the PEMT rs7926 
polymorphism, where women with the variant allele with low betaine intake have 2 times the 
risk of breast cancer as women with high betaine intake and wildtype alleles.293 Colorectal 
cancer in individuals with ulcerative colitis has been associated with variants within solute 
carrier family 22 (SLC22A4), a choline membrane protein. 294 Colorectal cancer has been 
associated with variants in SLC22A3 (solute carrier family 22, member 3) and phospholipase D2 
(PLD2) in Korean and Japanese populations respectively. 295,296  A case-control GWA study 
identified rs9364554 in SLC22A3 to be positively associated with prostate cancer.297 
1.5.4 Summary of Literature on Vitamin A, Folate and Choline Pathways 
Although an association between maternal intake of specific vitamins and neuroblastoma 
has never been studied, low levels of vitamin A, choline and folate have been associated with 
adverse birth outcomes including neural tube defects and some other forms of childhood cancer.  
These vitamins are important to the differentiation and development of cells within a developing 
fetus.  Disruption of transport and metabolism of these vitamins can lead to poor birth outcomes 
similar to those with vitamin deficiency. Common variants in genes within these vitamin 
pathways have also been a consistently associated with both adult and childhood cancers and 
birth defects, including those that arise from the neural crest.  Additionally variants within genes 
have been shown to affect uptake and levels of these vitamins and their metabolites within the 
body. With evidence from diseases that are similar to neuroblastoma, it is plausible that these 
vitamins affect the risk of neuroblastoma.  
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1.6 Summary of Literature Review 
Neuroblastoma accounts for 28% of malignancy in infants under one year of age.4  Each 
year approximately 1,500 cases in Europe and 700 cases in the United States (U.S.) are 
diagnosed.2,46 Neuroblastoma has not shown the dramatic improvement in survival that has been 
seen with some other childhood cancers.50 The five-year survival rate for all neuroblastoma is 
69%, but the five-year survival for high-risk neuroblastoma is 20%.1,50 Treatment for 
neuroblastoma can lead to lasting effects in the survivors, such as growth and developmental 
delays and loss of function in organs affected by the cancer.51-53 The 20-year incidence of 
chronic health conditions in survivors of neuroblastoma is 41%.2  
Currently there are no clear risk factors for neuroblastoma. Conflicting results have been 
reported for risk factors such as maternal or paternal smoking,103,104,135,221 maternal medication 
use,11,120 or maternal or paternal age.122,125,131 Maternal vitamin intake 10,11 shows a suggestive 
inverse association.  Genetic variants within vitamin-related genes could be associated with risk 
and interact with vitamin exposures to modify risk, as seen in other embryonic diseases.  
Additionally, low levels of vitamin A, folate and choline have been associated with cancer and 
birth defects, including some that originate from the same embryonic cells as neuroblastoma. 
There is evidence for a genetic basis for neuroblastoma. Highly penetrant variants within 
the anaplastic lymphoma receptor tyrosine kinase (ALK) gene have been determined to be causal 
for family-based neuroblastoma, which occurs in about 1% of cases. 77 Additionally, genome-
wide association (GWA) studies and sequencing studies have identified common and rare 
variants associated with neuroblastoma.6,79,81  
Current GWA studies derive from the Children’s Oncology Group (COG), a national 
clinical trials group that enrolls children with cancer from U.S. hospitals, but the controls were 
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recruited from the children’s hospital located in Philadelphia.6,79,81 Since neuroblastoma is rare 
disease, the cases are very geographically dispersed. This lack of geographically dispersed 
controls could introduce bias into the study due to geographic differences in allele frequencies.  
However, since these studies were restricted to European Americans, population stratification 
was likely not a factor.298 Since there are many loci that are being tested with no a priori 
hypothesis, the p-values were Bonferroni corrected, which is conservative.299 Although GWA 
studies are currently the standard within genetic epidemiologic studies, with rare diseases there is 
a need to conduct studies that are not dependent on controls and methodology to gain power 
without recruiting more people, such as the case-parent triad design.  
Candidate pathways enable the researcher to focus on genes with a strong prior evidence 
and gain efficiency by selecting single nucleotide polymorphisms (SNPs) within haplotype 
groups300 which allows for a targeted approach using densely measured genetic variation. Since 
neuroblastoma arises from the neural crest, primitive sympathetic neural precursor cells,301 
maternal vitamin A, choline and folate status and vitamin pathways can greatly  influence neural 
differentiation and development.  Animal studies have shown that dysregulation of these 
pathways can lead to birth defects, and epidemiologic studies have shown that genetic variants 
are associated with cancers and birth defects.  These pathway-defined genes thus offer strong 
prior plausibility for a role in the etiology of neuroblastoma. 
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CHAPTER 2. AIMS AND METHODS 
2.1 Study population 
2.1.1 COG and CCRN 
The Children’s Oncology Group (COG) has about 200 member institutions in the United 
States and Canada that treat many cases of childhood cancers diagnosed in children less than 15 
years of age. A study considering data from 1992 to 1997 estimated 71% of cancer cases 
younger than 15 years of age in the US or Canada were seen at a COG institution.302  
The Childhood Cancer Research Network (CCRN) was created by COG to create a 
network that facilitated future research. The COG constitution requires that institutions register 
all cases diagnosed in the hospital with the case birth date, type and characteristics of the cancer, 
date of diagnosis, gender, race and residential zip code regardless if the patient is being treated 
on an active COG protocol.  The parents are asked to consent to collection of personal identifiers 
and permission to be contacted for future non-therapeutic studies.  If the parents do not consent 
to the collection of personal identifiers, the case is registered with a unique identifier and only 
the default information.  If the parents do consent to the collection of personal identifiers, but do 
not to future contact for studies, they are registered in the CCRN with patient’s and parent’s 
names and address and a flag for no future contact.  If the parents do consent to all levels, then 
the case is registered with personal identifiers and a flag for future contact. 
In a pilot study, among those who have registered for CCRN, 93% gave permission to be 
contacted for future non-therapeutic studies.  Only 1% refused collection of personal identifiers
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and denied permission to be contacted for future non-therapeutic studies.303 Although COG 
hospitals may not see all the cases and may disproportionately see cases based on race and 
location,304 the CCRN is currently the only mechanism for assembling a large number of cases 
and obtaining DNA from cases that have died.  The use of a case-parents design also protects 
from bias due to self-selection and guarantees internal validity because in effect the non-
transmitted parental alleles are serving as controls that are ideally well-matched to the case. 
2.1.2 Neuroblastoma Epidemiology in North America (NENA) 
The Neuroblastoma Epidemiology in North America (NENA) study is a case-parent triad 
of families with neuroblastoma. Cases were eligible if they had a primary diagnosis of 
neuroblastoma (including ganglioneuroblastoma, but excluding ganglioneuromas; International 
Classification of Childhood Cancer (ICCC): 9490, 9500) before the age of 6 years at a North 
America COG institution, located either in the U.S. or Canada, from December 24, 2007 to July 
31, 2013 and with the biologic mother alive and willing to participate. The case offspring did not 
have to be alive to be eligible. All eligible parent respondents understood either English or 
Spanish for the written questionnaire. Children over the age of 6 years were not recruited since 
NENA and this proposed study are interested in the etiology of early pediatric cancer and 
maternal exposures during pregnancy.   
2.1.3 Recruitment 
There are 3 phases to recruitment in NENA: institutional phase, phase I and phase II.  
2.1.3.1 Institutional phase 
Potential subjects were enrolled in the CCRN and agreed to be contacted for non-
therapeutic studies.  The contact information for these subjects and the treating institution and 
staff were released to the University of North Carolina at Chapel Hill (UNC) from 2007 to 2013. 
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In the institutional phase, NENA created a sub-registry of all potential subjects identified in the 
CCRN who met NENA criteria. 
As many families were still going through treatment during recruitment, the treating 
institution was contacted first.  This allowed NENA to learn the case status and better select a 
timeline for recruitment.  A passive-consent letter sent to the principle investigator (PI) of the 
hospital to inform then that a patient was eligible for NENA. The PI only needed to respond if 
they advised a delay or avoidance of recruitment.  
The institution’s Lead Clinical Research Associate (LCRA) was contacted and NENA 
requested feedback pertaining to the family’s readiness for recruitment. The LCRA Cover Letter 
explained the study and asked the LCRA to complete and return the Communication Guide using 
an enclosed prepaid Business Reply (US) or International Business Reply envelope (Canada) or 
to contact study staff by fax, email, or phone with their answer.  The Communication Guide 
listed the patient's CCRN ID, and provided a space for the LCRA to note if there was any reason 
to delay or cancel recruitment for a particular family.  Separate sections requested feedback for 
living and deceased cases.  If no response was received within three weeks from the date of the 
initial mailing, a reminder letter was mailed or emailed to the LCRA, followed by an email or a 
phone call two weeks after that reminder mailing. The first contact was initiated at least 8 weeks 
after diagnosis. Procedures for contacting the parent and consent forms were different based on 
the offspring case status. 
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2.1.3.2 Case Status 
These fall into three overarching recruitment categories (Alive, Deceased and Canadian).  
Canadian was separated out due to differences in mailing procedures due to customs. Within 
these categories, there are 8 types of cases that were enrolled in NENA. 
Alive Cases 
Unprocessed cases are families that contacted NENA prior to case recruitment. When 
this occurred, the staff checked their names and information about the diagnosing hospital 
against the registry.  If the case was eligible, the staff initiated the institutional phase.  The case 
was contacted again after the institutional phase had been completed.  
Biological mothers were the first point of contact, since it was critical for NENA to 
assess maternal exposures. During recruitment, the mother was asked to confirm her biological 
relationship to the case child. If a biological mother could not be identified for a case due to 
surrogacy, adoption or step-parenthood, the family became ineligible for the study. If the 
biological mother was identified and willing to participate, the biological father, or secondary 
father, was then recruited separately.   
Secondary fathers were recruited if the confirmed biological mother agreed that he would 
participate or if the study contacted the father separately.  
Primary fathers were contacted if the father but not the mother was listed in the CCRN.  
The staff verbally confirmed his biological relationship with the child. If the father allowed 
verbal or written identification of and contact with the biological mother, the study could then 
approach the biological mother of the case child.    
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Guardian only cases are situations in which neither mother or father is listed in the 
CCRN. In these, NENA contacted the guardian and asked for contact information for the 
biological mother. If the mother could not be identified, the family was deemed ineligible.  
Deceased Cases 
There are 3 types of deceased cases, each with a different recruitment protocol: known 
deceased, learned deceased, and recruited deceased.  Known deceased cases are those for whom 
the staff learned at the institutional stage that the case was deceased.  Learned deceased cases are 
those for whom communication was initiated but there had been no response when the staff 
learned the case was deceased.  Recruited deceased are cases from families that had already 
agreed to participate and study materials had already been mailed out when NENA staff learned 
the case was deceased.  
Canadian cases 
Canadian cases are separated out because there were customs requirements and 
postage/mailing needs and the families had to be made aware that incentive payments would 
come in the form of a check from a US bank.  Other than these, Canadian cases were recruited 
with the same guidelines as above. 
2.1.3.3 Phase I 
Once an optimal time for contact was determined, a Study Introduction Letter was sent 
informing the parents that the child’s treatment center participates for research purposes with 
COG and the CCRN and that more information will be coming in the mail.  Most families were 
recruited 2 to 6 months after diagnosis.  
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A recruitment packet was sent 10 days after the Study Introduction Letter with more 
comprehensive information about study procedures and including a response form to accept or 
decline the invitation to be in the study. If at least one parent was willing to participate, consent 
forms, saliva collection kits, questionnaires and return kits were sent.  If parents lived apart, the 
introductory letter and recruitment packet was first sent to the custodial parent.  When study 
materials were received, families were compensated $20 for participation in this study. 
A slightly different packet was sent to Canadian cases.  Canadian families received an 
additional document called the Canadian Recruitment Insert, which summarized three details 
which pertained only to Canadian-based participants: 1) the prepaid Business Reply envelope 
was a different color than the one described in the Interest/Deceased Interest letter; 2) return 
mailings in Canada for the questionnaire and saliva kits had to come from a post office due to 
customs regulations for those size packages; and 3) compensation for returned study materials 
from Canadian participants would be coming in the form of a check from a US bank account.  
If there was no response within a 21-day period, the NENA staff mailed a 1 page 
reminder about the study and invited the parent to visit the website.  The flyer also stated that if 
the NENA staff did not hear back in 3 weeks, a staff member would call and leave a message if 
no one answered. NENA staff attempted up to 4 phone calls. If there was no response within 30 
days of the reminder, the case was moved to Phase II and the staff did not attempt to contact the 
family for at least 6 months.  
2.1.3.4 Phase II 
If Phase I did not result in a response, before contacting families again, NENA staff 
conducted an in-depth search to assess optimal time to re-contact in case the child had passed 
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away or was still involved in treatment.  If a favorable time lapse could be established, then 
Phase II continued similar to Phase I. Only eligible mothers who did not respond during the first 
phase of recruitment were eligible for a second phase of recruitment after the waiting period.  
2.1.3.5 Recruitment for Deceased Cases 
For recruitment for deceased cases, language was altered to be sensitive to parents of a 
child who recently died. Deceased Study Introduction Letter and Deceased Interest Cover Letter 
were used. For such families, contact was delayed to 15 months from the date of death.  
Deceased cases were not followed up in Phase II.  
When NENA learned that that a child had died during the process of recruitment, the 
Learned Decease protocol replaced the current protocol. A Condolence Letter was sent 
expressing sympathy for their loss and respecting their need to grieve.  The letter also let the 
parents know that the study staff would be contacting them at a later date.  Although no response 
was required of the parent, if the parent contacted the study office with a participation decision, 
NENA communicated with the parent or utilized the Deceased Study Introduction Letter and 
Deceased Interest Cover Letter. 
If the child had died during the data collection, the families were sent a Deceased Follow-
Up letter, Response Form and a prepaid Business Reply or International Business Reply 
Envelope once 15 months had passed from the child’s date of death. The letter reiterated what 
participation in the study involved. The parents were asked to complete a Response Form, which 
requested a decision about continuing their study participation. If we did not receive a response 
from the parent within 30 days, the letter, the form, and either a prepaid Business Reply (US) or 
International Business Reply Envelope (Canada) was resent. If there was no response from the 
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parent after the mailings, the study stopped all attempts at contact and determined that 
participation for that family had ended. 
2.1.4 Study population  
From 2007 to 2013, the diagnosing institution was contacted for 1,642 cases from the 
CCRN.  Figure 7 is a flow chart of the data collection for NENA. Feedback from institutions was 
received from 1,564 of the cases and 1,379 cases had institutional approval for contact.  After 
contact, 930 cases were determined to be eligible for the study and 870 case parents agreed to 
participate in the study.  There were 14 “learned” deceased or “recruited” deceased children and 
37 known “deceased” children. Overall, after consent, the response rate for the DNA sample was 
72%, 71%, and 72% for mother, father and child respectively. The maternal questionnaire 
response rate was similar at 72%.  Table 5 outlines the number of parent-child triads and parent-
child dyads with and without DNA.   There were a total of 647 case families, including 626 with 
a completed questionnaire and 91 dyads and 497 triads with both DNA and a completed 
questionnaire.  
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Figure 7. Flowchart of NENA recruitment 
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Table 5. Number of returned materials 
Child Specimen Mother Specimen Questionnaire Father Specimen Number 
Yes Yes Yes Yes 497 
Yes Yes Yes No 91 
Yes Yes No Yes 8 
Yes Yes No No 6 
Yes No No Yes 1 
No Yes Yes Yes 13 
No Yes Yes No 8 
No Yes No Yes 1 
No No Yes Yes 1 
No No Yes No 16 
No No No Yes 3 
   Total 647 
2.2 Measurements 
2.2.1 Clinical and Biologic outcomes 
Patient clinical and biologic characteristics of the tumor were obtained from COG, 
including risk-classifications. (Please see 1.2.4 Neuroblastoma Risk-Classifications) for those 
patients who were enrolled in a COG protocol.  
2.2.2 Environmental Exposures 
Exposure data was assessed with a mailed paper questionnaire to be completed by the 
biologic mother. The questionnaire was pretested and contained modules from validated 
instruments and previous COG surveys.  Each questionnaire also included tailored date reference 
sheet that included an approximate date of conception and date of each trimester as well as the 
offspring birth date to guide accurate recall of exposures. 
2.2.2.1 Maternal Dietary Questionnaire 
The main focus of the questionnaire was maternal diet during pregnancy. The current 
maternal usual diet was first assessed.  Then information about changes in diet that may have 
taken place during pregnancy was elicited.  Maternal usual diet was estimated through a self-
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administered semi-quantified food frequency questionnaire (FFQ) called the Dietary History 
Questionnaire that consists of 124 food items and portion size questions developed by Risk 
Factor Monitoring and Methods Branch (RFMMB) of the National Cancer Institute. Replication 
studies demonstrated that the DHQ provides reasonably valid estimates of nutrient intake.305  
Paper questionnaires were scanned and created into an ASCII text file, which was then processed 
in Diet*Calc (version 1.5.0). The nutrient and food group database is based on a compilation of 
national 24-hour dietary recall data from the National Health and Nutrition Examination Surveys 
(NHANES) conducted in 2001-02, 2003-04, and 2005-06 
(http://riskfactor.cancer.gov/dhq2/database/).  Certain foods not included in the original database 
were added by NENA staff in 100 gram amounts using the USDA database, standard release 24 
such as papayas and bulgur. 
The original database contained information for vitamin A and folate, but not choline. 
Choline values common in food were included based on the USDA database.  Additionally, there 
were foods that were not included in the original database and were included for 100 gram 
amounts using the USDA database.  
The relevant time for assessing diet for this study would be before and during neural crest 
migration and differentiation which occurs about 5 weeks after conception.  However, the 
questionnaire asked about usual maternal diet in the last year.  Two previous studies examined 
changes in a woman’s dietary patterns from preconception through postpartum.  One study found 
no major changes in diet due to pregnancy.306  The other study found that women tended to 
increase their consumption of fruits and vegetables during pregnancy and in the 2 years 
postpartum.  However, milk consumption increased during pregnancy, but the increase did not 
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continue postpartum.307  Other studies have suggested that it is important to query specifically 
about foods that may be subject to aversions during pregnancy such as alcohol and caffeine.308   
To gather information about changes in diet during pregnancy, specific foods prone to 
change were targeted such as dairy, citrus, juices, fruit, meat, coffee, diet soda and alcohol 
drinks.309  The mothers were asked if during pregnancy intake was “Much less than it is now”, 
“Somewhat less than it is now”,  “Same as it is now”,  “Somewhat more than it is now”, and 
“Much more than it is now”. This information determined whether the mother’s consumption of 
certain foods that are prone to change during pregnancy were different during pregnancy with the 
case child than her current consumption.   
2.2.2.2 Maternal Prenatal Vitamin Supplementation 
The questionnaire also asked about maternal vitamin and mineral supplements as well as 
dietary supplements during pregnancy.  The mother was asked whether she took prenatal 
vitamins or multivitamins 1 month before conception and separately in the 1st trimester, 2nd 
trimester or 3rd trimester.  If the mother said she did, she was then asked if she took prenatal 
vitamins, multivitamins or both and on average if the vitamins were taken daily, 4-6 times a 
week, or 3 times a week or less. Mothers were also asked if they could recall the name and the 
manufacturer of the vitamin, including ones prescribed by the doctor.  In addition to 
multivitamins, single vitamins were also queried, but for the duration of the whole pregnancy.  
2.2.2.3 Nutrients 
From the FFQ in the NENA questionnaire, the Diet*Calc program calculated the usual 
nutrient intake.  To assure the best quality data, the individuals below 5th percentile and above 
the 97th percentile of calories per day (below 854.47 and above 4508.75 calories per day) were 
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excluded.  There were 31 mothers who reported a usual daily caloric intake less than 854.47 and 
18 mothers with intake greater than 4508.75 calories per day.  The nutrients of interest include 
total choline, total folate measured in µg dietary folate equivalence (DFE), folic acid, and 
vitamin A measured in µg  retinol activity equivalent (RAE).  DFE takes into account that folic 
acid has higher bioavailability than food folates.  Similarly, RAE for vitamin A accounts for the 
differing bioactivities of retinol and provitamin A carotenoids.   
Almost all of the women took either prenatal vitamins or multivitamins at some point in 
their pregnancy (Table 6), and by the end of the first trimester over 85% of women were taking 
vitamins.  We decided to focus on prenatal or multivitamin supplementation pre-pregnancy, 
since it is the most relevant for the research question since the neural crest migrates early in 
pregnancy.71 Since about 50% of the women were not able to recall the specific vitamin they 
took, the formulations of the vitamins could not be determined.
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Table 6. Descriptive statistics of NENA. Continuous variables are represented as mean ± standard deviation and categorical variables 
are N (%) 
  COG Risk-Group  Age Group 
 
 
All 
(N = 626) 
Low-Risk 
(N = 175) 
Intermediate-Risk 
(N = 142) 
High-Risk 
(N = 198) 
Missing 
(N = 111)  
< 1 year 
(N = 260) 
≥1 year 
(N = 366) 
Age (weeks) 87.5±74.37 75±74.49 44.5±40.07 132.8±62.29 84.5±85.36  20.5±15.14 135.6±61.91 
Maternal Age (Years) 29.7±5.31 29.4±5.13 29.6±5.32 29.9±5.32 30±5.58  29.7±4.8 29.8±5.65 
         
Vital Statistics         
     Deceased 38 (6.1%) 1 (0.6%) 3 (2.1%) 32 (16.1%) 2 (1.8%)  7 (2.7%) 31 (8.5%) 
     Alive 585 (93.5%) 174 (99.4%) 139 (97.9%) 164 (82.4%) 108 (97.3%)  253 (97.3%) 332 (90.7%) 
     Unknown 3 (0.5%) 0 (0.0%) 0 (0.0%) 3 (1.5%) 1 (0.9%)  0 (0.0%) 3 (0.8%) 
Gender         
     Male 341 (54.5%) 87 (49.7%) 72 (50.7%) 110 (77.5%) 72 (64.9%)  147 (56.5%) 194 (53.0%) 
     Female 285 (45.5%) 88 (50.3%) 70 (49.3%) 88 (62.0%) 39 (35.1%)  113 (43.5%) 172 (47.0%) 
Race         
     White 532 (85%) 141 (80.6%) 118 (83.1%) 175 (88.4%) 98 (88.3%)  217 (83.5%) 315 (86.1%) 
     Black 24 (3.8%) 12 (6.9%) 3 (2.1%) 6 (3.0%) 3 (2.7%)  9 (3.5%) 15 (4.1%) 
     Hispanic 36 (5.8%) 13 (7.4%) 10 (7.0%) 7 (3.5%) 6 (5.4%)  20 (7.7%) 16 (4.4%) 
     Other 34 (5.4%) 9 (5.1%) 11 (7.7%) 10 (5.1%) 4 (3.6%)  14 (5.4%) 20 (5.5%) 
Pregnancy Vitamin Use         
     1 month before pregnancy         
          No 247 (40.6%) 71 (41.8%) 56 (40.3%) 79 (40.9%) 41 (38.7%)  105 (41.3%) 142 (40.1%) 
          Yes 361 (59.4%) 99 (58.2%) 83 (59.7%) 114 (59.1%) 65 (61.3%)  149 (58.7%) 212 (59.9%) 
          Missing 18 5 3 5 5  6 12 
     1st trimester         
          No 54 (8.7%) 11 (6.3%) 12 (8.5%) 22 (11.2%) 9 (8.2%)  22 (8.5%) 32 (8.8%) 
          Yes 569 (91.3%) 163 (93.7%) 130 (91.5%) 175 (88.8%) 101 (91.8%)  237 (91.5%) 332 (91.2%) 
          Missing 3 1 0 1 1  1 2 
     2nd trimester         
          No 85 (13.7%) 19 (10.9%) 17 (12.0%) 37 (19.0%) 12 (10.9%)  34 (13.1%) 51 (14.1%) 
          Yes 536 (86.3%) 155 (89.1%) 125 (88.0%) 158 (81.0%) 98 (89.1%)  225 (86.9%) 311 (85.9%) 
          Missing 5 1 0 3 1  1 4 
     3rd trimester         
          No 96 (15.5%) 23 (13.3%) 21 (14.8%) 39 (20.0%) 13 (11.8%)  37 (14.3%) 59 (16.3%) 
          Yes 524 (84.5%) 150 (86.7%) 121 (85.2%) 156 (80.0%) 97 (88.2%)  222 (85.7%) 302 (83.7%) 
          Missing 6 2 0 3 1  1 5 
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2.2.2.4 Maternal Questionnaire 
The questionnaire also collected basic information on maternal demographics, birth 
characteristics, and other risk factors such as fertility treatment, medications during pregnancy, 
pregnancy characteristics and family history of cancer.  
2.2.3 Genetic Exposure 
2.2.3.1 DNA collection and extraction 
DNA was collected from the child, if still alive, and biologic mother and father. Oragene 
saliva collection kits were sent to the mother after the consent form was received. Adult kits 
included a small bottle of mouthwash, a pre-labeled specimen cup, a plastic bag, instructions, 
and a mailer with return postage. For the child, a cytobrush kit was included. For deceased cases, 
with parental consent, stored biologic samples were requested from the COG Neuroblastoma 
Biology Protocol, which banks serum, pretreatment whole blood, and paraffin-embedded or 
fresh-frozen tumor tissue. 
DNA extraction and amplification was completed by the UNC Biospecimens Processing 
Facility. The DNA from the cytobrush and the mouthwash kit was extracted with a magnetic-
bead capture method on the MSMI robotic system (PerkinElmer). All samples extracted were 
quantitated with Applied Biosystems® TaqMan® RNase P Detection kit for cytobrushes kits and 
the Quant-iT™ PicoGreen® dsDNA Assay Kit from Molecular Probes by Life Technologies for 
mouthwash kits.  For genotyping, any DNA concentration below 35 ng/ µL was concentrated 
using the Zymo Research: gDNA Clean & Concentrator Kit. After this concentration, the sample 
was re-quantitated using the TaqMan® RNase P Detection kit. 
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2.2.3.2 Genotyping 
Genotyping was performed on 1,536 single nucleotide polymorphisms by UNC’s 
Mammalian Genotyping Core Facility on the GoldenGate Assay using the Illumina BeadStation 
500GX Genetic Analysis System.310 Allelic discrimination was based on allele-specific primer 
extension followed by ligation. GoldenGate also included sample-dependent, sample-
independent and contamination checks to ensure high quality including checks of allele-specific 
extension, gender, first hybridization, PCR uniformity, extension gap, and second hybridization.  
2.2.3.3 Candidate genes 
Candidate genes (  
) were selected from the vitamin A, choline and folate transport and metabolism as 
described in 1.5 Literature on Vitamin Pathways. Genes were selected based on evidence in the 
literature that they were related to the transport and metabolism of vitamin A, folate or choline. 
Genes with prior evidence for biologic or epidemiologic relationship with birth defects and 
cancer were given priority.  Additionally, a few vitamin A target genes that are related to 
neuroblastoma were also selected.  
Haplotype tagging SNPs with a minor allele frequency greater than 5% were selected 
20kb upstream to 10kb downstream from the candidate gene. Genotyping error rates are higher 
at lower frequencies and the power to detect effects is drastically reduced.311 Since NENA is 
predominately European American, TAGster312 with the greedy algorithm was used to capture 
haplotype tagging SNPs (minor allele frequency ≥ 5%) that tag SNPs in high linkage 
disequilibrium (LD; r2≥0.8) in Hapmap 3 release III CEU population.  Additional candidate 
SNPs were chosen based on consistent epidemiologic literature suggesting an association with 
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birth defects or cancer.  Since the case-parent triad design is not subject to confounding by 
population stratification, ancestry informative markers were not included.  A total of 94 genes 
were selected and 1,536 SNPs were genotyped (  
). 
To assist in quality control, control samples were included within each plate of sample. A 
Centre de l'Étude du Polymorphisme (CEPH) family trio and duplicates were included on each 
plate to identify apparent violations of Mendelian inheritance and assess genotyping consistency. 
Poorly genotyped SNPs were identified based on poorly defined clusters in the intensity data, 
poor genotyping success rates, and Mendelian or genotyping inconsistencies. SNPs that failed 
genotyping quality control were excluded from analysis.   
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Table 7. Candidate gene list 
 Gene 
Number 
TagSNPs 
Number 
Candidate SNPs Total 
Vitamin A ADH1A 8 0 8 
 ADH4 1 0 1 
 ADH7 23 0 23 
 ALDH1A1 18 0 18 
 ALDH1A2 14 0 14 
 ALDH1A3 8 0 8 
 ALDH8A1 8 0 8 
 BCMO1 22 0 22 
 BCO2 13 0 13 
 CEL 6 0 6 
 CES1 6 0 6 
 CRABP1 8 0 8 
 CRABP2 12 0 12 
 CYP26A1/CYP26C1 1 0 1 
 CYP26B1 13 0 13 
 DGAT1 1 0 1 
 ISX 26 0 26 
 LRAT 7 0 7 
 PNLIP 4 0 4 
 RARA 6 0 6 
 RARB 11 0 11 
 RARG 12 0 12 
 RBP1 12 0 12 
 RBP2 6 0 6 
 RBP3 13 0 13 
 RBP4 15 0 15 
 RDH1 11 0 11 
 RDH5 1 0 1 
 RXRA 24 0 24 
 RXRB 9 0 9 
 RXRG 36 0 36 
 STRA6 14 0 14 
 TTR 3 0 3 
Folate/Choline AHCY 2 0 2 
 ALDH1L1 4 0 4 
 AMT 3 0 3 
 ATIC 11 0 11 
 BHMT 7 5 12 
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 Gene 
Number 
TagSNPs 
Number 
Candidate SNPs Total 
 BHMT2/DMGDH 25 0 25 
 CBS 19 6 25 
 CEPT1 15 0 15 
 CHDH 14 0 14 
 CHKA 1 0 1 
 CHKB 11 0 11 
 CHPT1 13 0 13 
 CTH 14 0 14 
 DHFR 5 7 12 
 DNMT1 6 0 6 
 DNMT3A 22 0 22 
 DNMT3B 16 0 16 
 FOLH1 8 0 8 
 FOLR1 2 1 3 
 FOLR2 3 2 5 
 FOLR3 9 0 9 
 FPGS 3 0 3 
 FTCD 24 0 24 
 GART 7 0 7 
 MAT1A 22 0 22 
 MAT2A 5 0 5 
 MAT2B 1 0 1 
 MTHFD1 17 7 24 
 MTHFD1L 15 0 15 
 MTHFD2 4 3 7 
 MTHFD2L 12 0 12 
 MTHFR 11 8 19 
 MTHFS 24 0 24 
 MTR 5 21 26 
 MTRR 18 8 26 
 NOS3 14 0 14 
 PCYT1A 21 0 21 
 PEMT 17 1 18 
 PLD1 14 0 14 
 PLD2 12 0 12 
 SARDH 43 0 43 
 SHMT1 7 1 8 
 SHMT2 7 0 7 
 SLC19A1 1 8 9 
 SLC22A2 22 0 22 
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 Gene 
Number 
TagSNPs 
Number 
Candidate SNPs Total 
 SLC22A3 24 0 24 
 SLC22A4 16 0 16 
 SLC22A5 1 0 1 
 SLC44A1 11 0 11 
 SLC44A2 1 0 1 
 SLC44A3 45 0 45 
 SLC44A4 14 0 14 
 SLC44A5 42 0 42 
 SLC46A1 5 0 5 
 SLC5A7 19 0 19 
 TCN2 18 0 18 
 TYMS 19 4 23 
Other RET 19 0 19 
 ZNF423 33 0 33 
 
 
2.2.4 Covariates 
Figure 8 is a causal diagram (or directed acyclic graph) between maternal and offspring 
variants and neuroblastoma.313  Since there is not a factor that that temporally occurs before the 
maternal variant, with the exception of genetic ancestry, nothing is associated with the maternal 
SNP without being on the causal path.  Additionally, since the case-parent triad analyzes the 
transmission of alleles from the parents to the child without a control group, adjustments for 
covariates are not needed. 
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Figure 8. Causal diagram. Blue is the “environmental” variable and orange represents the 
exposure and outcome 
 
 
2.2.4.1 Genetic Ancestry 
Genetic ancestry can lead to spurious results through population stratification in case-
control studies. This results from differing allele frequencies and risks of disease across 
subpopulations (or ancestries) rather than due to causal associations with the disease.314  This 
bias is particularly a concern in recently admixed populations such as Hispanic Americans or 
African Americans, but can also be present in European Americans.315  However, this source of 
bias is inherently controlled for in a case-parent triad design since the analysis is conditional on 
parental genotypes (section 2.3.2 Offspring Genetic effect). However, for maternal genetic 
effects, if mating is selective with respect to the SNP and there could be bias because the father 
is serving as control for the mother. 
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2.2.4.2 Covariate description 
Table 6 describes the participants who have completed the questionnaire by risk-
classification and offspring age of diagnosis less than 1 year and greater than or equal to 1 year.  
Most mothers in this sample are European Americans, which is expected since neuroblastoma is 
most commonly diagnosed in European Americans.  Additionally, similar to what is seen in 
SEER, there are more male than female children diagnosed with neuroblastoma.  There are more 
deceased cases in the high-risk classification and cases greater than 1 year of age. 
2.3 Analysis 
There were three main analytic goals for the vitamin A, folate and choline genetic 
pathways.  1) Estimate the association of the offspring genotypes and the maternal genotypes 2) 
Analyze offspring genotypes and the maternal genotypes within strata defined by COG 
neuroblastoma risk-classification and offspring age at diagnosis 3) Determine if there is gene-
environment interaction between the maternal and offspring genetic variants and the maternal 
vitamin consumption  
2.3.1 Genotyping Quality Control 
SNPs that had a call rate less than 95% were excluded from analysis.  Individuals with 
gender discrepancies that could not be resolved (i.e. sample swap within family between mother, 
father and child) and had a genotyping rate less than 95% were also excluded.  After these 
exclusions, the CEPH trio results were compared to their known genotypes to assess genotyping 
accuracy. 
Initial data description consisted of the estimation of allele frequencies separately for the 
parents and the cases by racial/ethnic groups. Departures from Hardy-Weinberg equilibrium 
(HWE) were assessed for the European American race group with chi-square tests in the parents 
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with SAS 9.4. SNPs that failed HWE at a false discovery rate significance level < 0.02 were 
flagged, but not excluded.  Mendelian errors were also assessed for each trio using PLINK v1.07. 
Relatedness was assessed for each trio through measures of identity by descent, alleles that share 
the same parental origin, with all alleles.  The proportions of zero, one, or two alleles that are 
identical by descent are denoted by the notations P(Z=0), P(Z=1), and P(Z=2), respectively. A 
combined measure, ?̂? = 𝑃(𝑍 = 2) ∗ 0.5(𝑃(𝑍 = 1)), can be used to assess relatedness.  A ?̂? was 
calculated for each mother-child, father-child and mother-father pair in the trios. Within each 
trio, the parents were expected to have ?̂? < 12.5%, which is less than third-degree relatives, and 
for parent-child pairs a ?̂? ≅ 0.5 would expected. Reported fathers who are found not to be the 
biological father were excluded from further analysis. 
2.3.2 Offspring Genetic effect 
Genetic effects for the offspring genotype was evaluated using the log-linear model.19 
Although the transmission disequilibrium test (TDT) is the most common method for assessing 
genetic effects in case-parent triads, the log-linear model is comparable in terms of power, type 1 
error, and robustness to population stratification, but allows estimation of genotype offspring and 
maternal risks ratios and assessment of gene-environment interaction and full and unbiased 
incorporation of triads that are incomplete due to missing paternal genotypes.316 
Case-parent triads were classified according to the number of variant alleles carried by 
the mother (M), father (F) and child (C), resulting in a 15-cell multinomial distribution (Table 8), 
where variant alleles were defined as the allele with the lower minor allele frequency within the 
population.  Hardy Weinberg equilibrium is not required for the valid application of log-linear 
models.  Column 2 show the distribution under HWE, in which p is the proportion of the 
population with the variant allele. Column 3 shows the distribution of allele frequencies not 
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under HWE in the population, in which μ, a marker for the mating types, allows full stratification 
on parental mating type and confers robustness against population stratification. In the study 
sample, because triads were selected based on the disease occurrence in the offspring, the 
multinomial distribution is distorted by the risk ratios (R1, R2) (Table 8, Column 4). Two 
inherited copies of a variant allele increase the offspring risk by a factor of R2 (risk ratio for 2 
variant alleles) and one copy increases it by a factor of R1 (risk ratio for 1 variant allele). Here 
mating symmetry is assumed, meaning that for couples in the source population M = 1 and F = 2 
is as frequent as M = 2 and F = 1. If there are no maternally-mediated genetic effects, then under 
this log-linear model the expected count for each cell in the multinomial distribution can be 
written as 
ln[𝐸(𝑛𝑀,𝐹,𝐶)] = 𝛾𝑗 + 𝛽1𝐼(𝐶=1) + 𝛽2𝐼(𝐶=2) + ln(2) 𝐼(𝑀=𝐹=𝐶=1) (1) 
where the index j corresponds to the mating type, and where I(comparison statement) = 1 when the 
comparison statement is true and 0 otherwise.19 This can be modified for a dominant model 
(𝛽1 = 𝛽2) or a recessive model (𝛽1 = 0).
19 The multinomial likelihood can be maximized with 
Poisson regression software available in SAS. R1 and R2 can then be estimated by exponentiating 
𝛽1 and 𝛽2, respectively. 95% confidence intervals can be calculated as  
95% 𝐶𝐼 =  (𝑒(𝛽−1.96∗𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝐸𝑟𝑟𝑜𝑟), 𝑒(𝛽+1.96∗𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝐸𝑟𝑟𝑜𝑟))  (2) 
All family-based models, including the log-linear model, must assume Mendelian 
transmission of alleles. Since there are no controls in this analysis, the null background is 
discerned from the parental genotypes under the assumption of Mendelian inheritance.  
Disruption of Mendelian inheritance at a particular locus, for example if homozygotes for the 
variant allele do not survive, would lead to results where two alleles appear to confer lower risk 
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than one allele.  On the other hand, such an allele would be very quickly selected out of the 
population so that scenario is not a plausible one. 
Table 8. Mating types and frequencies in case-parent triad 
 
Mating type 
 
Population Frequencies Case-parent Triad 
Frequencies* 
M,F,C  In HWE Without HWE 
2,2,2  p4 μ1 R2μ1 
2,1,2  p3(1 − p) μ2 R2μ2 
1,2,2  p3(1 − p) μ2 R2μ2 
2,1,1  p3(1 − p) μ2 R1μ2 
1,2,1  p3(1 − p) μ2 R1μ2 
2,0,1  p2(1 − p)2 μ3 R2μ3 
0,2,1  p2(1 − p)2 μ3 R1μ3 
1,1,2  p2(1 − p)2 μ4 R2μ4 
1,1,1  2p2(1 − p)2 2μ4 2R1μ4 
1,1,0  p2(1 − p)2 μ4 μ4 
1,0,1  p(1 − p)3 μ5 R1μ5 
0,1,1  p(1 − p)3 μ5 R1μ5 
1,0,0  p(1 − p)3 μ5 μ5 
0,1,0  p(1 − p)3 μ5 μ5 
0,0,0  (1 − p)4 μ6 μ6 
* μ is numerically distinct from the population frequencies without HWE 
M: Mother; F: Father; C: Child; HWE: Hardy Weinberg Equilibrium; 𝐑𝟏: Risk ratio for 1 allele 
𝐑𝟐: Risk ratio for 2 alleles, compared with offspring having no copies.  
2.3.3 Maternal Effect 
The log-linear model can be expanded to test for maternal effects.  As was true for the 
offspring genotype, maternal effects can also be estimated.317  If there is a deleterious effect on 
the fetus due to a variant maternal allele then mothers will tend to have more copies than fathers 
among case families.  This means that the distribution of the alleles will be biased by the 
maternal risk ratio S1 and S2 for 1 risk allele and 2 risk alleles, respectively. Table 9 shows the 
distributions of the case-parent triads in terms of S1 and S2. 
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Table 9. Mating types and frequencies in case-parent triad for maternal effects 
Mating type  Case-parent Triad Frequencies 
M,F,C  Maternal Effect  Maternal and Child Effect 
2,2,2  S2μ1  R2S2μ1 
2,1,2  S2μ2  R2S2μ2 
1,2,2  S1μ2  R2S1μ2 
2,1,1  S2μ2  R1S2μ2 
1,2,1  S1μ2  R1S1μ2 
2,0,1  S2μ3  R2S2μ3 
0,2,1  μ3  R1μ3 
1,1,2  μ4  R2μ4 
1,1,1  2S1μ4  2R1S1μ4 
1,1,0  S1μ4  S1μ4 
1,0,1  S1μ5  R1S1μ5 
0,1,1  μ5  R1μ5 
1,0,0  S1μ5  S1μ5 
0,1,0  μ5  μ5 
0,0,0  μ6  μ6 
 M: Mother F: Father C: Child  
The expected count for each cell in the multinomial distribution can be modeled as 
ln[𝐸(𝑛𝑀,𝐹,𝐶)] = 𝜇𝑗 + 𝛼1𝐼(𝑀=1) + 𝛼2𝐼(𝑀=2) + ln(2) 𝐼(𝑀=𝐹=𝐶=1),  (3) 
where the index j corresponds to the mating type, and where I(comparison statement) = 1 when the 
comparison statement is true and 0 otherwise. Similar to case genotype model, S1 and S2 then can 
be estimated by exponentiating α1and α2, respectively.  If the triad data are complete, the 
estimations of maternal effects and offspring genotype effects are independent of each other 
despite the correlation between the mother and offspring genotypes. 
In practice, some triads are usually incomplete and a priori it is unknown if the candidate 
gene has a maternally mediated effect or an offspring genetic effect.  Since both scenarios are 
possible, the model can be altered to include both terms as  
ln[𝐸(𝑛𝑀,𝐹,𝐶)] = 𝜇𝑗 + 𝛽1𝐼(𝐶=1) + 𝛽2𝐼(𝐶=2) + 𝛼1𝐼(𝑀=1) + 𝛼2𝐼(𝑀=2) + ln(2) 𝐼(𝑀=𝐹=𝐶=1),  (4) 
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where again the index j corresponds to the mating type, and where I(comparison statement) = 1 
when the comparison statement is true and 0 otherwise.   This model allows for the simultaneous 
evaluation of the maternal and offspring genetic effect.  A likelihood ratio test can also be used 
to determine if the offspring genotype carries any predictive value after adjusting for the 
maternal genotype or vice versa. 95% confidence intervals can be calculated by equation 2 for 
the offspring effect and by substituting α for β. 
In addition to the assumption of Mendelian inheritance, this model requires stronger 
assumptions than the test the offspring genetic effect.  Since this model compares the allele 
counts in the father with the allele counts in the mother, this model assumes the symmetry of 
allele counts that does not need to hold for the test of the offspring genetic effects only.    
2.3.4 Gene-Environment Interaction 
The model of gene-environment interaction is just an extension of the offspring genetic 
only model, only there is term for the interaction of the gene and the environment. The expected 
count for a binary exposure is modeled as 
𝑙𝑛[𝐸(𝑛𝑀,𝐹,𝐶,𝐸)] = 𝜇𝑗 + 𝛿𝑗𝑒𝐼(𝐸=𝑒) + 𝛽1𝐼(𝐶=1) + 𝛽2𝐼(𝐶=2) + 𝛼1𝐼(𝑀=1) + 𝛼2𝐼(𝑀=2)𝛽𝑐𝐼(𝐶=𝑐) +
𝜂𝑐𝑒𝐼(𝐶=𝑐)𝐼(𝐸=𝑒) + 𝛾𝑚𝑒𝐼(𝐶=𝑐)𝐼(𝑀=𝑚) + 𝑙𝑛(2) 𝐼(𝑀=𝐹=𝐶=1),  (5) 
where j indexes the mating types, 𝜇𝑗 + 𝛿𝑗𝑒  are the corresponding stratum parameters of different 
levels of exposed triads and 𝛿𝑗0 = 0 for each j.  The β1and β2 are natural logarithms of the 
unexposed offspring genotype risk ratio associated with C=1 and C=2.  The 𝛽1 + 𝜂1𝑒  and 𝛽2 +
2 ∗ 𝜂2𝑒 are the natural logarithms of the exposed offspring genotype risk ratio of the C=1 triads 
and C=2 triads. The α1and α2 are natural logarithms of the maternal genotype risk ratio 
associated with M=1 and M = 2 of the unexposed triads. The 𝛼1 + 𝛾𝑚𝑒  and 𝛼2 + 2 ∗ 𝛾𝑚𝑒 are the 
natural logarithms of the maternal genotype risk ratio of the C=1 and the E=e triads and C=2 and 
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the E=e triads. If there is a dichotomous variable, then there will be 4 risk ratios for the offspring 
genotype and 4 risk ratios for the maternal genotype, or two for each level of the exposure. The 
95% confidence interval for those who are unexposed will be equation 2.  The 95% confidence 
intervals for those who are exposed will be  
95% 𝐶𝐼(𝑅𝑅𝑐𝑒) =
[𝑒(𝛽𝑐+𝜂𝑐𝑒)−√ 𝑉𝑎𝑟(𝛽𝑐)+𝑣𝑎𝑟(𝜂𝑐𝑒)+2𝑐𝑜𝑣(𝛽𝑐,𝜂𝑐𝑒), 𝑒(𝛽1+𝜂11)+√ 𝑉𝑎𝑟(𝛽𝑐)+𝑣𝑎𝑟(𝜂𝑐𝑒)+2𝑐𝑜𝑣(𝛽𝑐,𝜂𝑐𝑒)].  (6) 
This can also be calculated by separating the data into the two strata and applying (2) to each. 
Similar to the child genotype model, the gene-environment interaction model also assumes 
Mendelian transmission, but within each level of the exposure. Additionally this model also 
assumes conditional independence, which states conditional on parental genotypes, an 
individual’s exposure status is independent of their genotype.  For example, this assumption 
would be violated if neither the genotype nor the exposure is associated with the outcome, but if 
fetal inheritance of the variant allele somehow caused increased maternal exposure. This would 
not be a problem for the fetal gene-environment effects, but for maternal effects the maternal 
race may need to be adjusted for in the model, but only if there are many biracial couples.  
Alternatively, the model can be restricted to same-race parents to see if the results are similar. 
2.3.5 Missing Paternal Genotype 
Parent-child dyads can also be included in the analysis. Missing paternal genotype are 
accounted for by maximizing the observed data log-linear likelihood using the expectation 
maximization (EM) algorithm.20 The EM algorithm maximizes the observed-data likelihood by 
fractionally assigning incomplete triads into their data-compatible cells on the basis of the 
current parameter estimates, and then repeating the calculations iteratively up to convergence 
and maximization of the likelihood. A crucial assumption is that the missingness is non-
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informative, meaning that missingness is conditionally independent of the paternal genotype, 
conditional on the observed mother-child genotype.  This assumption can be violated if 
missingness is related to race, but one can potentially deal with this issue by stratifying on race 
and doing the maximizations of mating type parameters within racial categories.   
2.3.6 Stratifying by Risk-Classification and Offspring Age at Diagnosis  
Since there is evidence that these subtypes are neuroblastoma may be different diseases 
rather than progressions of the same disease,1 the offspring genetic and maternal genetic model 
was stratified for each neuroblastoma risk group defined by COG (see section1.2.4 
Neuroblastoma Risk-Classifications).  Similarly, the model was stratified by infant versus 
childhood cases. Infant cases are those that are less than 1 year of age at diagnosis and childhood 
cases are those greater than or equal to 1 year of age.  Unlike risk-classification, age is available 
for all cases, which allows greater power for detecting an effect.  Additionally, cases that are 
diagnosed after 1 year of age tend to have more severe outcomes, although they might have 
similar morphologies.23 
2.3.7 Definition of Genetic Model and Environment 
The model was fit log-additively for the maternal and offspring genetic effects. For the 
gene-environment model, the main genetics effects were fit co-dominantly, but the interaction 
term was modeled log-additively, to improve power.  
Gene-environment interaction was modeled in three ways.  First, the vitamin information 
from the FFQ was used.  Second, a dichotomous variable for any prenatal/ multivitamin use 1 
month before pregnancy was used.   Lastly, we created a “total” exposure grouping for folate, 
folic acid and vitamin A by grouping women into two categories (sufficient and insufficient 
intake).  Women with either greater than the 33rd percentile nutrient from diet or taken a prenatal 
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or multivitamin 1 month pre-pregnancy were classified as sufficient intake.  Women with less 
than the 33rd percentile and did not take a prenatal or multivitamin 1 month pre-pregnancy were 
classified as insufficient.  
The nutrients of interest are dietary maternal vitamin A, folate, and choline levels.  Total 
choline, total folate dietary folate equivalent (DFE), folic acid and vitamin A retinol activity 
equivalent (RAE) were nutrients used from the FFQ.  These values were dichotomized at the 25th 
percentile for gene-environment analysis. 
A dichotomous variable based on dietary recommendations was also used. 18,318,319 
Recommendations for folate and vitamin A are from the Recommended Dietary Allowances 
(RDA). Choline is based on Adequate Intake – a commonly used recommendation level in the 
absence of RDA values.320  Folic acid is does not have a recommended amount, but the Institute 
of Medicine recommends women who are trying to get pregnant consume 400 mg/day folic acid 
in addition to a varied diet. The recommended cutoffs are as follows: 
a. Folic acid for women who may get pregnant is 400 μg  
b. Folate for women who may get pregnant is 600 μg dietary folate equivalents 
c. Vitamin A for women is 700 μg retinol activity equivalents per day (No 
recommendation is given for women trying to get pregnant 
d. Choline for women above the age of 19 years is 425 mg/day.  
2.3.8 Replication 
Dr. John Maris and colleagues at the Children Hospital of Philadelphia (CHOP) 
previously conducted a genome-wide association (GWA) case-control study with 2,101 
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neuroblastoma cases and 4,202 healthy controls of European American ancestry.  This study was 
used to as a replication study for the offspring results in NENA. 
Detailed information on this study can be found elsewhere.8 Briefly, the cases were 
diagnosed with neuroblastoma or ganglioneuroblastoma and identified through the 
Neuroblastoma Bio-repository for specimen collection at the time of diagnosis.  The controls 
with no known medical disorder were recruited from multiple sites within the CHOP Health Care 
Network, including four primary care clinics and several group practices and outpatient practices 
that included well child visits.  At least 1.5 µg of high quality DNA was extracted from either a 
blood sample or bone marrow mononuclear cells for cases and blood samples of the controls.  
Based on genome-wide IBS estimates for all pairwise comparisons among all case and control 
subjects, they identified two matched controls for each case.  Since both CHOP and NENA 
recruited cases from the same population, cases that were enrolled in NENA were excluded from 
the CHOP sample, resulting in 2,052 cases and 4,104 controls. 
Imputation was performed with IMPUTE2 on all GWA data using the world-wide 1000 
Genomes Project Phase 1 interim data as reference (June 2011 release).  Detailed information on 
the imputation can be found elsewhere.8 All SNPs were tested for association with 
neuroblastoma using the under the additive model in SNPTEST.  Associations with for all 
neuroblastoma cases as well as by risk-classification and age at diagnosis were provided to 
NENA. 
SNPs that are in both the NENA dataset and the CHOP dataset were included in the 
replication (N=1173) and 66.6% of these SNPs were genotyped. The CHOP SNPs were adjusted 
with false discovery rate and any SNP <0.2 was considered significant. 
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2.3.9 Analytical Considerations 
2.3.9.1 Correction for Multiple Testing 
To account for multiple testing a false discovery rate (FDR) Q-value was calculated 
instead of p-values. We considered any FDR Q-values < 0.2 as significant and as meriting 
additional follow-up. The FDR is less stringent than other tests for multiple corrections and thus 
provides a more useful approach for identifying genetic contributions to risk.321 
2.3.9.2 Bias in measuring pregnancy diet and exposures 
There is a potential for differential accuracy of recall since mothers had to recall 
exposures during and pre-pregnancy, which means mothers with older children, and generally 
more severe cases of neuroblastoma, will have longer to recall. Few studies have looked at 
maternal recall of medications during pregnancy and birth characteristics postpartum, but 
findings suggest that most birth characteristics and medications are accurately recalled by the 
mother with little difference by case or control status.322,323  
NENA also did not collect dietary information from the pregnancy, but rather collected 
current dietary data and then asked about dietary changes during pregnancy compared to current 
diet.  Since vitamin consumption was split into quartiles and recommended values and the 
comparisons are relative to other women within the study, we presume that few women would 
shift vitamin quartiles. There is also evidence that consumption of many foods does not change 
after pregnancy,306,307,324  
Additionally, sensitivity analyses were done shifting nutrients based on changes in diet 
due to pregnancy.  We used the questions that asked about changes in diet during pregnancy and 
concentrated on fish and diary, since these two foods changed the most during pregnancy.  Fish 
and dairy contribute to choline and dairy contributes to vitamin A. We didn’t analyze folate 
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changes since most women derive folate from breads and these are generally stable though 
pregnancy.  We calculated the average amount fish and dairy contributed to choline and dairy 
contributed to vitamin A in NENA mothers. We increased the average amount dairy contributed 
to choline and vitamin A among women who reported greatly increasing dairy during pregnancy. 
Similarly, we decreased choline the average amount fish contributed choline in NENA for 
women who reported they had greatly decreased fish consumption during the pregnancy. The 
nutrients were then re-dichotomized and the gene-environment interaction was re-fit.  
2.3.9.3 Selection  
The CCRN has good coverage of neuroblastoma cases in the US. According to 
Musselman et al., the coverage of CCRN when compared to expected values from SEER is 60% 
to 70% for children younger than 5 years.  The proportions of expected cases under 1 year of age 
is 37%, which is very similar to the 41% found in NENA.304 The proportions of neuroblastoma 
subtypes and cancer origins in NENA are very similar to that seen in data from SEER.  Although 
there are limitations for using the CCRN, it remains the best method for obtaining cases of 
neuroblastoma within the United States. 
In addition to enrollment in the CCRN, there are many levels of recruitment in NENA, 
which can further introduce loss and potential selection bias. However, since this is a case-
parents study and the parents are providing the comparison group, any form of selection would 
have a small possible effect on the generalizability of the inference rather than the validity of the 
results.   
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2.3.9.4 Assumptions for a case-parent triads 
Since the underlying basis for case-parent triad studies is determining if observed data 
deviate from Mendelian expectations, the key assumption required for a valid analysis is the 
assumption of Mendelian transmission to offspring and that the proportions persist to the age in 
which cases are collected.  Although deviations in Mendelian inheritance through biologic 
mechanisms are rare, it is possible that a variant is associated with survival, thus violating this 
assumption. For example, among children of parents who are both heterozygous, the ratio of 
offspring with 2, 1, and 0 copies of the variant allele would be 1:2:1. If a ratio of 4:2:1 were seen, 
deviation from this would be consistent with a recessive genetic risk of 4.  However if this 
deviation were to occur because the variant is associated with survival rather than disease, the 
risk ratio estimate would be invalid.  There is some evidence that the variants in this present 
study, such as MTHFR C677T and A1298C are related to survival,325 but these studies are small 
and it is hard to determine if these variants are related to survival since most embryonic death 
occurs before the women knows she is pregnant.  Additionally, the deviations that are present are 
very small and unlikely to affect the study. 
2.4 Statistical Power 
2.4.1 Genetic effect 
All power calculations were done with QUANTO Version 1.2.4.  There are 603 case-
parent triads or parent-child dyads with DNA.  Assuming an alpha of 0.001, this yields greater 
than 80% power to detect minimum risk ratios at 1.5 at a minor allele frequency (MAF) of 20% 
for a log-additive genetic effect (Table 10).  The power is not greater than 80% for the detection 
of a risk ratio of 1.3 at a genotype prevalence of 30%. Previous GWA study analyses of 
neuroblastoma have found hits at that magnitude.6 For a recessive genetic effect (two variant 
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alleles versus one or none), there is about 52% power to detect risk ratios above 1.7 and with a 
MAF of 30%.  The dominant genetic effect (one or two variant alleles versus none) has power 
greater than 80% to detect risk ratios greater than or equal to 1.7 at a MAF of 20%.   Research 
has shown that it is likely that these work in an additive fashion, where homozygotes for a 
variant have greater impairment of vitamin metabolism than those who are heterozygotes.326 
Table 10. Power for offspring genetic effect 
Genotype 
Prevalence 
Risk 
Ratio Study Power (N = 603) 
  Additive Recessive Dominant 
10% 1.3 10.44% 0.34% 7.90% 
 1.5 47.43% 0.92% 36.88% 
 1.7 84.73% 2.13% 73.62% 
20% 1.3 26.84% 1.44% 15.50% 
 1.5 81.91% 6.40% 59.40% 
 1.7 98.88% 18.36% 90.85% 
30% 1.3 39.32% 4.16% 17.51% 
 1.5 92.19% 21.02% 62.64% 
 1.7 99.82% 51.92% 91.86% 
Assumptions: α = 0.001 
2.4.2 Stratification by Risk-Classification and Age 
Assuming the same numbers that were displayed in Table 6 for risk group and age group, 
there is less than 80% power to detect risk ratios up 1.7 for all risk-groups (Table 11). There is 
better power by age group since this is available for all cases, where there is power greater than 
80% with a risk ratio of 1.7 and a MAF of 80% in cases greater than 1 year.   
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Table 11. Power for risk-classification and < 1 year and greater than or equal to 1 year of age 
  COG Risk-Group  Age Group 
Genotype 
Prevalence 
Risk 
Ratio 
Low-Risk 
(N = 175) 
Intermediate Risk 
(N = 142) 
High-Risk 
(N = 198) 
 < 1 year 
(N = 260) 
≥1 year 
(N = 366) 
10% 1.3 1.41% 1.06% 1.68%  2.53% 4.40% 
 1.5 6.03% 4.23% 7.47%  12.06% 21.85% 
 1.7 16.71% 11.58% 20.67%  32.38% 52.82% 
20% 1.3 3.21% 2.31% 3.93%  6.23% 11.35% 
 1.5 15.23% 10.54% 18.88%  29.77% 49.34% 
 1.7 38.68% 27.91% 46.16%  64.42% 85.37% 
30% 1.3 4.81% 3.40% 5.94%  9.55% 17.41% 
 1.5 22.55% 15.73% 27.68%  42.13% 64.73% 
 1.7 51.94% 38.88% 60.31%  78.22% 93.81% 
Assumptions: α = 0.001 
2.4.3 Gene Environment Interaction 
There are 588 case-parent triads or parent-child dyads that have both DNA and 
questionnaire data. Assuming that the genetic risk ratio is 1.3 for an additive genetic effect, 
which is reasonable given the previous literature, and the environment risk ratio is 1.667 for 
those with low vitamin consumption, there is power greater than 80% to detect a joint gene-
environment risk ratio above 2.2 (that is, among exposed individuals the effect of each copy of 
the variant is increased by a factor of 2.2) for a MAF of 30% (Table 12). Thus, the relative risk 
for an exposed carrier of one copy, assuming a (no interaction) multiplicative joint effect, would 
be 2.17. Under the detectable interaction alternative, the joint relative risk, comparing the 
exposed carrier of one copy to an unexposed non-carrier, would be 2.17*2.2=4.77. 
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Table 12. Power for gene-environment interaction 
Genotype 
Prevalence 
GXE Risk 
Ratio 
Exposure Prevalence 
20% 30% 40% 
10% 1.8 14.32% 16.47% 15.33% 
 2.0 26.24% 29.07% 26.59% 
 2.2 40.42% 43.24% 39.20% 
20% 1.8 35.22% 37.83% 34.10% 
 2.0 56.78% 58.36% 52.47% 
 2.2 74.77% 74.79% 67.94% 
30% 1.8 48.99% 50.18% 44.34% 
 2.0 71.72% 70.97% 63.28% 
 2.2 86.57% 84.64% 77.02% 
Assumptions: α = 0.001, Genetic Risk Ratio = 1.3, Environment Risk Ratio =1.7, n = 588; GXE = 
Gene-environment interaction 
2.5 Strengths and Limitations 
Neuroblastoma is the second most common solid tumor diagnosed in children and the 
most common malignancy diagnosed in infants.1  Due to the embryonic origins of 
neuroblastoma, it is likely that there is a strong genetic component of both the maternal genetics 
and the offspring genetics that is modified by the fetal environment.1,68 NENA is the only study 
that is able to study both maternal genetic effects as well as gene-environment interaction with 
maternal pre-pregnancy and pregnancy vitamin consumption. 
One strength of this study is the use of the case-parent triad, which prevents selection bias 
through recruitment of controls that are not from the study base or have a low response.  
Additionally, with key assumptions, we can validly estimate maternal effects and gene-
environment effects. Also, case-control approaches are inevitably vulnerable to confounding of 
offspring genetics by maternal genetics, whereas those two causal mechanisms can be 
distinguished clearly using a case-parent design.  In a rare disease setting like neuroblastoma, 
which requires recruiting cases North America-wide, population-based controls are difficult to 
recruit.  Additionally, through the COG, DNA samples had been previously collected and stored 
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for deceased cases.  The ability to genotype these “fast progessors” enabled us to study 
neuroblastoma as a whole rather than the cases that have survived. The case-parent triad also 
accounts for population stratification without additional genotyping, since the calculations are 
conditional on parental genotype. 
The CCRN provides a good platform to accumulate neuroblastoma cases.  NENA is the 
largest study of this rare childhood cancer that is able to look at gene-environment interactions.  
Since neuroblastoma is a rare disease and amassing cases is difficult, even within the context of 
the CCRN, hypothesis-driven candidate genes allow us to look at functionally relevant genetic 
variants without sacrificing power. The selected genes give good coverage of vitamin A, folate, 
and choline pathways that have a priori plausibility of a relationship with neuroblastoma.  
This study has a few limitations as well.  First there is a potential for measurement bias 
for maternal diet. Since we must use reported current diet from a FFQ, we relied on women’s 
current diet to approximate her pre-pregnancy and early pregnancy diet.  However, data was 
collected on the estimated amount of dietary change of certain foods due to pregnancy. This is 
the only study to look at the joint effects of maternal diet during pregnancy and the genetics of 
both the child and the mother.   There are a few assumptions to the case-parent triad such as 
Mendelian inheritance and conditional independence of the exposure and the transmitted 
genotype, but these needed assumptions are less severe than the assumption that the controls are 
representative of the study base and that population stratification is adequately accounted for. 
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CHAPTER 3: AIM 1 RESULTS 
Maternal and offspring variants in vitamin A-related genes and gene-environment interaction with 
vitamin A and neuroblastoma: A report of the Children’s Oncology Group 
3.1 Overview 
Multivitamins and prenatal vitamin intake has been associated with decreased risk of 
neuroblastoma, a childhood cancer of the sympathetic nervous system.  Retinoic acid is a 
chemical compound related to vitamin A that stimulates differentiation of neuroblastoma cells in 
vitro.  13-cis-retinoic acid has been used to reduce recurrence after treatment for high-risk 
neuroblastoma. We hypothesized that common variants in vitamin A-related genes are associated 
with risk of neuroblastoma and are modified by maternal vitamin A intake.  The Neuroblastoma 
Epidemiology of North America (NENA) study recruited 563 case-parent sets through the 
Children’s Oncology Group’s (COG) Childhood Cancer Research Network. NENA used 
questionnaires to ascertain pre-pregnancy supplementation and estimate usual maternal dietary 
intake. We genotyped 463 SNPs related to vitamin A pathways, used a log-linear model to 
estimate log-additive child and maternal risk ratios and stratum-specific risk ratios for gene-
nutrient interactions. We corrected for multiple testing using the false discover rate. In the 
overall study group, no offspring variants were significantly associated with risk of 
neuroblastoma. The maternal variant rs12442054 was significantly associated with overall 
decreased risk of neuroblastoma. After stratification by the COG prognostic risk-classification, 
nine offspring
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SNPs (rs4842196, rs1229977, rs1045570, rs1007971, rs7139068, rs904092, rs3118523, 
rs7169439, and rs1465057) were significantly associated with the intermediate-risk 
neuroblastoma. Maternal rs6776706 and rs11103603 were also significantly associated with 
decreased risk of high-risk neuroblastoma and cases in which diagnosis was made at age less 
than 1 year, respectively.  We found a maternal rs729147-vitamin A interaction when maternal 
vitamin A consumption was dichotomized at the Recommended Dietary Allowance.  Our results 
suggest that some genetic variants involved in vitamin A may be associated with neuroblastoma.  
The significant maternal variants and their joint effects with maternal vitamin A intake, suggest a 
relationship between neuroblastoma and vitamin A.  
3.2 Introduction 
Neuroblastoma is an embryonal tumor arising from the neural crest and is the most 
common extracranial solid tumor in children.1,2 Its incidence is slightly higher in males than in 
females (7.7 per million vs 6.9 per million).327  Neuroblastoma has an embryonic origin, 
implying that the prenatal environment as well as offspring and maternal genetics are likely 
involved in its etiology. Genome-wide association (GWA) studies and studies of familial case 
have identified rare and common offspring germline variants associated with the risk of 
neuroblastoma.6,328   
Previous epidemiologic studies have found evidence of an inverse association between 
maternal prenatal vitamin use and neuroblastoma,10,11 suggesting that maternal pregnancy 
vitamin status may play a role in neuroblastoma development.  Vitamin A in the form of beta-
carotene is found in most prenatal vitamins and is required for many growth and developmental 
processes including embryonic neuronal differentiation and development.12,13  When cultured 
neuroblastoma cells are treated with retinoic acid, a metabolite of vitamin A, they exhibit 
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decreased proliferation and improved differentiation.14,15  Therefore, 13-cis-retinoic acid is 
clinically used to prevent the recurrence of disease after treatment for some cases of 
neuroblastoma.170,171   
Due to the importance of vitamin A in neuronal development and differentiation as well 
as the epidemiologic associations between vitamin use and neuroblastoma, we hypothesized that 
common maternal and offspring SNPs in genes involved in vitamin A metabolism and transport 
are associated with neuroblastoma.  Furthermore, we hypothesized that these variants are 
modified by maternal vitamin A intake through diet and prenatal vitamin supplementation. 
However, no studies have been conducted to evaluate gene-environment interaction with 
maternal intake of specific nutrients, such as vitamin A, or studied the effects of maternal genetic 
variants. The present study is the first to examine the risk of neuroblastoma and genetic variants 
involved in vitamin A processing and transport.   
3.3 Methods 
3.3.1 Study Sample 
The Neuroblastoma Epidemiology in North America (NENA) study used a case-parent 
triad design to investigate gene and gene-environment interactions in the etiology of 
neuroblastoma.  NENA recruited families who agreed for future contact and were registered in 
the Childhood Cancer Research Network (CCRN) a registry system of newly diagnosed cases 
maintained by the Children’s Oncology Group (COG).304. To be eligible for NENA, cases had to 
have a primary diagnosis of neuroblastoma (including ganglioneuroblastoma but excluding 
ganglioneuroma) before the age of 6 years at a U.S. or Canadian COG institution from December 
24, 2007 to July 31, 2013. The biologic mother was alive and willing to participate. The 
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University of North Carolina at Chapel Hill (UNC) Institutional Review Board approved this 
study. 
NENA located and sent a recruitment packet to 1347 families located through the CCRN.  
Once the families agreed to participate (N = 870), we sent study materials containing a consent 
form, the maternal questionnaire, a mouthwash Oragene saliva spit tube collection kit for the 
parents, and an Oragene saliva sponge/disc kit for the child.  If the child was deceased, 
communication was delayed by 15 months after date of death and a different protocol was used.  
A previously collected blood sample was obtained from the COG Neuroblastoma Bio-repository 
at the Children’s Hospital of Philadelphia (CHOP).  
We collected saliva samples from 626 biological mothers, 592 living children, 525 
biological fathers and blood samples used for 19 deceased children (Figure 9).  Questionnaires 
were returned by 630 mothers.  However, two did not have a corresponding signed consent form 
and two were incomplete, which resulted in 626 completed questionnaires for analysis. 
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Figure 9. Flowchart of DNA collection, genotyping and genetic quality control for mothers, 
fathers and children in NENA. 
 
3.3.2 Candidate Genes and SNP selection 
Candidate genes were selected based on their role in the transport and metabolism of 
vitamin A. We tagged SNPs in the region between 20kb upstream to 10kb downstream from 
each gene.312,329  We used TAGster with the greedy algorithm to capture haplotype tagging SNPs 
with a minor allele frequency ≥ 5% that tag SNPs in high linkage disequilibrium (LD; r2≥0.8) in 
the Hapmap 3 release III CEU population.  Since the case-parent triad design is not subject to 
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confounding by population stratification, ancestry-informative markers were not included.317  A 
463 SNPs in 30 genes were selected for genotyping. 
3.3.3 DNA collection and Genotyping 
UNC Biospecimen Processing Facility performed the DNA extraction. Saliva samples 
from parents were collected in DNA Genotek’s OGR-250 collections kits. Saliva from the child 
was also collected into these kits by the parents using 5 provided swabs to collect the saliva.  
DNA was extracted using the Perkin-Elmer's Chemagic MSMI magnetic-bead extraction robotic 
system and quality was assessed with Nanodrop Optical Density and quantitated with Applied 
Biosystems® Taqman® RNase P detection kit.  A total of 498 triads, 99 mother-child dyads, 5 
father-child dyads and 27 other (mother-father dyads and singleton cases) with DNA yields 
greater than 2 µg were sent for genotyping. 
Genotyping was performed by UNC’s Mammalian Genotyping Core Facility on the 
GoldenGate Assay using the Illumina BeadStation 500GX Genetic Analysis System.  Allelic 
discrimination was based on allele-specific primer extension followed by ligation.  
3.3.4 Genetic Quality Control 
For quality control purposes, a Centre de l'Étude du Polymorphisme Humain (CEPH) 
family triad and blinded duplicates were included on each plate.  SNPs with a genotyping call 
rate less than 95% were excluded.  Individual genotypes for SNPs showing a lack of defined 
clusters in the raw genetic intensity data or showing apparent Mendelian errors in a particular 
family were treated as missing. A total of 427 vitamin A-related SNPs passed quality control. 
We assessed Hardy-Weinberg (HWE) equilibrium among parents who self-identified as white 
using chi-square tests in PLINK (v1.07) and flagged (n=5), but did not exclude, SNPs that failed 
HWE at a false discovery rate (FDR) significance level of < 0.2.330,331 
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Individuals with genotyping rates <95% or gender discrepancies were excluded. 
Relatedness was confirmed for each triad through measures of identity by descent and triads with 
unexpected relatedness were excluded. For example, when non-paternity was detected, the 
paternal data was excluded. A total of 465 triads, 94 mother-child dyads, 4 father-child dyads, 13 
mother-father dyads and 48 singletons passed genetic quality control (Figure 10).   
Figure 10. Flowchart for genetic and questionnaire quality control for triads and dyads. 
 
3.3.5 Biological and Clinical Variables 
Clinical and biologic characteristics of the tumor such as tumor genetics and stage were 
obtained from the COG Statistical and Data Center, which maintains data for cases enrolled in a 
COG clinical protocol.  However, for 89 cases who were not enrolled in a COG protocol, these 
data were not available. The data also included the COG “risk-classification” using a schema that 
defined three prognostic risk-classifications: low-risk, intermediate-risk and high-risk.  These 
risk-classifications are based on pathology, tumor stage, MYCN amplification, ploidy, and patient 
age dichotomized at 1 year.43  
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3.3.6 Maternal Vitamin Use  
The mother’s current and usual maternal diet during the preceding year was ascertained 
with the Dietary History Questionnaire, a self-administered semi-quantified food frequency 
questionnaire (FFQ). We assumed maternal usual diet in the last year approximates pre-
pregnancy diet. 
To address potential differences between “usual” diet and diet during pregnancy the 
questionnaire asked if women changed their diet relative to current diet in foods prone to 
change.309 The mothers were asked if during pregnancy intake of these foods was “Much less 
than it is now”, “Somewhat less than it is now”,  “Same as it is now”,  “Somewhat more than it is 
now”, and “Much more than it is now”.   
Diet*Calc (version 1.5.0) was used to process the FFQs and to derive usual nutrient 
intake per day for previous last year. The nutrient and food group database was based on a 
compilation of national 24-hour dietary recall data from the National Health and Nutrition 
Examination Surveys (NHANES) conducted in 2001-02, 2003-04, and 2005-06 
(http://riskfactor.cancer.gov/dhq2/database/).  Certain foods not included in the original database 
were added by NENA staff in 100 gram amounts using the USDA database, standard release 24. 
Mothers were also questioned about maternal dietary supplementation use 1 month pre-
pregnancy and within each trimester of pregnancy.  To aid in recall, an estimated conception date 
was provided; calculated by subtracting gestational age at delivery from infant birthdate. Since 
we are most interested in vitamin intake pre-pregnancy and early pregnancy, we focused on 
prenatal vitamin or multivitamin use 1 month pre-pregnancy.  
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3.3.7 Diet and Nutrient Classification 
Maternal questionnaires that reported calories per day below the 5th percentile (N = 31; 
below 854.47 calories) or above the 97th percentile (N = 18; above 4508.75 calories) were 
excluded (Figure 10).  Vitamin A is estimated in micrograms retinoic acid equivalents (μg RAE), 
which accounts for the differing bioactivities of retinol and provitamin A carotenoids. We 
explored two cutoffs for vitamin A: 25th percentile (460.94 μg RAE) and Recommended Dietary 
Allowance (RDA) for women of child-bearing age (700 μg RAE).332   
Since we are unable to ascertain the formulations of the prenatal or multivitamins, we 
conducted a “total” exposure analysis by combining prenatal or multi-vitamin use and 
dichotomizing vitamin A from diet. Maternal total exposure was split into two groups: low 
intake and sufficient intake.  Women with intake less than the 33rd percentile of vitamin A from 
diet and no prenatal or multivitamin supplementation 1 month pre-pregnancy were defined as 
“low intake”. A woman was classified as “sufficient intake” if she has greater than the 33rd 
percentile of vitamin A from diet or took a prenatal or multivitamin supplement 1 month pre-
pregnancy  
3.3.8 Statistical Analysis 
There were three main analytic goals: 1) estimate the genetic risk ratios (RRs) of the 
offspring and maternal genotypes; 2) estimate stratum-specific RRs by COG neuroblastoma 
prognostic risk-classification and offspring age at diagnosis; and 3) assess multiplicative 
maternal and offspring gene-environment interactions with maternal vitamin A.  We used a 
codominant model to simultaneously assess the offspring and maternal log-additive genetic main 
effects and a log-additive model for gene-environment interaction.317  
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The null genetic background genotype is discerned from the parental genotypes under the 
assumption of Mendelian transmission in the source population, which allows us to estimate RRs 
without controls.317  An additional assumption of mating symmetry in the source population is 
needed to estimate the maternally-mediated genetic association, since the maternal genotype 
frequencies.  The maternal and offspring log-additive RRs were calculated simultaneously and 
are mutually adjusted.  We can also account for missing paternal genotype with the expectation-
maximization algorithm, which maximizes the observed-data likelihood by fractionally assigning 
incomplete triads into their data-compatible cells on the basis of the current parameter estimates, 
and then repeating the calculations iteratively up to convergence and maximization of the 
likelihood.20 
The offspring and maternal genetic models were separately fitted for each prognostic 
COG risk-classification and offspring age at diagnosis dichotomized at 1 year with separate 
“mating type” and risk parameters allowed within each stratum. Offspring age at diagnosis was 
dichotomized into less than 1 year of age at diagnosis or “infant cases” and greater than or equal 
to 1 year of age or “childhood cases”. This age dichotomy represents two different peaks in 
neuroblastoma age at diagnosis distribution.333 
The gene-environment interaction model is an extension of the genetic only model with 
an additional term for the interaction of the offspring or maternal genotype and maternal vitamin 
intake.21  This model enables estimation of genotypic RRs that can differ across levels of vitamin 
intake. The main genotype effects were coded co-dominantly, while the interaction term is fit 
log-additively to enhance power.  If interaction terms were significant after multiple correction, 
then the interaction model was refit co-dominantly to characterize the interaction in a more 
flexible way.  
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To account for multiple comparisons, we corrected all p-values with the false discovery rate 
(FDR) and all reported results considered significant are FDR-corrected significant at Q-value 
less than 0.2.334 . All estimated RRs will be presented in relation to the minor allele at the 
specified SNP.   
3.3.9 Replication Study 
We were able to provide replication for the results from offspring genotypes using 
genetic data and imputation from a previously conducted GWA offspring case-control study.  Dr. 
John Maris and colleagues at the Children’s Hospital of Philadelphia (CHOP) conducted GWA 
case-control study.  Information on this study has been described elsewhere.8  Briefly, the cases 
were identified through the Neuroblastoma Bio-repository maintained by the COG which 
collects germline and tumor specimens at the time of diagnosis. Controls with no known medical 
disorder were recruited from multiple sites within the CHOP Health Care Network that includes 
four primary care clinics and several group practices and outpatient practices.  Population 
stratification was accounted for by adjusting for principle component scores. Since both the 
CHOP case-control and NENA studies recruited cases from the COG, there are an overlap of 
cases.  Cases enrolled in NENA were excluded from the CHOP sample, resulting in 2,052 cases 
and 4,104 controls. 
Because the platforms used for genotyping were not the same, analysis based on imputed 
genotypes was required. Imputation was performed on all CHOP GWA data with IMPUTE2 
using the world-wide 1000 Genomes Project Phase 1 interim data as reference (June 2011 
release).335  The SNPs selected based on NENA (N=1173) were tested for association with 
neuroblastoma using SNPTEST under an additive model.335 About a third of these SNPs were 
imputed in the CHOP replication sample.  Odds ratios (ORs) for all neuroblastoma cases as well 
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as stratification by risk-classification and age at diagnosis were FDR-corrected.  These results 
were then compared with the RRs from NENA.  
3.3.10 Sensitivity Analysis 
Many women increase dairy consumption during pregnancy and dairy is a large 
contributor of vitamin A, we performed sensitivity analyses adjusting vitamin A nutrient levels 
depending on self-reported change in dairy intake due to pregnancy. After this vitamin A intake 
adjustment, vitamin A was then dichotomized at the new 25th percentile and the gene-
environment model was fit again.  Additional methods are included in the supplementary 
methods. 
Because women who breastfeed are advised to consume more calories, which alters 
nutrient intake additional sensitivity analyses were done excluding currently breastfeeding 
women.336 
3.4 Results 
We had genetic data for 465 triads and 98 dyads. Descriptive statistics for triads with 
genetic data are shown in Table 13. The mean age at diagnosis for the offspring was 1.7 years.  
As expected, the age at diagnosis differed across COG risk-classifications (p-value < 0.001) and 
the high-risk classification had the oldest age at diagnosis (2.6 years).  Maternal age at birth was 
consistent across risk groups with the overall average maternal age of 29.8 years. There were 
more male (53.6%) than female cases in the study.  This pattern of male excess was consistent 
across COG risk-classification groups except for the low-risk group (52.4% females).  The 
predominant maternal race was white (84.8%).  The median vitamin A maternal consumption 
was 672.21 μg RAE (Interquartile range: 458.18-978.16). 
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Table 13. Descriptive statistics for triads with genetic data 
 Total  Low-risk Intermediate-risk High-risk  
 N 
Mean 
(Std) 
 
N 
Mean 
(Std) N 
Mean 
(Std) N 
Mean 
(Std) p 
Maternal Age (Yrs) 606 
29.7 
(5.30) 
 186 
29.4 
(5.14) 
146 
29.5 
(5.38) 
204 
30.0 
(5.34) 
0.591 
Age at diagnosis (Yrs) 618 
1.7 
(1.43) 
 181 
1.4 
(1.40) 
149 
0.9 
(0.87) 
204 
2.6 
(1.20) 
<0.001 
           
 N %  N % N % N %  
Offspring gender           
Female 285 45.7  94 51.9 71 47.7 88 43.6 0.078 
Male 339 54.3  87 48.1 78 52.3 114 56.4  
Maternal race           
White 513 84.7  140 79.6 120 82.2 174 87.9 0.042 
Black 24 4.0  12 6.8 3 2.1 7 3.5  
Hispanic 36 5.9  16 9.1 11 7.5 7 3.5  
Other 33 5.5  8 4.6 12 8.2 10 5.1  
Missing 18 --  5 -- 3 -- 4 --  
Yrs: Years; Std: Standard Deviation; p: p-value 
Among offspring, no SNPs were significantly associated with neuroblastoma (Appendix 
1). With stratification by COG-risk group, nine SNPs were significantly associated with 
intermediate-risk neuroblastoma (Table 14). These 9 SNPs are located near or in four genes: 
RXRA, ADH1A, RARG, and ALDH1A2 (highest r2=0.72). 
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Table 14. Offspring FDR-corrected significant SNPs results for intermediate risk group  
  NENA  CHOP 
Gene SNP 
Effect 
Allele 
Major 
Allele RR (95% CI) P-value 
FDR 
Q-value  
Effect 
Allele 
Major 
Allele OR (95% CI) P-value 
FDR 
Q-value 
RXRA rs4842196 C A 1.97(1.32, 2.93) 0.001 0.185  -- -- -- -- -- 
ADH1A rs1229977 T C 0.48(0.31, 0.75) 0.001 0.185  C T 0.87(0.67, 1.12) 0.278 0.933 
RXRA rs1045570 T G 2.07(1.32, 3.24) 0.002 0.185  -- -- -- -- -- 
RXRA rs1007971 G C 1.94(1.27, 2.97) 0.002 0.185  -- -- -- -- -- 
RARG rs7139068 T A 0.40(0.21, 0.73) 0.003 0.185  -- -- -- -- -- 
ADH1A rs904092 A G 0.48(0.29, 0.78) 0.003 0.185  G A 0.74(0.56, 0.98) 0.038 0.933 
RXRA rs3118523 G A 2.09(1.27, 3.43) 0.004 0.185  -- -- -- -- -- 
ALDH1A2 rs7169439 A G 2.75(1.39, 5.45) 0.004 0.185  -- -- -- -- -- 
RARG rs1465057 C T 0.37(0.19, 0.73) 0.004 0.185  C T 1.10(0.75, 1.62) 0.609 0.933 
CHOP: Children’s Hospital of Philadelphia case control replication study; RR: Risk Ratio; CI: Confidence Interval; OR: Odds Ratio; 
--: Unavailable in replication study 
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Maternal rs12442054, selected for its proximity to STRA6, was significantly inversely 
associated with neuroblastoma overall (log-additive RR for each A allele: 0.61; 95% Confidence 
Interval (CI): 0.47, 0.79; Table 15).  We also found significant results among the COG high-risk 
and infant cases. Maternal rs6776706 was significantly associated with decreased risk of high-
risk neuroblastoma (log-additive RR for each A allele: 0.49; 95% CI: 0.33, 0.72).  Each 
additional maternal copy of the C allele of rs11103603 conferred a risk ratio of 0.60 (95% CI: 
0.45, 0.79) for infant neuroblastoma.  Maternal results from all the SNPs can be found in 
Appendix 2. 
Table 15.  Maternal FDR-corrected significant SNPs results 
SNP Gene RR (95% CI) P-value Q-value 
Overall     
rs12442054 STRA6 0.61(0.47, 0.79) <0.001 0.076 
High-Risk     
rs6776706 RARB 0.49(0.33, 0.72) 0.0004 0.161 
Infants     
rs11103603 RXRA 0.6(0.45, 0.79) 0.0003 0.127 
RR: Risk Ratio; CI: Confidence Interval 
We found no significant gene-environment interactions with pre-pregnancy vitamin 
supplementation or when vitamin A dietary intake was dichotomized at the first quartile (results 
not shown) for either offspring or maternal genetic variants. We did find a significant additive 
interaction with maternal rs729147 (Figure 11) for maternal vitamin A intake dichotomized at 
the RDA (700 μg RAE) (Additive interaction p-value<0.001; Q-value=0.156).  The interaction 
was modeled co-dominantly to allow more flexibility when estimating RRs. When maternal 
vitamin A intake was below the RDA, one G allele of maternal rs729147 was significantly 
associated with increased risk of neuroblastoma (RR G/A vs. A/A: 1.49; 95% CI: 1.04, 2.13).  
When maternal intake was above the RDA, one or two G alleles were associated with a 
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decreased risk of neuroblastoma (RR for G/A vs. A/A: 0.58; 95% CI: 0.38, 0.87 and RR G/G vs. 
A/A: 0.51; 95% CI: 0.26, 1.03).  The maternal rs729147 was also significant for “total exposure” 
with very similar point estimates, but wider confidence intervals due to low numbers of variant 
alleles in “low vitamin A intake” (Figure 12).
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Figure 11. A) Offspring and B) Maternal interaction with co-dominant rs729147 with vitamin A dichotomized at the RDA (700 µg 
RAE)   
 
Int.P: Interaction p-value 
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Figure 12. A) Offspring and B) Maternal interaction with co-dominant rs729147 “total” maternal vitamin A exposure 
 
Int. P.: Interaction p-value 
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3.4.1 Replication Study 
Maternal genotyping and questionnaire data were not available from CHOP, thus only 
offspring genetic results were compared. Similar to NENA’s results, none of the offspring SNPs 
from CHOP were significant (Appendix 1), but unlike NENA, results based on CHOP were non-
significant with stratification by risk-classification and offspring age at diagnosis (Results not 
shown).  Additionally, the significant NENA results for intermediate-risk neuroblastoma, 3 of 
which were available in CHOP, did not replicate (Table 2). 
3.4.2 Sensitivity Analysis 
Among women below the RDA for vitamin A (700 μg RAE), 29 women reported that 
they had greatly increased their dairy intake during pregnancy compared to current diet.  When 
these women were re-classified and the model refit, the maternal rs729147 was still significant.  
After breastfeeding mothers were excluded (N=47), no SNPs were significant, but the point 
estimate for the effect of rs729147 was in the same direction 
3.5 Discussion 
Vitamin A is crucial for proper differentiation of neuronal cells, and given the previous 
epidemiologic association with maternal vitamin supplementation pre-pregnancy, we 
hypothesized that common variants in the vitamin A pathway is associated with neuroblastoma 
and may be modified by maternal vitamin intake.  Overall, no offspring SNPs were associated 
with neuroblastoma. Although some SNPs were associated with intermediate-risk 
neuroblastoma, these 3 SNPs did not replicate in the CHOP case-control validation study. 
Results from this study suggest that maternal variants may play a larger in neuroblastoma 
development (including different neuroblastoma subtypes) than offspring genetics. Moreover, 
maternal genetic effects may be modified by maternal vitamin A intake.  However, since 
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maternal genotypes were not collected in the CHOP validation, the robustness of these findings 
is uncertain. 
The A allele of maternal rs12442054 (minor allele frequency in mother = 6.1% and minor 
allele frequency in father = 13.7%), was associated with decreased risk of neuroblastoma.  
Although selected for its proximity to STRA6, this SNP is closest to the start site of ISLR.  The 
exact function of ISLR in humans has yet to be determined, but in mice it is expressed the heart, 
thyroid, spinal cord and retina.337  We were more inclusive when selecting variants, extending far 
beyond cis-regulatory elements, allowing us to capture some of the trans-regulatory elements. 
Research has shown that these intergenic regions can code for trans-regulatory elements such as 
intergenic binding sites for transcription factors or non-coding RNA – RNA not translated to 
proteins such as transfer RNA or ribosomal RNA.338  There is evidence that rs12442054 is 
located within non-coding RNA, but the function of the non-coding RNA is unknown.32 
We found 9 offspring SNPs significantly associated with intermediate-risk 
neuroblastoma. The functionality of these variants are unknown and they have not previously 
been associated with any disease. We found no SNPs of interest highly correlated (r2>0.8) with 
these SNPs in 1000 Genomes CEU population using the SNAP software developed by the Broad 
Institute.339  The intermediate-risk neuroblastoma group, as defined for prognostic use, is 
genetically very heterogeneous and the etiologic significance of our finding is unclear.  Three of 
these significant SNPs were available in the CHOP validation case-control study and were not 
even directionally consistent with the NENA results, further highlighting the heterogeneity of 
intermediate-risk neuroblastoma phenotype and the uncertainty of the interpretation of these 
findings. 
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Two maternal SNPs were associated with neuroblastoma in our stratified analysis.  We found 
that mothers with the T allele of the intronic rs6776706 in RARB had decreased risk of an 
offspring with high-risk neuroblastoma.  No association was seen for this SNP with either low-
risk or intermediate-risk neuroblastoma. Genome-wide association studies have found distinct 
variants associated with high-risk neuroblastoma, suggesting this prognostic category may have 
etiologic relevance.44,79,81,83  One SNP, rs6800566, is in linkage disequilibrium with rs6776706 
(r2=0.96) and has been previously associated with measles virus antibodies and IL-10, IFN-α and 
TNF-α secretion in 745 Caucasian subjects.340 However, the relevance of this SNP to 
neuroblastoma is unknown.   
The T allele of maternal rs11103603, almost 10kbp downstream from RXRA, was 
associated with decreased risk of neuroblastoma in infants.  This maternal variant was not 
associated with neuroblastoma in children older than 1 year (RR: 1.07; 95% CI: 0.84, 1.37).  It is 
located in a CTCF binding site, which is a transcription regulatory site in embryonic human stem 
cell cultures; but how this SNP affects the binding site in unknown.341,342  A variant in rs9409929 
that is in high linkage disequilibrium with rs11103603 (r2= 0.898), has been previously reported 
to be associated with increased levels of calcitriol – a hormonally active vitamin D metabolite.343  
Because vitamin D has been previously associated with decreased cancer risk,344 this warrants 
additional study of the region in relation to vitamin D levels and neuroblastoma in infants. 
Unfortunately, since NENA did not collect blood samples, we are unable to directly address 
hypotheses related to vitamin D with the present study. 
We found one significant result for a maternal gene-vitamin A interaction when vitamin 
A was dichotomized at the RDA value.  This variant (rs729147) is 500bp downstream from 
ADH7, which encodes a gene that converts retinol to retinoic acid. ADH7 is involved with 
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alcohol metabolism and rs729147 has been previously studied but no association with alcoholism 
was found.345,346  SNPs in LD with this SNP have not been previously associated with any 
diseases.  This SNP has never been studied in relation to vitamin A processing and transport and 
merits additional investigation. 
This present study has a few limitations.  Since the neural crest starts responding to 
differentiation signals at 5 weeks, our exposure window of interest is early pregnancy and pre-
pregnancy.71  However, we are using post-pregnancy usual diet as a proxy for this period and 
thus our dietary intake data is subject to measurement error.  A few studies have demonstrated 
that maternal diet tends not to shift drastically during pregnancy,306,307 but it is possible that 
current diet does not reflect early pregnancy diet, but rather pre-pregnancy diet before morning 
sickness if that occurred in the women.  We also conducted a sensitivity analysis altering vitamin 
A due to dairy changes during pregnancy and confirmed that the association was not measurably 
affected by diet changes due to pregnancy.  Additionally, our mothers were potentially 
interviewed during a time when their child was suffering from a critical illness, which could have 
substantially disrupted their routine behavioral patterns or influenced their reporting.  However, 
we found little change in vitamin A consumption by risk-classification, a measure of severity of 
neuroblastoma. 
Although we believe we had excellent coverage for the genes with SNPs selected from 
the CEU population, small proportion of the participants (93 mothers) are non-white, which may 
had less than ideal coverage.  The violation of the assumption that the alleles of the mothers can 
be validly compared with the fathers can occur if there is uneven pairing by race leading to 
spurious maternal associations.  However, when the non-white families were excluded, the point 
estimates were stable, suggesting that there is no violation of this assumption in NENA. 
 111 
 
This study also had multiple strengths.  Importantly, vitamin A has strong biologic 
plausibility with the etiology of neuroblastoma. Vitamin A is essential to the differentiation of 
neuronal cells.  In neuroblastoma, less differentiated tumors present in a more aggressive 
fashion. Thus, 13-cis-retinoic acid is commonly used as maintenance treatment in conjunction 
with antibody therapy for high-risk neuroblastoma.170  Vitamin A, in the form of retinol and 
retinyl ester or beta-carotene, is transferred from the mother to the placenta, highlighting the role 
of maternal genetics in fetal development and subsequent neuroblastoma malignant 
transformation.139  Our use of the case-parent triad approach allowed for the assessment of these 
maternal genetic effects. 
Additionally, this is the largest study to date with both genetic and maternal questionnaire 
data to allow for the study of gene-environment interaction. The case-parent triad approach 
eliminates the need for a control group. The Children’s Oncology Group is the primary resource 
to collect a large number of cases.  However, to collect population-based controls for a North-
America-wide study would have presented a logistical and validity challenge.  Additionally, the 
case-parent triad design is robust against bias due to population stratification and bias due to self-
selection based on ethnicity.  We also had access to the CHOP case-control study recruited from 
the same base population as NENA to independently validate the results from NENA. 
In conclusion, we targeted variants in genes from the vitamin A pathway and found 
evidence that some genetic variants in vitamin A metabolism and transport may play a role in 
neuroblastoma etiology.  However, due to the uncertain functionality of these SNPs, and the fact 
that some associations were seen only for sub-phenotypes, additional studies and replications of 
these results are warranted. .  
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CHAPTER 4: AIM 2 RESULTS 
A family-based study of gene variants and maternal folate and choline in neuroblastoma: A Report 
from the Children’s Oncology Group 
4.1 Overview 
Neuroblastoma is a childhood cancer of the sympathetic nervous system with embryonic 
origins. Previous epidemiologic studies suggest maternal vitamin supplementation during 
pregnancy reduces the risk of neuroblastoma. We hypothesized offspring and maternal genetic 
variants in folate-related and choline-related genes are associated with neuroblastoma and 
modify the effects of maternal intake of folate, choline and folic acid.  The Neuroblastoma 
Epidemiology in North America (NENA) study recruited 563 affected children and their parents 
through the Children’s Oncology Group’s Children Cancer Research Network. We used 
questionnaires to ascertain pre-pregnancy supplementation and estimate usual maternal dietary 
intake of folate, choline and folic acid. We genotyped 955 genetic variants related to folate or 
choline using DNA extracted from buccal cell samples and used a log-linear model to estimate 
both child and maternal risk ratios and stratum-specific risk ratios for gene-environment 
interactions. Overall, no maternal or offspring genotypic results met criteria for a false discovery 
rate (FDR) Q-value <0.2.  Associations were also null for gene-environment interaction with pre-
pregnancy vitamin supplementation, dietary folic acid and folate.  FDR significant gene-choline 
interactions were found for offspring SNPs rs10489810 and rs9966612 located in MTHFD1L and 
TYMS, respectively, with maternal choline dietary intake dichotomized at the first quartile. 
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These results suggest that variants related to one-carbon metabolism are not strongly associated 
with neuroblastoma.  Some choline-related variants may play a role, however the functional 
consequences of the interacting variants of interest are unknown and require independent 
replication. 
4.2 Background 
Neuroblastoma is an embryonal tumor of the neural crest portion of the sympathetic 
nervous system and usually presents in children less than 1 year of age.1,2  Each year 
approximately 770 children in North America are diagnosed with neuroblastoma, in which 
incidence rates slightly higher in males than females (7.7 per million vs 6.9 per million).2,46,47,327  
Familial cases of neuroblastoma have been associated with specific mutations in the PHOX2B 
and ALK genes and among non-familial cases, recent genome-wide association (GWA) studies 
have identified several common variants of interest.6-9   
  Due to the embryonic origins of neuroblastoma, pre-pregnancy and early pregnancy 
exposures are crucial its development. Epidemiologic studies have found evidence of an inverse 
association between maternal prenatal vitamin use and risk of neuroblastoma.10,11  One study 
reported a 60% reduction in risk for daily vitamin use in the month before, or during pregnancy.  
Although these studies did not indicate which vitamins(s) may underlie the association 
with neuroblastoma, folate and choline may be important. Folate is essential for one-carbon 
metabolism and is important in cell proliferation and differentiation of neural crest cells.16,17  
Choline is also involved in one-carbon metabolism and an essential building block for membrane 
development.18   
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Due to the key role of folate and choline in fetal and neuronal development and the 
suggestive epidemiological evidence, we hypothesized that genetically-based alterations in the 
levels of folate and choline during development, acting jointly with maternal nutrition, may 
impact the risk of neuroblastoma.  This study is the first to examine the risk of neuroblastoma 
with maternal and offspring single nucleotide polymorphisms (SNPs) as well as gene-
environment interactions with maternal folate and choline dietary intake and pre-pregnancy 
maternal vitamin supplementation.   
4.3 Methods 
4.3.1 Study Sample 
The Neuroblastoma Epidemiology in North America (NENA) study used a case-parent 
triad design.  Cases were identified from the Childhood Cancer Research Network (CCRN) – a 
registry system of newly diagnosed cases maintained by the Children’s Oncology Group 
(COG).304  NENA approached families registered in the CCRN registry who had agreed to be 
contacted for future research. Eligible cases had a primary diagnosis of neuroblastoma, including 
ganglioneuroblastoma but excluding ganglioneuroma.  Cases had to be diagnosed before 6 years 
of age at a U.S. or Canadian COG institution from December 24, 2007 to July 31, 2013, and the 
biologic mother had to be alive and willing to participate. The University of North Carolina at 
Chapel Hill (UNC) Institutional Review Board approved this study. 
After the cases were identified through the CCRN, we sent a recruitment packet to 1347 
families and 870 families agreed to enroll. Study materials sent included a consent form, 
questionnaire to be filled out by the mother, a mouthwash Oragene saliva spit tube collection kit 
for the parents, and an Oragene saliva sponge/disc kit for the child.   If the child was deceased, 
we delayed communication by 15 months after date of death and obtained a previously collected 
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blood DNA sample from the COG Neuroblastoma Bio-repository at the Children’s Hospital of 
Philadelphia (CHOP).  
Saliva samples were collected for 626 biological mothers, 592 living children, 525 
biological fathers and blood samples were obtained for 19 deceased children (Figure 9).  Of the 
630 maternal questionnaires received, two did not have a corresponding signed consent form and 
two were incomplete, resulting in 626 completed questionnaires for analysis (Figure 10).  Of the 
630 maternal questionnaires received, two did not have a corresponding signed consent form and 
two were incomplete, resulting in 626 completed questionnaires for analysis. 
4.3.2 Candidate Genes and SNP selection 
Genes were selected based on their role in the transport and metabolism of folate and 
choline as well as one-carbon metabolism. Since most of the mothers self-identified as white, 
TAGster with the greedy algorithm was used to capture haplotype tagging SNPs (minor allele 
frequency ≥ 5%) that tag SNPs in high linkage disequilibrium (LD; r2≥0.8) for Hapmap 3 release 
III CEU population, located between 20kb upstream to 10kb downstream from the gene.312,329  
The case-parent triad design is not subject to confounding by population stratification, thus 
ancestry-informative markers were not included.317  A total of 693 SNPs in 38 folate-related and 
302 SNPs in 19 choline-related genes were selected for genotyping. 
4.3.3 DNA collection and Genotyping 
DNA extraction and amplification was completed by the UNC Biospecimen Processing 
Facility. DNA was extracted using the Perkin-Elmer's Chemagic MSMI magnetic-bead 
extraction robotic system. Saliva samples from parents were collected in DNA Genotek’s OGR-
250 collection kits. Saliva from the child was also collected by the parents using 5 provided 
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swabs to collect the saliva.  The DNA quality was assessed with Nanodrop Optical Density and 
quantitated with Applied Biosystems® Taqman® RNase P detection kit. A total of 498 triads, 99 
mother-child dyads, 5 father-child dyads and 27 other (mother-father dyads and singleton cases) 
with DNA yields greater than 2 µg were sent for genotyping. 
Genotyping was performed by UNC’s Mammalian Genotyping Core Facility using the 
GoldenGate Assay with the Illumina BeadStation 500GX Genetic Analysis System. Allelic 
discrimination was based on allele-specific primer extension followed by ligation.  
4.3.4 Genotyping Quality Control 
For quality control purposes, a Centre de l'Étude du Polymorphisme Humain (CEPH) 
family triad and blinded duplicates were included on each plate. SNPs with a genotyping call rate 
less than 95% and showing a lack of defined clusters in the raw genetic intensity data were 
excluded.  Individual genotypes for SNPs showing apparent Mendelian errors in a particular 
family were treated as missing. In total, 599 folate-related SNPs and 277 choline-related SNPs 
passed quality control. We assessed Hardy-Weinberg (HWE) equilibrium among parents who 
self-identified as white using chi-square tests in PLINK (v1.07) and flagged (n=5), but did not 
exclude, SNPs that failed HWE at a false discovery rate (FDR) significance level of < 0.2.330,331 
Individuals with genotyping rates <95% or gender discrepancies were excluded. 
Relatedness was confirmed for each triad through measures of identity by descent. Triads and 
individuals with unexpected relatedness were excluded. For example, for non-paternity the 
paternal data was excluded. A total of 465 triads, 94 mother-child dyads, 4 father-child dyads 
and 61 others (13 mother-father dyads and 48 singletons) passed genetic quality control (Figure 
10).   
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4.3.5 Biological and Clinical Variables 
We obtained clinical and biologic characteristics of the tumor, such as tumor genetics and 
stage, from the COG Statistical and Data Center for all cases enrolled in a COG clinical protocol 
except 89 cases who were not enrolled. The data also included the COG “risk-classification” 
variable using a schema that defined three prognostic risk-classifications: low-risk, intermediate-
risk and high-risk.  These risk-classifications are based on tumor characteristics, including stage 
and MYCN amplification, ploidy and patient age dichotomized at 1 year.43  
4.3.6 Maternal Vitamin Use  
We ascertained the current and usual maternal diet during the preceding year using the 
Dietary History Questionnaire, a self-administered semi-quantified food frequency questionnaire 
(FFQ). We assumed maternal usual diet in the last year approximates pre-pregnancy diet. 
Completed FFQs were processed in Diet*Calc (version 1.5.0) to derive usual nutrient intake per 
day for the previous year. The nutrient and food group database was based on a compilation of 
national 24-hour dietary recall data from the National Health and Nutrition Examination Surveys 
(NHANES) conducted in 2001-2002, 2003-2004, and 2005-2006 
(http://riskfactor.cancer.gov/dhq2/database).  Certain foods not included in the original database 
were added by NENA staff in 100 gram amounts using the USDA database, standard release 24. 
To address potential differences between “usual” diet and diet during pregnancy, the 
questionnaire also asked if women had changed their consumption of foods prone to change, 
including dairy and fish.309 The mothers were asked if during pregnancy intake of these foods 
was “Much less than it is now”, “Somewhat less than it is now”,  “Same as it is now”,  
“Somewhat more than it is now”, and “Much more than it is now”. 
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Mothers were also questioned about maternal dietary supplementation, including single 
vitamins and prenatal or multi-vitamin use 1 month pre-pregnancy and within each trimester of 
pregnancy.  To aid in recall, an estimated conception date was provided; calculated by 
subtracting gestational age at delivery from infant birthdate. Since we are interested in pre-
pregnancy and early pregnancy exposures, we focused on prenatal vitamin or multivitamin use 1 
month pre-pregnancy.  
4.3.7 Diet and Nutrient classification 
We excluded questionnaires that reported calories per day below the 5th percentile (N=31; 
<854.47 calories) or above the 97th percentile (N=18; >4508.75 calories) (Figure 10).  We 
focused on folate, folic acid and choline for gene-environment interaction.  To take into account 
the different bioavailability of food folate and folic acid, dietary folate equivalent (DFE) was 
used to estimate total folate.  To explore different dietary cutoffs, nutrients from the FFQ were 
dichotomized at the 25th percentile (<209.70 mg for choline; <389.83 μg DFE; and <100.69 µg 
folic acid) and current daily recommendation for adult women. For total folate, the 
recommended dietary allowance (RDA) is 600 μg DFE for pregnant women. 27 Given choline 
and folic acid does not have an RDA we used the choline Adequate Intake – a recommendation 
level when RDA is not available – for women (425 mg/day) and for folic acid we used the Public 
Health Service Task Force recommendation for women trying to get pregnant (400µg/day).320,347   
We conducted an analysis combining prenatal or multi-vitamin use and folic acid and 
folate from diet. Maternal total exposure was split into two groups: low intake and sufficient 
intake.  Women with intake in the lowest tertile of micronutrients from diet and with no prenatal 
or multivitamin supplementation 1 month pre-pregnancy were defined as “low intake”. A woman 
was classified as “sufficient intake” if she had greater than the 33rd percentile of micronutrients 
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from diet and/or took a prenatal or multivitamin supplement 1 month pre-pregnancy.  We only 
combined vitamin use with folic acid and folate from diet, because choline is not commonly 
found in prenatal vitamins. 
4.3.8 Statistical Analysis 
There were three main analytic goals: 1) estimate the genotypic maternal and offspring 
risk ratios (RRs); 2) estimate stratum-specific RRs by neuroblastoma prognostic risk-
classification and offspring age at diagnosis; and 3) assess multiplicative maternal and offspring 
gene-environment interactions with maternal choline, folate and folic acid intake.  We used a 
log-linear model to simultaneously assess the offspring and maternal log-additive genetic main 
effects and gene-environment interaction.317  
Since there are no study controls in this analysis, the null background is discerned from 
the parental genotypes under the assumption of Mendelian transmission in the source 
population.317  For assessing a maternally-mediated genetic association, the maternal genotype 
frequencies are compared to the paternal genotype frequencies under a further assumption of 
mating symmetry in the source population.   The maternal and offspring log-additive RRs were 
calculated simultaneously and thus are mutually adjusted. Missing parent genotypes can be 
accounted for with the expectation-maximization algorithm, which maximizes the observed-data 
likelihood by fractionally assigning incomplete triads into their data-compatible cells on the basis 
of the current parameter estimates, and then repeating the calculations iteratively up to 
convergence and maximization of the likelihood.20 
For the stratified analysis, the offspring and maternal genetic models were separately fit 
for each prognostic COG risk-classification and offspring age at diagnosis dichotomized at 1 
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year with separate “mating type” and risk parameters allowed within each stratum. “Infant cases” 
are less than 1 year of age at diagnosis, while “childhood cases” are those greater than or equal to 
1 year of age. This age dichotomy represents the two peaks in the neuroblastoma age at diagnosis 
distribution. 
The gene-environment interaction model is an extension of the genetic only model with 
an additional term for the interaction of the offspring or maternal genotype and maternal vitamin 
intake.21 This model allows genotypic RRs to differ across levels of vitamin intake. The main 
genotype effects were coded co-dominantly, while the interaction term is fit additively to 
enhance power.  If interaction terms were significant after multiple testing correction, then the 
interaction model was refit co-dominantly to characterize the interaction in a more flexible way.  
All p-values were corrected for the number of tests by false discovery rate (FDR).334 
Results were considered significant if the FDR-corrected Q-value was less than 0.2. All 
estimated RRs are presented in relation to the minor allele at the specified SNP.   
4.3.9 Replication Study 
We were able to provide replication of our findings for offspring genotypes using 
genotyping data from a previously conducted GWA study.  Dr. John Maris and colleagues at 
CHOP conducted a GWA case-control study with 2,101 neuroblastoma cases and 4,202 healthy 
controls of European-American ancestry.  Information on this study has been described 
elsewhere.8 Briefly, the cases were diagnosed with neuroblastoma and identified through the 
Neuroblastoma Bio-repository maintained by the COG, which collects germline and tumor 
specimens at the time of diagnosis. Controls with no known medical disorder were recruited 
from multiple sites within the CHOP Health Care Network, including four primary care clinics 
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and several group practices and outpatient practices.  Principle component scores were used to 
adjust for population stratification. Cases that were enrolled in NENA were excluded from the 
CHOP sample, resulting in 2,052 cases and 4,104 controls. 
Imputation was performed on all CHOP case-control GWA data with IMPUTE2 using 
the world-wide 1000 Genomes Project Phase 1 interim data as reference (June 2011 release).335  
Additional information about the imputation has been previously published.8 The same SNPs 
used for the NENA case-parent analysis (N=1173) were tested for case-control association with 
neuroblastoma using SNPTEST under the additive model.335  About a third of these SNPs were 
imputed in the CHOP replication study. Odds ratios (ORs) were FDR-corrected and compared 
with the RRs from NENA.  
4.3.10 Sensitivity Analysis 
Since many women increase dairy consumption and decrease fish consumption during 
pregnancy, and both are large contributors to choline, we performed sensitivity analyses.  The 
questionnaire asked if women changed their diet relative to current diet in foods prone to change, 
including dairy and fish.309 The mothers were asked if during pregnancy intake was “Much less 
than it is now”, “Somewhat less than it is now”,  “Same as it is now”,  “Somewhat more than it is 
now”, and “Much more than it is now”.   
Choline levels were manually changed for women to reported increasing dairy 
consumption and decreasing fish consumption during pregnancy. We calculated the average 
amount fish and dairy contributes to choline in NENA. Choline levels for mothers who reported 
that their fish consumption during the pregnancy had been “much less than it is now” were 
decreased by 8.55 mg.  For mothers who reported that their dairy consumption during the 
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pregnancy had been “much more than it is now”, their choline levels were increased by 73.87 
mg, the average amount of choline. After this choline intake adjustment, choline was then 
dichotomized at the 25th percentile and the gene-environment model was fit again.   
Since women who breastfeed are advised to consume more calories, which alters current 
nutrient intake, additional sensitivity analyses were done excluding breastfeeding women. 
4.4 Results  
4.4.1 Descriptive Statistics 
We had genetic data for 465 triads and 98 dyads. Descriptive statistics for triads with 
genetic data are shown in Table 13. The mean age at diagnosis for the offspring was 1.7 years.  
As expected, the age at diagnosis differed across COG risk-classifications (p-value < 0.001) and 
the high-risk classification had the oldest age at diagnosis (2.6 years).  Maternal age at birth was 
consistent across risk groups with the overall average maternal age of 29.8 years. There were 
more male (53.6%) than female cases in the study.  This pattern of male excess was consistent 
across COG risk-classification groups except for the low-risk group (52.4% females).  The 
predominant maternal race was white (84.8%).  The median vitamin A maternal consumption 
was 672.21 μg RAE (Interquartile range: 458.18-978.16). 
Table 13 describes the demographics of our analytic sample of families (465 triads and 
98 dyads). The mean age at diagnosis for the offspring was 1.7 years.  As expected, the age at 
diagnosis differed across COG risk-classifications (p-value<0.001); the high-risk classification 
had the oldest mean age at diagnosis (2.6 years).  Maternal age at birth of the case was similar 
across risk-classification categories.   This study included more male cases (53.6%) than female 
cases. This male excess was similar across COG risk-classification groups except for the low-
risk classification (52.4% females).  The predominant maternal race was white (84.8%).  Almost 
 123 
 
60% of mothers (N=349) reported using vitamin supplementation 1 month before conception.  
(Table 16). 
Table 16. Descriptive statistics of maternal usual dietary nutrient levels and supplemental pre-
pregnancy vitamin consumption 
 N % 
Vitamin use 1 month pre-pregnancy   
Yes 349 59.4 
No 239 40.6 
Missing 36 -- 
 N Median (IQR) 
Choline (mg) 559 279.78 (208.28-372.39) 
Folate (Dietary Folate Equivalent) 559 511.29 (389.71 - 698.35) 
Folic Acid (µg) 559 162.11 (100.69-233.79) 
4.4.2 Folate  
We found no significant associations between folate-related maternal and offspring SNPs 
and neuroblastoma overall, or when stratified by COG risk-classification or offspring age at 
diagnosis (Appendix 3 and 4). 
We observed no significant gene-environment interaction in relation to maternal or 
offspring genotypes for maternal vitamin supplementation 1 month pre-pregnancy or for 
maternal dietary folic acid or total folate intake.  Results from the total exposure analysis 
combining prenatal and multi-vitamins and diet were also non-significant. 
4.4.3 Choline 
We found no significant associations for maternal or offspring choline SNPs, either 
overall or stratified by risk-classification or offspring age at diagnosis. 
For the gene-choline interaction, we observed two significant log-additive interaction p-
values for the 25th percentile in maternal choline consumption with the offspring SNP rs1738575 
(interaction p-value<0.001; Q-value=0.076), and with the offspring SNP rs9966612 (p-
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value<0.001; Q-value=0.140).  We refit the interaction model co-dominantly to provide allele-
count-specific point estimates resulting in wider confidence intervals due to the rarity of 
homozygotes. For mothers below the 25th percentile of choline consumption (Figure 13), when 
maternal choline consumption was below the 25th percentile (RR for A/G versus G/G: 0.46, 95% 
CI: 0.30-0.70; RR for A/A versus G/G: 0.5, 95% CI: 0.21-1.21), with both lower than the relative 
risks among triads with maternal choline greater than the 25th percentile (RR for A/G versus 
G/G: 1.35, 95% CI: 1.04-1.75; RR for A/A versus G/G: 1.08, 95% CI: 0.31-3.75).  
When choline was dichotomized at the Adequate Intake level (425 mg), the log-additive 
interaction was significant for the offspring SNP rs10489810 (interaction p-value<0.001; Q-
value=0.173). Among mothers with below Adequate Intake of choline consumption, we found 
offspring with one T allele had little evidence for association (RR T/A vs. A/A: 0.91, 95% CI: 
0.71-1.17) while those with 2 T alleles had an inverse association (RR T/T vs. A/A: 0.43, 95% 
CI: 0.26-0.70). Among mothers with above Adequate Intake level of choline, offspring with 1 T 
allele and those with 2 T alleles had an increased risk (RR T/A vs. A/A: 2.00, 95% CI: 1.11-3.60; 
RR T/T vs. A/A: 2.85, 95% CI: 0.98-8.30) of neuroblastoma. 
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Figure 13. A) Offspring and B) maternal interaction with codominant rs173857 and maternal choline dichotomized at the 25th percentile 
 
Int.P: Interaction p-value 
 
  
 
1
2
6
 
Figure 14. A) Offspring and B) maternal interaction with codominant rs9966612 and maternal choline dichotomized at the 25th 
percentile 
 
 Int. P.: Interaction p-value 
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4.4.5 Replication Study 
Maternal genotyping and questionnaire data were not available from CHOP, thus only 
offspring genetic results were compared. There are a few CHOP study results that are significant 
(Appendix 3).  However, the results from NENA for these SNPs were not also significant and 
the RRs were not directionally consistent between studies. 
4.4.6 Sensitivity Analysis 
Among women who were below the 25th percentile for choline, 10 mothers increased 
dairy consumption and 2 increased fish consumption during pregnancy.  For women with greater 
than the 25th percentile for choline consumption, 8 decreased dairy consumption, but 83 
decreased fish consumption during pregnancy.  In the sensitivity analyses, both alleles for 
rs10489810 and rs9966612 remained significant (Table 17) and the point estimates changed 
little.   We also found a significant interaction with offspring alleles in rs9478157 and 
rs1052751, neither of which had previously been significant. 
We found no new significant results when women who were breastfeeding were excluded 
(N=46).  The previously identified gene-choline interactions for offspring SNPs rs10489810 and 
rs9966612 remained nominally significant and were directionally unchanged. 
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Table 17. Choline sensitivity analysis with offspring SNPs 
  Below 209.70 mg Choline Consumption  Above 209.70 mg Choline Consumption 
SNP Gene 
RR - (95% CI) 
1 Allele P Q 
RR (95% CI) 
2 Alleles P Q 
 RR(95% CI) 
1 Allele 
RR (95% CI) 
2 Alleles Int. P Int. Q 
rs1052751 PLD2 2.63(1.42,4.86) 0.002 0.398 6.49(2.05,20.6) 0.002 0.534  0.88(0.66,1.17) 0.72(0.34,1.52) 0.001 0.133 
rs1738575 MTHFD1L 2.06(1.35,3.16) 0.001 0.398 2.60(1.27,5.33) 0.009 0.825  0.99(0.76,1.31) 0.60(0.40,0.91) 0.001 0.133 
rs9478157 MTHFD1L 1.87(1.22,2.87) 0.004 0.508 2.89(1.3,6.44) 0.009 0.825  0.86(0.67,1.1) 0.61(0.39,0.95) 0.001 0.133 
rs9966612 TYMS 0.53(0.35,0.8) 0.003 0.398 0.21(0.09,0.52) 0.001 0.520  1.25(0.97,1.63) 1.20(0.72,1.99) 0.000 0.133 
RR: Risk Ratio; CI: Confidence Interval; P: P-value; Q: FDR Q-Value; Int. P:  Interaction P-value; Int. Q:  Interaction FDR Q-value
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4.5 Discussion 
These analyses were motivated by prior epidemiologic evidence suggesting that 
inadequate maternal consumption of folate, folic acid, and choline is increases the risk of 
neuroblastoma. Although SNPs within the one-carbon metabolism pathway have been previously 
associated with birth defects and childhood cancers, our study suggests these SNPs may not play 
a direct role in the etiology of neuroblastoma.178,232,252,348  SNPs from either choline or folate-
related genes were not associated with neuroblastoma overall, within COG risk-classification, or 
by age at diagnosis.  While significant SNPs were found in the CHOP case-control replication 
study, those SNPs were not significant and were not directionally consistent with NENA results. 
The gene-environment interaction results suggest gene variants in choline pathways may modify 
effects of choline intake; however, since the identified SNPs lie within non-coding regions, the 
exact implications of these associations are unclear at present. 
We found no offspring or maternal associations for the SNPs that were selected because 
they had previously been associated with cancer or birth defects. MTHFR 667C>T (rs1801133), 
one of the most highly studied variants with known functional effects on one-carbon 
metabolism,228,233,235 had a non-significant offspring RR of 0.99 (95% CI: 0.84-1.19) and a weak 
maternal RR of 1.16 (95% CI: 0.97-1.38). Two previous studies of candidate SNPs from folate-
related genes identified SLC19A1 80G>A (rs1051266) as positively associated with 
neuroblastoma in Brazil.85,86 Montalvão-de-Azevedo et al. found maternal carriers of the G had 3 
times the risk of offspring with neuroblastoma and offspring carriers had approximately 2.5 
times the risk, which was replicated by de Miranda et al.85,86  We found no association in NENA 
(Maternal RR: 1.12, 95%: CI: 0.96-1.32; offspring log-additive RR: 0.94, 95% CI: 0.79-1.11). 
The inconsistent findings may be due to chance, differences in ancestry, confounding by 
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maternal genotype, or possibly different dietary and vitamin supplementation intake patterns in 
Brazil. 
We found significant gene-choline results for two offspring SNPs, rs1738575 and 
rs9966612, respectively located in an intron of MTHFD1L and upstream from TYMS. MTHFD1L 
is involved in tetrahydrofolate conversion in the mitochondria during one-carbon metabolism.16  
Offspring SNP rs9966612 is about 8 kbp upstream from TYMS but within the intron of CLUL1 
and 500 bp downstream from TYMSOS.  However, there is no compelling evidence either 
TYMSOS or CLUL1 is related to neuroblastoma development.349   Since we used haplotype 
tagging, these SNPs could be in LD with the casual SNP. To further explore correlated SNPs, we 
used SNP Annotation and Proxy Search (SNAP) developed by the Broad Institute to find SNPs 
in high LD (r2>0.8) based on the 1000 Genome CEU population.339  SNPs in high LD with 
rs1738575 and rs9966612 have not previously been associated with disease. Given these SNPs 
are located in regions not previously identified as transcriptionally active, their impact is unclear. 
When choline was dichotomized at the Adequate Intake level, we found one additional 
interacting offspring SNP, which appeared to increase the risk of neuroblastoma among those 
above the Adequate Intake level but decrease risk among offspring below.  The offspring SNP 
rs10489810 is located within an intron of SLC44A3, a choline transporter. SNPs in SLC44A3 and 
those in high LD with rs10489810 have not previously been associated with any disease. 
This present study has some limitations. Our assessment of pre-pregnancy maternal diet 
is retrospective.  Studies have demonstrated that maternal preconception nutritional status is 
critical for early fetal development but the critical etiologic window specific to neuroblastoma is 
nonetheless unknown; thus, our exposure window extends from pre-pregnancy until early 
 131 
pregnancy.350 The mothers in NENA completed the FFQ shortly after enrollment (2 months to 9 
years after the offspring birth date).  This assessment of diet more likely mirrors pre-pregnancy 
diet rather than early pregnancy when mothers may have changed diet due to morning 
sickness.351 Moreover, the FFQ occurred during a time when their child was suffering with a 
critical illness or may have died, leading to the potential for substantial disruption of their routine 
eating patterns.  However, in our data nutrient levels of folic acid, folate and choline from diet 
did not significantly differ by risk-classification or vital status, suggesting that nutrient levels do 
not differ by severity of disease. Furthermore, our sensitivity analysis revealed the FDR-
significant SNPs for gene-choline interaction were stable to differences in the estimation of 
choline levels related to reported changes in fish and dairy consumption during pregnancy.  The 
population studied in NENA were mostly white and highly educated (over 50% graduated 
college), and thus have greater rates of vitamin consumption and nutrient intake compared to the 
general population in the United States.98 Although the nature of our study sample does not 
affect the validity of the study, it could reduce generalizability and introduces the possibility that 
we are not capturing the “high risk” population that could benefit the most from intervention. 
The study has multiple strengths. This is the largest study conducted to date with both 
genetic and maternal questionnaire data to allow for the study of gene-environment interaction 
for genes in exposure pathways with evidence for an association with neuroblastoma. The case-
parent triad approach eliminates the need for a control group, a logistical and validity challenge 
for a North America-wide study.  Additionally, the case-parent triad design is robust against bias 
due to population stratification and self-selection based on ethnicity.  The case-parent triad 
approach also allows for the estimation of maternal risk ratios, which is especially important for 
diseases that can originate in utero.  We employed the use of an independent Replication study 
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that provided additional evidence for the robustness of our null results for offspring SNPs and 
neuroblastoma. 
This study suggests that maternal and offspring SNPs in folate and choline-related genes 
are not strongly associated with neuroblastoma.  Further, gene-environment interactions were not 
found for maternal vitamin supplementation or total folate or folic acid intake from diet, 
suggesting there is no appreciable modification of effects of SNPs near folate and choline-related 
genes by maternal diet or vitamin supplementation. We did find some suggestive associations for 
the choline pathway, which warrant further study. 
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CHAPTER 5: DISCUSSION AND CONCLUSIONS 
5.1 Summary of Specific Aims 
In epidemiologic studies, there have been suggestive associations between maternal 
vitamin supplementation during pregnancy and a decreased risk of neuroblastoma. This suggests 
that micronutrients in prenatal vitamins may be important to neuroblastoma development.10,11  
We decided to focus on vitamin A, folate and choline because of strong biologic plausibility. 
Vitamin A is involved in the differentiation of neuroblasts during fetal development and used in 
the preventative therapy of neuroblastoma recurrence after treatment.12,13,170  Folate and choline 
both are involved with DNA maintenance through one-carbon metabolism.16,18  
We assessed the importance of these vitamin pathways by investigating maternal and 
offspring single nucleotide polymorphisms (SNPs). In Aim 1, we estimated the association 
between haplotype tagging SNPs in or near genes involved in vitamin A metabolism and 
transport and neuroblastoma overall and stratified by Children’s Oncology Group (COG) 
prognostic risk-classification or offspring age at diagnosis.  Additionally, we assessed the 
interaction of these variants with maternal vitamin A consumption measured through diet and 
use of prenatal vitamin or multivitamin supplementation pre-pregnancy.  
In Aim 2.  We estimated the association between maternal and offspring SNPs from 
genes involved in the metabolism and transport of choline and folate on neuroblastoma overall 
and stratified by COG risk-classification and offspring age at diagnosis.  We also assessed the
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interaction of these maternal and offspring variants with maternal folate, choline and folic acid 
consumption measured through diet and use of vitamin supplementation pre-pregnancy. 
We also performed an independent a replication case-control study of offspring SNPs 
using genome-wide association (GWA) data provided by Dr. Maris and colleagues at the 
Children’s Hospital of Philadelphia (CHOP). 
5.2 Summary of Results 
5.2.1 Aim 1 
We found rs12442054, selected for its proximity to STRA6, inversely associated with 
neuroblastoma at a false discovery rate (FDR) Q-value < 0.2.  We found 9 offspring FDR-
corrected SNPs significantly associated with intermediate-risk neuroblastoma in 4 genes (RXRA, 
ADH1A, RARG, and ALDH1A2).  However, of the three SNPs also available in the CHOP 
replication case-control study, none were significantly associated with intermediate-risk 
neuroblastoma.  In our stratification analysis, one maternal SNP was associated with high-risk 
neuroblastoma and another SNP was associated with infant neuroblastoma (age of diagnosis <1 
year).  We found mothers with the T allele of the intronic rs6776706 in RARB had a decreased 
risk of an offspring with high-risk neuroblastoma.  The T allele of maternal rs11103603, located  
almost 10kbp downstream from RXRA, was associated with decreased risk of neuroblastoma in 
infants. 
We found no FDR-corrected significant interaction with SNPs in or near vitamin A-
related genes with maternal prenatal or multi-vitamin supplementation pre-pregnancy.  A FDR-
corrected significant gene-vitamin A interaction was observed when vitamin A intake was 
dichotomized at the Recommended Dietary Allowance (RDA).  Among mothers with vitamin A 
intake below the RDA, the maternal SNP rs729147, located near ADH7, was associated with 
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increased risk of neuroblastoma.  When maternal intake was above the RDA, the SNP was 
associated with a decreased risk of neuroblastoma.  
To test gene-environment interaction with “total” nutrient exposure, we combined 
nutrients from vitamin use pre-pregnancy and diet by classifying women with above the 33rd 
percentile nutrients from diet or taking vitamin pre-pregnancy as sufficient nutrient intake and 
those without vitamin pre-pregnancy use and low nutrient intake as low nutrient intake.  When 
we assessed gene-vitamin A interaction with “total” vitamin A exposure, rs729147 was also 
significant. 
5.2.2 Aim 2 
Overall, none of the selected offspring or maternal SNPs in or near folate and choline-
related genes were FDR-corrected significant overall, or after stratification by COG risk-
classification or offspring age at diagnosis.  Moreover, most SNPs that had been previously 
reported to be associated with birth defects and childhood cancers (including neuroblastoma) 
were not significant, even at an uncorrected nominal alpha of 0.05.86,227,352,353 
We found FDR-corrected significant gene-environment interactions for 3 SNPs with 
maternal choline, but none with folic acid, folate, pre-pregnancy vitamin supplementation or 
“total” exposure for folic acid and folate.  Two offspring SNPs (rs1738575 and rs9966612) had a 
significant gene-choline interaction with maternal choline consumption dichotomized at the 25th 
percentile.  Among mothers with choline intake in the 25th percentile, offspring with the G allele 
of rs1738575 had an increased risk of neuroblastoma.  However, among mothers with intake 
greater than the 25th percentile, no association was found with offspring rs1738575. Among 
mothers with choline intake in the 25th percentile, offspring with the A allele of rs9966612 was 
inversely associated with neuroblastoma. However, among mothers with intake greater than the 
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25th percentile, the offspring A allele of rs9966612 had a positive association.   When choline 
was dichotomized at the Adequate Intake (the recommended value in the absence of an 
established RDA) for choline, we found that the T allele of offspring rs10489810 increased the 
risk of neuroblastoma among those above the Adequate Intake, but decreased risk among 
offspring with maternal choline consumption below the Adequate Intake. 
5.3 Strengths and Limitations 
5.3.1 Strengths 
This study is the largest epidemiologic study with both genetic and exposure data to date, 
allowing us to assess gene-environment interaction.  Previous studies either only examined 
genetic associations8,84 or only examined environmental exposures.119,120,122,132,137   Previous 
genome-wide association (GWA) studies have identified offspring variants associated with non-
familial neuroblastoma, indicating that there is a genetic component to neuroblastoma.8,84  
We chose to focus on a candidate gene approach to explore gene regions with strong 
biologic plausibility and have greater power to study gene-environment interactions and 
stratification by COG risk-classifications.  Due to the previous epidemiologic associations with 
prenatal vitamin use and biologic plausibility, we focused on three vitamins (vitamin A, folate 
and choline).  Since vitamin A is essential for neuronal development and differentiation, cis-13 
retinoic acid (a metabolite of vitamin A) is used a preventative therapy in children after treatment 
for high-risk neuroblastoma. Low levels of choline and folate from diet and genetic variation 
have been associated with a myriad of developmental disorders.285,286,291  Previous candidate 
SNP studies that have assessed maternal and offspring folate-related SNPs have had small 
sample sizes (fewer than 100 cases) and concentrated on a few SNPs.85,86 
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This is the first study to examine gene-environment interaction after initiation of folic 
acid fortification in the United States and Canada. This makes the study more generalizable to 
the current population in the United States, in which folic acid and folate consumption in general 
increased in the United States.354  This increase in folate consumption has shifted the distribution 
where more women have folate consumption above the RDA thus increasing the power to detect 
an association.223 
Since neuroblastoma is embryonal in nature, the fetal developmental environment plays a 
large role in its development.  The maternal ability to process and transport micronutrients is 
essential for proper fetal environment.139,355 The case-parent triad design allows us to estimate 
maternal genetic risk ratios and assess maternal gene-environment interaction.1  The case-parent 
triad approach is also robust against population stratification without having to genotype 
additional ancestry informative markers. This is particularly beneficial for this study.  Since 
neuroblastoma is rare, to amass the proper number of cases, families were recruited from both 
Canada and the United States.  Given the wide scope of the case ascertainment encompassing 
many different racial groups, to properly conduct a case-control study by recruiting a proper 
North American control group presented a logistical as well as a validity challenge.  
Additionally, case-parent triads allow the inclusion of families with missing paternal genotypes 
though the expectation maximization algorithm, which makes full use of the available data to 
boost power.20 
5.3.2 Limitations 
This study had a few limitations. We are interested in maternal nutrition status early 
pregnancy and pre-pregnancy because the neural crest migrates and begins to differentiate by 5 
weeks into pregnancy.71 We are assuming that current usual maternal diet is an adequate 
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approximation for diet during our exposure window of interest.  Nonetheless, we assumed that 
the misclassification that could be introduced by a long recall period (average recall from 
questionnaire completion to conception: 3.1 years).356  Moreover, studies conducted to assess 
changes in diet due to pregnancy determined that in general diet does not vary in relation to other 
individuals.306-308 Our measurement of diet post-pregnancy should be representative of pre-
pregnancy diet before morning sickness alters diet dramatically. The maternal current diet may 
be influenced by the offspring’s neuroblastoma diagnosis.  However, nutrient levels did not 
significantly vary across COG risk-classification – a proxy for the severity of disease – 
suggesting the diagnosis event did not alter levels diet drastically.  The questionnaire also asked 
about diet for the last year to minimize the influence of the diagnosis and to capture usual diet. 
To help address the possible differences between current usual diet and diet during 
pregnancy, the NENA questionnaire asked the mothers if during pregnancy intake of foods prone 
to change – such as dairy, citrus, juices, fruit, meat, coffee, diet soda and alcohol drinks – was 
“Much less than it is now”, “Somewhat less than it is now”,  “Same as it is now”,  “Somewhat 
more than it is now”, and “Much more than it is now”.309  Within NENA, fish was commonly 
reported decreasing during pregnancy and dairy was commonly reported increasing during 
pregnancy compared to the current usual diet.  To assess the robustness of our FDR-corrected 
significant vitamin A and choline gene-environment interaction results, we altered vitamin A and 
choline levels for women increasing dairy or decreasing fish.  After dichotomizing the new 
altered nutrient levels and refitting the gene-environment model, our point estimates were 
similar, suggesting that our significant results are stable to changes in diet. 
Because many women (~50%) were not able to recall the brand of prenatal or multi-
vitamin taken, we could not calculate the amount of a nutrient derived from supplementation and 
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accurately combine vitamins from diet and supplementation.  However, we were able to 
calculate a “total” exposure by defining sufficient intake as women who either had above the 33rd 
percentile or had taken pre-pregnancy vitamin supplementation.   
We are also underpowered to detect weak associations.  We have power to detect risk 
ratios of 1.5 at an alpha of 0.001.  Since we are underpowered, we only corrected for the number 
of SNPs studied by the nutrient-specific pathway rather than for all the SNPs studied and for 
each risk-stratification of neuroblastoma.  This gives us more power, but also makes it more 
likely to have committed a type 1 error.   
The case-parent triad approach also has a few assumptions that could be violated, such as 
Mendelian inheritance and parental symmetry.19  Disruption of Mendelian inheritance could 
occur if embryos that are homozygotes for a variant allele do not survive, in which such attrition 
would lead to results where two alleles appear to confer lower risk than one allele.  However, if 
this were the case, such an allele would be quickly selected out of the population. Spurious 
significant maternal associations can arise if the mating symmetry is violated (i.e. a genotype is 
over represented in either the mother or father not due to the disease state of the offspring).  The 
most likely scenario for violation is racial differences between the parents.  When we restricted 
the analysis to only white mother-father pairings, the maternal results remained significant and 
unchanged, implying that this assumption is not likely violated.  Another crucial assumption is 
that missingness is non-informative. The most likely source of this violation would be if paternal 
genotype and participation both depend on paternal race, conditional on the observed mother-
child genotype. This is unlikely to have a major influence, given the small number of non-white 
mothers and fathers in NENA.   
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We are also unable to study any trimester specific gene-environment interactions with 
maternal vitamin supplementation because of high number of mothers taking prenatal or multi-
vitamins.  Most of the mothers enrolled in NENA reported taking a multivitamin or prenatal 
vitamin 1 month pre-pregnancy (60%) and by the 1st trimester over 90% of the mothers had 
started taking vitamins.  This prevalence of vitamin use was much higher than reported for 
another neuroblastoma case series pre-fortification in the United States and previous reports of 
vitamin supplementation among pregnant women.10,97  The majority of NENA mothers were 
white and highly educated (over 50% have at least some college education), a sub-group that has 
been previously shown to have higher levels of vitamin supplementation during pregnancy.97,357  
Moreover, during the time period of previous neuroblastoma case series (1992–1995), 
knowledge of the prenatal vitamin supplementation was low.  Public Health Service did not 
recommend folic acid supplementation until 1992.  In a March of Dimes telephone survey in 
1995, only 52% of women have heard of folic acid and only 28% took a supplement.358  Women 
who enrolled in our study were more likely to have health seeking behavior, possibly explaining 
our higher prevalence of vitamin supplementation. Since this study is not dependent on a control 
population, the higher prevalence of maternal vitamin supplementation does not affect the 
internal validity of the study, but could affect the generalizability.  We could also be focusing on 
a population with low heterogeneity in vitamin consumption and the null results in the study may 
be due to the select population with higher vitamin intake levels.  
A few limitations arise from the lack of population-based control group.  It precludes us 
from studying the main effects of pre-pregnancy vitamin supplementation and nutrients from 
diet.  Although we did not find gene-environment interaction with vitamin supplementation pre-
pregnancy, this does not suggest that vitamin supplementation pre-pregnancy is not related to 
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neuroblastoma.  Only multiplicative interaction can be assessed in a case-parent triad.359 
However, additive interaction may be more biologically relevant and can influence public health 
decisions more, given the nature of the case-parent We are unable to code these interactions with 
a common referent and thus unable to discern the “baseline” risk for homozygous major alleles 
in each exposure group. 
5.4 Implications and Conclusions 
5.4.1 SNP Main effects 
5.4.1.1 Previously studied SNPs 
Folate from diet and SNPs in folate-related genes have been consistently linked with 
neural tube defects.195,227,249  Additionally, genetic variants in the one-carbon pathway have been 
associated with increased plasma homocysteine levels and decreased plasma and red blood cell 
folate levels.222-225,240,241  However, we did not find any associations between known folate-
related SNPs and neuroblastoma.  de Miranda et al. found an positive offspring association 
[G/A+A/A vs. G/G OR: 3.01 (95% CI: 1.06, 10.31)] between SLC19A1 80G>A (rs1051266) in a 
case-control study in Brazil comprised of 31 cases and 92 controls.85  Montalvao-de-Azevedo et 
al. conducted a Brazilian mother-child dyad study of 66 case mother-child dyads and 453 control 
mother child dyads which replicated this offspring association [G/A+A/A vs. G/G OR: 2.51 
(95% CI: 1.24, 5.08)] and found a maternal association [G/A+A/A vs. G/G OR: 3.11 (05% CI: 
1.09, 8.90).86  However, our study did not replicate these results (Appendix 3 and 4), possibly 
due to maternal confounding in their studies or differences in sample size and study population 
characteristics such as diet, race and vitamin supplementation.  
Folic acid and folate has been inconsistently linked with neuroblastoma. An ecologic 
study demonstrated a decrease in the incidence of neuroblastoma in Ontario, Canada after folic 
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acid fortification.   However, this study only reported 37 post-fortification cases.99  When a 
similar study was conducted in the US with a larger sample in Surveillance, Epidemiology, and 
End Results Program, the incidence remained steady after folic acid fortification.48  Folic acid 
fortification in the United States and Canada could have an appreciable effect on our results.  
Studies have demonstrated that MTHFR 667C>T has less of an effect on folate levels when 
folate from diet is high.353,360  Although the effects of other one-carbon metabolism variants in 
relation folate consumption have not been established, it is possible any genetic effect would be 
diminished due the higher levels of folate due to fortification or the high level of 
supplementation of mothers enrolled in NENA.   
5.4.1.2 Offspring and Maternal SNP Main effects 
Maternal rs12442054 was selected for its proximity to STRA6 – a retinoid transmembrane 
protein – and was FDR-corrected significantly associated with neuroblastoma.  Additionally, the 
QQ plot also demonstrates that this SNP deviates from the expected normal distribution of p-
values (Appendix 5). Unfortunately, the SNP is intergenic within a region of unknown function 
and not in high linkage disequilibrium (r2>0.8) with any other SNPs.  A study suggested that this 
SNP is located within non-coding RNA but this location has never been replicated and the 
function of this non-coding RNA is unknown. Non-coding RNA can encode for regulatory and 
housekeeping RNAs such as ribosomal RNA, transfer RNA and microRNAs. Studies are being 
conducted to determine the function of variation within these non-coding RNA regions.361 
Neuroblastoma is clinically and biologically heterogeneous. Some cases present with 
aggressive disease and others with tumors that spontaneously regress with no treatment.1,43  A 
risk-classification schema was defined by the COG to help with prognostication.43  Although 
these categories were created for prognostic purposes, they may be etiologically relevant. 
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Previous studies have identified genetic variants associated with high-risk and low-risk 
neuroblastoma,6,79,83 suggesting each risk-stratification might have a distinct set of underlying 
variants contributing to its development. One study demonstrated MYCN amplification status – a 
strong prognostic marker for high-risk neuroblastoma – does not change over time.45  Our study 
further strengthens the argument that the prognostic risk-categories could be related to etiology. 
However, without additional studies, we cannot be sure if this is due to the sample size or the 
inherent heterogeneity of the disease. 
We found nine offspring SNPs in or near genes related to vitamin A associated with 
intermediate-risk neuroblastoma. Intermediate-risk is the most clinically heterogeneous risk-
classification and recent tumor genomic profiling suggests the intermediate risk-classification 
warrant updating.362  Additionally, three of these SNPs were available in the CHOP case-control 
replication study and did not replicate NENA findings. Thus further highlighting the 
heterogeneity of the intermediate-risk classification and the uncertainty in the interpretation of 
these results. 
Maternal rs6776706 near RARB was significantly positively associated with high-risk 
neuroblastoma. The promoter to RARB is often hyper-methylated in small cell lung cancer, 
prostate cancer and head and neck cancers.363-365 Although RARB is not methylated in 
neuroblastoma cell lines and tumors,366 there is evidence in mice and in vitro studies that RARB 
is involved in neuronal differentiation through retinoic acid signaling.367,368 However, how this 
SNP affects RARB expression and the exact function of this region is unknown. 
Maternal rs11103603, located in RXRA, was associated with infant neuroblastoma (age at 
diagnosis < 1 year). Variants in RXRA have been associated with serum vitamin D levels as well 
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as decreased risk of colon adenoma recurrence.343,369  Additionally, studies have suggested that 
vitamin D can inhibit neuroblastoma growth in mice.370  However, we are unable to explore the 
gene-environment interaction of this variant with vitamin D in NENA.  Since vitamin D can be 
synthesized dermally from sunlight, skin color and amount of sun exposure plays a larger role in 
vitamin D levels than diet. 371   Even with a reliably measured diet, it would be invalid to assume 
that the synthesized vitamin D would be equal among all NENA mothers since families were 
recruited from across all of North America, encompassing many different races and geographic 
locations. 
5.4.1.3 Gene-environment interaction 
 We found a FDR-corrected significant gene-environment interaction with vitamin A 
from diet when classified at the RDA.  ADH7 is involved in the conversion of retinol to retinoic 
acid, as well as alcohol metabolism.151,372,373  Mice with an adh7 knockout have an increased risk 
of embryonic lethality at low levels of vitamin A, but not with sufficient intake.374,375 SNPs 
located in ADH7 have been associated with cancers with a strong alcohol component, such as 
squamous cell carcinoma of the head and neck and colorectal cancer.376,377  Since mouse studies 
do suggest that adh7 may be more involved with vitamin A metabolism and this present study 
suggests a link between neuroblastoma, vitamin A and ADH7, additional studies are warranted to 
further explore this link.165,346 
Our results suggest that choline may play an important role in neuroblastoma 
development. It has been noted that during pregnancy, choline demand is high and is transported 
across the placenta against a concentration gradient.378,379 Although choline can be synthesized 
de novo, diet is a major contributor to choline.355 Choline is not typically contained in prenatal 
vitamins and for the few that do contain some, the amount of choline tends to be much lower 
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than the recommended Adequate Intake. Since the ability to synthesize choline de novo is 
dependent on gender, menopausal status and genetic variation and all women in the study are 
pre-menopausal, choline levels in NENA participants can be assumed to depend on genetics and 
diet.277,286  Choline is synthesized de novo in the liver, through a process catalyzed by PEMT.380  
We did not observe any association with SNPs near or in PEMT and neuroblastoma.  However, 
the candidate PEMT SNP rs12325817, which has been previously associated with choline levels, 
was unable to be genotyped due to low genotyping scores.286  The offspring SNP is available in 
the CHOP replication study, and a null association was seen with offspring rs12325817 (OR: 
0.98) and neuroblastoma.  However, since choline is transmitted to the fetus in utero, further 
studies with maternal variants should be studied. 
Two of the gene-environment interactions in NENA (vitamin A dichotomized at the RDA 
and choline dichotomized at the Adequate Intake) are “pure” interactions in that the genetic 
effect crosses the null between the two exposure states.  Such “pure” interactions tend to work 
against the detection of marginal associations for genetic effects.  Although “pure” interactions 
can occur, only a few examples have been consistently replicated in epidemiologic studies.381-384 
Moreover, the function of these two SNPs and gene regions are unknown, and our results should 
be interpreted with caution. 
5.4.2 Consideration for Future Studies 
Neuroblastoma GWA case-control studies found SNPs that are associated with 
neuroblastoma.6,7  However, like many other GWA studies of complex diseases, these SNPs are 
likely to individually contribute little to the development of neuroblastoma.385  The underlying 
hypothesis of GWA studies is “common disease, common variant” or that if the disease is 
common in the population (1-10%) and heritable, the variant will also be common in the 
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population.386  GWA study SNP arrays, which are designed to capture common genetic variation, 
would not be as appropriate for neuroblastoma to find large effect sizes.299  However, common 
variants likely have small effect sizes, but could be involved with gene-environment interaction 
where certain subgroups have large effect sizes. Some sequencing has been done with case-
control studies and neuroblastoma with promising results that merit further studies of rare 
variants.84   
We found some interesting results with maternal variants, which warrant additional study 
and replication. Future studies should consider designs that can study maternal associations with 
rare variants as well as interaction with other maternal exposures.21,317,387   Maternal environment 
exposures, maternal genotype and offspring genotype all contribute to the fetal environment.  
The fetal environment is important to the development and malignant transformation of 
neuroblastoma.  Associations have been found with maternal environmental exposures and 
offspring genotype,7,80,106,110,113,119,121,385 but few have studied maternal genotype and 
neuroblastoma.86  Maternal variants may be important to cancers that have early life origins such 
as childhood acute lymphoblastic leukemia352,388 and medulloblastoma.389  In addition to 
replicating our results, future studies can focus on maternal variants that in pathways that been 
previously associated with neuroblastoma such as genes related to maternal metabolism or 
detoxification of painkillers and occupational exposures linked to neuroblastoma.  
Family-based studies also allow for the assessment of parent-of-origin effects, including 
imprinting.390 If not properly accounted for, such effects can mask associations.  Imprinted genes 
have been implicated with common diseases such as autism, breast cancer and diabetes.391  The 
genes that were genotyped in NENA have no evidence of imprinting.  We are also not powered 
to look at imprinting effects without an a prior hypothesis.392 However, there are few population 
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based studies with parental data available and as more genetic research is conducted in 
neuroblastoma, it could be worthwhile to explore imprinting the NENA.  
Our independent replication study only had offspring genotyping. Few offspring SNPs in 
NENA were significant and these did not replicate in CHOP. A few maternal variants within this 
study were significant, and should be replicated and functionality should be further explored with 
mice and in vitro studies.  All the FDR-corrected significant SNPs were in non-coding regions. 
Intronic SNPs are known to affect splicing and intergenic SNPs can code for intergenic 
transcription factor binding sites or non-coding RNA.338  A few the significant SNPs are located 
in intergenic regions that may code for transcription factors, but these have not been 
replicated.393 Additionally, we were not able to capture the candidate PEMT variant due to the 
limitations of the genotyping chip in NENA.  Given the suggestive maternal gene-choline 
interaction, future studies, including NENA, can explore choline though synthesis de novo and 
diet. 
5.4.3 Public Health Implications 
Genetic studies have plagued with the “missing heritability” problem.394  GWA studies 
have failed to identify the variants that contribute the most to the heritability of complex 
diseases.394  This lack of heritability could be explained by gene-environment or gene-gene 
interactions in which the variants themselves do not have an appreciable marginal effect.  
Moreover, gene-environment interaction studies allow for the discovery of a genetic 
subpopulation susceptible to environment hazards.  This information could further inform risk 
prediction models and have implications for personalized medicine.395 If there is no an adverse 
effect of the “environment” variable, gene-environment interaction could inform dietary 
recommendations. 
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This study suggests that maternal pre-pregnancy vitamin supplementation or folic acid 
and folate from diet do not multiplicatively modify the effects on neuroblastoma risks of SNPs 
that are in vitamin A, choline and folate pathways.  In the era of folic acid fortification it is 
feasible that maternal pre-pregnancy vitamin supplementation or folate does not modify the 
effects of other SNPs that have been previously associated with neuroblastoma.  
While folic acid is beneficial to the prevention of neural tube defects, 93,195 our null 
associations seen with SNPs that are known to modify maternal serum folate levels suggest that 
folate may not play a large role in neuroblastoma development.   However, this does not preclude 
the recommendation of prenatal vitamins for women of child bearing age or during pregnancy 
due to their protective effect for other outcomes. Although one study should not prompt any wide 
sweeping policy changes, this study does highlight the need for further studies into vitamin A 
and choline in relation to neuroblastoma.  Vitamin A is used in the treatment of neuroblastoma 
and has potential importance with the development of neuroblastoma.170,171 Choline has only 
recently been identified as a necessary nutrient for pregnant women because of its role in fetal 
development.18 Additional studies should be conducted elucidating the effect of choline and 
vitamin A on fetal and neuronal development. 
5.5 Summary 
This study evaluated associations between maternal and offspring variants in vitamin A, 
choline and folate-related genes and gene-environment interaction in case-parent triads. Overall, 
these analyses suggest that folate is not as important to the risk of neuroblastoma as it is to birth 
defects or other childhood cancers.  There is a potential for interaction with certain SNPs and 
choline from diet that warrants additional larger studies to further confirm the interaction.  SNPs 
in vitamin A-related genes may be related to risk of neuroblastoma and such a role is supported 
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by relevant biologic plausibility. Since we are the first study to look into this hypothesis, our 
results do warrant replication and further attempts to characterize the interactions between gene 
variants and vitamin consumption. 
 RR: Risk Ratio; CI: Confidence Interval; OR: Odds Ratio; --: Unavailable in replication study  
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APPENDIX 1. RESULTS FROM OFFSPRING VITAMIN A-RELATED SNPS IN NENA AND CHOP REPLICATION 
STUDY 
  NENA  CHOP 
SNP Gene Minor 
Allele 
Major 
Allele RR (95% CI) P-value 
FDR 
Q-value  
Minor 
Allele 
Major 
Allele OR (95% CI) P-value 
FDR 
Q-value 
rs4842196 RXRA C A 1.30(1.08, 1.57) 0.006 0.833  -- -- -- -- -- 
rs4699720 ADH4 C T 1.30(1.07, 1.58) 0.008 0.833  T C 0.98(0.90, 1.08) 0.709 >0.999 
rs4699710 ADH4 C T 1.27(1.06, 1.52) 0.010 0.833  T C 0.97(0.90, 1.06) 0.536 >0.999 
rs4646684 ALDH1A3 A G 0.81(0.68, 0.96) 0.014 0.833  G A 0.96(0.88, 1.03) 0.263 >0.999 
rs1007971 RXRA G C 1.28(1.05, 1.56) 0.015 0.833  -- -- -- -- -- 
rs1229977 ADH1A T C 0.78(0.63, 0.95) 0.016 0.833  C T 1.04(0.95, 1.15) 0.384 >0.999 
rs284792 ADH7 A G 1.42(1.07, 1.89) 0.016 0.833  T C 1.09(0.95, 1.25) 0.236 >0.999 
rs6771831 RBP2 A G 1.22(1.03, 1.45) 0.021 0.833  A G 0.95(0.88, 1.03) 0.26 >0.999 
rs12730752 CRABP2 T C 1.22(1.03, 1.44) 0.024 0.833  T C 0.98(0.90, 1.07) 0.623 >0.999 
rs2462936 RDH5 T C 0.79(0.64, 0.97) 0.024 0.833  -- -- -- -- -- 
rs11170466 RARG A G 1.53(1.05, 2.21) 0.026 0.833  -- -- -- -- -- 
rs3118523 RXRA G A 1.26(1.03, 1.55) 0.026 0.833  -- -- -- -- -- 
rs12512110 ADH1A T G 0.70(0.52, 0.96) 0.026 0.833  T G 1.04(0.90, 1.20) 0.588 >0.999 
rs7670060 ADH4 T G 1.24(1.02, 1.50) 0.029 0.833  T G 1.05(0.97, 1.15) 0.226 >0.999 
rs167187 RBP1 G A 1.20(1.01, 1.42) 0.034 0.833  A G 1.05(0.96, 1.13) 0.278 >0.999 
rs16844995 RXRG C T 1.25(1.02, 1.54) 0.034 0.833  C T 0.93(0.84, 1.03) 0.194 >0.999 
rs2156731 ADH4 A G 0.72(0.53, 0.98) 0.037 0.833  T C 1.03(0.89, 1.19) 0.679 >0.999 
rs7959622 RDH5 C T 1.50(1.02, 2.21) 0.040 0.833  -- -- -- -- -- 
rs2364120 RARB G A 1.37(1.01, 1.85) 0.042 0.833  A G 0.96(0.84, 1.10) 0.563 >0.999 
rs100537 RXRG A G 1.19(1.01, 1.40) 0.044 0.833  G A 1.02(0.94, 1.11) 0.585 >0.999 
rs1730221 RARB G C 1.20(1.01, 1.43) 0.044 0.833  G C 0.99(0.91, 1.07) 0.77 >0.999 
rs4889291 BCMO1 G A 0.84(0.71, 1.00) 0.046 0.833  G A 0.96(0.88, 1.05) 0.349 >0.999 
rs8187945 ALDH1A1 T C 1.48(1.00, 2.18) 0.049 0.833  A G 0.88(0.73, 1.06) 0.178 >0.999 
rs283690 RXRG G A 1.18(1.00, 1.39) 0.052 0.833  A G 0.99(0.92, 1.07) 0.871 >0.999 
rs11707637 RARB G A 1.18(1.00, 1.40) 0.056 0.833  G A 1.03(0.95, 1.11) 0.523 >0.999 
rs4646678 ALDH1A3 T C 1.23(0.99, 1.53) 0.056 0.833  T C 1.01(0.91, 1.11) 0.912 >0.999 
rs6795340 RARB A G 1.20(0.99, 1.46) 0.058 0.833  A G 1.00(0.91, 1.09) 0.983 >0.999 
rs1045570 RXRA T G 1.23(0.99, 1.53) 0.059 0.833  -- -- -- -- -- 
rs11264527 CRABP2 C T 1.17(0.99, 1.39) 0.062 0.833  T C 1.01(0.93, 1.10) 0.79 >0.999 
rs455696 RXRG C T 1.20(0.99, 1.46) 0.069 0.833  A G 1.01(0.91, 1.11) 0.907 >0.999 
rs1805343 RXRA G A 1.17(0.99, 1.39) 0.071 0.833  -- -- -- -- -- 
 RR: Risk Ratio; CI: Confidence Interval; OR: Odds Ratio; --: Unavailable in replication study  
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  NENA  CHOP 
SNP Gene Minor 
Allele 
Major 
Allele RR (95% CI) P-value 
FDR 
Q-value  
Minor 
Allele 
Major 
Allele OR (95% CI) P-value 
FDR 
Q-value 
rs4646669 ALDH1A3 T C 1.23(0.98, 1.53) 0.072 0.833  T C 1.01(0.90, 1.12) 0.911 >0.999 
rs283697 RXRG A C 0.83(0.67, 1.02) 0.072 0.833  C A 1.00(0.91, 1.10) 0.99 >0.999 
rs6767543 RARB G A 0.85(0.71, 1.02) 0.078 0.833  A G 0.98(0.90, 1.07) 0.614 >0.999 
rs3138136 RDH5 A G 1.29(0.97, 1.70) 0.078 0.833  T C 1.04(0.92, 1.18) 0.53 >0.999 
rs6774691 RBP2 A G 1.26(0.97, 1.64) 0.080 0.833  A G 0.88(0.77, 1.00) 0.046 >0.999 
rs12906432 ALDH1A3 T G 0.84(0.69, 1.02) 0.083 0.833  -- -- -- -- -- 
rs3767343 RXRG A G 1.16(0.98, 1.37) 0.085 0.833  A G 0.99(0.92, 1.07) 0.814 >0.999 
rs4266713 ALDH1A1 A T 0.79(0.61, 1.04) 0.087 0.833  A T 1.00(0.89, 1.13) 0.977 >0.999 
rs2715553 RARA C T 0.87(0.74, 1.02) 0.087 0.833  A G 0.99(0.92, 1.07) 0.838 >0.999 
rs1154473 ADH7 T C 1.15(0.98, 1.35) 0.089 0.833  G A 1.05(0.96, 1.14) 0.3 >0.999 
rs11917304 RARB C T 1.22(0.97, 1.55) 0.090 0.833  C T 1.02(0.91, 1.15) 0.691 >0.999 
rs3772868 RBP1 T C 1.24(0.97, 1.59) 0.091 0.833  A G 0.99(0.88, 1.11) 0.862 >0.999 
rs748964 RXRA C G 1.22(0.97, 1.54) 0.093 0.833  -- -- -- -- -- 
rs6564859 BCMO1 G A 1.17(0.97, 1.40) 0.094 0.833  G A 1.08(0.99, 1.18) 0.081 >0.999 
rs11204208 RBP3 T G 1.26(0.96, 1.65) 0.096 0.833  T G 0.92(0.80, 1.05) 0.213 >0.999 
rs2413292 ISX T C 1.18(0.97, 1.44) 0.096 0.833  T C 1.01(0.92, 1.11) 0.803 >0.999 
rs6909923 ALDH8A1 G A 1.31(0.95, 1.81) 0.096 0.833  G A 1.03(0.88, 1.20) 0.742 >0.999 
rs6803265 RARB A T 1.21(0.97, 1.51) 0.097 0.833  A T 0.93(0.84, 1.03) 0.184 >0.999 
rs2072827 ALDH8A1 A G 0.87(0.74, 1.03) 0.099 0.833  A G 1.00(0.92, 1.09) 0.961 >0.999 
rs10009145 ADH4 A G 0.87(0.73, 1.03) 0.100 0.833  A G 0.96(0.89, 1.04) 0.342 >0.999 
rs41419946 RXRG T A 1.32(0.95, 1.84) 0.103 0.839  T A 1.03(0.88, 1.20) 0.709 >0.999 
rs4657438 RXRG C A 0.78(0.57, 1.06) 0.106 0.839  C A 1.15(0.98, 1.35) 0.097 >0.999 
rs1864907 RARB G A 1.34(0.94, 1.92) 0.106 0.839  -- -- -- -- -- 
rs1800759 ADH4 A C 1.15(0.97, 1.36) 0.110 0.842  G T 0.96(0.89, 1.04) 0.341 >0.999 
rs6762247 RARB T C 0.82(0.64, 1.05) 0.112 0.842  T C 1.01(0.89, 1.15) 0.842 >0.999 
rs41356949 RBP2 T C 0.79(0.60, 1.06) 0.113 0.842  T C 1.11(0.97, 1.28) 0.139 >0.999 
rs913422 CYP26A1 C T 0.87(0.74, 1.03) 0.115 0.842  G A 0.94(0.86, 1.02) 0.145 >0.999 
rs482284 RARA A G 1.15(0.97, 1.38) 0.118 0.850  G A 1.03(0.94, 1.12) 0.557 >0.999 
rs4681063 RARB C T 0.87(0.73, 1.04) 0.122 0.860  C T 1.03(0.95, 1.12) 0.464 >0.999 
rs7905501 CYP26A1 T C 1.18(0.96, 1.47) 0.123 0.860  T C 0.96(0.87, 1.06) 0.473 >0.999 
rs11580324 CRABP2 C G 1.17(0.96, 1.44) 0.129 0.870  C G 1.15(1.01, 1.29) 0.028 >0.999 
rs904092 ADH1A A G 0.84(0.67, 1.05) 0.131 0.870  G A 1.02(0.92, 1.14) 0.668 >0.999 
rs1229966 ADH1A C T 1.14(0.96, 1.35) 0.134 0.870  G A 0.97(0.89, 1.05) 0.406 >0.999 
rs9879736 RBP1 T C 1.19(0.95, 1.50) 0.137 0.870  C T 1.09(0.98, 1.22) 0.125 >0.999 
rs6564863 BCMO1 T C 0.88(0.73, 1.04) 0.138 0.870  C T 0.99(0.91, 1.07) 0.745 >0.999 
 RR: Risk Ratio; CI: Confidence Interval; OR: Odds Ratio; --: Unavailable in replication study  
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  NENA  CHOP 
SNP Gene Minor 
Allele 
Major 
Allele RR (95% CI) P-value 
FDR 
Q-value  
Minor 
Allele 
Major 
Allele OR (95% CI) P-value 
FDR 
Q-value 
rs3773438 RARB A G 1.20(0.94, 1.54) 0.142 0.870  T C 0.96(0.85, 1.07) 0.435 >0.999 
rs7235277 TTR C G 1.14(0.96, 1.36) 0.146 0.870  C G 1.04(0.96, 1.13) 0.376 >0.999 
rs4240705 RXRA G A 1.13(0.96, 1.34) 0.148 0.870  -- -- -- -- -- 
rs285428 RXRG C T 0.85(0.68, 1.06) 0.150 0.870  C T 1.12(1.00, 1.26) 0.051 >0.999 
rs1154460 ADH7 A G 0.89(0.75, 1.04) 0.151 0.870  A G 1.05(0.97, 1.13) 0.244 >0.999 
rs1902715 RBP3 A G 1.17(0.94, 1.45) 0.154 0.870  T C 0.97(0.88, 1.08) 0.603 >0.999 
rs1108197 RBP4 A G 0.89(0.75, 1.05) 0.154 0.870  A G 0.97(0.89, 1.05) 0.405 >0.999 
rs11264518 CRABP2 T C 1.13(0.96, 1.34) 0.154 0.870  T C 0.99(0.92, 1.08) 0.864 >0.999 
rs2120200 RARA G A 1.21(0.93, 1.56) 0.158 0.870  G A 0.97(0.84, 1.11) 0.615 >0.999 
rs1286773 RARB G C 0.84(0.66, 1.07) 0.159 0.870  G C 0.98(0.87, 1.10) 0.695 >0.999 
rs1286650 RARB A T 1.13(0.95, 1.33) 0.161 0.870  T A 0.99(0.92, 1.08) 0.888 >0.999 
rs955243 LRAT A G 0.89(0.76, 1.05) 0.170 0.870  G A 1.02(0.94, 1.10) 0.615 >0.999 
rs17016570 RARB G A 1.26(0.90, 1.76) 0.172 0.870  G A 0.90(0.77, 1.05) 0.174 >0.999 
rs2116703 RARB A G 1.16(0.94, 1.44) 0.172 0.870  A G 0.91(0.82, 1.01) 0.075 >0.999 
rs157862 RXRG T A 1.17(0.93, 1.47) 0.175 0.870  T A 1.04(0.92, 1.17) 0.531 >0.999 
rs7428398 RBP1 A G 0.82(0.62, 1.09) 0.175 0.870  A G 1.10(0.96, 1.26) 0.183 >0.999 
rs211585 RBP1 C T 0.89(0.76, 1.05) 0.179 0.870  C T 1.02(0.94, 1.10) 0.682 >0.999 
rs1371338 RBP2 C T 0.89(0.76, 1.05) 0.180 0.870  A G 0.99(0.92, 1.07) 0.79 >0.999 
rs13120304 ADH1A A T 1.13(0.95, 1.34) 0.180 0.870  A T 1.04(0.96, 1.13) 0.291 >0.999 
rs755661 RARB T C 1.12(0.95, 1.33) 0.183 0.870  C T 0.92(0.85, 0.99) 0.035 >0.999 
rs17587689 ADH7 A G 1.16(0.93, 1.45) 0.186 0.870  A G 0.96(0.86, 1.06) 0.427 >0.999 
rs1123944 RXRG T C 1.17(0.93, 1.46) 0.187 0.870  A G 0.98(0.88, 1.10) 0.757 >0.999 
rs10882273 RBP4 C T 1.12(0.95, 1.34) 0.187 0.870  C T 1.00(0.92, 1.09) 0.957 >0.999 
rs5750041 ISX T C 1.16(0.93, 1.46) 0.188 0.870  T C 0.96(0.86, 1.07) 0.448 >0.999 
rs4144005 ALDH1A2 T C 0.89(0.75, 1.06) 0.188 0.870  T C 0.99(0.92, 1.07) 0.829 >0.999 
rs991316 ADH7 A G 0.89(0.75, 1.06) 0.192 0.870  C T 0.99(0.92, 1.08) 0.888 >0.999 
rs17016773 RARB T C 1.15(0.93, 1.42) 0.194 0.870  T C 1.07(0.97, 1.18) 0.207 >0.999 
rs10885982 PNLIP A G 1.21(0.91, 1.61) 0.195 0.870  A G 1.12(0.96, 1.31) 0.134 >0.999 
rs3818730 RXRA A G 0.89(0.74, 1.06) 0.195 0.870  A G 1.03(0.95, 1.12) 0.495 >0.999 
rs9934274 BCMO1 G C 1.12(0.94, 1.32) 0.197 0.870  G C 1.04(0.96, 1.13) 0.314 >0.999 
rs2602884 ADH4 C T 1.17(0.92, 1.48) 0.200 0.870  T C 1.00(0.90, 1.11) 0.999 >0.999 
rs10776909 RXRA T C 1.14(0.93, 1.39) 0.204 0.870  C T 1.00(0.91, 1.10) 0.976 >0.999 
rs12512714 LRAT G C 1.12(0.94, 1.33) 0.206 0.870  G C 1.00(0.92, 1.08) 0.99 >0.999 
rs9886504 RDH10 A G 1.15(0.93, 1.42) 0.206 0.870  A G 0.94(0.85, 1.03) 0.183 >0.999 
rs2071025 RXRB C T 0.88(0.73, 1.07) 0.207 0.870  G A 0.98(0.90, 1.07) 0.679 >0.999 
 RR: Risk Ratio; CI: Confidence Interval; OR: Odds Ratio; --: Unavailable in replication study  
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rs1153592 RARB A T 0.87(0.69, 1.08) 0.208 0.870  A T 0.98(0.87, 1.09) 0.659 >0.999 
rs1153606 RARB G A 0.88(0.71, 1.08) 0.212 0.878  G A 0.97(0.88, 1.07) 0.548 >0.999 
rs11856111 CRABP1 C T 1.12(0.94, 1.35) 0.216 0.879  C T 1.03(0.95, 1.12) 0.447 >0.999 
rs994772 ADH7 A G 0.85(0.66, 1.10) 0.220 0.879  T C 0.98(0.87, 1.11) 0.797 >0.999 
rs7620632 RARB C T 0.86(0.68, 1.10) 0.227 0.879  C T 0.86(0.77, 0.96) 0.01 >0.999 
rs1881705 RARB G A 0.90(0.76, 1.07) 0.229 0.879  T C 0.96(0.88, 1.04) 0.278 >0.999 
rs970902 RXRB G A 0.91(0.77, 1.06) 0.229 0.879  T C 1.03(0.95, 1.11) 0.513 >0.999 
rs1286738 RARB T C 1.13(0.93, 1.38) 0.230 0.879  T C 1.02(0.93, 1.12) 0.705 >0.999 
rs729147 ADH7 G A 0.89(0.73, 1.08) 0.237 0.879  A G 0.96(0.87, 1.05) 0.368 >0.999 
rs7169439 ALDH1A2 A G 1.17(0.90, 1.52) 0.239 0.879  -- -- -- -- -- 
rs12573026 RBP4 C T 1.16(0.91, 1.47) 0.240 0.879  -- -- -- -- -- 
rs11776584 RDH10 A G 1.13(0.92, 1.38) 0.241 0.879  A G 1.06(0.96, 1.16) 0.238 >0.999 
rs3772879 RBP2 T A 1.17(0.90, 1.52) 0.243 0.879  A T 1.01(0.89, 1.14) 0.862 >0.999 
rs1372369 ALDH1A2 C A 0.91(0.77, 1.07) 0.244 0.879  G T 0.97(0.89, 1.05) 0.417 >0.999 
rs6564854 BCMO1 G A 1.11(0.93, 1.33) 0.247 0.879  G A 1.07(0.98, 1.16) 0.13 >0.999 
rs2899611 ALDH1A2 G T 0.91(0.77, 1.07) 0.247 0.879  G T 1.01(0.93, 1.10) 0.765 >0.999 
rs4681027 RARB G T 1.23(0.86, 1.76) 0.250 0.879  G T 1.02(0.84, 1.23) 0.836 >0.999 
rs3817776 ALDH8A1 C T 1.10(0.93, 1.30) 0.251 0.879  T C 1.00(0.92, 1.08) 0.936 >0.999 
rs12739596 RXRG C A 0.89(0.72, 1.09) 0.253 0.879  C A 1.05(0.96, 1.15) 0.309 >0.999 
rs3852534 RDH5 A G 1.10(0.93, 1.30) 0.253 0.879  -- -- -- -- -- 
rs8187876 ALDH1A1 A G 1.20(0.88, 1.64) 0.259 0.879  T C 0.99(0.84, 1.17) 0.904 >0.999 
rs12648206 ADH7 G A 0.89(0.73, 1.09) 0.260 0.879  G A 0.93(0.84, 1.02) 0.117 >0.999 
rs17016778 RARB G A 1.11(0.92, 1.35) 0.263 0.879  G A 1.06(0.96, 1.16) 0.263 >0.999 
rs9821204 RBP1 A C 0.89(0.73, 1.09) 0.264 0.879  A C 1.04(0.94, 1.14) 0.468 >0.999 
rs7187507 BCMO1 T A 1.10(0.93, 1.31) 0.266 0.879  A T 0.97(0.89, 1.05) 0.477 >0.999 
rs2899240 ISX G A 0.91(0.76, 1.08) 0.267 0.879  A G 0.99(0.92, 1.08) 0.898 >0.999 
rs7071684 RBP3 T C 1.11(0.93, 1.32) 0.269 0.879  T C 0.93(0.85, 1.01) 0.103 >0.999 
rs6518932 ISX T C 0.89(0.72, 1.10) 0.270 0.879  T C 1.06(0.96, 1.18) 0.274 >0.999 
rs1286658 RARB T C 1.16(0.89, 1.52) 0.270 0.879  C T 0.99(0.88, 1.13) 0.923 >0.999 
rs1153603 RARB A G 0.91(0.76, 1.08) 0.276 0.879  T C 1.00(0.92, 1.09) 0.92 >0.999 
rs2925455 RDH10 C A 0.82(0.57, 1.18) 0.279 0.879  C A 1.08(0.90, 1.29) 0.407 >0.999 
rs9835241 RBP1 G A 1.11(0.92, 1.35) 0.280 0.879  G A 1.00(0.91, 1.09) 0.992 >0.999 
rs3758495 RBP3 A G 0.87(0.68, 1.12) 0.281 0.879  G A 1.07(0.95, 1.21) 0.277 >0.999 
rs11865869 BCMO1 G A 0.90(0.74, 1.09) 0.286 0.879  G A 0.96(0.88, 1.06) 0.422 >0.999 
rs7080494 CYP26A1 G A 1.10(0.92, 1.31) 0.286 0.879  A G 0.98(0.90, 1.07) 0.726 >0.999 
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rs3118529 RXRA C T 1.10(0.92, 1.31) 0.287 0.879  T C 1.09(1.00, 1.19) 0.061 >0.999 
rs1286730 RARB G C 1.14(0.90, 1.46) 0.287 0.879  G C 1.00(0.89, 1.12) 0.961 >0.999 
rs9373116 ALDH8A1 C G 1.09(0.93, 1.29) 0.296 0.879  G C 1.01(0.93, 1.10) 0.763 >0.999 
rs156500 LRAT C A 0.88(0.68, 1.13) 0.300 0.879  G T 0.98(0.86, 1.11) 0.698 >0.999 
rs11187549 RBP4 G A 1.15(0.88, 1.51) 0.301 0.879  -- -- -- -- -- 
rs1286750 RARB C A 0.91(0.75, 1.09) 0.301 0.879  C A 0.94(0.86, 1.03) 0.197 >0.999 
rs3819197 ADH1A T C 1.11(0.91, 1.34) 0.308 0.879  T C 0.96(0.88, 1.06) 0.429 >0.999 
rs3767342 RXRG C T 1.13(0.89, 1.44) 0.310 0.879  C T 1.00(0.89, 1.13) 0.937 >0.999 
rs3821629 RARB G A 1.11(0.91, 1.34) 0.310 0.879  C T 0.95(0.86, 1.04) 0.252 >0.999 
rs7541159 RXRG T G 1.09(0.92, 1.29) 0.312 0.879  G T 0.97(0.90, 1.05) 0.489 >0.999 
rs6776706 RARB A T 1.09(0.92, 1.31) 0.324 0.879  A T 1.01(0.93, 1.10) 0.745 >0.999 
rs1465057 RARG C T 0.87(0.67, 1.14) 0.325 0.879  C T 1.10(0.96, 1.25) 0.171 >0.999 
rs17029657 RARB G T 1.10(0.91, 1.33) 0.325 0.879  G T 1.06(0.97, 1.17) 0.173 >0.999 
rs1538648 CYP26C1 C T 0.92(0.78, 1.09) 0.327 0.879  G A 0.97(0.89, 1.05) 0.46 >0.999 
rs6580936 RARG G A 1.11(0.90, 1.37) 0.331 0.879  G A 1.00(0.90, 1.11) 0.99 >0.999 
rs11103473 RXRA T A 1.09(0.92, 1.28) 0.331 0.879  A T 1.06(0.97, 1.15) 0.229 >0.999 
rs9871002 RARB T A 0.89(0.70, 1.13) 0.332 0.879  T A 0.89(0.79, 0.99) 0.04 >0.999 
rs12502290 ADH7 A G 0.92(0.77, 1.09) 0.333 0.879  A G 0.97(0.90, 1.06) 0.55 >0.999 
rs17108978 RBP4 A G 1.10(0.91, 1.32) 0.334 0.879  A G 1.01(0.93, 1.10) 0.808 >0.999 
rs1128977 RXRG T C 1.09(0.92, 1.30) 0.335 0.879  A G 0.99(0.91, 1.07) 0.77 >0.999 
rs752739 RXRG T C 0.91(0.75, 1.11) 0.336 0.879  A G 1.02(0.92, 1.12) 0.741 >0.999 
rs4646607 ALDH1A2 T G 1.09(0.92, 1.28) 0.339 0.879  A C 1.00(0.92, 1.08) 0.999 >0.999 
rs11214139 BCO2 G A 0.88(0.68, 1.14) 0.339 0.879  G A 0.99(0.87, 1.11) 0.824 >0.999 
rs157861 RXRG G C 1.11(0.90, 1.36) 0.340 0.879  G C 1.03(0.93, 1.13) 0.603 >0.999 
rs974456 STRA6 T C 1.09(0.91, 1.32) 0.343 0.879  T C 1.02(0.93, 1.13) 0.653 >0.999 
rs4148887 ADH4 C T 0.89(0.69, 1.14) 0.347 0.879  G A 0.96(0.85, 1.08) 0.48 >0.999 
rs11898950 CYP26B1 G A 0.91(0.75, 1.11) 0.348 0.879  -- -- -- -- -- 
rs3935542 CRABP2 G C 0.92(0.77, 1.10) 0.350 0.879  C G 0.93(0.86, 1.02) 0.116 >0.999 
rs3138142 RDH5 A G 1.10(0.90, 1.35) 0.351 0.879  -- -- -- -- -- 
rs8181419 RBP4 G T 1.12(0.89, 1.41) 0.352 0.879  G T 0.99(0.89, 1.10) 0.88 >0.999 
rs10910 STRA6 G A 1.09(0.91, 1.29) 0.355 0.879  T C 0.99(0.91, 1.08) 0.878 >0.999 
rs10110749 RDH10 G C 1.08(0.92, 1.27) 0.362 0.879  G C 0.99(0.91, 1.07) 0.727 >0.999 
rs2017543 ISX C T 0.88(0.67, 1.16) 0.363 0.879  C T 1.08(0.95, 1.23) 0.259 >0.999 
rs3806412 CRABP2 G T 1.08(0.91, 1.29) 0.363 0.879  T G 1.01(0.93, 1.09) 0.873 >0.999 
rs1286654 RARB T G 1.09(0.91, 1.31) 0.364 0.879  A C 0.97(0.89, 1.06) 0.454 >0.999 
 RR: Risk Ratio; CI: Confidence Interval; OR: Odds Ratio; --: Unavailable in replication study  
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rs1286664 RARB T C 0.91(0.73, 1.12) 0.366 0.879  T C 1.01(0.92, 1.12) 0.777 >0.999 
rs3758494 RBP3 G C 1.10(0.90, 1.35) 0.368 0.879  G C 0.98(0.89, 1.08) 0.672 >0.999 
rs6738598 CYP26B1 G A 1.17(0.83, 1.63) 0.371 0.879  G A 0.99(0.84, 1.17) 0.908 >0.999 
rs149225 LRAT C A 1.08(0.91, 1.28) 0.380 0.879  G T 0.98(0.90, 1.06) 0.582 >0.999 
rs12256889 CYP26C1 A C 0.93(0.78, 1.10) 0.382 0.879  C A 0.92(0.84, 1.00) 0.055 >0.999 
rs3810619 ISX T C 0.92(0.77, 1.11) 0.382 0.879  C T 1.06(0.98, 1.16) 0.159 >0.999 
rs913423 CYP26A1 C T 1.08(0.91, 1.28) 0.382 0.879  A G 1.00(0.93, 1.08) 0.949 >0.999 
rs6669441 RXRG A G 1.10(0.89, 1.34) 0.383 0.879  A G 0.99(0.89, 1.09) 0.787 >0.999 
rs361741 ISX T C 1.08(0.91, 1.27) 0.384 0.879  A G 0.94(0.87, 1.01) 0.106 >0.999 
rs1946518 BCO2 T G 0.93(0.79, 1.10) 0.387 0.879  G T 1.03(0.95, 1.12) 0.472 >0.999 
rs11187519 RBP4 A C 1.13(0.86, 1.47) 0.389 0.879  A C 0.96(0.85, 1.08) 0.489 >0.999 
rs2017362 ALDH1A1 T C 0.93(0.78, 1.10) 0.390 0.879  T C 0.94(0.87, 1.02) 0.163 >0.999 
rs10918179 RXRG A C 1.08(0.91, 1.28) 0.390 0.879  C A 0.99(0.91, 1.07) 0.755 >0.999 
rs10800091 RXRG G A 0.93(0.79, 1.10) 0.391 0.879  G A 1.03(0.95, 1.11) 0.524 >0.999 
rs17016718 RARB C T 1.10(0.88, 1.37) 0.393 0.879  C T 0.99(0.89, 1.10) 0.836 >0.999 
rs6799734 RARB C G 0.93(0.79, 1.10) 0.394 0.879  C G 1.03(0.94, 1.12) 0.549 >0.999 
rs7629902 RARB A G 1.11(0.87, 1.42) 0.395 0.879  A G 1.10(0.98, 1.23) 0.105 >0.999 
rs10032099 ADH4 G A 1.09(0.90, 1.32) 0.395 0.879  G A 1.02(0.93, 1.12) 0.723 >0.999 
rs12442054 STRA6 A G 0.89(0.68, 1.16) 0.396 0.879  A G 1.09(0.95, 1.24) 0.207 >0.999 
rs7663410 ADH7 C A 1.10(0.88, 1.38) 0.399 0.879  C A 0.92(0.83, 1.01) 0.094 >0.999 
rs7620852 RARB C T 0.91(0.73, 1.13) 0.399 0.879  C T 1.07(0.96, 1.19) 0.198 >0.999 
rs5755550 ISX C T 1.08(0.91, 1.27) 0.404 0.879  T C 1.00(0.93, 1.08) 0.94 >0.999 
rs17117895 RDH5 T C 0.85(0.59, 1.24) 0.406 0.879  T C 1.07(0.89, 1.28) 0.471 >0.999 
rs1881704 RARB G C 1.12(0.86, 1.45) 0.408 0.879  C G 1.04(0.92, 1.17) 0.574 >0.999 
rs348458 ALDH1A1 A G 0.93(0.79, 1.10) 0.409 0.879  T C 0.94(0.87, 1.02) 0.131 >0.999 
rs11926758 RARB T G 1.14(0.83, 1.57) 0.410 0.879  T G 1.11(0.96, 1.30) 0.168 >0.999 
rs1506951 RXRG T C 0.91(0.73, 1.14) 0.410 0.879  A G 1.00(0.89, 1.12) 0.956 >0.999 
rs7624894 RARB C T 1.12(0.86, 1.45) 0.415 0.879  C T 0.94(0.82, 1.08) 0.398 >0.999 
rs12934922 BCMO1 T A 1.07(0.91, 1.27) 0.416 0.879  T A 1.02(0.94, 1.10) 0.696 >0.999 
rs284794 ADH7 T A 1.13(0.84, 1.51) 0.417 0.879  A T 0.94(0.80, 1.09) 0.403 >0.999 
rs3129200 RXRB C T 0.90(0.70, 1.16) 0.417 0.879  G A 0.95(0.84, 1.06) 0.331 >0.999 
rs4681028 RARB T G 1.08(0.89, 1.32) 0.427 0.880  T G 1.08(0.98, 1.19) 0.116 >0.999 
rs6775425 RARB C T 1.08(0.90, 1.30) 0.428 0.880  T C 0.97(0.89, 1.06) 0.514 >0.999 
rs1286657 RARB G C 1.07(0.90, 1.28) 0.430 0.880  G C 0.98(0.90, 1.07) 0.689 >0.999 
rs10489745 RXRG C T 0.90(0.68, 1.18) 0.430 0.880  C T 1.04(0.90, 1.19) 0.613 >0.999 
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rs4889293 BCMO1 G C 1.07(0.90, 1.26) 0.434 0.880  G C 1.01(0.93, 1.09) 0.899 >0.999 
rs517456 RXRG C G 0.92(0.74, 1.14) 0.437 0.880  C G 1.03(0.92, 1.15) 0.613 >0.999 
rs8031689 CRABP1 T C 0.93(0.78, 1.12) 0.442 0.880  T C 0.93(0.86, 1.01) 0.101 >0.999 
rs11214106 BCO2 C T 0.90(0.70, 1.17) 0.442 0.880  C T 0.97(0.86, 1.09) 0.613 >0.999 
rs12915846 STRA6 A G 0.93(0.77, 1.12) 0.442 0.880  A G 0.94(0.86, 1.02) 0.156 >0.999 
rs361788 ISX G A 0.94(0.80, 1.11) 0.443 0.880  T C 0.95(0.88, 1.03) 0.203 >0.999 
rs7094671 RBP4 A G 1.08(0.89, 1.30) 0.445 0.880  A G 0.99(0.91, 1.09) 0.895 >0.999 
rs1154470 ADH7 A G 0.93(0.78, 1.12) 0.448 0.880  A G 1.04(0.96, 1.13) 0.362 >0.999 
rs1303629 RARB G T 0.93(0.77, 1.13) 0.449 0.880  G T 1.01(0.92, 1.11) 0.892 >0.999 
rs3814160 RBP3 T C 1.10(0.86, 1.42) 0.449 0.880  T C 0.92(0.81, 1.03) 0.149 >0.999 
rs4384231 CRABP2 T C 0.93(0.78, 1.12) 0.451 0.880  T C 1.09(1.00, 1.18) 0.043 >0.999 
rs1483856 RARB C A 1.11(0.85, 1.43) 0.454 0.880  T G 0.99(0.88, 1.12) 0.9 >0.999 
rs1547387 RXRB C G 0.91(0.70, 1.17) 0.454 0.880  G C 0.95(0.84, 1.08) 0.445 >0.999 
rs17583753 ADH1A A G 1.10(0.86, 1.41) 0.456 0.880  A G 0.99(0.88, 1.11) 0.87 >0.999 
rs918776 BCMO1 T C 0.94(0.80, 1.11) 0.457 0.880  C T 1.00(0.92, 1.08) 0.912 >0.999 
rs941022 RDH5 G T 0.94(0.79, 1.11) 0.459 0.881  C A 0.90(0.83, 0.97) 0.009 >0.999 
rs7629478 RARB G T 0.93(0.77, 1.12) 0.462 0.882  G T 0.93(0.84, 1.03) 0.177 >0.999 
rs7289450 ISX C G 1.07(0.89, 1.29) 0.467 0.884  C G 1.02(0.93, 1.11) 0.696 >0.999 
rs190910 RBP1 A T 1.06(0.90, 1.26) 0.468 0.884  T A 0.96(0.89, 1.04) 0.369 >0.999 
rs17016584 RARB G C 1.12(0.82, 1.53) 0.471 0.884  G C 0.89(0.77, 1.02) 0.099 >0.999 
rs3758538 RBP4 C A 1.08(0.87, 1.35) 0.472 0.884  G T 0.96(0.86, 1.07) 0.474 >0.999 
rs3768647 CYP26B1 C G 1.09(0.87, 1.36) 0.473 0.884  C G 0.95(0.85, 1.06) 0.353 >0.999 
rs12420140 BCO2 A G 1.07(0.89, 1.28) 0.479 0.884  A G 1.02(0.93, 1.11) 0.701 >0.999 
rs4492611 CRABP2 A G 1.06(0.90, 1.25) 0.479 0.884  -- -- -- -- -- 
rs7182884 ALDH1A3 C A 1.06(0.90, 1.27) 0.479 0.884  C A 0.95(0.87, 1.03) 0.186 >0.999 
rs1154477 ADH7 T C 0.94(0.79, 1.12) 0.482 0.885  A G 1.04(0.96, 1.12) 0.376 >0.999 
rs11185662 RXRA C T 0.93(0.77, 1.13) 0.487 0.890  C T 1.00(0.91, 1.10) 0.943 >0.999 
rs7613553 RARB A C 0.94(0.79, 1.12) 0.489 0.890  A C 0.94(0.86, 1.01) 0.097 >0.999 
rs1902716 RBP3 C T 0.93(0.76, 1.14) 0.491 0.890  A G 1.01(0.91, 1.11) 0.869 >0.999 
rs7845956 RDH10 A G 0.88(0.60, 1.29) 0.496 0.895  G A 0.98(0.83, 1.16) 0.816 >0.999 
rs749759 RXRA A G 1.07(0.88, 1.30) 0.499 0.896  -- -- -- -- -- 
rs7606254 CYP26B1 T C 0.93(0.74, 1.16) 0.507 0.902  T C 0.95(0.85, 1.06) 0.377 >0.999 
rs12723379 RXRG G A 1.06(0.90, 1.25) 0.511 0.902  G A 0.99(0.92, 1.08) 0.898 >0.999 
rs975020 BCO2 A G 0.93(0.73, 1.17) 0.514 0.902  A G 0.97(0.87, 1.09) 0.637 >0.999 
rs1500372 LRAT A G 1.09(0.83, 1.43) 0.523 0.902  A G 0.99(0.86, 1.14) 0.867 >0.999 
 RR: Risk Ratio; CI: Confidence Interval; OR: Odds Ratio; --: Unavailable in replication study  
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rs11170481 RARG A G 0.91(0.67, 1.23) 0.524 0.902  -- -- -- -- -- 
rs707718 CYP26B1 A C 0.93(0.76, 1.15) 0.524 0.902  T G 0.99(0.90, 1.10) 0.876 >0.999 
rs875444 RXRA G A 1.06(0.89, 1.25) 0.526 0.902  A G 1.03(0.94, 1.13) 0.488 >0.999 
rs6989495 RDH10 T G 1.06(0.89, 1.25) 0.531 0.902  T G 1.04(0.96, 1.13) 0.368 >0.999 
rs12578814 RDH5 A G 0.94(0.77, 1.14) 0.535 0.902  -- -- -- -- -- 
rs10736370 RBP3 C T 0.95(0.80, 1.12) 0.535 0.902  T C 0.98(0.90, 1.06) 0.592 >0.999 
rs3010493 PNLIP C T 1.10(0.82, 1.47) 0.535 0.902  T C 0.81(0.70, 0.93) 0.003 >0.999 
rs6537944 RXRA C T 1.10(0.82, 1.48) 0.536 0.902  -- -- -- -- -- 
rs11187536 RBP4 T G 1.06(0.88, 1.29) 0.539 0.902  T G 1.01(0.92, 1.10) 0.895 >0.999 
rs5999690 ISX C T 0.94(0.76, 1.16) 0.539 0.902  C T 1.03(0.93, 1.14) 0.611 >0.999 
rs4393871 RARB T C 0.95(0.80, 1.13) 0.539 0.902  C T 1.01(0.93, 1.09) 0.866 >0.999 
rs7768278 ALDH8A1 C T 1.06(0.89, 1.25) 0.541 0.902  C T 1.00(0.92, 1.08) 0.943 >0.999 
rs34571439 RBP4 C A 1.07(0.87, 1.32) 0.541 0.902  C A 1.04(0.94, 1.15) 0.483 >0.999 
rs284789 ADH7 C T 0.95(0.79, 1.13) 0.542 0.902  G A 1.03(0.94, 1.12) 0.528 >0.999 
rs13314209 RARB A G 0.91(0.67, 1.24) 0.548 0.902  A G 0.99(0.85, 1.15) 0.859 >0.999 
rs283694 RXRG T C 1.05(0.89, 1.25) 0.553 0.902  T C 1.06(0.97, 1.15) 0.195 >0.999 
rs1554753 RARG G A 0.94(0.77, 1.15) 0.553 0.902  G A 1.01(0.92, 1.12) 0.793 >0.999 
rs10048138 BCMO1 A G 1.07(0.86, 1.34) 0.555 0.902  G A 1.10(0.98, 1.24) 0.092 >0.999 
rs1286764 RARB A T 1.05(0.89, 1.25) 0.561 0.902  T A 1.00(0.92, 1.08) 0.994 >0.999 
rs13099641 RARB A T 1.08(0.84, 1.38) 0.561 0.902  A T 0.94(0.84, 1.06) 0.313 >0.999 
rs1286646 RARB G A 0.92(0.70, 1.21) 0.562 0.902  A G 0.94(0.83, 1.07) 0.341 >0.999 
rs1286740 RARB G C 1.05(0.89, 1.25) 0.562 0.902  C G 1.03(0.95, 1.12) 0.452 >0.999 
rs7039190 RXRA C A 0.88(0.58, 1.34) 0.562 0.902  C A 0.99(0.82, 1.20) 0.938 >0.999 
rs8187910 ALDH1A1 G A 0.92(0.70, 1.21) 0.562 0.902  C T 1.00(0.87, 1.14) 0.982 >0.999 
rs3138140 RDH5 A G 0.93(0.71, 1.21) 0.565 0.902  -- -- -- -- -- 
rs17016781 RARB G A 1.06(0.86, 1.32) 0.571 0.902  G A 1.02(0.92, 1.13) 0.663 >0.999 
rs3010496 PNLIP A G 1.06(0.86, 1.32) 0.576 0.902  G A 0.90(0.81, 1.00) 0.053 >0.999 
rs922939 RARB G T 0.95(0.80, 1.13) 0.577 0.902  A C 1.07(0.98, 1.16) 0.111 >0.999 
rs12907038 ALDH1A2 G C 0.95(0.81, 1.13) 0.579 0.902  G C 0.98(0.90, 1.06) 0.584 >0.999 
rs2072915 RXRB T A 1.05(0.88, 1.25) 0.583 0.902  A T 0.99(0.91, 1.07) 0.754 >0.999 
rs6426914 RXRG G A 0.91(0.66, 1.26) 0.585 0.902  A G 1.08(0.92, 1.28) 0.355 >0.999 
rs2715554 RARA C T 0.93(0.73, 1.20) 0.586 0.902  G A 0.98(0.87, 1.10) 0.7 >0.999 
rs4681064 RARB G C 1.06(0.87, 1.29) 0.588 0.902  -- -- -- -- -- 
rs10786068 CYP26A1 C G 1.05(0.88, 1.26) 0.590 0.902  G C 0.97(0.89, 1.05) 0.417 >0.999 
rs12442110 CRABP1 C G 1.05(0.88, 1.26) 0.594 0.902  C G 1.04(0.95, 1.13) 0.421 >0.999 
 RR: Risk Ratio; CI: Confidence Interval; OR: Odds Ratio; --: Unavailable in replication study  
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rs3767339 RXRG A C 1.05(0.88, 1.24) 0.595 0.902  C A 0.98(0.90, 1.07) 0.643 >0.999 
rs17526721 RARB G A 1.09(0.79, 1.52) 0.597 0.902  G A 1.08(0.93, 1.24) 0.327 >0.999 
rs13070407 RARB C T 0.95(0.78, 1.15) 0.597 0.902  C T 0.93(0.85, 1.01) 0.088 >0.999 
rs4922517 RBP3 T G 0.96(0.81, 1.13) 0.599 0.902  A C 1.03(0.95, 1.11) 0.521 >0.999 
rs4238328 ALDH1A2 A G 1.06(0.86, 1.30) 0.600 0.902  A G 0.99(0.89, 1.09) 0.773 >0.999 
rs2194899 RXRG A G 0.96(0.81, 1.13) 0.605 0.902  G A 0.97(0.89, 1.05) 0.458 >0.999 
rs9937350 BCMO1 C T 0.95(0.79, 1.15) 0.606 0.902  T C 1.05(0.96, 1.15) 0.264 >0.999 
rs351219 STRA6 C T 1.05(0.88, 1.24) 0.612 0.902  C T 1.02(0.94, 1.11) 0.575 >0.999 
rs9494108 ALDH8A1 T C 0.92(0.68, 1.26) 0.612 0.902  T C 0.99(0.83, 1.17) 0.868 >0.999 
rs12751264 RXRG T G 0.91(0.64, 1.31) 0.613 0.902  T G 1.02(0.85, 1.23) 0.828 >0.999 
rs6774124 RARB G C 0.96(0.80, 1.14) 0.616 0.902  G C 1.04(0.95, 1.13) 0.425 >0.999 
rs10203870 CYP26B1 A C 0.94(0.75, 1.19) 0.618 0.902  A C 1.06(0.96, 1.18) 0.251 >0.999 
rs2654848 ADH7 A T 1.04(0.88, 1.24) 0.618 0.902  T A 1.05(0.97, 1.14) 0.231 >0.999 
rs283695 RXRG A G 1.04(0.89, 1.23) 0.620 0.902  A G 1.05(0.97, 1.13) 0.246 >0.999 
rs9622121 ISX C T 1.04(0.88, 1.24) 0.623 0.902  T C 1.05(0.97, 1.14) 0.224 >0.999 
rs736118 STRA6 T C 0.94(0.71, 1.22) 0.623 0.902  T C 1.05(0.92, 1.21) 0.466 >0.999 
rs10212330 RARB A T 0.95(0.78, 1.16) 0.624 0.902  T A 1.01(0.92, 1.11) 0.874 >0.999 
rs5995056 ISX G C 0.96(0.80, 1.14) 0.624 0.902  C G 1.03(0.95, 1.12) 0.424 >0.999 
rs1800458 TTR A G 0.92(0.66, 1.28) 0.625 0.902  A G 1.03(0.89, 1.19) 0.693 >0.999 
rs3803651 BCMO1 G A 1.05(0.87, 1.27) 0.627 0.902  G A 1.00(0.91, 1.10) 0.963 >0.999 
rs4147531 ADH1A T C 1.04(0.88, 1.24) 0.631 0.905  A G 1.05(0.97, 1.14) 0.213 >0.999 
rs17326524 STRA6 C T 0.92(0.66, 1.29) 0.635 0.905  C T 1.09(0.93, 1.27) 0.278 >0.999 
rs13085878 RARB T C 0.95(0.78, 1.17) 0.638 0.905  T C 0.98(0.88, 1.08) 0.664 >0.999 
rs5744222 BCO2 A C 1.05(0.87, 1.27) 0.638 0.905  T G 1.05(0.95, 1.15) 0.332 >0.999 
rs2855425 RXRB C T 0.96(0.79, 1.15) 0.642 0.908  A G 1.01(0.93, 1.10) 0.788 >0.999 
rs3764478 TTR A C 1.06(0.81, 1.39) 0.650 0.917  T G 1.04(0.92, 1.19) 0.513 >0.999 
rs11089728 ISX T C 1.04(0.88, 1.24) 0.654 0.918  T C 1.03(0.95, 1.11) 0.532 >0.999 
rs7324 CEL A G 0.96(0.80, 1.15) 0.661 0.918  T C 1.00(0.92, 1.09) 0.967 >0.999 
rs6495089 STRA6 C T 1.04(0.88, 1.23) 0.663 0.918  T C 1.00(0.92, 1.08) 0.945 >0.999 
rs1367038 BCO2 C A 1.04(0.87, 1.25) 0.665 0.918  T G 0.97(0.89, 1.06) 0.503 >0.999 
rs17529377 ADH7 C T 0.95(0.74, 1.21) 0.666 0.918  C T 0.98(0.87, 1.11) 0.774 >0.999 
rs348464 ALDH1A1 T A 1.04(0.86, 1.27) 0.667 0.918  A T 0.91(0.83, 1.00) 0.049 >0.999 
rs1286766 RARB T A 0.96(0.81, 1.14) 0.668 0.918  T A 1.03(0.95, 1.12) 0.444 >0.999 
rs1286772 RARB C G 0.96(0.81, 1.15) 0.669 0.918  G C 1.03(0.95, 1.11) 0.539 >0.999 
rs941138 RARG C T 0.94(0.69, 1.27) 0.672 0.918  -- -- -- -- -- 
 RR: Risk Ratio; CI: Confidence Interval; OR: Odds Ratio; --: Unavailable in replication study  
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rs887844 CYP26B1 C T 0.96(0.81, 1.15) 0.673 0.918  -- -- -- -- -- 
rs1997353 RARB G A 0.97(0.81, 1.14) 0.678 0.919  T C 0.99(0.91, 1.07) 0.805 >0.999 
rs8187889 ALDH1A1 C T 0.93(0.65, 1.33) 0.679 0.919  G A 1.03(0.87, 1.23) 0.731 >0.999 
rs1286769 RARB T C 1.04(0.88, 1.23) 0.680 0.919  A G 1.02(0.94, 1.10) 0.658 >0.999 
rs9937486 BCMO1 G C 1.07(0.76, 1.51) 0.683 0.919  G C 1.08(0.90, 1.30) 0.415 >0.999 
rs2192332 CYP26B1 G T 1.04(0.86, 1.26) 0.686 0.919  C A 0.98(0.90, 1.07) 0.662 >0.999 
rs157865 RXRG A C 0.97(0.82, 1.14) 0.691 0.919  A C 1.00(0.92, 1.08) 1 >0.999 
rs3132301 RXRA T C 1.04(0.85, 1.29) 0.694 0.919  G A 0.99(0.90, 1.10) 0.907 >0.999 
rs11187545 RBP4 G A 1.06(0.78, 1.44) 0.695 0.919  G A 0.96(0.83, 1.11) 0.595 >0.999 
rs28709456 CES1 C A 0.95(0.74, 1.22) 0.696 0.919  -- -- -- -- -- 
rs4646870 ALDH8A1 T G 1.04(0.87, 1.23) 0.701 0.919  A C 1.01(0.93, 1.10) 0.741 >0.999 
rs6721368 CYP26B1 G T 0.94(0.69, 1.29) 0.702 0.919  G T 0.91(0.78, 1.07) 0.273 >0.999 
rs362166 ISX A G 0.94(0.70, 1.28) 0.704 0.919  T C 0.83(0.70, 0.98) 0.032 >0.999 
rs7621140 RARB C T 1.05(0.82, 1.33) 0.705 0.919  C T 0.96(0.85, 1.08) 0.493 >0.999 
rs360722 BCO2 T C 0.95(0.74, 1.23) 0.705 0.919  G A 1.02(0.90, 1.15) 0.729 >0.999 
rs11187531 RBP4 C T 1.06(0.79, 1.42) 0.707 0.919  C T 0.96(0.84, 1.10) 0.604 >0.999 
rs12169293 ISX A G 1.05(0.81, 1.38) 0.708 0.919  A G 1.03(0.90, 1.17) 0.687 >0.999 
rs7922067 CYP26C1 G A 0.97(0.82, 1.15) 0.710 0.920  A G 0.96(0.88, 1.04) 0.28 >0.999 
rs6587052 RBP3 C T 0.97(0.80, 1.16) 0.715 0.923  C T 1.01(0.93, 1.11) 0.788 >0.999 
rs10427677 ISX C A 1.04(0.84, 1.30) 0.718 0.923  C A 1.06(0.95, 1.18) 0.313 >0.999 
rs6778350 RARB A G 1.04(0.82, 1.32) 0.722 0.925  G A 1.01(0.90, 1.12) 0.926 >0.999 
rs16938613 RDH10 C A 0.95(0.73, 1.24) 0.725 0.925  C A 0.96(0.84, 1.09) 0.493 >0.999 
rs17525900 RARB C T 0.96(0.74, 1.23) 0.726 0.925  C T 1.03(0.91, 1.16) 0.663 >0.999 
rs8187950 ALDH1A1 C T 0.92(0.57, 1.49) 0.728 0.925  G A 1.02(0.83, 1.25) 0.834 >0.999 
rs7616467 RARB T C 1.03(0.87, 1.22) 0.736 0.933  -- -- -- -- -- 
rs4890109 RARA T G 0.93(0.60, 1.44) 0.738 0.933  T G 0.92(0.75, 1.11) 0.379 >0.999 
rs1154454 ADH7 C T 0.96(0.77, 1.20) 0.742 0.934  G A 1.06(0.95, 1.18) 0.282 >0.999 
rs2073821 CEL T C 1.04(0.81, 1.34) 0.743 0.934  T C 1.02(0.90, 1.16) 0.757 >0.999 
rs17016566 RARB G C 0.95(0.70, 1.29) 0.746 0.935  G C 1.00(0.86, 1.17) 0.956 >0.999 
rs1799908 RXRB T A 0.97(0.83, 1.15) 0.749 0.935  A T 1.02(0.95, 1.11) 0.545 >0.999 
rs11103603 RXRA C T 0.97(0.82, 1.16) 0.751 0.935  -- -- -- -- -- 
rs1968481 RARB G A 0.95(0.68, 1.33) 0.767 0.935  G A 1.04(0.89, 1.21) 0.659 >0.999 
rs5750056 ISX T C 1.05(0.76, 1.45) 0.768 0.935  T C 1.17(0.99, 1.39) 0.072 >0.999 
rs156499 LRAT C A 0.97(0.80, 1.18) 0.772 0.935  G T 0.98(0.89, 1.08) 0.658 >0.999 
rs11858606 ALDH1A2 C T 1.04(0.79, 1.38) 0.773 0.935  -- -- -- -- -- 
 RR: Risk Ratio; CI: Confidence Interval; OR: Odds Ratio; --: Unavailable in replication study  
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rs595958 ALDH1A1 A G 1.03(0.86, 1.22) 0.774 0.935  T C 0.95(0.87, 1.03) 0.204 >0.999 
rs11214125 BCO2 T C 1.04(0.78, 1.39) 0.776 0.935  T C 1.06(0.92, 1.22) 0.388 >0.999 
rs10082776 RARG G A 0.96(0.73, 1.27) 0.781 0.935  G A 1.09(0.95, 1.26) 0.229 >0.999 
rs12526336 RXRB A G 0.97(0.76, 1.23) 0.786 0.935  A G 1.04(0.92, 1.18) 0.515 >0.999 
rs4646548 ALDH1A1 C T 1.04(0.78, 1.39) 0.787 0.935  G A 1.10(0.93, 1.29) 0.257 >0.999 
rs1583977 ADH7 T A 0.97(0.75, 1.24) 0.789 0.935  A T 1.07(0.94, 1.20) 0.296 >0.999 
rs8027180 CRABP1 A G 1.02(0.87, 1.21) 0.789 0.935  G A 1.00(0.93, 1.09) 0.908 >0.999 
rs11187529 RBP4 T C 1.06(0.69, 1.63) 0.791 0.935  T C 1.07(0.86, 1.33) 0.53 >0.999 
rs11818333 RBP3 A T 1.04(0.77, 1.42) 0.793 0.935  A T 1.06(0.91, 1.24) 0.462 >0.999 
rs17016408 RARB C G 1.03(0.81, 1.33) 0.794 0.935  C G 1.03(0.91, 1.17) 0.64 >0.999 
rs7637031 RARB T G 1.02(0.86, 1.21) 0.796 0.935  T G 1.03(0.95, 1.12) 0.475 >0.999 
rs11630924 STRA6 C G 1.03(0.83, 1.27) 0.796 0.935  C G 0.95(0.86, 1.05) 0.327 >0.999 
rs4738315 RDH10 A G 0.98(0.81, 1.18) 0.801 0.935  A G 1.05(0.96, 1.15) 0.283 >0.999 
rs1992005 RARB T C 1.04(0.77, 1.40) 0.803 0.935  A G 1.06(0.91, 1.23) 0.45 >0.999 
rs1888202 ALDH1A1 G C 1.02(0.87, 1.20) 0.803 0.935  G C 1.06(0.98, 1.16) 0.147 >0.999 
rs925987 CRABP1 C T 1.02(0.86, 1.21) 0.804 0.935  T C 0.96(0.89, 1.05) 0.389 >0.999 
rs6805350 RARB G T 1.04(0.75, 1.44) 0.804 0.935  G T 1.14(0.97, 1.34) 0.117 >0.999 
rs7139068 RARG T A 0.97(0.73, 1.28) 0.804 0.935  -- -- -- -- -- 
rs3138144 RDH5 G C 0.98(0.83, 1.16) 0.806 0.935  -- -- -- -- -- 
rs1432603 RARB C T 0.98(0.80, 1.19) 0.808 0.935  T C 1.01(0.92, 1.11) 0.895 >0.999 
rs6805482 RARB A G 1.02(0.86, 1.21) 0.808 0.935  -- -- -- -- -- 
rs11214127 BCO2 A G 0.98(0.81, 1.18) 0.808 0.935  A G 0.99(0.91, 1.09) 0.871 >0.999 
rs6835524 ADH7 T C 0.97(0.76, 1.25) 0.810 0.935  C T 0.95(0.84, 1.07) 0.389 >0.999 
rs3803435 ALDH1A3 G C 1.03(0.80, 1.32) 0.813 0.937  -- -- -- -- -- 
rs285482 RXRG T G 0.98(0.82, 1.17) 0.816 0.937  T G 1.02(0.93, 1.11) 0.739 >0.999 
rs11999628 ALDH1A1 T G 0.96(0.66, 1.41) 0.833 0.954  T G 0.99(0.83, 1.19) 0.942 >0.999 
rs3899272 RXRA T A 1.04(0.74, 1.45) 0.836 0.954  T A 0.99(0.84, 1.15) 0.873 >0.999 
rs12635733 RARB C T 0.97(0.71, 1.33) 0.841 0.958  C T 1.05(0.90, 1.22) 0.522 >0.999 
rs13325144 RBP2 A G 1.03(0.79, 1.33) 0.844 0.959  A G 1.00(0.89, 1.12) 0.974 >0.999 
rs351224 STRA6 T A 0.98(0.84, 1.16) 0.846 0.959  A T 1.05(0.97, 1.13) 0.24 >0.999 
rs3757971 DGAT1 G A 0.98(0.83, 1.17) 0.857 0.964  C T 0.98(0.90, 1.07) 0.686 >0.999 
rs11645428 BCMO1 A G 0.98(0.83, 1.17) 0.857 0.964  A G 1.03(0.95, 1.12) 0.506 >0.999 
rs6550981 RARB G C 1.02(0.86, 1.19) 0.858 0.964  -- -- -- -- -- 
rs12753930 CRABP2 A G 0.99(0.83, 1.17) 0.860 0.965  G A 1.08(0.99, 1.17) 0.079 >0.999 
rs380518 RXRG C T 1.02(0.82, 1.27) 0.863 0.965  T C 1.00(0.90, 1.12) 0.944 >0.999 
 RR: Risk Ratio; CI: Confidence Interval; OR: Odds Ratio; --: Unavailable in replication study  
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rs1286665 RARB T C 0.99(0.83, 1.18) 0.866 0.966  T C 0.96(0.88, 1.05) 0.382 >0.999 
rs746332 RXRG A C 1.02(0.81, 1.28) 0.870 0.968  A C 1.00(0.89, 1.12) 0.973 >0.999 
rs12249434 PNLIP T C 0.98(0.73, 1.30) 0.872 0.968  T C 1.01(0.88, 1.15) 0.938 >0.999 
rs2012147 ALDH1A2 T C 0.97(0.68, 1.39) 0.878 0.968  G A 0.82(0.68, 0.99) 0.038 >0.999 
rs4349972 RDH10 T C 1.01(0.85, 1.20) 0.878 0.968  C T 1.07(0.99, 1.16) 0.091 >0.999 
rs7536331 RXRG G A 1.01(0.86, 1.19) 0.881 0.968  A G 0.98(0.91, 1.07) 0.683 >0.999 
rs11715516 RARB G C 0.98(0.79, 1.23) 0.883 0.968  C G 0.97(0.88, 1.08) 0.576 >0.999 
rs4935984 BCO2 A G 1.01(0.85, 1.21) 0.884 0.968  A G 1.00(0.92, 1.09) 0.987 >0.999 
rs1626875 RARB T C 0.99(0.80, 1.21) 0.891 0.969  A G 0.95(0.86, 1.05) 0.312 >0.999 
rs4887066 STRA6 T C 0.98(0.76, 1.27) 0.892 0.969  C T 0.94(0.82, 1.07) 0.325 >0.999 
rs12903202 ALDH1A2 G A 0.98(0.72, 1.33) 0.893 0.969  G A 0.94(0.82, 1.08) 0.406 >0.999 
rs213210 RXRB C T 1.02(0.76, 1.37) 0.894 0.969  -- -- -- -- -- 
rs11642457 BCMO1 G A 1.01(0.85, 1.20) 0.902 0.973  A G 1.02(0.94, 1.10) 0.653 >0.999 
rs2272301 RARG G C 1.02(0.79, 1.31) 0.904 0.973  -- -- -- -- -- 
rs295492 RBP1 T C 0.99(0.83, 1.18) 0.906 0.973  C T 0.97(0.89, 1.05) 0.473 >0.999 
rs6564851 BCMO1 T G 1.01(0.86, 1.19) 0.907 0.973  G T 1.03(0.95, 1.11) 0.535 >0.999 
rs12759184 CRABP2 T C 1.01(0.85, 1.21) 0.914 0.976  T C 0.93(0.86, 1.01) 0.097 >0.999 
rs4607073 RARB G T 0.99(0.84, 1.17) 0.915 0.976  T G 1.01(0.93, 1.09) 0.839 >0.999 
rs2041666 CYP26B1 A C 0.99(0.79, 1.23) 0.917 0.976  T G 0.99(0.89, 1.10) 0.912 >0.999 
rs8187884 ALDH1A1 T G 0.98(0.71, 1.37) 0.919 0.976  A C 1.01(0.88, 1.17) 0.85 >0.999 
rs348483 ALDH1A1 C T 0.99(0.79, 1.25) 0.926 0.982  C T 0.90(0.81, 1.00) 0.054 >0.999 
rs1286754 RARB T C 0.99(0.84, 1.18) 0.929 0.982  T C 1.02(0.94, 1.10) 0.693 >0.999 
rs6569976 ALDH8A1 C A 1.01(0.85, 1.19) 0.935 0.982  A C 1.02(0.94, 1.11) 0.633 >0.999 
rs11143419 ALDH1A1 C G 1.01(0.86, 1.19) 0.936 0.982  -- -- -- -- -- 
rs12929595 BCMO1 A G 0.99(0.82, 1.21) 0.936 0.982  G A 1.02(0.93, 1.12) 0.66 >0.999 
rs12932003 BCMO1 G A 1.01(0.85, 1.19) 0.940 0.983  G A 0.95(0.87, 1.04) 0.233 >0.999 
rs7620529 RARB A C 1.01(0.85, 1.20) 0.941 0.983  C A 1.03(0.95, 1.12) 0.413 >0.999 
rs3762894 ADH4 C T 0.99(0.80, 1.24) 0.950 0.987  C T 1.00(0.90, 1.11) 0.99 >0.999 
rs3813573 CRABP1 A G 0.99(0.80, 1.23) 0.950 0.987  T C 0.99(0.90, 1.09) 0.834 >0.999 
rs1286641 RARB T A 1.00(0.85, 1.19) 0.960 0.988  T A 0.95(0.88, 1.04) 0.259 >0.999 
rs4418728 CYP26A1 T G 1.00(0.84, 1.18) 0.964 0.988  T G 1.03(0.96, 1.12) 0.417 >0.999 
rs11089722 ISX G C 1.00(0.83, 1.20) 0.967 0.988  G C 1.01(0.93, 1.10) 0.744 >0.999 
rs34745537 RARG A G 1.00(0.85, 1.18) 0.972 0.988  -- -- -- -- -- 
rs4646615 ALDH1A2 T G 1.00(0.84, 1.19) 0.975 0.988  A C 1.02(0.93, 1.11) 0.679 >0.999 
rs10518951 ALDH1A2 A C 1.01(0.72, 1.40) 0.976 0.988  A C 0.95(0.81, 1.10) 0.47 >0.999 
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rs351229 STRA6 C A 1.00(0.78, 1.30) 0.976 0.988  T G 0.98(0.86, 1.12) 0.775 >0.999 
rs3741434 RARG G A 1.00(0.78, 1.28) 0.976 0.988  C T 1.01(0.90, 1.13) 0.82 >0.999 
rs11635868 STRA6 T C 1.00(0.75, 1.33) 0.979 0.988  T C 0.96(0.83, 1.10) 0.531 >0.999 
rs348463 ALDH1A1 C T 1.00(0.83, 1.20) 0.980 0.988  C T 0.95(0.87, 1.04) 0.257 >0.999 
rs6564864 BCMO1 T G 1.00(0.85, 1.18) 0.980 0.988  T G 1.04(0.96, 1.12) 0.364 >0.999 
rs2070706 RBP3 A G 1.00(0.84, 1.19) 0.984 0.988  C T 1.06(0.97, 1.15) 0.188 >0.999 
rs5750044 ISX T G 1.00(0.72, 1.40) 0.985 0.988  T G 1.13(0.95, 1.33) 0.159 >0.999 
rs7291929 ISX A G 1.00(0.73, 1.38) 0.987 0.988  A G 0.99(0.85, 1.16) 0.933 >0.999 
rs1435705 RARB A G 1.00(0.76, 1.32) 0.987 0.988  A G 1.04(0.91, 1.19) 0.542 >0.999 
rs17778240 ISX T A 1.00(0.85, 1.19) 0.988 0.988  T A 1.02(0.94, 1.10) 0.657 >0.999 
RR: Risk Ratio; CI: Confidence Interval; OR: Odds Ratio; --: Unavailable in replication study     
 
 
 RR: Risk ratio; CI: Confidence interval 
163 
 
APPENDIX 2. RESULTS FROM MATERNAL VITAMIN A-RELATED SNPS 
 SNP Gene Minor Allele Major Allele RR (95% CI) P-value Q-value 
rs4842196 RXRA C A 0.90(0.76, 1.06) 0.189 0.820 
rs1229977 ADH1A T C 0.88(0.73, 1.06) 0.185 0.820 
rs1045570 RXRA T G 1.01(0.81, 1.26) 0.930 0.984 
rs1007971 RXRA G C 0.98(0.83, 1.16) 0.804 0.984 
rs7139068 RARG T A 0.90(0.74, 1.09) 0.268 0.876 
rs904092 ADH1A A G 0.76(0.59, 0.99) 0.043 0.696 
rs3118523 RXRA G A 0.78(0.66, 0.93) 0.005 0.274 
rs7169439 ALDH1A2 A G 0.94(0.76, 1.18) 0.616 0.927 
rs1465057 RARG C T 0.89(0.74, 1.08) 0.250 0.876 
rs748964 RXRA C G 0.97(0.78, 1.22) 0.811 0.984 
rs362166 ISX A G 0.96(0.77, 1.19) 0.695 0.947 
rs6569976 ALDH8A1 C A 1.08(0.80, 1.45) 0.618 0.927 
rs2899240 ISX G A 0.70(0.49, 0.99) 0.044 0.696 
rs10032099 ADH4 G A 1.12(0.94, 1.32) 0.206 0.854 
rs10009145 ADH4 A G 0.85(0.69, 1.05) 0.137 0.784 
rs4699710 ADH4 C T 1.06(0.89, 1.25) 0.539 0.911 
rs28709456 CES1 C A 0.98(0.83, 1.16) 0.856 0.984 
rs6778350 RARB A G 1.07(0.90, 1.26) 0.462 0.904 
rs11917304 RARB C T 0.82(0.62, 1.07) 0.148 0.784 
rs283695 RXRG A G 0.89(0.75, 1.06) 0.192 0.820 
rs7670060 ADH4 T G 1.00(0.84, 1.19) 0.971 0.984 
rs12526336 RXRB A G 1.09(0.92, 1.27) 0.316 0.876 
rs5995056 ISX G C 0.99(0.83, 1.18) 0.904 0.984 
rs380518 RXRG C T 1.10(0.92, 1.31) 0.312 0.876 
rs3758495 RBP3 A G 0.90(0.76, 1.07) 0.237 0.864 
rs283694 RXRG T C 0.85(0.72, 1.00) 0.054 0.703 
rs11170481 RARG A G 0.96(0.82, 1.13) 0.615 0.927 
rs12753930 CRABP2 A G 0.75(0.52, 1.08) 0.120 0.784 
rs9373116 ALDH8A1 C G 0.90(0.66, 1.22) 0.493 0.904 
rs6799734 RARB C G 0.92(0.76, 1.13) 0.443 0.904 
rs1538648 CYP26C1 C T 1.04(0.81, 1.33) 0.764 0.962 
rs11926758 RARB T G 0.90(0.61, 1.34) 0.618 0.927 
rs1554753 RARG G A 1.11(0.84, 1.47) 0.453 0.904 
rs2364120 RARB G A 1.06(0.88, 1.27) 0.561 0.919 
rs11858606 ALDH1A2 C T 1.03(0.75, 1.42) 0.852 0.984 
rs5755550 ISX C T 1.03(0.78, 1.36) 0.856 0.984 
rs4266713 ALDH1A1 A T 0.72(0.56, 0.94) 0.014 0.447 
rs2120200 RARA G A 0.79(0.61, 1.03) 0.087 0.778 
rs6550981 RARB G C 0.76(0.57, 1.03) 0.075 0.778 
rs3817776 ALDH8A1 C T 0.76(0.63, 0.91) 0.004 0.274 
rs941138 RARG C T 0.83(0.64, 1.08) 0.170 0.807 
 RR: Risk ratio; CI: Confidence interval 
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 SNP Gene Minor Allele Major Allele RR (95% CI) P-value Q-value 
rs10885982 PNLIP A G 1.20(0.95, 1.51) 0.129 0.784 
rs2116703 RARB A G 0.98(0.82, 1.17) 0.849 0.984 
rs285482 RXRG T G 1.00(0.84, 1.20) 0.973 0.984 
rs6805350 RARB G T 1.00(0.84, 1.19) 1.000 1.000 
rs1286658 RARB T C 0.91(0.73, 1.13) 0.407 0.904 
rs12730752 CRABP2 T C 1.02(0.85, 1.21) 0.858 0.984 
rs4681064 RARB G C 1.12(0.91, 1.38) 0.287 0.876 
rs17526721 RARB G A 1.02(0.82, 1.28) 0.832 0.984 
rs5750056 ISX T C 0.94(0.80, 1.12) 0.497 0.904 
rs1286740 RARB G C 0.96(0.80, 1.15) 0.671 0.947 
rs1805343 RXRA G A 1.00(0.84, 1.18) 0.976 0.985 
rs10082776 RARG G A 1.03(0.87, 1.23) 0.727 0.947 
rs3810619 ISX T C 1.13(0.91, 1.39) 0.273 0.876 
rs1902716 RBP3 C T 1.09(0.89, 1.34) 0.386 0.904 
rs6767543 RARB G A 0.82(0.62, 1.09) 0.173 0.807 
rs11264527 CRABP2 C T 0.87(0.75, 1.03) 0.099 0.778 
rs5750044 ISX T G 1.00(0.84, 1.20) 0.957 0.984 
rs12648206 ADH7 G A 1.10(0.93, 1.29) 0.255 0.876 
rs1800759 ADH4 A C 0.94(0.76, 1.17) 0.603 0.927 
rs17778240 ISX T A 1.21(1.00, 1.46) 0.056 0.703 
rs6495089 STRA6 C T 0.80(0.60, 1.06) 0.120 0.784 
rs4492611 CRABP2 A G 1.13(0.94, 1.35) 0.191 0.820 
rs4738315 RDH10 A G 0.83(0.62, 1.11) 0.213 0.854 
rs2073821 CEL T C 0.82(0.67, 0.99) 0.041 0.696 
rs9622121 ISX C T 0.91(0.74, 1.11) 0.350 0.899 
rs6669441 RXRG A G 1.23(0.96, 1.57) 0.108 0.778 
rs10918179 RXRG A C 1.02(0.75, 1.39) 0.911 0.984 
rs4646548 ALDH1A1 C T 0.75(0.51, 1.10) 0.137 0.784 
rs4240705 RXRA G A 0.99(0.75, 1.31) 0.943 0.984 
rs17016570 RARB G A 0.80(0.60, 1.07) 0.128 0.784 
rs12573026 RBP4 C T 1.14(0.96, 1.37) 0.145 0.784 
rs1864907 RARB G A 0.96(0.81, 1.14) 0.631 0.930 
rs1286750 RARB C A 1.07(0.87, 1.31) 0.501 0.904 
rs2070706 RBP3 A G 1.06(0.88, 1.28) 0.537 0.911 
rs2194899 RXRG A G 0.61(0.47, 0.79) 0.000 0.076 
rs3010493 PNLIP C T 1.07(0.89, 1.27) 0.474 0.904 
rs17583753 ADH1A A G 0.94(0.79, 1.11) 0.445 0.904 
rs3899272 RXRA T A 1.28(0.96, 1.71) 0.096 0.778 
rs1500372 LRAT A G 1.03(0.88, 1.22) 0.699 0.947 
rs10910 STRA6 G A 1.03(0.81, 1.32) 0.800 0.984 
rs17108978 RBP4 A G 0.93(0.73, 1.19) 0.568 0.920 
rs11214139 BCO2 G A 0.94(0.77, 1.14) 0.538 0.911 
rs1153592 RARB A T 0.85(0.62, 1.15) 0.292 0.876 
 RR: Risk ratio; CI: Confidence interval 
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 SNP Gene Minor Allele Major Allele RR (95% CI) P-value Q-value 
rs6795340 RARB A G 0.98(0.80, 1.19) 0.842 0.984 
rs482284 RARA A G 1.04(0.88, 1.22) 0.629 0.930 
rs1286664 RARB T C 1.01(0.85, 1.19) 0.947 0.984 
rs1730221 RARB G C 1.06(0.87, 1.28) 0.573 0.921 
rs3803651 BCMO1 G A 0.85(0.61, 1.20) 0.363 0.904 
rs6909923 ALDH8A1 G A 0.90(0.75, 1.07) 0.230 0.864 
rs11865869 BCMO1 G A 1.03(0.86, 1.24) 0.729 0.947 
rs752739 RXRG T C 1.04(0.88, 1.23) 0.649 0.946 
rs3767339 RXRG A C 1.12(0.87, 1.44) 0.386 0.904 
rs156499 LRAT C A 1.02(0.86, 1.20) 0.840 0.984 
rs9879736 RBP1 T C 1.04(0.87, 1.24) 0.692 0.947 
rs3762894 ADH4 C T 1.07(0.90, 1.27) 0.434 0.904 
rs11580324 CRABP2 C G 0.94(0.72, 1.23) 0.677 0.947 
rs348458 ALDH1A1 A G 0.93(0.76, 1.14) 0.491 0.904 
rs11187549 RBP4 G A 1.07(0.89, 1.29) 0.451 0.904 
rs3818730 RXRA A G 1.13(0.91, 1.39) 0.275 0.876 
rs4646669 ALDH1A3 T C 1.11(0.91, 1.34) 0.300 0.876 
rs11089722 ISX G C 1.16(0.98, 1.38) 0.088 0.778 
rs8187945 ALDH1A1 T C 1.01(0.85, 1.20) 0.951 0.984 
rs2715553 RARA C T 1.00(0.85, 1.18) 0.963 0.984 
rs13120304 ADH1A A T 1.12(0.95, 1.33) 0.164 0.807 
rs1153606 RARB G A 0.82(0.70, 0.97) 0.022 0.609 
rs2156731 ADH4 A G 1.16(0.99, 1.36) 0.074 0.778 
rs12906432 ALDH1A3 T G 0.94(0.79, 1.11) 0.469 0.904 
rs6564851 BCMO1 T G 1.00(0.79, 1.26) 0.996 0.998 
rs3803435 ALDH1A3 G C 1.05(0.77, 1.41) 0.771 0.963 
rs5750041 ISX T C 1.04(0.87, 1.25) 0.669 0.947 
rs4238328 ALDH1A2 A G 1.06(0.90, 1.25) 0.509 0.904 
rs1286650 RARB A T 0.85(0.70, 1.04) 0.108 0.778 
rs749759 RXRA A G 1.15(0.94, 1.41) 0.173 0.807 
rs283697 RXRG A C 0.85(0.72, 1.00) 0.051 0.703 
rs157861 RXRG G C 1.08(0.91, 1.28) 0.399 0.904 
rs348483 ALDH1A1 C T 0.93(0.77, 1.13) 0.477 0.904 
rs12907038 ALDH1A2 G C 1.22(1.01, 1.47) 0.038 0.696 
rs1229966 ADH1A C T 0.85(0.69, 1.05) 0.143 0.784 
rs1154460 ADH7 A G 1.13(0.88, 1.45) 0.340 0.891 
rs8187884 ALDH1A1 T G 0.94(0.79, 1.12) 0.520 0.911 
rs11264518 CRABP2 T C 1.13(0.81, 1.57) 0.469 0.904 
rs351224 STRA6 T A 1.21(0.94, 1.56) 0.136 0.784 
rs4646678 ALDH1A3 T C 0.91(0.76, 1.09) 0.327 0.882 
rs7922067 CYP26C1 G A 1.09(0.92, 1.29) 0.315 0.876 
rs4890109 RARA T G 0.99(0.85, 1.16) 0.935 0.984 
rs361788 ISX G A 0.91(0.75, 1.10) 0.319 0.876 
 RR: Risk ratio; CI: Confidence interval 
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 SNP Gene Minor Allele Major Allele RR (95% CI) P-value Q-value 
rs1108197 RBP4 A G 0.88(0.66, 1.17) 0.378 0.904 
rs941022 RDH5 G T 0.87(0.67, 1.13) 0.302 0.876 
rs3813573 CRABP1 A G 0.94(0.73, 1.22) 0.657 0.947 
rs9937486 BCMO1 G C 0.86(0.72, 1.02) 0.089 0.778 
rs7663410 ADH7 C A 0.87(0.67, 1.14) 0.316 0.876 
rs6762247 RARB T C 0.93(0.74, 1.16) 0.509 0.904 
rs8181419 RBP4 G T 0.92(0.78, 1.09) 0.343 0.891 
rs3773438 RARB A G 0.95(0.73, 1.23) 0.703 0.947 
rs975020 BCO2 A G 0.87(0.71, 1.08) 0.210 0.854 
rs6771831 RBP2 A G 1.02(0.85, 1.24) 0.819 0.984 
rs4699720 ADH4 C T 1.19(0.94, 1.51) 0.148 0.784 
rs12512110 ADH1A T G 1.10(0.89, 1.36) 0.355 0.904 
rs167187 RBP1 G A 1.11(0.88, 1.40) 0.360 0.904 
rs17016566 RARB G C 0.99(0.83, 1.17) 0.871 0.984 
rs12420140 BCO2 A G 0.87(0.68, 1.11) 0.262 0.876 
rs7541159 RXRG T G 1.15(0.94, 1.41) 0.186 0.820 
rs6803265 RARB A T 0.93(0.78, 1.11) 0.424 0.904 
rs13314209 RARB A G 1.29(1.05, 1.58) 0.015 0.447 
rs16844995 RXRG C T 1.17(0.90, 1.53) 0.250 0.876 
rs6805482 RARB A G 1.13(0.87, 1.45) 0.364 0.904 
rs3772879 RBP2 T A 1.16(0.86, 1.57) 0.317 0.876 
rs970902 RXRB G A 1.29(0.92, 1.80) 0.141 0.784 
rs11089728 ISX T C 1.17(0.86, 1.59) 0.312 0.876 
rs12751264 RXRG T G 1.11(0.88, 1.40) 0.388 0.904 
rs12723379 RXRG G A 1.08(0.88, 1.32) 0.477 0.904 
rs7536331 RXRG G A 1.09(0.90, 1.33) 0.383 0.904 
rs11170466 RARG A G 1.03(0.84, 1.27) 0.764 0.962 
rs6774691 RBP2 A G 1.03(0.85, 1.25) 0.727 0.947 
rs1902715 RBP3 A G 1.02(0.85, 1.21) 0.856 0.984 
rs10110749 RDH10 G C 1.31(0.89, 1.94) 0.168 0.807 
rs974456 STRA6 T C 1.18(1.00, 1.39) 0.054 0.703 
rs4393871 RARB T C 1.02(0.73, 1.43) 0.897 0.984 
rs1123944 RXRG T C 0.82(0.63, 1.07) 0.146 0.784 
rs7182884 ALDH1A3 C A 1.15(0.85, 1.56) 0.374 0.904 
rs17326524 STRA6 C T 0.98(0.78, 1.24) 0.879 0.984 
rs8031689 CRABP1 T C 1.16(0.91, 1.48) 0.222 0.854 
rs11204208 RBP3 T G 1.12(0.89, 1.40) 0.336 0.891 
rs10203870 CYP26B1 A C 1.00(0.86, 1.18) 0.965 0.984 
rs11185662 RXRA C T 1.10(0.92, 1.30) 0.300 0.876 
rs11707637 RARB G A 1.05(0.76, 1.45) 0.781 0.973 
rs295492 RBP1 T C 1.16(0.98, 1.37) 0.088 0.778 
rs7428398 RBP1 A G 0.85(0.71, 1.00) 0.053 0.703 
rs41356949 RBP2 T C 0.92(0.65, 1.30) 0.638 0.935 
 RR: Risk ratio; CI: Confidence interval 
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 SNP Gene Minor Allele Major Allele RR (95% CI) P-value Q-value 
rs12929595 BCMO1 A G 0.99(0.77, 1.27) 0.927 0.984 
rs13325144 RBP2 A G 0.99(0.84, 1.17) 0.884 0.984 
rs1946518 BCO2 T G 1.09(0.93, 1.29) 0.286 0.876 
rs157865 RXRG A C 1.20(0.98, 1.48) 0.083 0.778 
rs8187889 ALDH1A1 C T 0.87(0.71, 1.06) 0.166 0.807 
rs360722 BCO2 T C 0.94(0.79, 1.11) 0.461 0.904 
rs922939 RARB G T 0.77(0.65, 0.91) 0.003 0.274 
rs3852534 RDH5 A G 1.23(0.85, 1.77) 0.277 0.876 
rs1968481 RARB G A 0.94(0.69, 1.27) 0.674 0.947 
rs1286773 RARB G C 1.09(0.92, 1.29) 0.312 0.876 
rs913422 CYP26A1 C T 1.00(0.70, 1.42) 0.982 0.989 
rs7289450 ISX C G 0.99(0.83, 1.16) 0.859 0.984 
rs5744222 BCO2 A C 1.09(0.83, 1.42) 0.549 0.917 
rs1286738 RARB T C 0.92(0.74, 1.13) 0.414 0.904 
rs875444 RXRA G A 0.93(0.79, 1.10) 0.384 0.904 
rs17016584 RARB G C 1.05(0.87, 1.27) 0.607 0.927 
rs7905501 CYP26A1 T C 1.04(0.88, 1.23) 0.613 0.927 
rs455696 RXRG C T 0.94(0.77, 1.13) 0.494 0.904 
rs6738598 CYP26B1 G A 0.88(0.68, 1.14) 0.325 0.882 
rs6989495 RDH10 T G 1.10(0.93, 1.30) 0.278 0.876 
rs3821629 RARB G A 1.21(0.98, 1.50) 0.082 0.778 
rs351219 STRA6 C T 0.72(0.56, 0.93) 0.012 0.441 
rs2072827 ALDH8A1 A G 0.88(0.66, 1.19) 0.415 0.904 
rs6537944 RXRA C T 1.24(0.93, 1.65) 0.139 0.784 
rs517456 RXRG C G 0.99(0.83, 1.19) 0.932 0.984 
rs755661 RARB T C 1.03(0.87, 1.21) 0.750 0.960 
rs1154454 ADH7 C T 1.05(0.82, 1.35) 0.701 0.947 
rs7624894 RARB C T 0.98(0.73, 1.31) 0.883 0.984 
rs11187545 RBP4 G A 1.01(0.82, 1.23) 0.951 0.984 
rs1547387 RXRB C G 1.14(0.94, 1.40) 0.192 0.820 
rs4147531 ADH1A T C 1.27(1.01, 1.60) 0.041 0.696 
rs156500 LRAT C A 1.01(0.85, 1.20) 0.880 0.984 
rs11103603 RXRA C T 1.07(0.90, 1.27) 0.453 0.904 
rs12635733 RARB C T 1.04(0.82, 1.32) 0.728 0.947 
rs1128977 RXRG T C 1.08(0.91, 1.28) 0.375 0.904 
rs3819197 ADH1A T C 1.01(0.85, 1.21) 0.885 0.984 
rs7959622 RDH5 C T 0.94(0.80, 1.12) 0.496 0.904 
rs1506951 RXRG T C 0.97(0.79, 1.19) 0.742 0.952 
rs17587689 ADH7 A G 1.06(0.89, 1.27) 0.510 0.904 
rs190910 RBP1 A T 0.87(0.65, 1.16) 0.343 0.891 
rs4889291 BCMO1 G A 0.98(0.74, 1.31) 0.900 0.984 
rs10776909 RXRA T C 0.98(0.78, 1.24) 0.891 0.984 
rs9494108 ALDH8A1 T C 1.07(0.90, 1.28) 0.442 0.904 
 RR: Risk ratio; CI: Confidence interval 
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 SNP Gene Minor Allele Major Allele RR (95% CI) P-value Q-value 
rs955243 LRAT A G 0.96(0.79, 1.17) 0.700 0.947 
rs3010496 PNLIP A G 0.93(0.74, 1.18) 0.565 0.920 
rs11187531 RBP4 C T 0.99(0.85, 1.16) 0.942 0.984 
rs10736370 RBP3 C T 0.99(0.85, 1.16) 0.886 0.984 
rs729147 ADH7 G A 0.89(0.62, 1.28) 0.531 0.911 
rs17525900 RARB C T 0.99(0.84, 1.18) 0.943 0.984 
rs9886504 RDH10 A G 0.95(0.71, 1.27) 0.739 0.951 
rs925987 CRABP1 C T 0.86(0.69, 1.06) 0.151 0.784 
rs2413292 ISX T C 1.06(0.86, 1.29) 0.603 0.927 
rs1154473 ADH7 T C 0.89(0.75, 1.06) 0.204 0.854 
rs7606254 CYP26B1 T C 1.18(0.91, 1.53) 0.208 0.854 
rs3138140 RDH5 A G 0.83(0.66, 1.03) 0.097 0.778 
rs11630924 STRA6 C G 1.04(0.79, 1.37) 0.762 0.962 
rs4681028 RARB T G 0.96(0.74, 1.25) 0.758 0.962 
rs1154470 ADH7 A G 0.96(0.79, 1.18) 0.709 0.947 
rs17117895 RDH5 T C 0.87(0.75, 1.02) 0.087 0.778 
rs34571439 RBP4 C A 0.97(0.79, 1.20) 0.786 0.977 
rs10212330 RARB A T 1.02(0.86, 1.20) 0.854 0.984 
rs12932003 BCMO1 G A 0.95(0.81, 1.11) 0.522 0.911 
rs7094671 RBP4 A G 1.03(0.86, 1.23) 0.734 0.950 
rs1800458 TTR A G 0.98(0.80, 1.19) 0.834 0.984 
rs11187519 RBP4 A C 1.08(0.86, 1.37) 0.496 0.904 
rs9937350 BCMO1 C T 1.01(0.85, 1.19) 0.928 0.984 
rs7235277 TTR C G 1.06(0.90, 1.25) 0.508 0.904 
rs12512714 LRAT G C 0.81(0.64, 1.04) 0.107 0.778 
rs4887066 STRA6 T C 0.78(0.60, 1.01) 0.058 0.703 
rs3758538 RBP4 C A 0.96(0.81, 1.14) 0.631 0.930 
rs2041666 CYP26B1 A C 1.04(0.88, 1.22) 0.667 0.947 
rs1286764 RARB A T 0.98(0.72, 1.34) 0.895 0.984 
rs2071025 RXRB C T 0.96(0.75, 1.21) 0.711 0.947 
rs348464 ALDH1A1 T A 0.93(0.79, 1.10) 0.407 0.904 
rs12442054 STRA6 A G 0.98(0.80, 1.20) 0.859 0.984 
rs1286657 RARB G C 0.92(0.72, 1.18) 0.507 0.904 
rs7291929 ISX A G 0.99(0.77, 1.26) 0.910 0.984 
rs11214127 BCO2 A G 0.95(0.77, 1.17) 0.630 0.930 
rs6564863 BCMO1 T C 0.91(0.70, 1.19) 0.500 0.904 
rs6564864 BCMO1 T G 0.94(0.79, 1.12) 0.466 0.904 
rs7613553 RARB A C 1.18(0.93, 1.49) 0.176 0.807 
rs6721368 CYP26B1 G T 1.09(0.92, 1.29) 0.308 0.876 
rs10518951 ALDH1A2 A C 0.89(0.71, 1.11) 0.302 0.876 
rs7637031 RARB T G 0.99(0.76, 1.29) 0.960 0.984 
rs11214106 BCO2 C T 0.81(0.62, 1.06) 0.129 0.784 
rs3767342 RXRG C T 1.22(0.96, 1.56) 0.109 0.778 
 RR: Risk ratio; CI: Confidence interval 
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 SNP Gene Minor Allele Major Allele RR (95% CI) P-value Q-value 
rs3767343 RXRG A G 1.07(0.82, 1.40) 0.610 0.927 
rs2012147 ALDH1A2 T C 1.04(0.85, 1.27) 0.680 0.947 
rs6835524 ADH7 T C 0.98(0.78, 1.24) 0.894 0.984 
rs7629478 RARB G T 0.88(0.75, 1.03) 0.122 0.784 
rs3129200 RXRB C T 0.95(0.79, 1.14) 0.549 0.917 
rs4349972 RDH10 T C 1.12(0.90, 1.39) 0.319 0.876 
rs4646870 ALDH8A1 T G 1.08(0.84, 1.38) 0.539 0.911 
rs6587052 RBP3 C T 0.93(0.79, 1.09) 0.383 0.904 
rs4657438 RXRG C A 0.83(0.69, 1.00) 0.044 0.696 
rs707718 CYP26B1 A C 0.85(0.70, 1.02) 0.085 0.778 
rs3118529 RXRA C T 1.24(1.02, 1.52) 0.033 0.696 
rs211585 RBP1 C T 1.17(1.00, 1.38) 0.057 0.703 
rs6580936 RARG G A 1.02(0.75, 1.37) 0.912 0.984 
rs595958 ALDH1A1 A G 0.93(0.77, 1.11) 0.417 0.904 
rs4935984 BCO2 A G 0.94(0.71, 1.25) 0.659 0.947 
rs157862 RXRG T A 1.10(0.79, 1.53) 0.581 0.927 
rs913423 CYP26A1 C T 0.98(0.84, 1.15) 0.791 0.979 
rs918776 BCMO1 T C 1.04(0.88, 1.23) 0.652 0.947 
rs41419946 RXRG T A 0.96(0.77, 1.20) 0.726 0.947 
rs7768278 ALDH8A1 C T 1.05(0.86, 1.29) 0.631 0.930 
rs11776584 RDH10 A G 0.85(0.72, 1.01) 0.066 0.754 
rs284794 ADH7 T A 1.12(0.86, 1.46) 0.394 0.904 
rs4148887 ADH4 C T 0.98(0.83, 1.16) 0.832 0.984 
rs3772868 RBP1 T C 1.02(0.85, 1.23) 0.811 0.984 
rs12502290 ADH7 A G 0.86(0.73, 1.02) 0.083 0.778 
rs13085878 RARB T C 1.10(0.94, 1.30) 0.235 0.864 
rs361741 ISX T C 1.01(0.86, 1.19) 0.910 0.984 
rs3741434 RARG G A 1.16(0.95, 1.42) 0.150 0.784 
rs12739596 RXRG C A 0.77(0.65, 0.91) 0.003 0.274 
rs11103473 RXRA T A 1.07(0.79, 1.45) 0.664 0.947 
rs11645428 BCMO1 A G 1.00(0.85, 1.18) 0.968 0.984 
rs11187529 RBP4 T C 1.05(0.88, 1.24) 0.601 0.927 
rs4922517 RBP3 T G 0.89(0.72, 1.10) 0.276 0.876 
rs1153603 RARB A G 0.93(0.76, 1.14) 0.484 0.904 
rs7071684 RBP3 T C 1.11(0.94, 1.31) 0.232 0.864 
rs1367038 BCO2 C A 0.96(0.81, 1.15) 0.678 0.947 
rs1371338 RBP2 C T 1.11(0.79, 1.56) 0.554 0.918 
rs17529377 ADH7 C T 1.24(0.87, 1.75) 0.228 0.864 
rs8187876 ALDH1A1 A G 1.08(0.88, 1.32) 0.453 0.904 
rs7620852 RARB C T 0.91(0.76, 1.08) 0.285 0.876 
rs16938613 RDH10 C A 1.01(0.84, 1.23) 0.887 0.984 
rs149225 LRAT C A 1.08(0.90, 1.29) 0.398 0.904 
rs994772 ADH7 A G 1.22(1.00, 1.49) 0.047 0.703 
 RR: Risk ratio; CI: Confidence interval 
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 SNP Gene Minor Allele Major Allele RR (95% CI) P-value Q-value 
rs4646607 ALDH1A2 T G 0.78(0.64, 0.95) 0.012 0.441 
rs11143419 ALDH1A1 C G 0.87(0.73, 1.03) 0.104 0.778 
rs2017362 ALDH1A1 T C 0.86(0.72, 1.04) 0.114 0.784 
rs2715554 RARA C T 0.83(0.64, 1.09) 0.176 0.807 
rs2855425 RXRB C T 0.98(0.83, 1.16) 0.857 0.984 
rs6426914 RXRG G A 1.15(0.97, 1.37) 0.106 0.778 
rs1286769 RARB T C 1.10(0.71, 1.70) 0.683 0.947 
rs1881705 RARB G A 1.05(0.89, 1.25) 0.560 0.919 
rs10427677 ISX C A 1.29(1.09, 1.54) 0.004 0.274 
rs6775425 RARB C T 0.88(0.71, 1.09) 0.245 0.876 
rs3758494 RBP3 G C 1.02(0.84, 1.24) 0.825 0.984 
rs12903202 ALDH1A2 G A 1.00(0.79, 1.26) 0.971 0.984 
rs1626875 RARB T C 1.02(0.74, 1.39) 0.907 0.984 
rs1286772 RARB C G 0.99(0.74, 1.34) 0.968 0.984 
rs10048138 BCMO1 A G 0.99(0.85, 1.17) 0.945 0.984 
rs991316 ADH7 A G 1.09(0.92, 1.29) 0.339 0.891 
rs2925455 RDH10 C A 0.97(0.82, 1.14) 0.713 0.947 
rs7080494 CYP26A1 G A 1.08(0.88, 1.33) 0.456 0.904 
rs1583977 ADH7 T A 0.98(0.71, 1.35) 0.900 0.984 
rs11818333 RBP3 A T 0.92(0.77, 1.09) 0.315 0.876 
rs348463 ALDH1A1 C T 1.04(0.84, 1.29) 0.701 0.947 
rs283690 RXRG G A 0.89(0.67, 1.17) 0.393 0.904 
rs17016773 RARB T C 1.07(0.90, 1.27) 0.443 0.904 
rs4681027 RARB G T 1.01(0.86, 1.19) 0.889 0.984 
rs6774124 RARB G C 0.82(0.69, 0.98) 0.026 0.609 
rs3935542 CRABP2 G C 0.83(0.69, 0.99) 0.036 0.696 
rs1992005 RARB T C 0.79(0.67, 0.93) 0.006 0.274 
rs2017543 ISX C T 1.15(0.98, 1.35) 0.094 0.778 
rs4681063 RARB C T 0.94(0.79, 1.12) 0.488 0.904 
rs2072915 RXRB T A 0.91(0.73, 1.13) 0.377 0.904 
rs3138142 RDH5 A G 1.02(0.85, 1.22) 0.854 0.984 
rs3768647 CYP26B1 C G 0.97(0.79, 1.19) 0.765 0.962 
rs1154477 ADH7 T C 1.24(0.88, 1.74) 0.214 0.854 
rs1432603 RARB C T 0.79(0.56, 1.10) 0.161 0.807 
rs11715516 RARB G C 0.99(0.78, 1.26) 0.935 0.984 
rs736118 STRA6 T C 0.94(0.79, 1.12) 0.507 0.904 
rs7629902 RARB A G 0.94(0.79, 1.12) 0.484 0.904 
rs3138144 RDH5 G C 0.97(0.82, 1.14) 0.689 0.947 
rs1435705 RARB A G 0.82(0.62, 1.08) 0.156 0.801 
rs1286654 RARB T G 0.80(0.67, 0.97) 0.024 0.609 
rs10882273 RBP4 C T 0.84(0.71, 1.01) 0.060 0.708 
rs1372369 ALDH1A2 C A 1.20(0.96, 1.49) 0.111 0.778 
rs11856111 CRABP1 C T 1.40(1.14, 1.72) 0.001 0.274 
 RR: Risk ratio; CI: Confidence interval 
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 SNP Gene Minor Allele Major Allele RR (95% CI) P-value Q-value 
rs284789 ADH7 C T 1.01(0.85, 1.19) 0.950 0.984 
rs4646684 ALDH1A3 A G 1.18(0.95, 1.47) 0.139 0.784 
rs1303629 RARB G T 1.09(0.79, 1.51) 0.606 0.927 
rs13070407 RARB C T 0.93(0.78, 1.11) 0.412 0.904 
rs7039190 RXRA C A 1.02(0.80, 1.29) 0.893 0.984 
rs3132301 RXRA T C 1.19(0.87, 1.62) 0.277 0.876 
rs2462936 RDH5 T C 1.27(1.06, 1.51) 0.008 0.340 
rs17016781 RARB G A 0.99(0.69, 1.43) 0.962 0.984 
rs2899611 ALDH1A2 G T 0.93(0.79, 1.09) 0.381 0.904 
rs1286665 RARB T C 1.08(0.87, 1.33) 0.492 0.904 
rs17016778 RARB G A 0.95(0.81, 1.11) 0.512 0.904 
rs7845956 RDH10 A G 1.01(0.84, 1.22) 0.920 0.984 
rs4144005 ALDH1A2 T C 0.85(0.65, 1.11) 0.220 0.854 
rs3814160 RBP3 T C 1.07(0.82, 1.40) 0.598 0.927 
rs11999628 ALDH1A1 T G 1.06(0.89, 1.26) 0.530 0.911 
rs11898950 CYP26B1 G A 0.93(0.78, 1.11) 0.432 0.904 
rs11187536 RBP4 T G 1.04(0.87, 1.24) 0.694 0.947 
rs12759184 CRABP2 T C 1.08(0.89, 1.32) 0.425 0.904 
rs9835241 RBP1 G A 0.96(0.79, 1.16) 0.654 0.947 
rs100537 RXRG A G 1.02(0.74, 1.39) 0.917 0.984 
rs12934922 BCMO1 T A 1.12(0.94, 1.34) 0.220 0.854 
rs4418728 CYP26A1 T G 0.80(0.61, 1.05) 0.110 0.778 
rs11214125 BCO2 T C 0.95(0.72, 1.25) 0.702 0.947 
rs351229 STRA6 C A 0.88(0.70, 1.11) 0.266 0.876 
rs6564854 BCMO1 G A 1.02(0.81, 1.29) 0.869 0.984 
rs12442110 CRABP1 C G 0.87(0.72, 1.06) 0.160 0.807 
rs3806412 CRABP2 G T 1.01(0.83, 1.23) 0.944 0.984 
rs6776706 RARB A T 1.05(0.90, 1.24) 0.529 0.911 
rs12578814 RDH5 A G 1.10(0.93, 1.29) 0.262 0.876 
rs1799908 RXRB T A 0.91(0.78, 1.08) 0.283 0.876 
rs8027180 CRABP1 A G 1.04(0.84, 1.29) 0.729 0.947 
rs746332 RXRG A C 1.06(0.90, 1.25) 0.500 0.904 
rs284792 ADH7 A G 1.07(0.90, 1.26) 0.461 0.904 
rs7620529 RARB A C 0.95(0.81, 1.13) 0.588 0.927 
rs1286646 RARB G A 1.07(0.86, 1.34) 0.536 0.911 
rs1881704 RARB G C 1.08(0.88, 1.33) 0.457 0.904 
rs17016718 RARB C T 0.93(0.74, 1.18) 0.571 0.921 
rs6564859 BCMO1 G A 0.88(0.69, 1.13) 0.322 0.879 
rs285428 RXRG C T 0.88(0.73, 1.06) 0.182 0.820 
rs12915846 STRA6 A G 1.07(0.83, 1.38) 0.602 0.927 
rs8187910 ALDH1A1 G A 0.94(0.80, 1.11) 0.497 0.904 
rs11635868 STRA6 T C 1.08(0.86, 1.35) 0.518 0.911 
rs12249434 PNLIP T C 1.06(0.88, 1.27) 0.549 0.917 
 RR: Risk ratio; CI: Confidence interval 
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rs1286730 RARB G C 0.95(0.80, 1.13) 0.581 0.927 
rs4384231 CRABP2 T C 1.00(0.68, 1.46) 0.990 0.994 
rs213210 RXRB C T 0.85(0.69, 1.05) 0.132 0.784 
rs2192332 CYP26B1 G T 1.08(0.92, 1.28) 0.346 0.892 
rs12256889 CYP26C1 A C 0.97(0.66, 1.40) 0.853 0.984 
rs4889293 BCMO1 G C 0.92(0.78, 1.08) 0.317 0.876 
rs10786068 CYP26A1 C G 0.95(0.81, 1.12) 0.555 0.918 
rs17016408 RARB C G 1.04(0.84, 1.30) 0.701 0.947 
rs5999690 ISX C T 0.77(0.57, 1.06) 0.110 0.778 
rs17029657 RARB G T 0.92(0.67, 1.27) 0.616 0.927 
rs7324 CEL A G 0.90(0.62, 1.32) 0.602 0.927 
rs4646615 ALDH1A2 T G 1.03(0.78, 1.37) 0.812 0.984 
rs3757971 DGAT1 G A 0.94(0.64, 1.40) 0.768 0.963 
rs7621140 RARB C T 0.84(0.53, 1.33) 0.457 0.904 
rs4607073 RARB G T 0.78(0.66, 0.93) 0.005 0.274 
rs1286754 RARB T C 0.95(0.80, 1.13) 0.567 0.920 
rs9821204 RBP1 A C 0.93(0.75, 1.14) 0.476 0.904 
rs9871002 RARB T A 0.96(0.81, 1.13) 0.608 0.927 
rs2272301 RARG G C 0.92(0.78, 1.08) 0.313 0.876 
rs2654848 ADH7 A T 1.11(0.94, 1.31) 0.234 0.864 
rs12169293 ISX A G 1.03(0.87, 1.21) 0.738 0.951 
rs8187950 ALDH1A1 C T 0.92(0.77, 1.09) 0.332 0.889 
rs10489745 RXRG C T 0.98(0.84, 1.16) 0.853 0.984 
rs1286641 RARB T A 0.83(0.70, 0.98) 0.024 0.609 
rs3138136 RDH5 A G 0.87(0.65, 1.17) 0.362 0.904 
rs11642457 BCMO1 G A 1.01(0.74, 1.37) 0.952 0.984 
rs9934274 BCMO1 G C 1.07(0.91, 1.26) 0.421 0.904 
rs13099641 RARB A T 0.97(0.82, 1.14) 0.711 0.947 
rs7187507 BCMO1 T A 1.05(0.88, 1.26) 0.556 0.918 
rs2602884 ADH4 C T 1.03(0.86, 1.24) 0.721 0.947 
rs1888202 ALDH1A1 G C 1.06(0.83, 1.34) 0.639 0.935 
rs7620632 RARB C T 1.11(0.91, 1.36) 0.289 0.876 
rs6518932 ISX T C 1.00(0.82, 1.21) 0.969 0.984 
rs3764478 TTR A C 1.15(0.92, 1.45) 0.223 0.854 
rs10800091 RXRG G A 0.86(0.69, 1.09) 0.210 0.854 
rs1483856 RARB C A 0.93(0.76, 1.14) 0.496 0.904 
rs34745537 RARG A G 0.97(0.83, 1.14) 0.755 0.962 
rs1286766 RARB T A 0.94(0.80, 1.11) 0.464 0.904 
rs1997353 RARB G A 0.82(0.68, 0.98) 0.033 0.696 
rs7616467 RARB T C 0.81(0.57, 1.16) 0.260 0.876 
rs887844 CYP26B1 C T 1.05(0.81, 1.36) 0.724 0.947 
 RR: Risk Ratio; CI: Confidence Interval; OR: Odds Ratio; --: Unavailable in replication study 
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APPENDIX 3. RESULTS FROM OFFSPRING FOLATE AND CHOLINE-RELATED SNPS IN NENA AND CHOP 
REPLICATION STUDY  
    NENA  CHOP 
SNP Gene 
Minor 
Allele 
Major 
Allele RR 95%(CI) P-value 
FDR Q-
value  
Minor 
Allele 
Major 
Allele OR 95%(CI) P-value 
FDR Q-
value 
rs3123634 SLC22A3 T C 1.34(1.14, 1.58) 0.001 0.459  T C 1.00(0.93, 1.09) 0.941 0.986 
rs2302327 PLD2 A G 1.70(1.23, 2.34) 0.001 0.502  T C 0.90(0.77, 1.04) 0.158 0.854 
rs316174 SLC22A3 T C 1.30(1.10, 1.54) 0.002 0.502  G A 1.02(0.94, 1.10) 0.621 0.969 
rs803456 MTHFD1L C T 0.78(0.66, 0.92) 0.003 0.621  G A 0.99(0.92, 1.08) 0.888 0.979 
rs663649 CTH T G 1.30(1.08, 1.57) 0.006 0.785  T G 1.06(0.97, 1.15) 0.173 0.866 
rs4869087 MAT2B C A 1.29(1.07, 1.55) 0.007 0.785  A C 0.95(0.87, 1.04) 0.285 0.909 
rs17421462 MTHFR A G 0.65(0.48, 0.89) 0.007 0.785  A G 1.01(0.88, 1.17) 0.865 0.979 
rs604745 SLC44A5 G T 0.76(0.62, 0.94) 0.010 0.785  A C 0.93(0.85, 1.02) 0.146 0.839 
rs3797546 BHMT C T 1.65(1.12, 2.44) 0.012 0.785  C T 1.03(0.84, 1.26) 0.799 0.979 
rs2221750 SLC22A3 A G 1.29(1.05, 1.58) 0.014 0.785  T C 1.00(0.90, 1.10) 0.936 0.986 
rs2424922 DNMT3B C T 1.23(1.04, 1.46) 0.016 0.785  C T 1.03(0.95, 1.11) 0.511 0.965 
rs17806489 SHMT1 A G 0.73(0.56, 0.94) 0.017 0.785  A G 1.09(0.96, 1.24) 0.174 0.866 
rs11202403 MAT1A T C 1.29(1.05, 1.59) 0.017 0.785  T C 1.08(0.98, 1.19) 0.136 0.839 
rs2083868 SLC44A5 G A 0.79(0.65, 0.96) 0.018 0.785  C T 0.98(0.90, 1.07) 0.689 0.972 
rs4819208 FTCD G A 1.28(1.04, 1.57) 0.018 0.785  A G 1.01(0.93, 1.11) 0.773 0.979 
rs7642538 ALDH1L1 A G 0.79(0.65, 0.96) 0.018 0.785  -- -- -- -- -- 
rs712208 MTHFD1L T C 0.78(0.63, 0.96) 0.019 0.785  A G 0.96(0.87, 1.06) 0.394 0.948 
rs7733775 MAT2B A G 1.22(1.03, 1.45) 0.019 0.785  G A 1.00(0.92, 1.08) 0.996 0.998 
rs17080476 MTHFD1L G A 0.77(0.62, 0.96) 0.019 0.785  G A 0.99(0.90, 1.10) 0.890 0.979 
rs4708867 SLC22A3 G A 1.38(1.05, 1.80) 0.021 0.785  G A 1.00(0.88, 1.14) 0.976 0.996 
rs1979277 SHMT1 A G 1.23(1.03, 1.47) 0.022 0.785  A G 0.97(0.89, 1.05) 0.442 0.962 
rs2504937 SLC22A3 G C 0.81(0.68, 0.97) 0.023 0.785  G C 0.99(0.91, 1.08) 0.785 0.979 
rs2504956 SLC22A3 A G 0.78(0.63, 0.97) 0.023 0.785  T C 0.98(0.89, 1.09) 0.755 0.979 
rs13373826 SLC44A5 G A 0.76(0.60, 0.97) 0.024 0.785  G A 0.97(0.87, 1.08) 0.600 0.969 
rs1650697 DHFR T C 0.80(0.65, 0.97) 0.027 0.785  G A 0.97(0.88, 1.06) 0.476 0.963 
rs1967613 ATIC A T 1.22(1.02, 1.46) 0.029 0.785  T A 1.00(0.92, 1.09) 0.965 0.993 
rs7604984 ATIC G A 1.20(1.02, 1.42) 0.029 0.785  A G 0.98(0.91, 1.06) 0.668 0.971 
rs17375901 MTHFR T C 1.51(1.03, 2.20) 0.033 0.785  T C 0.88(0.74, 1.05) 0.151 0.839 
rs4646703 ALDH1L1 A G 0.77(0.61, 0.98) 0.033 0.785  -- -- -- -- -- 
rs512077 SLC22A3 A G 1.27(1.02, 1.59) 0.034 0.785  G A 1.09(0.97, 1.22) 0.141 0.839 
rs3798156 SLC22A2 A G 1.32(1.02, 1.70) 0.034 0.785  T C 0.99(0.88, 1.12) 0.901 0.979 
 RR: Risk Ratio; CI: Confidence Interval; OR: Odds Ratio; --: Unavailable in replication study 
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    NENA  CHOP 
SNP Gene 
Minor 
Allele 
Major 
Allele RR 95%(CI) P-value 
FDR Q-
value  
Minor 
Allele 
Major 
Allele OR 95%(CI) P-value 
FDR Q-
value 
rs519861 MTHFD1L C T 1.26(1.02, 1.56) 0.035 0.785  A G 0.99(0.90, 1.09) 0.839 0.979 
rs3120137 SLC22A3 T C 1.31(1.02, 1.68) 0.036 0.785  A G 0.95(0.85, 1.06) 0.347 0.943 
rs1004053 SLC44A5 G A 0.83(0.70, 0.99) 0.036 0.785  T C 0.99(0.92, 1.07) 0.804 0.979 
rs7722729 MAT2B C T 1.27(1.01, 1.58) 0.038 0.785  C T 0.97(0.87, 1.08) 0.614 0.969 
rs627494 SLC44A5 G T 0.84(0.71, 0.99) 0.039 0.785  G T 1.01(0.94, 1.09) 0.779 0.979 
rs661620 DMGDH C T 0.84(0.71, 0.99) 0.041 0.785  C T 0.98(0.91, 1.06) 0.654 0.971 
rs2283124 SARDH T C 1.31(1.01, 1.71) 0.042 0.785  -- -- -- -- -- 
rs11663153 TYMS A C 1.22(1.01, 1.48) 0.043 0.785  A C 1.11(1.00, 1.24) 0.051 0.823 
rs17591295 SLC22A3 A G 1.47(1.01, 2.14) 0.045 0.785  A G 0.99(0.82, 1.19) 0.929 0.983 
rs2048327 SLC22A3 G A 1.20(1.00, 1.42) 0.046 0.785  C T 0.94(0.87, 1.02) 0.150 0.839 
rs28365862 SHMT2 G A 1.48(1.01, 2.18) 0.046 0.785  -- -- -- -- -- 
rs1771845 MTHFD1L T C 0.84(0.71, 1.00) 0.046 0.785  A G 0.94(0.87, 1.02) 0.142 0.839 
rs11040265 FOLH1 T C 1.34(1.00, 1.79) 0.047 0.785  -- -- -- -- -- 
rs3127575 SLC22A2 T C 1.30(1.00, 1.70) 0.048 0.785  T C 0.93(0.82, 1.05) 0.241 0.901 
rs12995526 ATIC T C 0.85(0.72, 1.00) 0.048 0.785  C T 1.06(0.98, 1.15) 0.135 0.839 
rs3918227 NOS3 A C 1.36(1.00, 1.86) 0.048 0.785  A C 1.03(0.90, 1.18) 0.711 0.979 
rs129886 SARDH T C 0.82(0.68, 1.00) 0.049 0.785  -- -- -- -- -- 
rs8016556 MTHFD1 C T 0.84(0.71, 1.00) 0.049 0.785  C T 0.97(0.89, 1.05) 0.467 0.963 
rs8127036 CBS T C 0.79(0.63, 1.00) 0.050 0.785  T C 0.94(0.85, 1.04) 0.261 0.905 
rs11755049 MTHFD1L T A 0.76(0.58, 1.00) 0.052 0.785  T A 0.94(0.82, 1.07) 0.332 0.943 
rs4709432 SLC22A3 G A 1.24(1.00, 1.55) 0.053 0.785  G A 1.10(0.99, 1.23) 0.082 0.831 
rs891512 NOS3 A G 0.82(0.66, 1.00) 0.054 0.785  G A 1.02(0.93, 1.13) 0.635 0.969 
rs7081756 MAT1A G T 1.18(1.00, 1.40) 0.055 0.785  T G 1.00(0.92, 1.08) 0.960 0.993 
rs2273027 SHMT1 A G 0.85(0.71, 1.00) 0.055 0.785  T C 1.03(0.95, 1.12) 0.483 0.963 
rs1205349 AHCY C G 1.27(0.99, 1.63) 0.056 0.785  -- -- -- -- -- 
rs316169 SLC22A3 A C 1.19(1.00, 1.42) 0.056 0.785  G T 1.02(0.93, 1.11) 0.702 0.977 
rs11908812 FTCD A G 1.33(0.99, 1.78) 0.056 0.785  A G 1.02(0.88, 1.18) 0.798 0.979 
rs10821578 SARDH T C 1.17(1.00, 1.37) 0.056 0.785  -- -- -- -- -- 
rs140514 CHKB C T 1.17(1.00, 1.38) 0.057 0.785  G A 0.94(0.86, 1.01) 0.096 0.831 
rs11080058 SLC46A1 A G 0.84(0.69, 1.01) 0.057 0.785  A G 0.94(0.86, 1.03) 0.177 0.871 
rs13063848 PLD1 A G 1.31(0.99, 1.73) 0.057 0.785  A G 1.10(0.98, 1.24) 0.120 0.837 
rs7556057 SLC44A5 T C 0.83(0.69, 1.01) 0.057 0.785  T C 1.09(1.00, 1.19) 0.051 0.823 
rs1544920 CHPT1 T C 0.79(0.61, 1.01) 0.058 0.785  -- -- -- -- -- 
rs3755817 CHDH C T 1.19(0.99, 1.43) 0.059 0.785  C T 0.98(0.90, 1.07) 0.636 0.969 
rs2457552 SLC22A3 T G 0.82(0.67, 1.01) 0.060 0.785  C A 0.99(0.91, 1.09) 0.909 0.979 
 RR: Risk Ratio; CI: Confidence Interval; OR: Odds Ratio; --: Unavailable in replication study 
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    NENA  CHOP 
SNP Gene 
Minor 
Allele 
Major 
Allele RR 95%(CI) P-value 
FDR Q-
value  
Minor 
Allele 
Major 
Allele OR 95%(CI) P-value 
FDR Q-
value 
rs13317328 CHDH C A 0.77(0.58, 1.01) 0.061 0.785  C A 1.05(0.90, 1.23) 0.500 0.963 
rs612893 DMGDH A G 0.85(0.72, 1.01) 0.061 0.785  G A 1.05(0.97, 1.14) 0.240 0.901 
rs2303080 MTRR A T 1.55(0.98, 2.47) 0.062 0.785  A T 0.82(0.65, 1.02) 0.080 0.831 
rs3733890 BHMT A G 0.84(0.70, 1.01) 0.065 0.812  A G 1.00(0.92, 1.09) 0.994 0.998 
rs2909854 BHMT C G 0.85(0.71, 1.01) 0.067 0.829  -- -- -- -- -- 
rs1567441 SLC22A3 G A 0.83(0.68, 1.01) 0.069 0.833  C T 0.98(0.89, 1.07) 0.639 0.969 
rs7533315 MTHFR T C 0.84(0.69, 1.02) 0.071 0.833  C T 0.96(0.88, 1.06) 0.440 0.962 
rs1891902 SLC44A5 T C 0.85(0.71, 1.01) 0.072 0.833  A G 1.00(0.92, 1.09) 0.975 0.996 
rs2295638 MTHFD1 T C 0.66(0.42, 1.04) 0.072 0.833  A G 1.20(0.94, 1.53) 0.152 0.839 
rs569919 SLC22A3 T C 0.84(0.70, 1.02) 0.076 0.833  T C 1.00(0.92, 1.09) 0.958 0.993 
rs1950902 MTHFD1 T C 0.82(0.66, 1.02) 0.078 0.833  G A 1.05(0.94, 1.16) 0.391 0.948 
rs3788190 SLC19A1 A G 0.86(0.73, 1.02) 0.079 0.833  A G 1.00(0.92, 1.08) 0.941 0.986 
rs6753886 SLC5A7 A G 0.86(0.72, 1.02) 0.081 0.833  A G 0.97(0.90, 1.06) 0.537 0.969 
rs10515861 MAT2B C T 0.85(0.71, 1.02) 0.083 0.833  C T 1.02(0.94, 1.11) 0.622 0.969 
rs1112444 SLC22A3 A C 1.18(0.98, 1.42) 0.083 0.833  A C 1.02(0.93, 1.11) 0.723 0.979 
rs17588242 SLC22A2 C T 0.84(0.69, 1.02) 0.083 0.833  C T 1.06(0.96, 1.18) 0.243 0.901 
rs803455 MTHFD1L T C 0.73(0.51, 1.04) 0.083 0.833  G A 0.92(0.78, 1.07) 0.282 0.909 
rs11595587 MAT1A A G 0.63(0.37, 1.06) 0.084 0.833  A G 0.90(0.71, 1.14) 0.380 0.948 
rs11664283 TYMS A G 1.18(0.98, 1.43) 0.086 0.833  A G 1.06(0.97, 1.15) 0.216 0.892 
rs17080461 MTHFD1L T C 0.80(0.61, 1.03) 0.088 0.833  T C 0.96(0.84, 1.09) 0.515 0.965 
rs492842 BHMT G A 0.87(0.73, 1.02) 0.090 0.833  T C 1.02(0.94, 1.11) 0.575 0.969 
rs4847361 SLC44A3 C T 0.81(0.63, 1.03) 0.091 0.833  T C 0.89(0.78, 1.02) 0.092 0.831 
rs2137407 SLC44A5 A G 1.41(0.95, 2.11) 0.091 0.833  T C 0.87(0.71, 1.06) 0.171 0.862 
rs7289549 TCN2 C G 1.23(0.97, 1.57) 0.092 0.833  C G 1.10(0.97, 1.26) 0.142 0.839 
rs3794186 CHKA T C 1.33(0.95, 1.86) 0.092 0.833  A G 0.81(0.70, 0.95) 0.009 0.446 
rs2304429 DNMT3A G A 0.86(0.73, 1.02) 0.093 0.833  T C 0.97(0.90, 1.05) 0.506 0.965 
rs316176 SLC22A3 G A 0.86(0.72, 1.03) 0.094 0.833  C T 1.04(0.95, 1.13) 0.421 0.959 
rs6668699 MTHFR C T 0.86(0.73, 1.03) 0.095 0.833  T C 0.98(0.90, 1.06) 0.582 0.969 
rs4846048 MTHFR G A 0.86(0.72, 1.03) 0.095 0.833  A G 0.99(0.91, 1.08) 0.800 0.979 
rs8019804 MTHFD1 G T 1.32(0.95, 1.84) 0.095 0.833  T G 0.96(0.83, 1.12) 0.637 0.969 
rs6814380 MTHFD2L G C 1.16(0.98, 1.37) 0.095 0.833  G C 1.06(0.97, 1.15) 0.195 0.891 
rs299299 MAT2B G T 1.20(0.97, 1.50) 0.095 0.833  G T 1.05(0.95, 1.17) 0.339 0.943 
rs1580820 PCYT1A C T 0.81(0.63, 1.04) 0.095 0.833  A G 0.99(0.88, 1.11) 0.811 0.979 
rs7730643 MTRR G A 1.21(0.97, 1.52) 0.096 0.833  G A 1.06(0.96, 1.18) 0.250 0.902 
rs2287779 MTRR A G 1.43(0.93, 2.18) 0.100 0.833  A G 0.84(0.68, 1.05) 0.122 0.837 
 RR: Risk Ratio; CI: Confidence Interval; OR: Odds Ratio; --: Unavailable in replication study 
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Allele RR 95%(CI) P-value 
FDR Q-
value  
Minor 
Allele 
Major 
Allele OR 95%(CI) P-value 
FDR Q-
value 
rs248381 DMGDH A G 1.15(0.97, 1.35) 0.100 0.833  A G 1.06(0.98, 1.14) 0.164 0.854 
rs1249655 SLC44A5 A T 1.16(0.97, 1.39) 0.101 0.833  T A 0.95(0.88, 1.03) 0.242 0.901 
rs140516 CHKB A G 1.18(0.97, 1.45) 0.101 0.833  C T 0.91(0.83, 0.99) 0.036 0.756 
rs9687295 DMGDH G A 0.83(0.66, 1.04) 0.102 0.833  G A 0.97(0.87, 1.08) 0.556 0.969 
rs17689595 SLC22A5 A G 0.83(0.67, 1.04) 0.102 0.833  A G 1.02(0.91, 1.15) 0.695 0.973 
rs819144 AHCY T G 1.24(0.96, 1.60) 0.102 0.833  G T 0.98(0.86, 1.10) 0.695 0.973 
rs2007053 GART C T 1.18(0.97, 1.44) 0.104 0.833  T C 1.04(0.95, 1.14) 0.384 0.948 
rs2424932 DNMT3B A G 0.87(0.73, 1.03) 0.105 0.833  G A 1.04(0.96, 1.13) 0.352 0.943 
rs9669539 CHPT1 C T 1.17(0.97, 1.40) 0.105 0.833  -- -- -- -- -- 
rs505358 MTHFD1L T C 1.16(0.97, 1.38) 0.106 0.833  A G 0.99(0.91, 1.08) 0.838 0.979 
rs7545324 SLC44A5 G A 1.18(0.96, 1.45) 0.107 0.835  G A 1.02(0.93, 1.13) 0.638 0.969 
rs17269293 SLC5A7 G C 1.19(0.96, 1.48) 0.109 0.843  G C 0.96(0.86, 1.06) 0.376 0.948 
rs333241 SLC5A7 T C 0.85(0.69, 1.04) 0.112 0.861  G A 1.03(0.94, 1.14) 0.498 0.963 
rs939885 PCYT1A G A 0.88(0.75, 1.03) 0.114 0.864  A G 0.97(0.89, 1.05) 0.459 0.963 
rs10791958 CHKA T A 1.24(0.95, 1.63) 0.114 0.864  A T 1.05(0.92, 1.19) 0.457 0.963 
rs9968875 MTHFD1L G A 0.81(0.63, 1.05) 0.117 0.876  G A 0.96(0.85, 1.08) 0.522 0.967 
rs2298582 TYMS C A 0.82(0.64, 1.05) 0.118 0.876  G T 1.05(0.90, 1.23) 0.540 0.969 
rs8130986 CBS A G 1.23(0.95, 1.58) 0.120 0.886  A G 0.92(0.81, 1.04) 0.170 0.862 
rs11163496 SLC44A5 T C 0.85(0.68, 1.05) 0.126 0.920  T C 0.98(0.89, 1.09) 0.712 0.979 
rs10265237 NOS3 A G 1.16(0.96, 1.39) 0.127 0.922  A G 0.99(0.90, 1.09) 0.847 0.979 
rs1363730 MAT2B T C 1.20(0.94, 1.54) 0.141 0.945  T C 1.05(0.93, 1.18) 0.467 0.963 
rs162889 SLC22A4 T C 0.87(0.72, 1.05) 0.141 0.945  T C 1.03(0.94, 1.13) 0.540 0.969 
rs17354394 MTHFD1L G A 1.28(0.92, 1.78) 0.142 0.945  G A 1.02(0.87, 1.20) 0.794 0.979 
rs12217395 MAT1A A G 1.15(0.95, 1.38) 0.142 0.945  A G 1.09(0.99, 1.19) 0.068 0.831 
rs1537514 MTHFR G C 1.23(0.93, 1.62) 0.143 0.945  C G 0.95(0.83, 1.08) 0.398 0.949 
rs2236225 MTHFD1 T C 1.13(0.96, 1.33) 0.143 0.945  A G 1.02(0.94, 1.10) 0.623 0.969 
rs17448447 ATIC G A 1.14(0.96, 1.35) 0.144 0.945  G A 1.03(0.95, 1.12) 0.500 0.963 
rs705415 DMGDH A G 1.21(0.94, 1.57) 0.144 0.945  T C 1.05(0.91, 1.21) 0.499 0.963 
rs16879334 MTRR G C 1.37(0.90, 2.11) 0.146 0.945  G C 0.84(0.68, 1.05) 0.122 0.837 
rs4869713 MTHFD1L C T 0.88(0.75, 1.04) 0.146 0.945  T C 1.01(0.93, 1.09) 0.894 0.979 
rs4934028 MAT1A A G 0.88(0.75, 1.04) 0.147 0.945  A G 0.96(0.89, 1.04) 0.366 0.948 
rs4659718 MTR C A 0.88(0.74, 1.05) 0.148 0.945  A C 1.03(0.95, 1.12) 0.432 0.962 
rs9397365 MTHFD1L T C 0.84(0.67, 1.06) 0.148 0.945  T C 1.13(1.00, 1.28) 0.046 0.823 
rs16876394 DMGDH C T 1.23(0.93, 1.63) 0.149 0.945  C T 1.02(0.90, 1.16) 0.730 0.979 
rs12626309 GART T A 0.86(0.70, 1.05) 0.149 0.945  T A 0.95(0.87, 1.05) 0.308 0.927 
 RR: Risk Ratio; CI: Confidence Interval; OR: Odds Ratio; --: Unavailable in replication study 
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rs1073083 CHPT1 T A 0.87(0.71, 1.05) 0.149 0.945  -- -- -- -- -- 
rs9478918 MTHFD1L T C 0.83(0.65, 1.07) 0.150 0.945  C T 0.98(0.88, 1.10) 0.778 0.979 
rs472703 MTHFD1L G A 0.85(0.68, 1.06) 0.151 0.945  C T 0.98(0.88, 1.10) 0.764 0.979 
rs698966 SLC44A3 G T 0.88(0.75, 1.05) 0.152 0.945  A C 0.96(0.89, 1.04) 0.318 0.934 
rs1232027 DHFR A G 1.14(0.95, 1.35) 0.153 0.945  A G 0.98(0.91, 1.07) 0.699 0.977 
rs12637288 PCYT1A G A 0.89(0.75, 1.05) 0.154 0.945  A G 1.00(0.93, 1.08) 0.950 0.988 
rs250513 DMGDH T C 0.87(0.72, 1.06) 0.156 0.945  T C 1.03(0.94, 1.13) 0.564 0.969 
rs12275064 FOLH1 T G 1.19(0.94, 1.51) 0.158 0.945  -- -- -- -- -- 
rs884534 PCYT1A T C 0.87(0.71, 1.06) 0.159 0.945  G A 0.98(0.89, 1.07) 0.619 0.969 
rs2041149 CHPT1 G A 1.13(0.95, 1.34) 0.160 0.945  G A 1.00(0.92, 1.08) 0.997 0.998 
rs2797836 SARDH A G 1.12(0.96, 1.32) 0.161 0.945  -- -- -- -- -- 
rs514933 FOLR2 G A 1.13(0.95, 1.33) 0.163 0.945  C T 1.01(0.93, 1.10) 0.748 0.979 
rs735937 SLC44A3 G A 1.13(0.95, 1.33) 0.163 0.945  C T 1.01(0.93, 1.09) 0.885 0.979 
rs476235 SLC22A2 T C 0.88(0.74, 1.05) 0.164 0.945  A G 0.95(0.88, 1.03) 0.257 0.905 
rs42418 DMGDH G C 1.12(0.95, 1.32) 0.164 0.945  C G 0.99(0.91, 1.07) 0.765 0.979 
rs12037733 SLC44A3 A G 0.87(0.71, 1.06) 0.164 0.945  A G 1.13(1.03, 1.25) 0.012 0.502 
rs576075 SLC22A2 T C 0.88(0.73, 1.05) 0.165 0.945  T C 1.03(0.95, 1.12) 0.488 0.963 
rs175853 MTHFD1L T C 1.13(0.95, 1.35) 0.167 0.951  G A 1.03(0.95, 1.12) 0.518 0.967 
rs12733999 CTH T C 1.36(0.88, 2.10) 0.169 0.951  T C 1.00(0.84, 1.20) 0.971 0.995 
rs9306264 TCN2 T C 1.23(0.91, 1.66) 0.169 0.951  T C 0.97(0.82, 1.15) 0.730 0.979 
rs742829 MTHFD1L G A 1.16(0.94, 1.44) 0.173 0.957  C T 0.92(0.82, 1.03) 0.137 0.839 
rs2295640 MTHFD1 G C 0.82(0.62, 1.09) 0.173 0.957  G C 1.07(0.93, 1.23) 0.351 0.943 
rs17520351 SLC44A3 T C 0.79(0.57, 1.11) 0.178 0.964  T C 1.01(0.86, 1.17) 0.944 0.986 
rs12469531 SLC5A7 C T 0.80(0.57, 1.11) 0.178 0.964  C T 0.88(0.72, 1.06) 0.175 0.866 
rs4270463 ALDH1L1 T C 1.31(0.88, 1.95) 0.179 0.964  -- -- -- -- -- 
rs1036145 NOS3 A G 0.89(0.75, 1.06) 0.181 0.964  T C 1.03(0.95, 1.11) 0.539 0.969 
rs642013 DMGDH T C 0.89(0.74, 1.06) 0.185 0.964  G A 1.05(0.97, 1.15) 0.244 0.902 
rs1570191 MTHFD1L C T 1.22(0.91, 1.64) 0.186 0.964  G A 0.97(0.85, 1.11) 0.652 0.971 
rs2741186 TYMS T C 0.90(0.76, 1.06) 0.192 0.964  G A 0.98(0.92, 1.05) 0.604 0.969 
rs7770982 MTHFD1L G A 0.84(0.64, 1.09) 0.193 0.964  G A 1.03(0.91, 1.17) 0.628 0.969 
rs2695284 CHPT1 C T 0.90(0.76, 1.06) 0.199 0.964  A G 1.01(0.93, 1.09) 0.886 0.979 
rs6893970 BHMT A G 1.20(0.91, 1.57) 0.200 0.964  A G 1.04(0.92, 1.18) 0.558 0.969 
rs4911263 DNMT3B T C 0.89(0.74, 1.06) 0.200 0.964  C T 1.05(0.96, 1.14) 0.303 0.927 
rs906713 CHKA A G 0.87(0.70, 1.08) 0.200 0.964  G A 0.98(0.88, 1.09) 0.709 0.979 
rs1915706 BHMT T C 1.12(0.94, 1.33) 0.201 0.964  T C 1.00(0.92, 1.08) 0.944 0.986 
 RR: Risk Ratio; CI: Confidence Interval; OR: Odds Ratio; --: Unavailable in replication study 
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rs11185518 PCYT1A T C 0.86(0.68, 1.08) 0.203 0.964  T C 0.97(0.87, 1.08) 0.577 0.969 
rs2853741 TYMS T C 1.12(0.94, 1.33) 0.204 0.964  C T 1.08(0.99, 1.19) 0.078 0.831 
rs698964 SLC44A3 A G 1.12(0.94, 1.33) 0.207 0.964  C T 0.98(0.90, 1.06) 0.584 0.969 
rs129902 SARDH C G 1.16(0.92, 1.45) 0.211 0.964  -- -- -- -- -- 
rs6058897 DNMT3B A C 0.90(0.76, 1.06) 0.213 0.964  C A 1.06(0.98, 1.15) 0.119 0.837 
rs175860 MTHFD1L A C 0.90(0.76, 1.06) 0.214 0.964  G T 1.07(0.99, 1.16) 0.107 0.837 
rs4911107 DNMT3B A G 1.11(0.94, 1.31) 0.214 0.964  A G 1.03(0.95, 1.11) 0.496 0.963 
rs12745827 CEPT1 G T 1.16(0.92, 1.46) 0.214 0.964  G T 1.12(1.01, 1.25) 0.033 0.720 
rs495139 TYMS G C 0.90(0.76, 1.06) 0.216 0.964  C G 0.98(0.91, 1.05) 0.493 0.963 
rs1050152 SLC22A4 T C 1.11(0.94, 1.32) 0.217 0.964  T C 0.88(0.81, 0.95) 0.001 0.170 
rs315984 SLC22A2 C T 1.13(0.93, 1.37) 0.217 0.964  T C 1.01(0.92, 1.11) 0.781 0.979 
rs3016432 FOLR1 G A 1.11(0.94, 1.31) 0.218 0.964  T C 0.98(0.90, 1.07) 0.675 0.971 
rs2450282 SLC5A7 A G 0.79(0.54, 1.15) 0.220 0.964  C T 0.99(0.83, 1.19) 0.944 0.986 
rs8142477 CHKB C G 0.87(0.69, 1.09) 0.221 0.964  C G 1.08(0.96, 1.22) 0.205 0.892 
rs1021737 CTH T G 0.89(0.74, 1.07) 0.222 0.964  T G 0.96(0.88, 1.04) 0.337 0.943 
rs41385949 SLC44A5 A G 0.79(0.53, 1.16) 0.222 0.964  T C 1.13(0.93, 1.36) 0.216 0.892 
rs10078190 DHFR T C 1.19(0.90, 1.59) 0.224 0.964  T C 1.05(0.91, 1.20) 0.536 0.969 
rs4694666 MTHFD2L C T 1.21(0.89, 1.63) 0.225 0.964  T C 1.02(0.86, 1.21) 0.854 0.979 
rs10179904 MAT2A A G 1.17(0.91, 1.51) 0.225 0.964  A G 1.04(0.92, 1.18) 0.496 0.963 
rs1023159 SLC19A1 A G 0.90(0.76, 1.07) 0.226 0.964  A G 1.05(0.96, 1.15) 0.315 0.928 
rs11746555 SLC22A5 A G 1.11(0.94, 1.32) 0.226 0.964  A G 0.88(0.82, 0.96) 0.002 0.269 
rs803454 MTHFD1L A G 0.83(0.61, 1.13) 0.229 0.964  -- -- -- -- -- 
rs10489810 SLC44A3 T A 0.90(0.75, 1.07) 0.230 0.964  T A 1.12(1.03, 1.22) 0.007 0.441 
rs652888 SLC44A4 C T 0.88(0.71, 1.09) 0.231 0.964  G A 0.92(0.82, 1.03) 0.151 0.839 
rs4120874 MTR G A 0.88(0.70, 1.09) 0.232 0.964  G A 0.97(0.88, 1.08) 0.605 0.969 
rs4894499 PLD1 C T 0.88(0.72, 1.08) 0.235 0.964  C T 0.94(0.85, 1.03) 0.197 0.892 
rs1980983 FTCD G A 0.90(0.75, 1.07) 0.235 0.964  G A 0.98(0.89, 1.07) 0.584 0.969 
rs12438477 MTHFS A C 0.90(0.77, 1.07) 0.239 0.964  A C 1.03(0.95, 1.12) 0.494 0.963 
rs11951068 DMGDH A G 1.19(0.89, 1.58) 0.240 0.964  A G 0.91(0.78, 1.06) 0.217 0.892 
rs12912711 MTHFS A G 1.19(0.89, 1.58) 0.242 0.964  A G 1.15(1.00, 1.31) 0.043 0.823 
rs2243393 CEPT1 T C 0.90(0.76, 1.07) 0.242 0.964  A G 1.04(0.96, 1.12) 0.394 0.948 
rs596881 SLC22A2 A G 0.86(0.66, 1.11) 0.242 0.964  C T 0.94(0.82, 1.07) 0.336 0.943 
rs1047665 MTHFD1L G A 1.23(0.87, 1.72) 0.242 0.964  G A 1.04(0.89, 1.22) 0.603 0.969 
rs2299644 FOLH1 T C 0.85(0.65, 1.12) 0.245 0.964  A G 0.99(0.86, 1.13) 0.887 0.979 
rs12401888 SLC44A5 T C 1.16(0.90, 1.50) 0.245 0.964  T C 1.03(0.92, 1.16) 0.578 0.969 
 RR: Risk Ratio; CI: Confidence Interval; OR: Odds Ratio; --: Unavailable in replication study 
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rs6693082 CTH G T 0.90(0.74, 1.08) 0.245 0.964  G T 0.95(0.87, 1.03) 0.203 0.892 
rs4563403 CHDH T C 0.87(0.68, 1.10) 0.247 0.964  T C 1.16(1.02, 1.32) 0.020 0.559 
rs10489586 SLC44A5 A G 0.78(0.51, 1.19) 0.247 0.964  A G 1.00(0.81, 1.22) 0.971 0.995 
rs2236484 SLC19A1 A G 0.91(0.76, 1.07) 0.248 0.964  A G 1.01(0.93, 1.10) 0.746 0.979 
rs2880456 MAT1A T G 0.85(0.64, 1.12) 0.248 0.964  T G 1.06(0.93, 1.22) 0.389 0.948 
rs3795823 CEPT1 T C 1.12(0.93, 1.35) 0.251 0.964  A G 1.03(0.94, 1.13) 0.479 0.963 
rs4817575 GART A G 0.86(0.66, 1.11) 0.251 0.964  A G 1.02(0.90, 1.16) 0.703 0.977 
rs1249839 SLC44A5 T C 1.11(0.93, 1.32) 0.253 0.964  G A 1.05(0.97, 1.13) 0.269 0.905 
rs7586969 ATIC G A 0.91(0.77, 1.07) 0.256 0.964  A G 1.06(0.98, 1.15) 0.133 0.839 
rs11654690 PLD2 A G 0.84(0.61, 1.14) 0.257 0.964  A G 1.05(0.91, 1.21) 0.513 0.965 
rs2484459 CEPT1 C G 0.89(0.72, 1.09) 0.257 0.964  C G 1.07(0.97, 1.19) 0.190 0.885 
rs2797853 SARDH A G 0.90(0.76, 1.08) 0.257 0.964  -- -- -- -- -- 
rs13214952 MTHFD1L G T 0.90(0.75, 1.08) 0.258 0.964  T G 1.04(0.96, 1.14) 0.348 0.943 
rs2431332 DMGDH G A 0.89(0.73, 1.09) 0.258 0.964  G A 1.00(0.92, 1.10) 0.924 0.983 
rs4818789 SLC19A1 G T 0.90(0.74, 1.08) 0.258 0.964  T G 1.02(0.92, 1.14) 0.682 0.971 
rs9290428 PLD1 G C 0.91(0.77, 1.07) 0.260 0.964  G C 0.94(0.87, 1.02) 0.116 0.837 
rs4646755 ALDH1L1 C A 0.90(0.74, 1.09) 0.261 0.964  G T 0.96(0.88, 1.05) 0.419 0.959 
rs3886314 SLC44A3 A C 1.10(0.93, 1.31) 0.262 0.964  C A 1.01(0.93, 1.10) 0.802 0.979 
rs631305 BHMT A G 0.88(0.70, 1.10) 0.263 0.964  C T 0.98(0.88, 1.09) 0.725 0.979 
rs6721036 SLC5A7 T C 0.86(0.66, 1.12) 0.263 0.964  C T 1.05(0.93, 1.19) 0.401 0.949 
rs4245407 FOLR3 A G 1.10(0.93, 1.29) 0.264 0.964  A G 1.00(0.93, 1.08) 0.996 0.998 
rs8076949 SLC46A1 T C 1.18(0.88, 1.56) 0.265 0.964  T C 0.96(0.84, 1.09) 0.504 0.965 
rs6479643 SARDH C G 0.91(0.77, 1.08) 0.266 0.964  -- -- -- -- -- 
rs333231 SLC5A7 A G 1.11(0.92, 1.34) 0.268 0.964  A G 1.08(0.99, 1.19) 0.090 0.831 
rs4687747 CHDH T G 1.18(0.88, 1.59) 0.268 0.964  T G 1.15(0.97, 1.35) 0.102 0.831 
rs12201472 MTHFD1L T C 1.17(0.89, 1.55) 0.269 0.964  T C 1.02(0.90, 1.17) 0.740 0.979 
rs12636371 ALDH1L1 A G 0.91(0.77, 1.08) 0.269 0.964  -- -- -- -- -- 
rs12210887 SLC44A4 T G 0.82(0.58, 1.16) 0.270 0.964  T G 1.05(0.89, 1.24) 0.578 0.969 
rs7550014 SLC44A3 T C 0.88(0.71, 1.10) 0.272 0.964  T C 0.91(0.82, 1.02) 0.100 0.831 
rs1557502 CHKB A G 0.89(0.73, 1.09) 0.272 0.964  T C 1.04(0.94, 1.15) 0.430 0.962 
rs7237052 TYMS A C 1.10(0.93, 1.30) 0.272 0.964  -- -- -- -- -- 
rs6766988 CHDH A T 0.86(0.66, 1.13) 0.272 0.964  A T 1.05(0.91, 1.21) 0.527 0.969 
rs36027301 CHKA T C 0.81(0.55, 1.18) 0.273 0.964  T C 1.02(0.85, 1.22) 0.841 0.979 
rs2373929 NOS3 T C 1.09(0.93, 1.29) 0.275 0.964  A G 1.04(0.96, 1.12) 0.350 0.943 
rs13060596 ALDH1L1 T G 0.91(0.76, 1.08) 0.277 0.964  -- -- -- -- -- 
 RR: Risk Ratio; CI: Confidence Interval; OR: Odds Ratio; --: Unavailable in replication study 
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rs7596024 DNMT3A A G 1.10(0.93, 1.30) 0.280 0.964  G A 1.12(1.03, 1.21) 0.006 0.439 
rs2288350 DNMT1 T C 0.85(0.63, 1.14) 0.280 0.964  T C 1.05(0.90, 1.24) 0.510 0.965 
rs3119309 SLC22A2 T C 1.16(0.89, 1.51) 0.281 0.964  T C 1.03(0.92, 1.16) 0.591 0.969 
rs140515 CHKB C G 0.91(0.77, 1.08) 0.281 0.964  -- -- -- -- -- 
rs13401241 DNMT3A C A 1.09(0.93, 1.29) 0.282 0.964  A C 1.07(0.99, 1.16) 0.085 0.831 
rs6546045 DNMT3A C T 1.10(0.92, 1.32) 0.282 0.964  T C 1.08(0.99, 1.17) 0.075 0.831 
rs2295084 MTHFD1L A G 1.13(0.90, 1.43) 0.285 0.964  T C 0.99(0.88, 1.11) 0.823 0.979 
rs4256166 PLD1 T C 0.90(0.75, 1.09) 0.285 0.964  T C 0.94(0.86, 1.03) 0.185 0.875 
rs3120976 MAT1A C A 0.91(0.76, 1.08) 0.287 0.964  A C 1.03(0.95, 1.12) 0.514 0.965 
rs836788 DHFR A G 0.91(0.77, 1.08) 0.288 0.964  T C 1.03(0.95, 1.12) 0.449 0.962 
rs6141803 DNMT3B C T 1.12(0.91, 1.40) 0.288 0.964  C T 1.05(0.94, 1.16) 0.381 0.948 
rs316033 SLC22A2 G A 1.10(0.92, 1.31) 0.288 0.964  G A 0.94(0.87, 1.02) 0.149 0.839 
rs129883 SARDH G C 1.10(0.92, 1.32) 0.289 0.964  -- -- -- -- -- 
rs7717 FTCD C G 1.13(0.90, 1.43) 0.289 0.964  C G 0.95(0.85, 1.06) 0.359 0.948 
rs9870993 ALDH1L1 T G 1.10(0.92, 1.30) 0.290 0.964  -- -- -- -- -- 
rs10204232 ATIC A C 1.18(0.86, 1.61) 0.295 0.964  C A 1.03(0.89, 1.20) 0.691 0.973 
rs9267658 SLC44A4 T C 1.14(0.89, 1.47) 0.297 0.964  C T 1.01(0.89, 1.15) 0.898 0.979 
rs1889036 SLC44A5 G T 1.10(0.92, 1.33) 0.299 0.964  G T 0.94(0.86, 1.02) 0.140 0.839 
rs10380 MTRR T C 1.15(0.89, 1.48) 0.299 0.964  T C 0.82(0.72, 0.94) 0.004 0.339 
rs4147779 CHKA G A 0.90(0.75, 1.09) 0.300 0.964  A G 1.01(0.92, 1.12) 0.784 0.979 
rs4847362 SLC44A3 A G 0.91(0.76, 1.09) 0.301 0.964  A G 0.99(0.91, 1.08) 0.808 0.979 
rs6495449 MTHFS A G 0.87(0.66, 1.14) 0.301 0.964  A G 1.07(0.94, 1.22) 0.313 0.928 
rs893363 CHDH C T 1.09(0.92, 1.30) 0.302 0.964  A G 1.00(0.92, 1.08) 0.981 0.997 
rs6760069 ATIC A G 0.88(0.70, 1.12) 0.302 0.964  A G 1.02(0.91, 1.14) 0.720 0.979 
rs11754661 MTHFD1L A G 0.84(0.59, 1.18) 0.304 0.964  A G 1.04(0.90, 1.22) 0.575 0.969 
rs35592604 SLC44A5 T C 1.12(0.90, 1.40) 0.309 0.964  T C 1.02(0.91, 1.15) 0.683 0.971 
rs333214 SLC5A7 C T 1.13(0.89, 1.43) 0.311 0.964  G A 0.89(0.79, 1.00) 0.060 0.831 
rs668641 MTHFS A G 1.09(0.92, 1.28) 0.311 0.964  T C 1.01(0.94, 1.10) 0.740 0.979 
rs1044988 PCYT1A C T 1.11(0.91, 1.36) 0.311 0.964  G A 0.95(0.86, 1.04) 0.278 0.909 
rs1405312 SLC44A5 T C 1.13(0.89, 1.42) 0.312 0.964  A G 0.99(0.89, 1.10) 0.838 0.979 
rs336520 DMGDH A G 1.13(0.89, 1.44) 0.315 0.964  T C 0.95(0.84, 1.08) 0.454 0.962 
rs2586183 MTHFS T A 0.92(0.78, 1.08) 0.316 0.964  T A 0.98(0.91, 1.06) 0.622 0.969 
rs3806531 SLC5A7 G A 1.09(0.92, 1.29) 0.316 0.964  C T 1.02(0.94, 1.10) 0.672 0.971 
rs8065874 SHMT1 T C 0.91(0.75, 1.10) 0.318 0.964  T C 1.07(0.97, 1.17) 0.161 0.854 
rs4120852 MAT1A C A 0.92(0.77, 1.09) 0.319 0.964  T G 1.04(0.96, 1.12) 0.378 0.948 
 RR: Risk Ratio; CI: Confidence Interval; OR: Odds Ratio; --: Unavailable in replication study 
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rs4646748 ALDH1L1 T C 1.11(0.90, 1.36) 0.320 0.964  A G 0.97(0.88, 1.06) 0.487 0.963 
rs2834233 GART G A 1.15(0.87, 1.52) 0.320 0.964  G A 1.13(0.99, 1.28) 0.076 0.831 
rs234785 CBS G C 0.92(0.77, 1.09) 0.323 0.964  G C 0.99(0.90, 1.10) 0.872 0.979 
rs1801394 MTRR A G 1.09(0.92, 1.29) 0.324 0.964  G A 1.05(0.98, 1.14) 0.181 0.875 
rs2077523 ALDH1L1 G T 0.92(0.78, 1.09) 0.325 0.964  -- -- -- -- -- 
rs3797535 DMGDH T C 1.17(0.86, 1.60) 0.326 0.964  T C 1.05(0.90, 1.22) 0.544 0.969 
rs7937515 FOLR3 G A 1.19(0.84, 1.69) 0.327 0.964  G A 1.01(0.86, 1.18) 0.918 0.983 
rs11849530 MTHFD1 G A 0.91(0.75, 1.10) 0.327 0.964  G A 1.03(0.93, 1.13) 0.604 0.969 
rs12209517 SLC22A3 G C 1.14(0.87, 1.49) 0.329 0.964  G C 1.01(0.89, 1.14) 0.895 0.979 
rs9897362 PEMT A G 0.84(0.60, 1.19) 0.329 0.964  A G 1.01(0.86, 1.19) 0.900 0.979 
rs2305795 DNMT1 G A 0.92(0.78, 1.09) 0.331 0.964  A G 0.97(0.90, 1.05) 0.464 0.963 
rs556808 MTHFD2L C T 0.85(0.61, 1.18) 0.332 0.964  G A 1.05(0.90, 1.23) 0.512 0.965 
rs9383858 MTHFD1L C T 1.09(0.92, 1.29) 0.335 0.964  C T 1.01(0.93, 1.10) 0.824 0.979 
rs2236224 MTHFD1 T C 1.09(0.92, 1.29) 0.338 0.964  A G 1.04(0.96, 1.13) 0.306 0.927 
rs12723350 CTH C T 1.19(0.83, 1.70) 0.338 0.964  C T 1.02(0.88, 1.18) 0.776 0.979 
rs10514154 DMGDH G A 0.90(0.73, 1.11) 0.339 0.964  G A 0.93(0.84, 1.02) 0.134 0.839 
rs12366105 FOLR3 C T 1.08(0.92, 1.28) 0.341 0.964  C T 1.02(0.94, 1.10) 0.673 0.971 
rs9478934 MTHFD1L G A 1.19(0.83, 1.69) 0.342 0.964  G A 1.01(0.86, 1.19) 0.881 0.979 
rs859101 SLC44A3 A C 1.08(0.92, 1.28) 0.342 0.964  T G 0.94(0.86, 1.01) 0.095 0.831 
rs2445887 DMGDH T C 0.92(0.78, 1.09) 0.343 0.964  A G 0.98(0.90, 1.06) 0.634 0.969 
rs1109859 PEMT C T 0.90(0.73, 1.12) 0.343 0.964  A G 0.96(0.86, 1.07) 0.445 0.962 
rs2286671 PLD2 C T 1.09(0.92, 1.29) 0.344 0.964  A G 1.04(0.96, 1.13) 0.294 0.915 
rs129956 SARDH C T 0.85(0.61, 1.19) 0.344 0.964  -- -- -- -- -- 
rs3744962 TYMS C T 1.15(0.86, 1.54) 0.346 0.964  G A 1.12(1.03, 1.23) 0.010 0.467 
rs17080689 MTHFD1L C A 0.88(0.67, 1.15) 0.347 0.964  C A 1.00(0.88, 1.14) 0.988 0.998 
rs4744533 SARDH T C 0.92(0.78, 1.09) 0.347 0.964  -- -- -- -- -- 
rs3796349 CHDH G A 0.86(0.62, 1.18) 0.347 0.964  G A 1.25(1.05, 1.50) 0.014 0.518 
rs12906758 MTHFS A T 1.11(0.90, 1.37) 0.348 0.964  A T 1.05(0.95, 1.16) 0.339 0.943 
rs4676168 SLC5A7 T C 0.92(0.77, 1.10) 0.348 0.964  T C 0.98(0.91, 1.07) 0.693 0.973 
rs131778 CHKB T C 0.93(0.79, 1.09) 0.349 0.964  -- -- -- -- -- 
rs3818239 MTHFD1 G A 0.88(0.68, 1.15) 0.349 0.964  C T 0.90(0.79, 1.02) 0.086 0.831 
rs11634787 MTHFS A G 0.86(0.63, 1.18) 0.349 0.964  A G 1.05(0.91, 1.20) 0.528 0.969 
rs316025 SLC22A2 A G 1.10(0.90, 1.33) 0.353 0.964  C T 0.97(0.89, 1.06) 0.490 0.963 
rs6774437 ALDH1L1 C A 0.93(0.79, 1.09) 0.353 0.964  -- -- -- -- -- 
rs6087988 DNMT3B T C 1.09(0.91, 1.32) 0.353 0.964  T C 0.97(0.89, 1.07) 0.578 0.969 
 RR: Risk Ratio; CI: Confidence Interval; OR: Odds Ratio; --: Unavailable in replication study 
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rs17597141 CHKA C G 0.91(0.74, 1.12) 0.353 0.964  C G 1.04(0.92, 1.17) 0.577 0.969 
rs2481030 SLC22A3 G A 0.92(0.77, 1.10) 0.355 0.964  G A 1.00(0.92, 1.08) 0.906 0.979 
rs12638724 ALDH1L1 A G 0.93(0.79, 1.09) 0.359 0.964  -- -- -- -- -- 
rs1800779 NOS3 G A 0.92(0.78, 1.09) 0.360 0.964  A G 1.02(0.94, 1.10) 0.664 0.971 
rs7236459 TYMS G A 1.14(0.86, 1.50) 0.360 0.964  G A 1.12(0.94, 1.33) 0.199 0.892 
rs9889584 PEMT A G 0.86(0.62, 1.19) 0.361 0.964  A G 1.01(0.86, 1.19) 0.871 0.979 
rs6669849 SLC44A3 T C 1.20(0.81, 1.80) 0.365 0.964  -- -- -- -- -- 
rs1256146 MTHFD1 A G 1.10(0.90, 1.34) 0.366 0.964  A G 1.01(0.92, 1.12) 0.793 0.979 
rs17824591 MTHFD1 A G 0.91(0.74, 1.12) 0.367 0.964  A G 1.03(0.93, 1.15) 0.558 0.969 
rs6910091 MTHFD1L G T 1.09(0.90, 1.31) 0.369 0.964  G T 1.05(0.96, 1.14) 0.315 0.928 
rs696620 SLC44A3 C T 1.08(0.92, 1.27) 0.369 0.964  G A 0.99(0.92, 1.07) 0.853 0.979 
rs17080776 MTHFD1L C T 1.08(0.91, 1.28) 0.370 0.964  C T 0.99(0.92, 1.08) 0.860 0.979 
rs10493570 SLC44A5 T C 1.12(0.87, 1.43) 0.374 0.964  T C 1.04(0.93, 1.17) 0.501 0.963 
rs859063 SLC44A3 A G 0.93(0.78, 1.10) 0.374 0.964  G A 1.02(0.94, 1.11) 0.626 0.969 
rs567754 BHMT T C 1.09(0.91, 1.30) 0.375 0.964  T C 1.00(0.92, 1.09) 0.969 0.995 
rs6792030 ALDH1L1 C T 1.10(0.89, 1.36) 0.375 0.964  -- -- -- -- -- 
rs6745054 MTHFD2 C T 0.90(0.72, 1.13) 0.376 0.964  C T 0.94(0.83, 1.06) 0.289 0.909 
rs3774609 CHDH G T 0.93(0.79, 1.09) 0.376 0.964  G T 1.02(0.94, 1.11) 0.589 0.969 
rs4920035 CBS A G 0.89(0.68, 1.16) 0.377 0.964  G A 0.91(0.80, 1.03) 0.131 0.839 
rs11627387 MTHFD1 A G 0.92(0.77, 1.10) 0.377 0.964  A G 0.95(0.87, 1.03) 0.237 0.901 
rs9383551 MTHFD1L C T 1.16(0.84, 1.60) 0.379 0.964  C T 1.01(0.85, 1.20) 0.907 0.979 
rs129940 SARDH G A 0.86(0.61, 1.21) 0.382 0.964  -- -- -- -- -- 
rs316002 SLC22A2 T C 0.90(0.72, 1.14) 0.387 0.964  T C 1.00(0.89, 1.13) 0.994 0.998 
rs161871 MTRR G A 1.09(0.89, 1.34) 0.388 0.964  G A 0.92(0.83, 1.02) 0.124 0.838 
rs11755633 MTHFD1L G A 1.11(0.87, 1.42) 0.392 0.964  G A 0.92(0.81, 1.03) 0.148 0.839 
rs2838951 SLC19A1 G C 1.08(0.91, 1.27) 0.394 0.964  C G 1.01(0.93, 1.09) 0.814 0.979 
rs131749 CHKB A G 0.93(0.78, 1.10) 0.395 0.964  C T 0.95(0.87, 1.03) 0.224 0.892 
rs11235451 FOLR3 A T 1.08(0.91, 1.28) 0.396 0.964  A T 1.02(0.94, 1.10) 0.681 0.971 
rs6919680 MTHFD1L G T 1.13(0.85, 1.49) 0.396 0.964  G T 0.86(0.73, 1.00) 0.056 0.831 
rs10819309 FPGS A G 0.93(0.78, 1.10) 0.398 0.964  G A 1.02(0.94, 1.11) 0.564 0.969 
rs3851059 MAT1A A G 0.93(0.77, 1.11) 0.400 0.964  A G 1.00(0.91, 1.08) 0.910 0.979 
rs957903 SLC44A1 C T 1.08(0.90, 1.31) 0.401 0.964  G A 1.02(0.93, 1.11) 0.661 0.971 
rs17677908 MAT1A G A 0.90(0.70, 1.15) 0.403 0.964  G A 0.99(0.88, 1.12) 0.845 0.979 
rs10195701 SLC5A7 C T 1.10(0.88, 1.37) 0.404 0.964  C T 0.91(0.82, 1.01) 0.088 0.831 
rs7763414 MTHFD1L T A 1.10(0.88, 1.38) 0.405 0.964  T A 1.01(0.91, 1.13) 0.793 0.979 
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rs3972 CBS T C 1.11(0.87, 1.41) 0.405 0.964  T C 1.08(0.96, 1.21) 0.206 0.892 
rs17232682 MTHFD2L C T 0.90(0.71, 1.15) 0.406 0.964  C T 0.99(0.88, 1.11) 0.843 0.979 
rs2071010 FOLR1 A G 0.88(0.64, 1.20) 0.413 0.964  A G 1.02(0.86, 1.20) 0.841 0.979 
rs4702506 MTRR C T 1.09(0.88, 1.36) 0.414 0.964  C T 1.12(1.01, 1.24) 0.028 0.689 
rs3821466 ALDH1L1 T C 0.93(0.78, 1.11) 0.416 0.964  A G 0.91(0.84, 0.99) 0.028 0.689 
rs12999687 DNMT3A T G 1.07(0.91, 1.26) 0.418 0.964  G T 1.10(1.01, 1.19) 0.020 0.559 
rs4244599 PEMT G A 0.93(0.79, 1.10) 0.419 0.964  C T 0.98(0.91, 1.07) 0.705 0.977 
rs16853723 ATIC C T 0.91(0.71, 1.15) 0.420 0.964  C T 1.02(0.91, 1.15) 0.679 0.971 
rs9975829 GART G A 1.07(0.90, 1.27) 0.420 0.964  G A 1.07(0.99, 1.17) 0.088 0.831 
rs12987326 DNMT3A G A 1.07(0.91, 1.27) 0.421 0.964  A G 1.12(1.03, 1.21) 0.006 0.439 
rs2177268 AMT A T 1.08(0.90, 1.30) 0.422 0.964  T A 1.02(0.94, 1.12) 0.617 0.969 
rs4817579 GART T C 1.07(0.90, 1.28) 0.424 0.964  C T 1.02(0.94, 1.11) 0.575 0.969 
rs4819130 SLC19A1 C T 0.93(0.79, 1.10) 0.424 0.964  T C 1.01(0.93, 1.09) 0.877 0.979 
rs2073643 SLC22A5 T C 0.93(0.79, 1.10) 0.425 0.964  C T 0.93(0.86, 1.01) 0.089 0.831 
rs2847607 TYMS A G 1.08(0.89, 1.32) 0.425 0.964  T C 1.01(0.93, 1.10) 0.732 0.979 
rs10874311 SLC44A5 T C 1.08(0.90, 1.29) 0.426 0.964  T C 0.93(0.85, 1.01) 0.078 0.831 
rs2987981 MTHFD1 C T 0.93(0.76, 1.12) 0.428 0.964  G A 1.04(0.96, 1.14) 0.341 0.943 
rs487637 MTHFD1L G T 1.08(0.90, 1.29) 0.433 0.964  A C 1.01(0.92, 1.09) 0.907 0.979 
rs316020 SLC22A2 T C 0.90(0.69, 1.17) 0.438 0.964  G A 0.97(0.85, 1.10) 0.615 0.969 
rs2510234 SARDH C T 1.07(0.90, 1.27) 0.440 0.964  -- -- -- -- -- 
rs694821 SARDH G A 1.06(0.91, 1.25) 0.440 0.964  -- -- -- -- -- 
rs3783731 MTHFD1 T C 1.09(0.88, 1.35) 0.440 0.964  A G 1.03(0.93, 1.14) 0.601 0.969 
rs4902278 MTHFD1 A G 0.87(0.60, 1.25) 0.442 0.964  G A 1.14(0.96, 1.36) 0.145 0.839 
rs617219 BHMT C A 1.07(0.90, 1.27) 0.445 0.964  C A 1.01(0.93, 1.10) 0.818 0.979 
rs734693 DNMT3A C T 0.93(0.78, 1.12) 0.446 0.964  T C 0.99(0.91, 1.08) 0.831 0.979 
rs9322301 MTHFD1L C T 1.07(0.90, 1.26) 0.447 0.964  C T 1.02(0.94, 1.10) 0.667 0.971 
rs12652027 MAT2B C T 1.16(0.79, 1.71) 0.449 0.964  C T 1.18(0.97, 1.42) 0.097 0.831 
rs10987742 FPGS T C 0.92(0.75, 1.14) 0.451 0.964  T C 1.04(0.94, 1.15) 0.431 0.962 
rs2073064 MTHFD1L G A 0.92(0.73, 1.15) 0.451 0.964  C T 1.08(0.94, 1.22) 0.274 0.905 
rs2163005 MTHFS G A 1.07(0.90, 1.26) 0.452 0.964  C T 1.06(0.98, 1.15) 0.139 0.839 
rs9397032 MTHFD1L T G 0.94(0.80, 1.11) 0.454 0.964  G T 1.02(0.94, 1.10) 0.621 0.969 
rs2076828 SLC22A3 G C 0.94(0.80, 1.11) 0.457 0.964  G C 1.04(0.97, 1.13) 0.279 0.909 
rs9869368 PLD1 G A 1.09(0.86, 1.38) 0.457 0.964  G A 0.98(0.88, 1.10) 0.734 0.979 
rs17102596 MAT1A C T 0.92(0.75, 1.14) 0.459 0.964  C T 0.97(0.87, 1.07) 0.515 0.965 
rs7544408 SLC44A5 C G 0.94(0.79, 1.11) 0.459 0.964  G C 0.94(0.87, 1.02) 0.153 0.839 
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rs17269265 SLC5A7 G A 1.08(0.88, 1.33) 0.459 0.964  G A 1.09(1.00, 1.20) 0.051 0.823 
rs17823744 DMGDH G A 1.11(0.85, 1.44) 0.460 0.964  G A 1.02(0.90, 1.15) 0.771 0.979 
rs1476413 MTHFR A G 1.08(0.89, 1.31) 0.460 0.964  T C 1.01(0.92, 1.10) 0.824 0.979 
rs12995245 DNMT3A C T 1.06(0.90, 1.25) 0.460 0.964  T C 1.11(1.03, 1.20) 0.009 0.446 
rs1045020 SLC22A5 T C 1.10(0.85, 1.44) 0.461 0.964  T C 1.04(0.92, 1.19) 0.522 0.967 
rs555671 CTH T C 0.88(0.63, 1.24) 0.461 0.964  A G 1.11(0.93, 1.31) 0.252 0.902 
rs17622208 SLC22A5 A G 1.07(0.90, 1.26) 0.464 0.964  A G 0.86(0.79, 0.93) 0.000 0.074 
rs523230 TYMS C T 1.07(0.89, 1.28) 0.470 0.964  A G 1.09(1.00, 1.20) 0.045 0.823 
rs1051266 SLC19A1 A G 0.94(0.79, 1.11) 0.470 0.964  C T 1.00(0.93, 1.09) 0.923 0.983 
rs1788484 CBS T C 0.94(0.78, 1.12) 0.471 0.964  T C 0.99(0.91, 1.08) 0.811 0.979 
rs2618372 DHFR A C 1.07(0.89, 1.28) 0.471 0.964  A C 0.99(0.91, 1.08) 0.835 0.979 
rs624249 SLC22A2 A C 0.94(0.79, 1.12) 0.472 0.964  A C 1.04(0.95, 1.14) 0.384 0.948 
rs7946 PEMT C T 1.07(0.89, 1.29) 0.472 0.964  T C 0.99(0.91, 1.08) 0.862 0.979 
rs4979631 SARDH A G 0.94(0.78, 1.12) 0.472 0.964  -- -- -- -- -- 
rs17535909 MAT2B A G 0.94(0.79, 1.12) 0.472 0.964  A G 0.96(0.88, 1.05) 0.412 0.959 
rs1643638 DHFR C T 1.07(0.89, 1.28) 0.473 0.964  C T 0.99(0.91, 1.08) 0.833 0.979 
rs9478908 MTHFD1L G A 0.93(0.77, 1.13) 0.473 0.964  G A 1.06(0.96, 1.16) 0.237 0.901 
rs10494126 CEPT1 A C 1.10(0.85, 1.42) 0.474 0.964  A C 0.98(0.87, 1.11) 0.764 0.979 
rs273915 SLC22A4 C G 0.94(0.78, 1.12) 0.474 0.964  C G 0.95(0.87, 1.03) 0.215 0.892 
rs859096 SLC44A3 C A 0.94(0.78, 1.12) 0.474 0.964  T G 1.03(0.95, 1.13) 0.446 0.962 
rs12344130 SLC44A1 T G 0.90(0.67, 1.21) 0.475 0.964  T G 1.03(0.88, 1.20) 0.730 0.979 
rs13306567 MTHFR C G 1.15(0.78, 1.69) 0.476 0.964  G C 0.92(0.78, 1.10) 0.363 0.948 
rs1643650 DHFR C T 1.07(0.89, 1.28) 0.476 0.964  C T 0.99(0.91, 1.08) 0.841 0.979 
rs1571511 MTHFD1 G A 0.93(0.75, 1.14) 0.477 0.964  C T 1.03(0.94, 1.13) 0.472 0.963 
rs1051319 CBS G C 1.09(0.85, 1.41) 0.477 0.964  C G 0.95(0.84, 1.07) 0.419 0.959 
rs10484779 MTHFD1L G T 0.92(0.73, 1.16) 0.481 0.964  G T 0.93(0.83, 1.04) 0.213 0.892 
rs2072197 TCN2 A C 0.92(0.73, 1.16) 0.481 0.964  C A 1.01(0.90, 1.13) 0.898 0.979 
rs12743566 SLC44A5 G A 1.11(0.83, 1.50) 0.482 0.964  -- -- -- -- -- 
rs17184211 MTRR T A 0.93(0.76, 1.14) 0.483 0.964  T A 0.96(0.87, 1.05) 0.364 0.948 
rs538017 MTHFD1L C T 1.07(0.89, 1.28) 0.484 0.964  G A 1.06(0.97, 1.17) 0.181 0.875 
rs6860806 SLC22A4 A G 0.94(0.80, 1.11) 0.484 0.964  G A 0.92(0.85, 0.99) 0.030 0.689 
rs4629694 MTHFD1L C T 1.19(0.73, 1.95) 0.486 0.964  C T 0.88(0.69, 1.11) 0.271 0.905 
rs3912161 SLC22A2 G A 1.12(0.81, 1.56) 0.486 0.964  -- -- -- -- -- 
rs4820887 TCN2 A G 0.91(0.69, 1.20) 0.488 0.964  A G 0.95(0.83, 1.09) 0.439 0.962 
rs647370 FOLH1 A G 0.94(0.77, 1.13) 0.493 0.964  T C 1.00(0.91, 1.10) 0.918 0.983 
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rs1256142 MTHFD1 C T 1.06(0.90, 1.24) 0.493 0.964  A G 1.00(0.92, 1.08) 0.926 0.983 
rs10857859 CEPT1 C G 1.06(0.89, 1.27) 0.495 0.964  C G 1.08(1.00, 1.18) 0.064 0.831 
rs3764897 PLD2 T C 1.08(0.86, 1.35) 0.496 0.964  A G 1.10(0.97, 1.25) 0.151 0.839 
rs558936 MTHFD1L A G 0.94(0.78, 1.13) 0.496 0.964  C T 0.95(0.87, 1.04) 0.291 0.911 
rs11908960 FTCD C T 0.92(0.73, 1.17) 0.496 0.964  C T 1.07(0.92, 1.23) 0.394 0.948 
rs4846052 MTHFR T C 0.94(0.80, 1.12) 0.496 0.964  C T 1.00(0.92, 1.08) 0.981 0.997 
rs272894 SLC22A4 G A 0.94(0.80, 1.12) 0.499 0.964  T C 0.90(0.83, 0.97) 0.008 0.446 
rs3849308 SLC44A3 G A 0.94(0.79, 1.12) 0.500 0.964  C T 0.93(0.85, 1.01) 0.076 0.831 
rs17096504 SLC44A5 A G 1.13(0.79, 1.64) 0.501 0.964  A G 1.10(0.93, 1.32) 0.274 0.905 
rs10854479 FTCD C T 0.94(0.78, 1.13) 0.502 0.964  T C 0.99(0.90, 1.09) 0.856 0.979 
rs16879258 MTRR A C 1.09(0.85, 1.39) 0.502 0.964  A C 0.96(0.85, 1.07) 0.435 0.962 
rs13161245 DHFR G A 1.06(0.89, 1.28) 0.503 0.964  G A 0.99(0.91, 1.08) 0.861 0.979 
rs1478834 DHFR A C 1.06(0.89, 1.28) 0.503 0.964  A C 0.99(0.91, 1.08) 0.860 0.979 
rs711352 PEMT C G 1.07(0.88, 1.29) 0.504 0.964  C G 0.98(0.89, 1.07) 0.592 0.969 
rs6087983 DNMT3B T G 1.08(0.87, 1.33) 0.506 0.964  T G 0.99(0.89, 1.10) 0.798 0.979 
rs7638797 PCYT1A C A 1.06(0.89, 1.25) 0.506 0.964  C A 0.96(0.88, 1.05) 0.362 0.948 
rs9432596 SLC44A3 A G 1.07(0.87, 1.31) 0.507 0.964  A G 0.96(0.87, 1.06) 0.376 0.948 
rs11155773 MTHFD1L A G 0.94(0.78, 1.13) 0.507 0.964  A G 0.94(0.86, 1.03) 0.196 0.892 
rs729352 MAT2B T C 1.06(0.89, 1.28) 0.507 0.964  T C 1.01(0.93, 1.11) 0.749 0.979 
rs12121543 MTHFR A C 1.07(0.88, 1.30) 0.507 0.964  -- -- -- -- -- 
rs803422 MTHFD1L T C 1.06(0.88, 1.28) 0.507 0.964  G A 1.01(0.93, 1.10) 0.741 0.979 
rs327588 MTRR C G 1.08(0.87, 1.34) 0.508 0.964  G C 0.95(0.86, 1.05) 0.350 0.943 
rs7830 NOS3 A C 1.06(0.89, 1.25) 0.509 0.964  T G 1.03(0.94, 1.13) 0.537 0.969 
rs274567 SLC22A5 A G 0.95(0.80, 1.12) 0.511 0.964  T C 1.11(1.02, 1.20) 0.015 0.531 
rs1548362 SARDH C T 0.94(0.78, 1.13) 0.513 0.964  -- -- -- -- -- 
rs6672579 SLC44A5 A G 1.06(0.90, 1.24) 0.514 0.964  A G 1.03(0.95, 1.11) 0.436 0.962 
rs9267649 SLC44A4 A G 1.08(0.86, 1.35) 0.514 0.964  G A 1.05(0.94, 1.18) 0.363 0.948 
rs11235466 FOLR2 C T 0.90(0.65, 1.24) 0.516 0.964  C T 1.01(0.86, 1.18) 0.934 0.986 
rs2847149 TYMS A G 1.05(0.90, 1.24) 0.516 0.964  A G 0.94(0.88, 1.01) 0.074 0.831 
rs13036246 DNMT3A T C 0.95(0.80, 1.12) 0.516 0.964  T C 1.09(1.01, 1.18) 0.029 0.689 
rs175862 MTHFD1L C T 1.06(0.88, 1.28) 0.516 0.964  A G 1.05(0.96, 1.14) 0.310 0.927 
rs2115540 MTHFS T C 0.95(0.80, 1.12) 0.519 0.964  G A 1.05(0.97, 1.13) 0.229 0.892 
rs737953 TCN2 G C 0.95(0.80, 1.12) 0.520 0.964  -- -- -- -- -- 
rs582326 SARDH G C 1.06(0.89, 1.26) 0.522 0.964  -- -- -- -- -- 
rs11235441 FOLR3 A G 0.87(0.56, 1.35) 0.522 0.964  A G 0.88(0.66, 1.18) 0.400 0.949 
 RR: Risk Ratio; CI: Confidence Interval; OR: Odds Ratio; --: Unavailable in replication study 
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rs416158 PLD1 A T 0.93(0.74, 1.16) 0.522 0.964  T A 0.98(0.87, 1.09) 0.684 0.971 
rs7639712 ALDH1L1 G A 0.93(0.73, 1.17) 0.522 0.964  -- -- -- -- -- 
rs1001761 TYMS T C 1.05(0.90, 1.24) 0.523 0.964  A G 0.94(0.89, 1.01) 0.082 0.831 
rs1476331 PCYT1A G A 1.05(0.90, 1.24) 0.524 0.964  C T 0.94(0.86, 1.01) 0.102 0.831 
rs2299648 FOLH1 A G 1.06(0.89, 1.26) 0.524 0.964  C T 1.02(0.93, 1.11) 0.730 0.979 
rs9644967 SLC44A1 A G 1.06(0.89, 1.25) 0.524 0.964  -- -- -- -- -- 
rs7712332 DHFR G A 1.06(0.89, 1.26) 0.525 0.964  G A 0.98(0.90, 1.06) 0.562 0.969 
rs2519154 SARDH G A 1.06(0.89, 1.25) 0.526 0.964  -- -- -- -- -- 
rs11880388 DNMT1 A G 1.05(0.90, 1.24) 0.526 0.964  A G 1.01(0.93, 1.09) 0.832 0.979 
rs497161 MTHFD1L A G 0.95(0.80, 1.12) 0.527 0.964  T C 1.07(0.98, 1.16) 0.113 0.837 
rs162029 MTRR A G 1.07(0.87, 1.30) 0.527 0.964  A G 0.96(0.86, 1.06) 0.385 0.948 
rs2277820 FTCD T C 0.94(0.78, 1.13) 0.528 0.964  T C 1.02(0.94, 1.11) 0.658 0.971 
rs315996 SLC22A2 A G 0.92(0.72, 1.18) 0.529 0.964  A G 1.01(0.89, 1.15) 0.821 0.979 
rs2241553 CHPT1 C A 0.94(0.79, 1.13) 0.530 0.964  G T 0.96(0.89, 1.05) 0.388 0.948 
rs2297291 SLC19A1 A G 0.95(0.80, 1.12) 0.531 0.964  G A 1.02(0.94, 1.11) 0.591 0.969 
rs3789699 SLC44A3 C T 0.92(0.70, 1.20) 0.531 0.964  C T 1.00(0.88, 1.13) 0.976 0.996 
rs1868138 ALDH1L1 T A 1.06(0.88, 1.29) 0.533 0.964  -- -- -- -- -- 
rs2502741 SARDH G A 0.95(0.81, 1.11) 0.533 0.964  -- -- -- -- -- 
rs7737937 SLC22A4 A G 0.93(0.74, 1.17) 0.535 0.964  A G 1.02(0.92, 1.14) 0.674 0.971 
rs3087896 PCYT1A T C 1.08(0.84, 1.40) 0.535 0.964  A G 0.91(0.81, 1.02) 0.116 0.837 
rs3760183 PEMT T G 1.08(0.84, 1.40) 0.536 0.964  T G 0.98(0.87, 1.11) 0.777 0.979 
rs2073067 MTHFD1L C G 1.06(0.89, 1.26) 0.537 0.964  G C 0.99(0.91, 1.07) 0.762 0.979 
rs13306560 MTHFR A G 1.13(0.77, 1.66) 0.539 0.964  T C 0.92(0.78, 1.09) 0.351 0.943 
rs4646767 ALDH1L1 T C 0.95(0.81, 1.12) 0.539 0.964  G A 0.96(0.89, 1.04) 0.357 0.948 
rs6502823 PLD2 T C 0.91(0.67, 1.23) 0.539 0.964  T C 1.00(0.86, 1.16) 0.998 0.998 
rs162031 MTRR T C 1.07(0.86, 1.32) 0.540 0.964  C T 0.96(0.87, 1.06) 0.447 0.962 
rs2839947 MTHFD1L C T 1.05(0.89, 1.25) 0.540 0.964  C T 0.99(0.91, 1.07) 0.724 0.979 
rs3816556 DNMT1 C G 0.94(0.79, 1.14) 0.541 0.964  C G 1.09(0.98, 1.20) 0.111 0.837 
rs12634587 PCYT1A G C 0.94(0.79, 1.13) 0.542 0.964  G C 0.98(0.90, 1.07) 0.659 0.971 
rs6902496 MTHFD1L T C 0.94(0.77, 1.15) 0.545 0.964  T C 1.02(0.92, 1.12) 0.711 0.979 
rs2275122 CEPT1 C A 1.09(0.83, 1.42) 0.546 0.964  G T 0.94(0.83, 1.07) 0.347 0.943 
rs4646398 PEMT G C 1.10(0.80, 1.52) 0.546 0.964  C G 1.02(0.87, 1.19) 0.825 0.979 
rs2838950 SLC19A1 T C 0.94(0.77, 1.15) 0.547 0.964  T C 1.05(0.95, 1.15) 0.346 0.943 
rs3850181 PLD1 A G 1.10(0.81, 1.50) 0.550 0.964  A G 1.06(0.89, 1.27) 0.522 0.967 
rs2516557 CHKB A G 1.10(0.80, 1.51) 0.550 0.964  -- -- -- -- -- 
 RR: Risk Ratio; CI: Confidence Interval; OR: Odds Ratio; --: Unavailable in replication study 
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rs2073191 MTHFD1L G A 0.94(0.78, 1.14) 0.551 0.964  C T 0.97(0.88, 1.06) 0.493 0.963 
rs859106 SLC44A3 C A 0.93(0.73, 1.19) 0.553 0.964  T G 0.81(0.72, 0.91) 0.000 0.074 
rs17097955 SLC44A5 C T 1.11(0.79, 1.56) 0.553 0.964  C T 1.04(0.88, 1.23) 0.627 0.969 
rs7173671 MTHFS A G 0.95(0.80, 1.13) 0.553 0.964  A G 1.00(0.92, 1.08) 0.989 0.998 
rs3776455 MTRR G A 1.05(0.88, 1.26) 0.554 0.964  T C 1.00(0.92, 1.09) 0.973 0.996 
rs2236479 SLC19A1 A G 1.05(0.89, 1.25) 0.555 0.964  A G 1.03(0.94, 1.13) 0.478 0.963 
rs4846049 MTHFR T G 1.06(0.88, 1.26) 0.555 0.964  G T 1.01(0.93, 1.10) 0.851 0.979 
rs17230459 MTHFD2L T C 1.07(0.86, 1.32) 0.556 0.964  T C 0.92(0.82, 1.03) 0.134 0.839 
rs2043305 SLC44A2 T C 1.06(0.87, 1.30) 0.556 0.964  G A 0.93(0.85, 1.03) 0.166 0.854 
rs96525 DMGDH T C 0.94(0.76, 1.16) 0.558 0.964  T C 1.03(0.93, 1.14) 0.604 0.969 
rs1563632 SHMT1 C T 0.95(0.79, 1.13) 0.558 0.964  A G 0.99(0.92, 1.08) 0.882 0.979 
rs10518120 MTHFD2L G A 1.07(0.86, 1.32) 0.561 0.964  G A 1.02(0.92, 1.13) 0.726 0.979 
rs2853532 TYMS T C 1.05(0.89, 1.25) 0.562 0.964  T C 0.97(0.91, 1.03) 0.307 0.927 
rs653753 SLC22A2 C G 1.07(0.84, 1.37) 0.562 0.964  G C 0.95(0.84, 1.08) 0.450 0.962 
rs7177659 MTHFS A C 0.95(0.81, 1.12) 0.563 0.964  C A 0.99(0.92, 1.08) 0.890 0.979 
rs12122907 SLC44A5 A G 1.06(0.86, 1.32) 0.564 0.964  A G 1.04(0.94, 1.15) 0.455 0.962 
rs4676169 SLC5A7 G A 0.95(0.81, 1.13) 0.564 0.964  G A 0.93(0.86, 1.00) 0.062 0.831 
rs13428812 DNMT3A G A 0.95(0.80, 1.13) 0.564 0.964  G A 1.05(0.96, 1.14) 0.283 0.909 
rs3827752 SLC44A3 C A 1.08(0.84, 1.38) 0.566 0.964  C A 0.97(0.85, 1.10) 0.606 0.969 
rs157572 SLC22A4 C G 1.05(0.88, 1.26) 0.567 0.964  G C 0.95(0.87, 1.04) 0.250 0.902 
rs9293761 DMGDH A G 0.95(0.80, 1.13) 0.568 0.964  A G 1.01(0.93, 1.09) 0.852 0.979 
rs10493879 SLC44A3 A C 0.93(0.72, 1.20) 0.569 0.964  T G 0.90(0.79, 1.03) 0.127 0.839 
rs11667630 DNMT1 A C 1.05(0.89, 1.24) 0.570 0.964  A C 0.97(0.89, 1.05) 0.419 0.959 
rs10925257 MTR G A 0.94(0.77, 1.15) 0.571 0.964  G A 1.02(0.93, 1.13) 0.640 0.969 
rs2839116 FTCD C A 1.05(0.88, 1.26) 0.571 0.964  C A 0.96(0.88, 1.04) 0.323 0.941 
rs13070856 ALDH1L1 A G 0.95(0.79, 1.14) 0.571 0.964  -- -- -- -- -- 
rs1956545 MTHFD1 G A 1.09(0.80, 1.49) 0.573 0.964  T C 1.16(1.00, 1.35) 0.048 0.823 
rs2073066 MTHFD1L C T 1.07(0.85, 1.33) 0.574 0.964  G A 1.04(0.94, 1.15) 0.443 0.962 
rs1371795 MTHFD2L G A 0.95(0.80, 1.13) 0.574 0.964  C T 0.91(0.83, 0.99) 0.037 0.756 
rs11724468 MTHFD2L G A 1.06(0.87, 1.29) 0.574 0.964  A G 0.94(0.86, 1.03) 0.201 0.892 
rs1805087 MTR G A 0.94(0.77, 1.15) 0.576 0.964  G A 1.02(0.93, 1.13) 0.683 0.971 
rs406193 DNMT3B T C 0.93(0.73, 1.19) 0.577 0.964  C T 1.04(0.93, 1.18) 0.478 0.963 
rs859057 SLC44A3 A C 0.94(0.76, 1.17) 0.580 0.964  C A 1.00(0.89, 1.11) 0.949 0.988 
rs10465165 SARDH T G 0.94(0.76, 1.17) 0.580 0.964  -- -- -- -- -- 
rs11612037 SHMT2 T C 1.11(0.77, 1.60) 0.580 0.964  -- -- -- -- -- 
 RR: Risk Ratio; CI: Confidence Interval; OR: Odds Ratio; --: Unavailable in replication study 
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rs859104 SLC44A3 G C 1.05(0.89, 1.24) 0.581 0.964  C G 0.92(0.85, 1.00) 0.044 0.823 
rs6923486 MTHFD1L A G 0.94(0.75, 1.18) 0.582 0.964  G A 0.94(0.85, 1.04) 0.251 0.902 
rs6676866 MTR T G 1.05(0.89, 1.23) 0.582 0.964  G T 0.96(0.89, 1.04) 0.364 0.948 
rs9325622 CBS G A 0.95(0.80, 1.13) 0.586 0.964  G A 1.03(0.95, 1.11) 0.545 0.969 
rs817580 CEPT1 A C 1.07(0.85, 1.35) 0.587 0.964  A C 0.96(0.86, 1.07) 0.417 0.959 
rs4659743 MTR A T 1.05(0.88, 1.24) 0.588 0.964  T A 1.00(0.92, 1.08) 0.924 0.983 
rs3768139 MTR G C 1.05(0.88, 1.24) 0.588 0.964  C G 1.00(0.92, 1.08) 0.949 0.988 
rs1868128 ALDH1L1 A G 1.05(0.89, 1.24) 0.588 0.964  -- -- -- -- -- 
rs11102218 CEPT1 G A 1.05(0.89, 1.23) 0.589 0.964  G A 1.05(0.97, 1.14) 0.223 0.892 
rs10802569 MTR G C 1.05(0.89, 1.24) 0.590 0.964  C G 0.99(0.91, 1.07) 0.776 0.979 
rs10932608 ATIC A T 1.06(0.86, 1.29) 0.590 0.964  A T 1.05(0.95, 1.16) 0.304 0.927 
rs859081 SLC44A3 T C 0.95(0.77, 1.16) 0.592 0.964  G A 0.99(0.90, 1.09) 0.807 0.979 
rs7518629 SLC44A5 T G 0.96(0.81, 1.13) 0.592 0.964  T G 1.02(0.94, 1.11) 0.590 0.969 
rs12137650 SLC44A3 T C 0.95(0.80, 1.14) 0.593 0.964  T C 1.03(0.95, 1.12) 0.450 0.962 
rs13307588 NOS3 A G 0.90(0.63, 1.30) 0.593 0.964  G A 1.00(0.85, 1.18) 0.985 0.998 
rs471547 FOLR3 G T 1.10(0.79, 1.53) 0.593 0.964  -- -- -- -- -- 
rs1058151 TYMS G A 0.96(0.81, 1.13) 0.594 0.964  C T 0.99(0.91, 1.08) 0.901 0.979 
rs7639752 PCYT1A G A 0.96(0.81, 1.13) 0.596 0.964  A G 0.95(0.88, 1.03) 0.218 0.892 
rs17349743 MTHFD1L C T 0.95(0.80, 1.14) 0.596 0.964  C T 0.95(0.88, 1.03) 0.243 0.901 
rs10491810 SLC44A1 A T 0.91(0.65, 1.28) 0.597 0.964  T A 0.96(0.80, 1.14) 0.619 0.969 
rs1327873 CTH C G 0.93(0.70, 1.23) 0.598 0.964  C G 0.99(0.86, 1.14) 0.901 0.979 
rs10887718 MAT1A C T 0.96(0.82, 1.13) 0.600 0.964  T C 0.99(0.92, 1.07) 0.872 0.979 
rs588885 CEPT1 T A 1.06(0.85, 1.33) 0.602 0.964  T A 0.99(0.89, 1.10) 0.794 0.979 
rs1266164 MTR A G 1.05(0.88, 1.24) 0.603 0.964  T C 1.00(0.93, 1.09) 0.908 0.979 
rs1013940 SLC5A7 C T 0.93(0.70, 1.23) 0.603 0.964  G A 1.01(0.87, 1.16) 0.937 0.986 
rs7631913 PCYT1A T C 0.96(0.81, 1.13) 0.603 0.964  C T 0.97(0.89, 1.04) 0.383 0.948 
rs1575219 MTHFD1L A G 0.95(0.77, 1.17) 0.604 0.964  C T 0.96(0.87, 1.06) 0.436 0.962 
rs12661281 SLC44A4 A T 1.06(0.84, 1.34) 0.604 0.964  -- -- -- -- -- 
rs13194204 MTHFD1L A G 1.09(0.79, 1.51) 0.606 0.965  A G 0.80(0.69, 0.92) 0.002 0.269 
rs2114635 SLC5A7 G A 1.04(0.88, 1.23) 0.610 0.967  A G 0.95(0.87, 1.03) 0.186 0.875 
rs4924892 PEMT C T 1.06(0.85, 1.32) 0.612 0.967  T C 0.94(0.84, 1.05) 0.279 0.909 
rs6795005 ALDH1L1 A G 1.05(0.86, 1.30) 0.613 0.967  -- -- -- -- -- 
rs681475 CTH A G 0.96(0.80, 1.14) 0.613 0.967  C T 0.98(0.90, 1.06) 0.607 0.969 
rs7237413 TYMS T C 1.05(0.87, 1.26) 0.613 0.967  -- -- -- -- -- 
rs1050993 MTR A G 1.04(0.88, 1.24) 0.615 0.967  G A 0.99(0.92, 1.07) 0.821 0.979 
 RR: Risk Ratio; CI: Confidence Interval; OR: Odds Ratio; --: Unavailable in replication study 
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rs3099820 MTHFD2 T C 1.06(0.85, 1.32) 0.615 0.967  C T 1.04(0.94, 1.16) 0.451 0.962 
rs1771798 MTHFD1L A G 1.08(0.81, 1.44) 0.616 0.967  C T 1.00(0.88, 1.15) 0.983 0.997 
rs10179195 MAT2A G A 1.04(0.88, 1.23) 0.618 0.967  G A 0.97(0.89, 1.05) 0.404 0.950 
rs242542 DNMT3B G A 0.93(0.71, 1.23) 0.619 0.967  G A 0.98(0.84, 1.14) 0.802 0.979 
rs9842910 ALDH1L1 A G 1.05(0.86, 1.30) 0.619 0.967  -- -- -- -- -- 
rs129934 SARDH T C 0.95(0.76, 1.17) 0.625 0.973  -- -- -- -- -- 
rs2290480 PLD1 A C 1.05(0.86, 1.29) 0.627 0.973  A C 0.98(0.89, 1.08) 0.662 0.971 
rs2662314 SLC22A4 T C 1.06(0.84, 1.34) 0.627 0.973  C T 0.94(0.84, 1.05) 0.266 0.905 
rs731991 TCN2 G A 0.96(0.82, 1.13) 0.629 0.973  G A 0.94(0.87, 1.02) 0.123 0.837 
rs3737967 MTHFR T C 0.90(0.60, 1.36) 0.629 0.973  A G 1.04(0.86, 1.25) 0.705 0.977 
rs7176987 MTHFS C A 0.95(0.76, 1.18) 0.633 0.974  C A 0.97(0.87, 1.08) 0.609 0.969 
rs657801 CEPT1 C T 0.96(0.80, 1.14) 0.634 0.974  T C 1.11(1.02, 1.21) 0.013 0.502 
rs2275566 MTR C T 1.04(0.88, 1.23) 0.637 0.974  A G 0.99(0.92, 1.08) 0.878 0.979 
rs2839111 FTCD T C 0.95(0.78, 1.16) 0.637 0.974  C T 1.06(0.96, 1.18) 0.265 0.905 
rs803470 MTHFD1L A G 0.94(0.74, 1.20) 0.637 0.974  C T 0.94(0.84, 1.05) 0.271 0.905 
rs7636149 PCYT1A A G 1.04(0.88, 1.23) 0.639 0.974  A G 0.99(0.91, 1.07) 0.762 0.979 
rs2275565 MTR A C 0.95(0.79, 1.16) 0.640 0.974  T G 1.05(0.96, 1.15) 0.303 0.927 
rs13212656 MTHFD1L G C 0.94(0.74, 1.20) 0.642 0.974  G C 1.04(0.93, 1.17) 0.488 0.963 
rs1889037 SLC44A5 G C 1.04(0.88, 1.23) 0.643 0.974  C G 0.93(0.86, 1.01) 0.093 0.831 
rs2853533 TYMS C G 1.05(0.84, 1.32) 0.644 0.974  C G 0.95(0.85, 1.07) 0.412 0.959 
rs3768142 MTR G T 1.04(0.88, 1.23) 0.645 0.974  T G 0.99(0.92, 1.08) 0.866 0.979 
rs4073394 FOLR3 G A 1.04(0.88, 1.23) 0.645 0.974  G A 0.95(0.88, 1.03) 0.245 0.902 
rs7175620 MTHFS C T 1.04(0.87, 1.26) 0.647 0.974  C T 1.04(0.95, 1.14) 0.389 0.948 
rs11965547 SLC44A4 A G 1.07(0.81, 1.40) 0.648 0.974  A G 1.09(0.95, 1.25) 0.213 0.892 
rs4820886 TCN2 G T 0.94(0.73, 1.22) 0.648 0.974  G T 0.91(0.80, 1.03) 0.119 0.837 
rs11950562 SLC22A4 C A 1.04(0.88, 1.23) 0.649 0.974  C A 0.86(0.80, 0.94) 0.000 0.074 
rs17751556 MTHFD1 C T 0.93(0.68, 1.27) 0.651 0.974  C T 1.04(0.88, 1.22) 0.675 0.971 
rs16853826 ATIC A G 1.06(0.84, 1.33) 0.651 0.974  A G 1.10(0.98, 1.23) 0.113 0.837 
rs5749131 TCN2 A G 1.04(0.88, 1.23) 0.652 0.974  G A 0.92(0.85, 1.00) 0.054 0.823 
rs17272671 FTCD C T 1.05(0.84, 1.31) 0.653 0.974  C T 0.98(0.89, 1.08) 0.711 0.979 
rs12483377 SLC19A1 A G 1.07(0.80, 1.41) 0.655 0.974  A G 0.97(0.84, 1.11) 0.662 0.971 
rs4646754 ALDH1L1 T C 0.96(0.81, 1.14) 0.657 0.974  A G 1.00(0.92, 1.08) 0.965 0.993 
rs859088 SLC44A3 T C 0.96(0.80, 1.15) 0.657 0.974  G A 1.00(0.92, 1.10) 0.942 0.986 
rs3747003 FTCD T C 0.96(0.80, 1.15) 0.658 0.974  T C 1.00(0.92, 1.09) 0.983 0.997 
rs17579604 SLC44A3 G A 0.95(0.77, 1.18) 0.658 0.974  G A 1.00(0.90, 1.11) 0.929 0.983 
 RR: Risk Ratio; CI: Confidence Interval; OR: Odds Ratio; --: Unavailable in replication study 
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rs13002567 DNMT3A C T 1.04(0.86, 1.26) 0.659 0.974  C T 1.00(0.92, 1.09) 0.928 0.983 
rs437302 DNMT3B A G 0.94(0.71, 1.25) 0.660 0.974  A G 0.97(0.85, 1.10) 0.601 0.969 
rs10181373 SLC5A7 A C 0.96(0.80, 1.15) 0.663 0.978  C A 1.01(0.92, 1.10) 0.842 0.979 
rs2307116 MTRR T C 0.96(0.80, 1.15) 0.667 0.981  A G 1.05(0.97, 1.14) 0.225 0.892 
rs6940322 MTHFD1L T A 0.96(0.81, 1.14) 0.668 0.981  T A 1.07(0.98, 1.16) 0.123 0.837 
rs2236222 MTHFD1 C T 0.94(0.70, 1.26) 0.669 0.981  G A 0.81(0.71, 0.94) 0.004 0.339 
rs466791 CBS T C 0.95(0.75, 1.21) 0.673 0.984  T C 1.03(0.92, 1.15) 0.619 0.969 
rs1571983 SLC44A5 C T 0.96(0.81, 1.15) 0.676 0.984  G A 1.01(0.92, 1.10) 0.891 0.979 
rs474244 SLC22A2 T C 1.04(0.86, 1.26) 0.677 0.984  G A 0.98(0.90, 1.07) 0.653 0.971 
rs1885031 MTHFD1 G A 0.94(0.71, 1.25) 0.679 0.984  T C 1.08(0.94, 1.25) 0.272 0.905 
rs402894 CBS C T 1.04(0.86, 1.25) 0.679 0.984  C T 0.99(0.91, 1.08) 0.831 0.979 
rs616827 SLC44A5 G T 1.04(0.87, 1.25) 0.679 0.984  T G 0.99(0.90, 1.08) 0.760 0.979 
rs3754255 MTR T C 1.03(0.88, 1.22) 0.680 0.984  T C 0.98(0.90, 1.06) 0.570 0.969 
rs11911976 CBS C T 0.96(0.81, 1.15) 0.680 0.984  T C 0.98(0.91, 1.06) 0.680 0.971 
rs181715 PLD1 A T 0.97(0.81, 1.14) 0.683 0.984  T A 0.99(0.92, 1.08) 0.867 0.979 
rs3849303 SLC44A3 T C 0.95(0.75, 1.21) 0.683 0.984  A G 0.90(0.80, 1.01) 0.085 0.831 
rs1770449 MTR G A 1.04(0.87, 1.23) 0.684 0.984  C T 1.00(0.93, 1.09) 0.959 0.993 
rs12211869 MTHFD1L T G 0.96(0.81, 1.15) 0.688 0.984  T G 0.96(0.88, 1.05) 0.371 0.948 
rs6058896 DNMT3B T C 1.08(0.75, 1.54) 0.688 0.984  T C 0.99(0.84, 1.17) 0.920 0.983 
rs688120 CEPT1 A T 0.97(0.81, 1.15) 0.690 0.984  A T 1.11(1.02, 1.21) 0.012 0.502 
rs1263781 CHPT1 T A 0.97(0.82, 1.14) 0.692 0.984  -- -- -- -- -- 
rs1072389 MTHFD2L A G 0.96(0.81, 1.15) 0.692 0.984  -- -- -- -- -- 
rs234706 CBS A G 1.04(0.87, 1.24) 0.692 0.984  A G 1.03(0.95, 1.12) 0.444 0.962 
rs6923669 MTHFD1L G A 1.05(0.83, 1.32) 0.695 0.984  G A 1.03(0.92, 1.15) 0.638 0.969 
rs3764899 PLD2 T C 0.97(0.81, 1.15) 0.697 0.984  A G 1.05(0.97, 1.14) 0.229 0.892 
rs13183229 MTRR A G 0.97(0.82, 1.15) 0.700 0.984  A G 0.96(0.88, 1.04) 0.295 0.915 
rs16961114 SHMT1 C G 0.96(0.80, 1.17) 0.701 0.984  C G 0.98(0.90, 1.07) 0.671 0.971 
rs162024 MTRR G T 0.97(0.82, 1.14) 0.703 0.984  T G 0.93(0.86, 1.00) 0.053 0.823 
rs2844458 SLC44A4 T G 1.03(0.87, 1.22) 0.704 0.984  A C 0.98(0.89, 1.06) 0.571 0.969 
rs10991622 SLC44A1 C T 0.92(0.59, 1.42) 0.705 0.984  C T 0.98(0.77, 1.26) 0.897 0.979 
rs11235468 FOLR2 G T 1.05(0.82, 1.34) 0.705 0.984  G T 0.94(0.83, 1.06) 0.323 0.941 
rs1249837 SLC44A5 A G 1.03(0.87, 1.22) 0.705 0.984  T C 1.04(0.96, 1.13) 0.339 0.943 
rs11155760 MTHFD1L T A 1.03(0.87, 1.23) 0.706 0.984  T A 0.94(0.86, 1.03) 0.185 0.875 
rs10158990 SLC44A5 G C 0.97(0.82, 1.14) 0.707 0.984  C G 0.94(0.87, 1.02) 0.122 0.837 
rs328006 SLC44A1 C G 1.05(0.80, 1.39) 0.709 0.984  C G 1.11(0.96, 1.28) 0.162 0.854 
 RR: Risk Ratio; CI: Confidence Interval; OR: Odds Ratio; --: Unavailable in replication study 
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rs2330183 SLC19A1 C T 0.97(0.82, 1.15) 0.710 0.984  T C 1.01(0.93, 1.09) 0.887 0.979 
rs9332 MTRR T C 1.05(0.82, 1.33) 0.710 0.984  A G 0.87(0.78, 0.99) 0.028 0.689 
rs5753220 TCN2 C T 0.97(0.80, 1.16) 0.713 0.984  C T 1.08(0.99, 1.18) 0.083 0.831 
rs2490334 CEPT1 A G 0.97(0.81, 1.15) 0.715 0.984  G A 1.10(1.01, 1.19) 0.030 0.689 
rs9840089 PCYT1A G A 0.97(0.82, 1.15) 0.716 0.984  A G 0.96(0.88, 1.03) 0.239 0.901 
rs859074 SLC44A3 T C 1.03(0.87, 1.23) 0.716 0.984  -- -- -- -- -- 
rs2427988 SARDH T C 0.95(0.74, 1.23) 0.717 0.984  -- -- -- -- -- 
rs17226802 BHMT2 C A 1.09(0.68, 1.75) 0.717 0.984  C A 1.01(0.78, 1.30) 0.960 0.993 
rs83615 PLD1 G A 0.96(0.77, 1.20) 0.718 0.984  A G 0.98(0.88, 1.10) 0.747 0.979 
rs4451422 FPGS C A 1.03(0.87, 1.22) 0.719 0.984  C A 1.02(0.94, 1.11) 0.610 0.969 
rs316171 SLC22A3 T G 0.97(0.82, 1.15) 0.721 0.984  A C 1.03(0.95, 1.12) 0.458 0.963 
rs4934027 MAT1A T C 0.97(0.79, 1.17) 0.722 0.984  T C 0.96(0.87, 1.06) 0.404 0.950 
rs2427995 SARDH T G 0.95(0.71, 1.27) 0.723 0.984  -- -- -- -- -- 
rs83616 PLD1 G A 1.03(0.87, 1.22) 0.724 0.984  A G 0.97(0.90, 1.05) 0.488 0.963 
rs3820571 MTR G T 1.03(0.87, 1.22) 0.724 0.984  T G 0.99(0.92, 1.08) 0.865 0.979 
rs7686861 MTHFD2L C T 1.03(0.87, 1.22) 0.725 0.984  -- -- -- -- -- 
rs6799991 ALDH1L1 A G 1.03(0.87, 1.21) 0.727 0.984  -- -- -- -- -- 
rs4573897 MTHFS A G 1.03(0.87, 1.22) 0.727 0.984  A G 1.05(0.97, 1.14) 0.214 0.892 
rs2619268 SLC22A2 A C 0.97(0.80, 1.17) 0.728 0.984  G T 0.94(0.86, 1.03) 0.185 0.875 
rs9901160 SHMT1 A G 0.96(0.77, 1.20) 0.728 0.984  A G 1.00(0.90, 1.12) 0.937 0.986 
rs2839127 FTCD A G 1.04(0.83, 1.30) 0.728 0.984  G A 0.96(0.86, 1.06) 0.398 0.949 
rs803447 MTHFD1L T C 0.97(0.82, 1.14) 0.729 0.984  G A 1.01(0.93, 1.09) 0.840 0.979 
rs2586167 MTHFS T C 0.97(0.81, 1.16) 0.729 0.984  A G 0.96(0.88, 1.04) 0.273 0.905 
rs7552892 SLC44A3 T C 0.96(0.77, 1.21) 0.736 0.988  T C 1.20(1.08, 1.34) 0.001 0.170 
rs2298444 FOLR2 G A 0.97(0.79, 1.18) 0.737 0.988  C T 1.04(0.94, 1.15) 0.448 0.962 
rs2850146 CBS G C 0.95(0.70, 1.28) 0.739 0.988  G C 0.91(0.79, 1.05) 0.191 0.885 
rs2073836 SARDH A T 1.03(0.87, 1.23) 0.739 0.988  -- -- -- -- -- 
rs3790715 CEPT1 C T 0.96(0.74, 1.24) 0.743 0.988  G A 0.95(0.84, 1.07) 0.421 0.959 
rs162899 SLC22A4 G A 0.97(0.81, 1.16) 0.743 0.988  G A 1.09(1.00, 1.20) 0.061 0.831 
rs11892646 DNMT3A T C 1.04(0.82, 1.33) 0.745 0.988  T C 0.94(0.83, 1.06) 0.302 0.927 
rs10515456 SLC22A5 A G 1.05(0.79, 1.38) 0.747 0.988  A G 1.10(0.97, 1.25) 0.150 0.839 
rs6464119 NOS3 T C 0.97(0.79, 1.19) 0.748 0.988  C T 1.07(0.97, 1.19) 0.161 0.854 
rs333216 SLC5A7 T C 0.97(0.81, 1.16) 0.751 0.988  A G 0.97(0.89, 1.06) 0.528 0.969 
rs614549 SLC44A4 C T 1.03(0.87, 1.21) 0.752 0.988  G A 0.98(0.90, 1.07) 0.627 0.969 
rs7715062 MTRR T G 0.97(0.82, 1.15) 0.752 0.988  T G 0.94(0.87, 1.02) 0.166 0.854 
 RR: Risk Ratio; CI: Confidence Interval; OR: Odds Ratio; --: Unavailable in replication study 
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rs7280485 FTCD A G 1.03(0.86, 1.23) 0.753 0.988  A G 1.01(0.93, 1.10) 0.763 0.979 
rs11656215 PEMT T C 1.03(0.87, 1.21) 0.753 0.988  T C 0.98(0.91, 1.07) 0.672 0.971 
rs3772423 ALDH1L1 A C 0.97(0.79, 1.18) 0.754 0.988  T G 1.04(0.94, 1.14) 0.472 0.963 
rs9371494 MTHFD1L G A 1.03(0.86, 1.23) 0.754 0.988  A G 0.96(0.88, 1.04) 0.326 0.942 
rs2283125 SARDH A C 1.03(0.86, 1.22) 0.754 0.988  -- -- -- -- -- 
rs6668344 MTR T C 1.03(0.87, 1.21) 0.755 0.988  T C 0.95(0.88, 1.03) 0.225 0.892 
rs10026687 MTHFD2L C T 1.03(0.84, 1.26) 0.758 0.988  C T 1.05(0.96, 1.15) 0.313 0.928 
rs10887721 MAT1A C G 1.04(0.82, 1.31) 0.758 0.988  C G 1.06(0.95, 1.19) 0.285 0.909 
rs2303629 CHPT1 G C 0.97(0.82, 1.16) 0.759 0.988  -- -- -- -- -- 
rs17004785 SLC19A1 C G 1.04(0.81, 1.34) 0.761 0.988  C G 0.98(0.86, 1.12) 0.749 0.979 
rs1738575 MTHFD1L G C 0.98(0.83, 1.14) 0.762 0.988  G C 0.94(0.87, 1.02) 0.142 0.839 
rs2073833 SARDH G C 1.03(0.87, 1.21) 0.767 0.988  -- -- -- -- -- 
rs10874305 SLC44A5 T C 1.03(0.84, 1.26) 0.768 0.988  T C 0.94(0.86, 1.04) 0.236 0.901 
rs12175302 MTHFD1L C G 1.04(0.79, 1.38) 0.768 0.988  C G 1.03(0.90, 1.18) 0.688 0.972 
rs6087982 DNMT3B G A 1.03(0.85, 1.25) 0.769 0.988  G A 0.98(0.89, 1.08) 0.627 0.969 
rs17780078 CHPT1 A G 1.06(0.72, 1.55) 0.774 0.988  -- -- -- -- -- 
rs4855877 AMT G A 0.98(0.83, 1.15) 0.775 0.988  C T 1.01(0.93, 1.09) 0.818 0.979 
rs190024 SLC44A5 C A 1.03(0.84, 1.26) 0.775 0.988  A C 0.95(0.86, 1.05) 0.309 0.927 
rs13089568 ALDH1L1 A G 1.02(0.87, 1.20) 0.775 0.988  -- -- -- -- -- 
rs2510257 SARDH A C 1.03(0.85, 1.25) 0.776 0.988  -- -- -- -- -- 
rs706209 CBS T C 0.98(0.82, 1.15) 0.777 0.988  A G 1.04(0.96, 1.13) 0.358 0.948 
rs11924478 ALDH1L1 T C 1.03(0.85, 1.24) 0.777 0.988  -- -- -- -- -- 
rs16988828 TCN2 G A 0.96(0.74, 1.25) 0.778 0.988  G A 1.01(0.89, 1.15) 0.887 0.979 
rs3826785 DNMT1 T C 1.04(0.81, 1.33) 0.778 0.988  T C 1.02(0.89, 1.16) 0.778 0.979 
rs502396 TYMS C T 1.02(0.87, 1.20) 0.779 0.988  T C 1.07(0.99, 1.15) 0.069 0.831 
rs7281816 FTCD T C 0.97(0.76, 1.23) 0.779 0.988  T C 1.07(0.95, 1.19) 0.266 0.905 
rs2586181 MTHFS T C 1.04(0.80, 1.35) 0.780 0.988  G A 1.03(0.91, 1.17) 0.670 0.971 
rs10196635 DNMT3A T A 1.04(0.79, 1.37) 0.780 0.988  T A 1.01(0.88, 1.15) 0.893 0.979 
rs6009931 CHKB G T 0.95(0.69, 1.32) 0.780 0.988  G T 0.96(0.82, 1.11) 0.551 0.969 
rs4659723 MTR T C 0.97(0.76, 1.23) 0.780 0.988  T C 1.01(0.90, 1.13) 0.850 0.979 
rs4869984 MTHFD1L T C 1.02(0.87, 1.21) 0.781 0.988  T C 1.01(0.94, 1.10) 0.764 0.979 
rs3819255 CHKA A T 0.98(0.82, 1.16) 0.784 0.988  T A 0.93(0.86, 1.01) 0.092 0.831 
rs12565150 SLC44A3 A T 0.97(0.79, 1.19) 0.785 0.988  A T 0.92(0.83, 1.02) 0.103 0.831 
rs2839121 FTCD G C 0.97(0.79, 1.20) 0.786 0.988  G C 1.02(0.92, 1.13) 0.733 0.979 
rs12661373 MTHFD1L A G 1.03(0.85, 1.24) 0.788 0.988  A G 0.98(0.90, 1.07) 0.643 0.971 
 RR: Risk Ratio; CI: Confidence Interval; OR: Odds Ratio; --: Unavailable in replication study 
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rs2424898 DNMT3B C T 1.03(0.85, 1.24) 0.788 0.988  C T 0.98(0.89, 1.07) 0.610 0.969 
rs828863 MTHFD2 A G 1.04(0.77, 1.41) 0.788 0.988  T C 0.96(0.84, 1.10) 0.573 0.969 
rs2230491 MTHFD1 T C 1.03(0.81, 1.32) 0.789 0.988  T C 1.01(0.90, 1.14) 0.839 0.979 
rs11751336 MTHFD1L C G 0.95(0.66, 1.37) 0.793 0.992  C G 1.02(0.86, 1.19) 0.856 0.979 
rs634841 MTHFS T C 1.03(0.82, 1.29) 0.795 0.993  T C 0.96(0.86, 1.06) 0.401 0.949 
rs11587108 SLC44A3 T C 1.03(0.83, 1.27) 0.797 0.994  T C 0.91(0.82, 1.02) 0.095 0.831 
rs16837183 ALDH1L1 C T 0.95(0.64, 1.41) 0.799 0.995  -- -- -- -- -- 
rs7560488 DNMT3A C T 1.02(0.87, 1.20) 0.800 0.995  C T 1.08(1.00, 1.17) 0.053 0.823 
rs1076504 PLD1 G C 1.03(0.84, 1.25) 0.801 0.995  G C 0.98(0.89, 1.08) 0.640 0.969 
rs8128028 CBS T C 0.98(0.82, 1.17) 0.803 0.995  T C 0.98(0.90, 1.07) 0.640 0.969 
rs7769613 MTHFD1L A G 0.97(0.80, 1.19) 0.805 0.995  A G 1.00(0.91, 1.10) 0.997 0.998 
rs7349940 MTHFD1L A T 0.97(0.75, 1.25) 0.807 0.995  A T 0.94(0.82, 1.07) 0.331 0.943 
rs12202291 MTHFD1L G A 0.98(0.82, 1.17) 0.809 0.995  G A 1.02(0.94, 1.12) 0.615 0.969 
rs10066017 MTRR G T 1.02(0.85, 1.23) 0.812 0.995  G T 1.05(0.97, 1.15) 0.251 0.902 
rs11165263 SLC44A3 C T 0.98(0.80, 1.20) 0.813 0.995  C T 0.94(0.85, 1.04) 0.228 0.892 
rs7700970 BHMT T C 1.02(0.85, 1.23) 0.817 0.995  T C 0.97(0.88, 1.06) 0.470 0.963 
rs4979632 SARDH T C 1.02(0.84, 1.24) 0.818 0.995  -- -- -- -- -- 
rs12205664 MTHFD1L T C 1.05(0.71, 1.55) 0.819 0.995  T C 0.83(0.68, 1.03) 0.087 0.831 
rs6271 SARDH T C 1.04(0.75, 1.43) 0.820 0.995  -- -- -- -- -- 
rs6446976 MTHFD2L C G 0.96(0.68, 1.36) 0.820 0.995  G C 0.98(0.80, 1.20) 0.868 0.979 
rs2057519 SLC44A5 G A 0.98(0.83, 1.16) 0.822 0.995  G A 1.06(0.97, 1.15) 0.194 0.891 
rs7594432 DNMT3A C T 0.98(0.83, 1.16) 0.823 0.995  C T 0.98(0.91, 1.07) 0.704 0.977 
rs17567259 SLC44A5 G A 1.04(0.72, 1.52) 0.824 0.995  G A 1.08(0.91, 1.29) 0.370 0.948 
rs881883 CHDH C T 1.03(0.81, 1.29) 0.824 0.995  G A 1.15(1.02, 1.30) 0.018 0.548 
rs10483080 SLC19A1 G C 1.03(0.81, 1.31) 0.825 0.995  G C 0.96(0.85, 1.08) 0.468 0.963 
rs9974320 FTCD A G 1.02(0.85, 1.23) 0.826 0.995  A G 1.03(0.93, 1.14) 0.581 0.969 
rs175864 MTHFD1L A C 0.97(0.71, 1.31) 0.829 0.995  T G 1.16(0.97, 1.38) 0.101 0.831 
rs9978174 FTCD C G 0.98(0.83, 1.17) 0.831 0.995  C G 0.99(0.90, 1.09) 0.840 0.979 
rs2733088 MTHFS A G 0.98(0.83, 1.16) 0.833 0.995  A G 0.96(0.88, 1.04) 0.271 0.905 
rs6586282 CBS T C 1.02(0.82, 1.29) 0.833 0.995  T C 0.99(0.89, 1.09) 0.823 0.979 
rs7238 CHKB C T 0.97(0.74, 1.27) 0.833 0.995  -- -- -- -- -- 
rs9606756 TCN2 G A 0.97(0.76, 1.24) 0.834 0.995  G A 0.96(0.85, 1.09) 0.535 0.969 
rs2342309 PCYT1A T C 0.98(0.82, 1.18) 0.835 0.995  T C 0.95(0.87, 1.04) 0.252 0.902 
rs316029 SLC22A2 T C 0.97(0.76, 1.25) 0.835 0.995  C T 0.96(0.86, 1.08) 0.529 0.969 
rs559088 DMGDH C G 1.02(0.86, 1.21) 0.836 0.995  C G 1.01(0.93, 1.10) 0.765 0.979 
 RR: Risk Ratio; CI: Confidence Interval; OR: Odds Ratio; --: Unavailable in replication study 
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rs575341 FOLR3 A G 0.97(0.76, 1.25) 0.839 0.995  C T 1.05(0.92, 1.20) 0.471 0.963 
rs6775861 PCYT1A T C 1.03(0.74, 1.45) 0.842 0.995  T C 1.04(0.88, 1.22) 0.643 0.971 
rs6557111 MTHFD1L A G 1.02(0.85, 1.22) 0.845 0.995  G A 0.95(0.88, 1.04) 0.258 0.905 
rs77905 SARDH T C 1.02(0.86, 1.20) 0.846 0.995  -- -- -- -- -- 
rs11203172 CBS T G 1.02(0.82, 1.28) 0.847 0.995  T G 1.04(0.93, 1.16) 0.476 0.963 
rs13194929 MTHFD1L G A 1.02(0.84, 1.24) 0.849 0.995  G A 0.98(0.89, 1.07) 0.637 0.969 
rs35020344 MTHFD1 G A 1.02(0.86, 1.20) 0.850 0.995  G A 0.98(0.91, 1.06) 0.685 0.972 
rs11953102 DMGDH C G 0.98(0.80, 1.20) 0.855 0.995  C G 0.96(0.87, 1.06) 0.443 0.962 
rs2286670 PLD2 A C 1.02(0.81, 1.29) 0.859 0.995  T G 0.98(0.88, 1.10) 0.747 0.979 
rs13069815 ALDH1L1 A C 0.98(0.74, 1.29) 0.862 0.995  -- -- -- -- -- 
rs2073063 MTHFD1L C T 1.02(0.86, 1.20) 0.863 0.995  G A 0.99(0.92, 1.08) 0.865 0.979 
rs1128162 SLC46A1 G T 1.01(0.86, 1.20) 0.864 0.995  A C 0.95(0.88, 1.03) 0.219 0.892 
rs182411 SLC44A5 A G 0.98(0.81, 1.19) 0.864 0.995  G A 0.98(0.90, 1.08) 0.742 0.979 
rs2164411 DNMT3A T C 0.98(0.79, 1.21) 0.864 0.995  A G 0.97(0.87, 1.07) 0.522 0.967 
rs828858 MTHFD2 A T 1.01(0.86, 1.20) 0.865 0.995  A T 1.02(0.94, 1.10) 0.674 0.971 
rs853858 DNMT3B A G 1.01(0.86, 1.19) 0.866 0.995  A G 1.01(0.93, 1.09) 0.838 0.979 
rs1541332 SARDH T C 0.99(0.84, 1.16) 0.866 0.995  -- -- -- -- -- 
rs4869970 MTHFD1L G A 1.03(0.75, 1.40) 0.867 0.995  G A 0.90(0.76, 1.08) 0.263 0.905 
rs2242665 SLC44A4 G A 0.99(0.84, 1.16) 0.867 0.995  T C 1.01(0.93, 1.10) 0.817 0.979 
rs859072 SLC44A3 G A 0.98(0.80, 1.21) 0.870 0.995  T C 1.00(0.90, 1.11) 0.965 0.993 
rs2993763 MAT1A A G 0.99(0.83, 1.17) 0.871 0.995  A G 0.96(0.89, 1.04) 0.346 0.943 
rs6424386 CTH A T 0.98(0.76, 1.26) 0.871 0.995  A T 0.93(0.82, 1.05) 0.240 0.901 
rs1045075 PCYT1A T C 0.99(0.84, 1.16) 0.872 0.995  A G 0.94(0.87, 1.02) 0.116 0.837 
rs2073815 SARDH C T 1.01(0.86, 1.19) 0.872 0.995  -- -- -- -- -- 
rs4659724 MTR A G 0.99(0.83, 1.17) 0.873 0.995  A G 0.94(0.87, 1.02) 0.167 0.854 
rs933683 DMGDH T G 0.99(0.82, 1.18) 0.874 0.995  T G 0.95(0.88, 1.04) 0.287 0.909 
rs161869 MTRR T C 1.01(0.86, 1.20) 0.876 0.995  T C 1.02(0.94, 1.10) 0.686 0.972 
rs7873937 SLC44A1 C G 1.02(0.77, 1.35) 0.877 0.995  C G 1.04(0.92, 1.18) 0.515 0.965 
rs211688 SLC44A5 A C 0.98(0.81, 1.20) 0.877 0.995  C A 0.97(0.88, 1.07) 0.532 0.969 
rs4820874 TCN2 G A 0.98(0.79, 1.23) 0.878 0.995  G A 1.05(0.94, 1.17) 0.388 0.948 
rs2070578 FTCD T C 0.99(0.84, 1.17) 0.878 0.995  T C 1.04(0.96, 1.13) 0.298 0.923 
rs4077829 MTR T G 0.99(0.84, 1.17) 0.879 0.995  T G 0.95(0.88, 1.03) 0.222 0.892 
rs234709 CBS T C 1.01(0.85, 1.20) 0.880 0.995  T C 1.01(0.94, 1.10) 0.728 0.979 
rs360402 PLD1 G A 0.99(0.82, 1.19) 0.883 0.995  A G 0.98(0.90, 1.06) 0.562 0.969 
rs4920037 CBS A G 1.01(0.83, 1.25) 0.892 0.995  A G 0.99(0.91, 1.09) 0.867 0.979 
 RR: Risk Ratio; CI: Confidence Interval; OR: Odds Ratio; --: Unavailable in replication study 
 
1
9
5
 
    NENA  CHOP 
SNP Gene 
Minor 
Allele 
Major 
Allele RR 95%(CI) P-value 
FDR Q-
value  
Minor 
Allele 
Major 
Allele OR 95%(CI) P-value 
FDR Q-
value 
rs7555627 SLC44A5 G A 0.99(0.83, 1.18) 0.893 0.995  G A 0.92(0.84, 1.00) 0.053 0.823 
rs273909 SLC22A4 C T 1.02(0.78, 1.33) 0.893 0.995  G A 1.09(0.95, 1.24) 0.215 0.892 
rs12614943 ATIC G A 0.99(0.82, 1.19) 0.894 0.995  G A 1.04(0.95, 1.13) 0.446 0.962 
rs2350631 PEMT T C 0.99(0.84, 1.17) 0.894 0.995  C T 1.03(0.96, 1.12) 0.418 0.959 
rs4646745 ALDH1L1 T C 0.99(0.81, 1.21) 0.896 0.995  A G 1.10(1.00, 1.21) 0.048 0.823 
rs12941217 PEMT A G 1.01(0.85, 1.20) 0.897 0.995  A G 1.03(0.95, 1.12) 0.419 0.959 
rs1052751 PLD2 A G 1.01(0.81, 1.27) 0.897 0.995  A G 1.08(0.97, 1.19) 0.162 0.854 
rs8118663 DNMT3B G A 0.99(0.82, 1.20) 0.899 0.995  G A 1.00(0.91, 1.10) 0.965 0.993 
rs11676382 MAT2A G C 1.02(0.76, 1.36) 0.900 0.995  G C 1.13(0.98, 1.30) 0.098 0.831 
rs2027963 SARDH A C 0.99(0.84, 1.17) 0.901 0.995  -- -- -- -- -- 
rs381870 SLC22A4 T A 1.01(0.83, 1.24) 0.902 0.995  T A 1.15(1.04, 1.27) 0.007 0.441 
rs3788205 SLC19A1 T C 1.01(0.84, 1.22) 0.903 0.995  C T 1.04(0.95, 1.13) 0.392 0.948 
rs12626746 FTCD T C 0.99(0.84, 1.17) 0.904 0.995  C T 1.02(0.94, 1.11) 0.674 0.971 
rs756682 SARDH G A 0.99(0.84, 1.17) 0.904 0.995  -- -- -- -- -- 
rs4819210 FTCD A G 0.99(0.82, 1.20) 0.904 0.995  G A 1.06(0.96, 1.17) 0.224 0.892 
rs3815743 MTRR G A 1.01(0.82, 1.26) 0.904 0.995  G A 0.98(0.88, 1.08) 0.651 0.971 
rs6780561 PLD1 G A 0.99(0.84, 1.17) 0.905 0.995  A G 0.99(0.91, 1.07) 0.776 0.979 
rs12038630 SLC44A3 A G 1.01(0.81, 1.28) 0.905 0.995  A G 0.95(0.85, 1.07) 0.412 0.959 
rs478651 DMGDH G A 0.99(0.84, 1.17) 0.906 0.995  C T 0.98(0.90, 1.06) 0.560 0.969 
rs3805673 SLC22A4 A G 0.98(0.74, 1.31) 0.906 0.995  A G 1.20(1.03, 1.39) 0.018 0.548 
rs10874314 SLC44A5 A G 1.01(0.86, 1.19) 0.907 0.995  G A 0.93(0.86, 1.00) 0.064 0.831 
rs685487 MTHFS C T 1.01(0.85, 1.20) 0.907 0.995  G A 0.96(0.89, 1.04) 0.336 0.943 
rs3204635 SHMT2 T C 0.99(0.82, 1.19) 0.908 0.995  A G 1.03(0.94, 1.13) 0.481 0.963 
rs17112592 SLC44A3 G A 1.01(0.83, 1.24) 0.909 0.995  G A 0.95(0.84, 1.06) 0.355 0.948 
rs9478847 MTHFD1L C T 1.02(0.70, 1.49) 0.909 0.995  C T 1.10(0.91, 1.34) 0.325 0.942 
rs1611123 SARDH A G 0.99(0.84, 1.17) 0.912 0.995  -- -- -- -- -- 
rs12209109 MTHFD1L C T 0.99(0.83, 1.18) 0.912 0.995  C T 1.00(0.92, 1.09) 0.988 0.998 
rs1789953 CBS T C 1.01(0.81, 1.26) 0.917 0.995  T C 1.02(0.92, 1.14) 0.662 0.971 
rs7525338 MTHFR T C 0.94(0.28, 3.18) 0.917 0.995  -- -- -- -- -- 
rs17719944 SLC46A1 G A 1.02(0.75, 1.38) 0.918 0.995  G A 0.98(0.85, 1.13) 0.797 0.979 
rs579283 MTHFD1L T C 0.99(0.84, 1.17) 0.919 0.995  A G 1.07(0.99, 1.16) 0.096 0.831 
rs509474 MTHFD1L C G 0.99(0.84, 1.17) 0.920 0.995  G C 1.02(0.95, 1.11) 0.569 0.969 
rs9322298 MTHFD1L G C 1.02(0.72, 1.43) 0.920 0.995  G C 0.89(0.75, 1.07) 0.211 0.892 
rs328012 SLC44A1 G T 0.99(0.82, 1.20) 0.921 0.995  C A 1.13(1.02, 1.24) 0.016 0.533 
rs486416 SLC44A4 C T 0.99(0.82, 1.19) 0.921 0.995  -- -- -- -- -- 
 RR: Risk Ratio; CI: Confidence Interval; OR: Odds Ratio; --: Unavailable in replication study 
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rs506500 BHMT T C 1.01(0.84, 1.21) 0.921 0.995  C T 0.99(0.91, 1.07) 0.742 0.979 
rs740234 TCN2 C T 1.01(0.82, 1.24) 0.922 0.995  G A 0.92(0.83, 1.01) 0.083 0.831 
rs1077872 NOS3 C G 0.99(0.84, 1.17) 0.923 0.995  C G 1.01(0.92, 1.10) 0.902 0.979 
rs7523188 CTH G A 0.99(0.81, 1.21) 0.924 0.995  G A 0.95(0.86, 1.05) 0.288 0.909 
rs672413 DMGDH T C 1.01(0.85, 1.20) 0.925 0.995  G A 1.07(0.98, 1.16) 0.130 0.839 
rs7029443 SLC44A1 A T 1.01(0.80, 1.27) 0.925 0.995  A T 1.04(0.92, 1.17) 0.575 0.969 
rs524732 MTHFD1L T C 1.01(0.83, 1.22) 0.925 0.995  A G 1.06(0.96, 1.16) 0.260 0.905 
rs12773664 MAT1A G A 0.99(0.84, 1.17) 0.925 0.995  G A 1.08(1.00, 1.17) 0.056 0.831 
rs162048 MTRR G A 0.99(0.78, 1.25) 0.928 0.995  A G 0.92(0.83, 1.02) 0.112 0.837 
rs156110 SLC22A4 G C 0.99(0.77, 1.28) 0.930 0.995  C G 1.11(0.97, 1.26) 0.121 0.837 
rs943199 SLC44A3 G T 0.99(0.83, 1.19) 0.930 0.995  T G 1.03(0.95, 1.13) 0.487 0.963 
rs7757336 SLC22A2 G T 1.01(0.80, 1.28) 0.932 0.995  G T 1.01(0.91, 1.13) 0.834 0.979 
rs2289209 CHDH A G 0.99(0.70, 1.38) 0.932 0.995  T C 1.27(1.04, 1.55) 0.017 0.548 
rs955516 MTR A T 0.99(0.84, 1.17) 0.932 0.995  A T 0.95(0.87, 1.02) 0.166 0.854 
rs3849306 SLC44A3 A C 0.99(0.79, 1.24) 0.933 0.995  T G 0.90(0.81, 1.01) 0.075 0.831 
rs12129440 MTR A G 0.99(0.82, 1.20) 0.933 0.995  A G 1.02(0.94, 1.12) 0.625 0.969 
rs6445607 CHDH G T 0.99(0.84, 1.18) 0.936 0.995  T G 1.00(0.92, 1.08) 0.908 0.979 
rs1131603 TCN2 C T 1.02(0.68, 1.52) 0.936 0.995  C T 1.06(0.87, 1.28) 0.562 0.969 
rs10889869 CTH A G 1.01(0.74, 1.39) 0.938 0.995  A G 0.99(0.86, 1.14) 0.929 0.983 
rs1593685 SLC5A7 G C 0.99(0.74, 1.32) 0.939 0.995  C G 1.07(0.92, 1.24) 0.370 0.948 
rs13050660 FTCD T C 0.99(0.83, 1.19) 0.939 0.995  C T 1.03(0.95, 1.11) 0.539 0.969 
rs2241933 PLD2 T G 1.01(0.84, 1.20) 0.941 0.995  G T 0.99(0.91, 1.07) 0.771 0.979 
rs17407097 SLC44A3 G A 1.01(0.80, 1.27) 0.941 0.995  G A 0.95(0.85, 1.06) 0.388 0.948 
rs17292141 FTCD G A 1.01(0.75, 1.37) 0.942 0.995  G A 0.99(0.86, 1.13) 0.850 0.979 
rs494620 SLC44A4 A G 1.01(0.85, 1.19) 0.944 0.995  A G 0.97(0.89, 1.05) 0.482 0.963 
rs9874508 ALDH1L1 A G 0.99(0.84, 1.17) 0.946 0.995  -- -- -- -- -- 
rs11612551 SHMT2 A G 1.01(0.84, 1.21) 0.946 0.995  -- -- -- -- -- 
rs12060570 MTR C G 0.99(0.84, 1.18) 0.951 0.995  C G 0.95(0.88, 1.03) 0.221 0.892 
rs17112682 SLC44A3 G A 1.01(0.72, 1.42) 0.953 0.995  G A 1.02(0.82, 1.27) 0.870 0.979 
rs326123 MTRR G A 1.00(0.84, 1.18) 0.953 0.995  A G 0.99(0.92, 1.08) 0.859 0.979 
rs316024 SLC22A2 A G 1.01(0.84, 1.20) 0.954 0.995  T C 0.96(0.88, 1.04) 0.344 0.943 
rs12053233 MTHFD2 T C 1.01(0.84, 1.21) 0.956 0.995  T C 1.01(0.93, 1.10) 0.743 0.979 
rs5997711 TCN2 T C 1.00(0.84, 1.18) 0.957 0.995  C T 0.94(0.87, 1.02) 0.132 0.839 
rs529087 MTHFD1L T C 1.01(0.83, 1.22) 0.958 0.995  A G 1.02(0.93, 1.12) 0.673 0.971 
rs12185084 MTHFS A G 0.99(0.81, 1.22) 0.959 0.995  A G 0.99(0.90, 1.09) 0.803 0.979 
 RR: Risk Ratio; CI: Confidence Interval; OR: Odds Ratio; --: Unavailable in replication study 
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rs10925252 MTR C T 1.00(0.84, 1.18) 0.959 0.995  C T 0.96(0.88, 1.04) 0.270 0.905 
rs9804151 CTH C T 0.99(0.80, 1.23) 0.959 0.995  C T 1.02(0.93, 1.13) 0.631 0.969 
rs12032960 SLC44A3 C T 1.01(0.82, 1.23) 0.960 0.995  C T 0.95(0.87, 1.05) 0.352 0.943 
rs4328397 MTHFS C T 1.01(0.79, 1.28) 0.960 0.995  C T 1.07(0.95, 1.20) 0.287 0.909 
rs10493878 SLC44A3 G A 0.99(0.80, 1.24) 0.961 0.995  C T 0.94(0.85, 1.05) 0.262 0.905 
rs10778137 CHPT1 A G 1.00(0.83, 1.19) 0.961 0.995  -- -- -- -- -- 
rs2075798 SLC44A4 T G 1.01(0.73, 1.39) 0.962 0.995  A C 1.07(0.91, 1.25) 0.437 0.962 
rs9383552 MTHFD1L G A 1.01(0.72, 1.41) 0.962 0.995  G A 0.90(0.75, 1.07) 0.222 0.892 
rs234784 CBS T C 1.00(0.85, 1.19) 0.964 0.995  C T 0.98(0.90, 1.06) 0.605 0.969 
rs2612092 TYMS A G 0.99(0.76, 1.30) 0.964 0.995  T C 0.94(0.86, 1.02) 0.122 0.837 
rs4646750 ALDH1L1 G A 0.99(0.73, 1.34) 0.964 0.995  C T 1.11(0.95, 1.28) 0.185 0.875 
rs10501409 FOLR1 C A 1.01(0.77, 1.31) 0.964 0.995  G T 0.96(0.84, 1.10) 0.585 0.969 
rs12528219 MTHFD1L C G 0.99(0.78, 1.28) 0.966 0.995  C G 1.02(0.90, 1.17) 0.730 0.979 
rs1806505 MTR T C 1.00(0.84, 1.18) 0.969 0.995  T C 0.95(0.88, 1.03) 0.226 0.892 
rs3935460 CHKA G A 1.00(0.84, 1.18) 0.971 0.995  T C 1.09(1.01, 1.18) 0.033 0.720 
rs803446 MTHFD1L T C 1.00(0.82, 1.21) 0.972 0.995  A G 1.03(0.94, 1.14) 0.513 0.965 
rs162023 MTRR A G 1.00(0.85, 1.17) 0.973 0.995  -- -- -- -- -- 
rs762684 MAT2A T C 1.00(0.83, 1.19) 0.974 0.995  A G 0.97(0.89, 1.06) 0.464 0.963 
rs2293160 PCYT1A C T 1.00(0.84, 1.19) 0.974 0.995  C T 1.01(0.93, 1.09) 0.885 0.979 
rs2297702 CEPT1 T C 0.99(0.71, 1.39) 0.974 0.995  A G 0.98(0.83, 1.16) 0.808 0.979 
rs380691 DHFR C T 1.00(0.84, 1.19) 0.976 0.995  G A 0.99(0.91, 1.07) 0.802 0.979 
rs17689550 SLC22A5 T C 1.00(0.77, 1.30) 0.976 0.995  T C 1.04(0.91, 1.18) 0.586 0.969 
rs9982015 CBS C T 1.00(0.72, 1.37) 0.976 0.995  C T 0.94(0.82, 1.08) 0.395 0.948 
rs2665355 SLC22A3 C G 1.00(0.85, 1.18) 0.977 0.995  C G 0.99(0.92, 1.07) 0.814 0.979 
rs1667627 MTHFD2 G A 1.00(0.85, 1.18) 0.979 0.995  T C 0.99(0.92, 1.07) 0.844 0.979 
rs9966612 TYMS A G 1.00(0.83, 1.19) 0.980 0.995  G A 0.93(0.85, 1.01) 0.080 0.831 
rs585800 BHMT T A 1.00(0.82, 1.21) 0.981 0.995  A T 1.00(0.91, 1.09) 0.918 0.983 
rs9478157 MTHFD1L G T 1.00(0.85, 1.19) 0.981 0.995  G T 1.05(0.96, 1.14) 0.285 0.909 
rs3772431 ALDH1L1 A G 1.00(0.84, 1.18) 0.983 0.996  C T 0.98(0.90, 1.07) 0.660 0.971 
rs12134663 MTHFR C A 1.00(0.79, 1.26) 0.984 0.996  C A 1.05(0.95, 1.16) 0.368 0.948 
rs333226 SLC5A7 G A 1.00(0.79, 1.27) 0.987 0.997  A G 0.99(0.88, 1.10) 0.841 0.979 
rs2502745 SARDH C G 1.00(0.85, 1.18) 0.991 0.997  -- -- -- -- -- 
rs3733075 CHDH T C 1.00(0.85, 1.18) 0.991 0.997  T C 0.97(0.89, 1.05) 0.460 0.963 
rs1801133 MTHFR T C 1.00(0.84, 1.19) 0.992 0.997  A G 0.92(0.85, 1.00) 0.059 0.831 
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rs698962 SLC44A3 A G 1.00(0.82, 1.23) 0.994 0.997  T C 0.91(0.83, 1.00) 0.059 0.831 
rs11082 CHPT1 G A 1.00(0.85, 1.18) 0.995 0.997  -- -- -- -- -- 
rs9432593 SLC44A3 G A 1.00(0.83, 1.21) 0.995 0.997  G A 0.94(0.86, 1.03) 0.188 0.883 
rs2851391 CBS T C 1.00(0.85, 1.18) 0.996 0.997  C T 1.03(0.95, 1.12) 0.427 0.962 
rs13212150 MTHFD1L C T 1.00(0.84, 1.19) 0.996 0.997  C T 0.98(0.90, 1.07) 0.637 0.969 
rs16948305 TYMS T C 1.00(0.79, 1.27) 0.998 0.998  T C 0.96(0.87, 1.06) 0.453 0.962 
RR: Risk Ratio CI: Confidence Interval; OR: Odd Ratio; --: Unavailable in replication study 
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APPENDIX 4. RESULTS FROM MATERNAL FOLATE AND CHOLINE-RELATED 
SNPS  
SNP Gene Minor Allele Major Allele RR (95% CI) P-value Q-value 
rs2302327 PLD2 A G 1.70(1.23,2.34) 0.001 0.502 
rs3123634 SLC22A3 T C 1.34(1.14,1.58) 0.001 0.459 
rs316174 SLC22A3 T C 1.30(1.10,1.54) 0.002 0.502 
rs803456 MTHFD1L C T 0.78(0.66,0.92) 0.003 0.621 
rs663649 CTH T G 1.30(1.08,1.57) 0.006 0.785 
rs17421462 MTHFR A G 0.65(0.48,0.89) 0.007 0.785 
rs4869087 MAT2B C A 1.29(1.07,1.55) 0.007 0.785 
rs604745 SLC44A5 G T 0.76(0.62,0.94) 0.010 0.785 
rs3797546 BHMT C T 1.65(1.12,2.44) 0.012 0.785 
rs2221750 SLC22A3 A G 1.29(1.05,1.58) 0.014 0.785 
rs2424922 DNMT3B C T 1.23(1.04,1.46) 0.016 0.785 
rs11202403 MAT1A T C 1.29(1.05,1.59) 0.017 0.785 
rs17806489 SHMT1 A G 0.73(0.56,0.94) 0.017 0.785 
rs2083868 SLC44A5 G A 0.79(0.65,0.96) 0.018 0.785 
rs4819208 FTCD G A 1.28(1.04,1.57) 0.018 0.785 
rs7642538 ALDH1L1 A G 0.79(0.65,0.96) 0.018 0.785 
rs17080476 MTHFD1L G A 0.77(0.62,0.96) 0.019 0.785 
rs712208 MTHFD1L T C 0.78(0.63,0.96) 0.019 0.785 
rs7733775 MAT2B A G 1.22(1.03,1.45) 0.019 0.785 
rs4708867 SLC22A3 G A 1.38(1.05,1.80) 0.021 0.785 
rs1979277 SHMT1 A G 1.23(1.03,1.47) 0.022 0.785 
rs2504937 SLC22A3 G C 0.81(0.68,0.97) 0.023 0.785 
rs2504956 SLC22A3 A G 0.78(0.63,0.97) 0.023 0.785 
rs13373826 SLC44A5 G A 0.76(0.60,0.97) 0.024 0.785 
rs1650697 DHFR T C 0.80(0.65,0.98) 0.027 0.785 
rs1967613 ATIC A T 1.22(1.02,1.46) 0.029 0.785 
rs7604984 ATIC G A 1.20(1.02,1.42) 0.029 0.785 
rs17375901 MTHFR T C 1.51(1.03,2.20) 0.033 0.785 
rs4646703 ALDH1L1 A G 0.77(0.61,0.98) 0.033 0.785 
rs3798156 SLC22A2 A G 1.32(1.02,1.70) 0.034 0.785 
rs512077 SLC22A3 A G 1.27(1.02,1.59) 0.034 0.785 
rs519861 MTHFD1L C T 1.26(1.02,1.56) 0.035 0.785 
rs1004053 SLC44A5 G A 0.83(0.70,0.99) 0.036 0.785 
rs3120137 SLC22A3 T C 1.31(1.02,1.68) 0.036 0.785 
rs7722729 MAT2B C T 1.27(1.01,1.58) 0.038 0.785 
rs627494 SLC44A5 G T 0.84(0.71,0.99) 0.039 0.785 
rs661620 DMGDH C T 0.84(0.71,0.99) 0.041 0.785 
rs2283124 SARDH T C 1.31(1.01,1.71) 0.042 0.785 
rs11663153 TYMS A C 1.22(1.01,1.48) 0.043 0.785 
rs17591295 SLC22A3 A G 1.47(1.01,2.14) 0.045 0.785 
rs1771845 MTHFD1L T C 0.84(0.71,1.00) 0.046 0.785 
rs2048327 SLC22A3 G A 1.20(1.00,1.42) 0.046 0.785 
rs28365862 SHMT2 G A 1.48(1.01,2.18) 0.046 0.785 
rs11040265 FOLH1 T C 1.34(1.00,1.79) 0.047 0.785 
rs12995526 ATIC T C 0.85(0.72,1.00) 0.048 0.785 
rs3127575 SLC22A2 T C 1.30(1.00,1.70) 0.048 0.785 
rs3918227 NOS3 A C 1.37(1.00,1.86) 0.048 0.785 
rs129886 SARDH T C 0.82(0.68,1.00) 0.049 0.785 
rs8016556 MTHFD1 C T 0.84(0.71,1.00) 0.049 0.785 
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rs8127036 CBS T C 0.80(0.63,1.00) 0.050 0.785 
rs11755049 MTHFD1L T A 0.76(0.58,1.00) 0.052 0.785 
rs4709432 SLC22A3 G A 1.24(1.00,1.55) 0.053 0.785 
rs891512 NOS3 A G 0.82(0.66,1.00) 0.054 0.785 
rs2273027 SHMT1 A G 0.85(0.71,1.00) 0.055 0.785 
rs7081756 MAT1A G T 1.18(1.00,1.40) 0.055 0.785 
rs10821578 SARDH T C 1.17(1.00,1.37) 0.056 0.785 
rs11908812 FTCD A G 1.33(0.99,1.78) 0.056 0.785 
rs1205349 AHCY C G 1.28(0.99,1.63) 0.056 0.785 
rs316169 SLC22A3 A C 1.19(1.00,1.42) 0.056 0.785 
rs11080058 SLC46A1 A G 0.84(0.69,1.01) 0.057 0.785 
rs13063848 PLD1 A G 1.31(0.99,1.73) 0.057 0.785 
rs140514 CHKB C T 1.17(1.00,1.38) 0.057 0.785 
rs7556057 SLC44A5 T C 0.83(0.69,1.01) 0.057 0.785 
rs1544920 CHPT1 T C 0.79(0.61,1.01) 0.058 0.785 
rs3755817 CHDH C T 1.19(0.99,1.43) 0.059 0.785 
rs2457552 SLC22A3 T G 0.82(0.67,1.01) 0.060 0.785 
rs13317328 CHDH C A 0.77(0.58,1.01) 0.061 0.785 
rs612893 DMGDH A G 0.85(0.72,1.01) 0.061 0.785 
rs2303080 MTRR A T 1.55(0.98,2.47) 0.062 0.785 
rs3733890 BHMT A G 0.84(0.70,1.01) 0.065 0.812 
rs2909854 BHMT C G 0.85(0.71,1.01) 0.067 0.829 
rs1567441 SLC22A3 G A 0.83(0.68,1.01) 0.069 0.833 
rs7533315 MTHFR T C 0.84(0.69,1.02) 0.071 0.833 
rs1891902 SLC44A5 T C 0.85(0.71,1.01) 0.072 0.833 
rs2295638 MTHFD1 T C 0.66(0.42,1.04) 0.072 0.833 
rs569919 SLC22A3 T C 0.84(0.70,1.02) 0.076 0.833 
rs1950902 MTHFD1 T C 0.82(0.66,1.02) 0.078 0.833 
rs3788190 SLC19A1 A G 0.86(0.73,1.02) 0.079 0.833 
rs6753886 SLC5A7 A G 0.86(0.72,1.02) 0.081 0.833 
rs10515861 MAT2B C T 0.85(0.71,1.02) 0.083 0.833 
rs1112444 SLC22A3 A C 1.18(0.98,1.42) 0.083 0.833 
rs17588242 SLC22A2 C T 0.84(0.69,1.02) 0.083 0.833 
rs803455 MTHFD1L T C 0.73(0.51,1.04) 0.083 0.833 
rs11595587 MAT1A A G 0.63(0.38,1.06) 0.084 0.833 
rs11664283 TYMS A G 1.18(0.98,1.43) 0.086 0.833 
rs17080461 MTHFD1L T C 0.80(0.61,1.03) 0.088 0.833 
rs492842 BHMT G A 0.87(0.73,1.02) 0.090 0.833 
rs2137407 SLC44A5 A G 1.41(0.95,2.11) 0.091 0.833 
rs4847361 SLC44A3 C T 0.81(0.63,1.04) 0.091 0.833 
rs3794186 CHKA T C 1.33(0.95,1.86) 0.092 0.833 
rs7289549 TCN2 C G 1.23(0.97,1.57) 0.092 0.833 
rs2304429 DNMT3A G A 0.87(0.73,1.03) 0.093 0.833 
rs316176 SLC22A3 G A 0.86(0.72,1.03) 0.094 0.833 
rs1580820 PCYT1A C T 0.81(0.63,1.04) 0.095 0.833 
rs299299 MAT2B G T 1.20(0.97,1.50) 0.095 0.833 
rs4846048 MTHFR G A 0.86(0.72,1.03) 0.095 0.833 
rs6668699 MTHFR C T 0.86(0.73,1.03) 0.095 0.833 
rs6814380 MTHFD2L G C 1.16(0.98,1.37) 0.095 0.833 
rs8019804 MTHFD1 G T 1.32(0.95,1.84) 0.095 0.833 
rs7730643 MTRR G A 1.21(0.97,1.52) 0.096 0.833 
rs2287779 MTRR A G 1.43(0.93,2.18) 0.100 0.833 
rs248381 DMGDH A G 1.15(0.97,1.35) 0.100 0.833 
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rs1249655 SLC44A5 A T 1.16(0.97,1.39) 0.101 0.833 
rs140516 CHKB A G 1.18(0.97,1.45) 0.101 0.833 
rs17689595 SLC22A5 A G 0.83(0.67,1.04) 0.102 0.833 
rs819144 AHCY T G 1.24(0.96,1.60) 0.102 0.833 
rs9687295 DMGDH G A 0.83(0.66,1.04) 0.102 0.833 
rs2007053 GART C T 1.18(0.97,1.44) 0.104 0.833 
rs2424932 DNMT3B A G 0.87(0.73,1.03) 0.105 0.833 
rs9669539 CHPT1 C T 1.17(0.97,1.40) 0.105 0.833 
rs505358 MTHFD1L T C 1.16(0.97,1.39) 0.106 0.833 
rs7545324 SLC44A5 G A 1.18(0.97,1.45) 0.107 0.835 
rs17269293 SLC5A7 G C 1.20(0.96,1.49) 0.109 0.843 
rs333241 SLC5A7 T C 0.85(0.69,1.04) 0.112 0.861 
rs10791958 CHKA T A 1.24(0.95,1.63) 0.114 0.864 
rs939885 PCYT1A G A 0.88(0.75,1.03) 0.114 0.864 
rs9968875 MTHFD1L G A 0.81(0.63,1.05) 0.117 0.876 
rs2298582 TYMS C A 0.82(0.64,1.05) 0.118 0.876 
rs8130986 CBS A G 1.23(0.95,1.58) 0.120 0.886 
rs11163496 SLC44A5 T C 0.85(0.68,1.05) 0.126 0.92 
rs10265237 NOS3 A G 1.16(0.96,1.39) 0.127 0.922 
rs1363730 MAT2B T C 1.20(0.94,1.54) 0.141 0.945 
rs162889 SLC22A4 T C 0.87(0.72,1.05) 0.141 0.945 
rs12217395 MAT1A A G 1.15(0.96,1.38) 0.142 0.945 
rs17354394 MTHFD1L G A 1.28(0.92,1.78) 0.142 0.945 
rs1537514 MTHFR G C 1.23(0.93,1.62) 0.143 0.945 
rs2236225 MTHFD1 T C 1.13(0.96,1.33) 0.143 0.945 
rs17448447 ATIC G A 1.14(0.96,1.35) 0.144 0.945 
rs705415 DMGDH A G 1.21(0.94,1.57) 0.144 0.945 
rs16879334 MTRR G C 1.37(0.90,2.11) 0.146 0.945 
rs4869713 MTHFD1L C T 0.89(0.75,1.04) 0.146 0.945 
rs4934028 MAT1A A G 0.88(0.75,1.05) 0.147 0.945 
rs4659718 MTR C A 0.88(0.74,1.05) 0.148 0.945 
rs9397365 MTHFD1L T C 0.84(0.67,1.06) 0.148 0.945 
rs1073083 CHPT1 T A 0.87(0.71,1.05) 0.149 0.945 
rs12626309 GART T A 0.86(0.71,1.05) 0.149 0.945 
rs16876394 DMGDH C T 1.23(0.93,1.63) 0.149 0.945 
rs9478918 MTHFD1L T C 0.83(0.65,1.07) 0.150 0.945 
rs472703 MTHFD1L G A 0.85(0.68,1.06) 0.151 0.945 
rs698966 SLC44A3 G T 0.88(0.75,1.05) 0.152 0.945 
rs1232027 DHFR A G 1.14(0.95,1.35) 0.153 0.945 
rs12637288 PCYT1A G A 0.89(0.75,1.05) 0.154 0.945 
rs250513 DMGDH T C 0.87(0.72,1.06) 0.156 0.945 
rs12275064 FOLH1 T G 1.19(0.94,1.51) 0.158 0.945 
rs884534 PCYT1A T C 0.87(0.71,1.06) 0.159 0.945 
rs2041149 CHPT1 G A 1.13(0.95,1.34) 0.160 0.945 
rs2797836 SARDH A G 1.12(0.96,1.32) 0.161 0.945 
rs514933 FOLR2 G A 1.13(0.95,1.33) 0.163 0.945 
rs735937 SLC44A3 G A 1.13(0.95,1.33) 0.163 0.945 
rs12037733 SLC44A3 A G 0.87(0.71,1.06) 0.164 0.945 
rs42418 DMGDH G C 1.12(0.95,1.33) 0.164 0.945 
rs476235 SLC22A2 T C 0.88(0.74,1.05) 0.164 0.945 
rs576075 SLC22A2 T C 0.88(0.73,1.06) 0.165 0.945 
rs175853 MTHFD1L T C 1.13(0.95,1.35) 0.167 0.951 
rs12733999 CTH T C 1.36(0.88,2.10) 0.169 0.951 
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rs9306264 TCN2 T C 1.23(0.91,1.67) 0.169 0.951 
rs2295640 MTHFD1 G C 0.82(0.62,1.09) 0.173 0.957 
rs742829 MTHFD1L G A 1.16(0.94,1.44) 0.173 0.957 
rs12469531 SLC5A7 C T 0.80(0.57,1.11) 0.178 0.964 
rs17520351 SLC44A3 T C 0.79(0.57,1.11) 0.178 0.964 
rs4270463 ALDH1L1 T C 1.31(0.88,1.95) 0.179 0.964 
rs1036145 NOS3 A G 0.89(0.75,1.06) 0.181 0.964 
rs642013 DMGDH T C 0.89(0.74,1.06) 0.185 0.964 
rs1570191 MTHFD1L C T 1.22(0.91,1.64) 0.186 0.964 
rs2741186 TYMS T C 0.90(0.76,1.06) 0.192 0.964 
rs7770982 MTHFD1L G A 0.84(0.64,1.09) 0.193 0.964 
rs2695284 CHPT1 C T 0.90(0.76,1.06) 0.199 0.964 
rs4911263 DNMT3B T C 0.89(0.75,1.06) 0.200 0.964 
rs6893970 BHMT A G 1.20(0.91,1.57) 0.200 0.964 
rs906713 CHKA A G 0.87(0.70,1.08) 0.200 0.964 
rs1915706 BHMT T C 1.12(0.94,1.33) 0.201 0.964 
rs11185518 PCYT1A T C 0.86(0.68,1.08) 0.203 0.964 
rs2853741 TYMS T C 1.12(0.94,1.33) 0.204 0.964 
rs698964 SLC44A3 A G 1.12(0.94,1.33) 0.207 0.964 
rs129902 SARDH C G 1.16(0.92,1.45) 0.211 0.964 
rs6058897 DNMT3B A C 0.90(0.77,1.06) 0.213 0.964 
rs12745827 CEPT1 G T 1.16(0.92,1.47) 0.214 0.964 
rs175860 MTHFD1L A C 0.90(0.76,1.06) 0.214 0.964 
rs4911107 DNMT3B A G 1.11(0.94,1.32) 0.214 0.964 
rs495139 TYMS G C 0.90(0.76,1.06) 0.216 0.964 
rs1050152 SLC22A4 T C 1.11(0.94,1.32) 0.217 0.964 
rs315984 SLC22A2 C T 1.13(0.93,1.37) 0.217 0.964 
rs3016432 FOLR1 G A 1.11(0.94,1.31) 0.218 0.964 
rs2450282 SLC5A7 A G 0.79(0.54,1.15) 0.220 0.964 
rs8142477 CHKB C G 0.87(0.69,1.09) 0.221 0.964 
rs1021737 CTH T G 0.89(0.74,1.07) 0.222 0.964 
rs41385949 SLC44A5 A G 0.79(0.53,1.16) 0.222 0.964 
rs10078190 DHFR T C 1.19(0.90,1.59) 0.224 0.964 
rs10179904 MAT2A A G 1.17(0.91,1.51) 0.225 0.964 
rs4694666 MTHFD2L C T 1.21(0.89,1.63) 0.225 0.964 
rs1023159 SLC19A1 A G 0.90(0.76,1.07) 0.226 0.964 
rs11746555 SLC22A5 A G 1.11(0.94,1.32) 0.226 0.964 
rs803454 MTHFD1L A G 0.83(0.61,1.13) 0.229 0.964 
rs10489810 SLC44A3 T A 0.90(0.75,1.07) 0.230 0.964 
rs652888 SLC44A4 C T 0.88(0.71,1.09) 0.231 0.964 
rs4120874 MTR G A 0.88(0.70,1.09) 0.232 0.964 
rs1980983 FTCD G A 0.90(0.75,1.07) 0.235 0.964 
rs4894499 PLD1 C T 0.88(0.72,1.08) 0.235 0.964 
rs12438477 MTHFS A C 0.91(0.77,1.07) 0.239 0.964 
rs11951068 DMGDH A G 1.19(0.89,1.58) 0.240 0.964 
rs1047665 MTHFD1L G A 1.23(0.87,1.72) 0.242 0.964 
rs12912711 MTHFS A G 1.19(0.89,1.58) 0.242 0.964 
rs2243393 CEPT1 T C 0.90(0.76,1.07) 0.242 0.964 
rs596881 SLC22A2 A G 0.86(0.66,1.11) 0.242 0.964 
rs12401888 SLC44A5 T C 1.16(0.90,1.51) 0.245 0.964 
rs2299644 FOLH1 T C 0.85(0.65,1.12) 0.245 0.964 
rs6693082 CTH G T 0.90(0.74,1.08) 0.245 0.964 
rs10489586 SLC44A5 A G 0.78(0.51,1.19) 0.247 0.964 
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rs4563403 CHDH T C 0.87(0.68,1.10) 0.247 0.964 
rs2236484 SLC19A1 A G 0.91(0.77,1.07) 0.248 0.964 
rs2880456 MAT1A T G 0.85(0.64,1.12) 0.248 0.964 
rs3795823 CEPT1 T C 1.12(0.93,1.35) 0.251 0.964 
rs4817575 GART A G 0.86(0.66,1.11) 0.251 0.964 
rs1249839 SLC44A5 T C 1.11(0.93,1.32) 0.253 0.964 
rs7586969 ATIC G A 0.91(0.77,1.07) 0.256 0.964 
rs11654690 PLD2 A G 0.84(0.62,1.14) 0.257 0.964 
rs2484459 CEPT1 C G 0.89(0.72,1.09) 0.257 0.964 
rs2797853 SARDH A G 0.90(0.76,1.08) 0.257 0.964 
rs13214952 MTHFD1L G T 0.90(0.75,1.08) 0.258 0.964 
rs2431332 DMGDH G A 0.89(0.73,1.09) 0.258 0.964 
rs4818789 SLC19A1 G T 0.90(0.74,1.08) 0.258 0.964 
rs9290428 PLD1 G C 0.91(0.77,1.07) 0.260 0.964 
rs4646755 ALDH1L1 C A 0.90(0.74,1.09) 0.261 0.964 
rs3886314 SLC44A3 A C 1.10(0.93,1.31) 0.262 0.964 
rs631305 BHMT A G 0.88(0.70,1.10) 0.263 0.964 
rs6721036 SLC5A7 T C 0.86(0.66,1.12) 0.263 0.964 
rs4245407 FOLR3 A G 1.10(0.93,1.29) 0.264 0.964 
rs8076949 SLC46A1 T C 1.18(0.88,1.57) 0.265 0.964 
rs6479643 SARDH C G 0.91(0.77,1.08) 0.266 0.964 
rs333231 SLC5A7 A G 1.11(0.92,1.34) 0.268 0.964 
rs4687747 CHDH T G 1.18(0.88,1.59) 0.268 0.964 
rs12201472 MTHFD1L T C 1.17(0.89,1.55) 0.269 0.964 
rs12636371 ALDH1L1 A G 0.91(0.77,1.08) 0.269 0.964 
rs12210887 SLC44A4 T G 0.82(0.58,1.16) 0.270 0.964 
rs1557502 CHKB A G 0.90(0.73,1.09) 0.272 0.964 
rs6766988 CHDH A T 0.86(0.66,1.13) 0.272 0.964 
rs7237052 TYMS A C 1.10(0.93,1.30) 0.272 0.964 
rs7550014 SLC44A3 T C 0.89(0.71,1.10) 0.272 0.964 
rs36027301 CHKA T C 0.81(0.55,1.18) 0.273 0.964 
rs2373929 NOS3 T C 1.10(0.93,1.29) 0.275 0.964 
rs13060596 ALDH1L1 T G 0.91(0.77,1.08) 0.277 0.964 
rs2288350 DNMT1 T C 0.85(0.63,1.14) 0.280 0.964 
rs7596024 DNMT3A A G 1.10(0.93,1.30) 0.280 0.964 
rs140515 CHKB C G 0.91(0.77,1.08) 0.281 0.964 
rs3119309 SLC22A2 T C 1.16(0.89,1.51) 0.281 0.964 
rs13401241 DNMT3A C A 1.09(0.93,1.29) 0.282 0.964 
rs6546045 DNMT3A C T 1.10(0.92,1.32) 0.282 0.964 
rs2295084 MTHFD1L A G 1.14(0.90,1.43) 0.285 0.964 
rs4256166 PLD1 T C 0.90(0.75,1.09) 0.285 0.964 
rs3120976 MAT1A C A 0.91(0.76,1.08) 0.287 0.964 
rs316033 SLC22A2 G A 1.10(0.92,1.31) 0.288 0.964 
rs6141803 DNMT3B C T 1.13(0.91,1.40) 0.288 0.964 
rs836788 DHFR A G 0.91(0.77,1.08) 0.288 0.964 
rs129883 SARDH G C 1.10(0.92,1.32) 0.289 0.964 
rs7717 FTCD C G 1.13(0.90,1.43) 0.289 0.964 
rs9870993 ALDH1L1 T G 1.10(0.92,1.30) 0.290 0.964 
rs10204232 ATIC A C 1.18(0.87,1.61) 0.295 0.964 
rs9267658 SLC44A4 T C 1.14(0.89,1.48) 0.297 0.964 
rs10380 MTRR T C 1.15(0.89,1.48) 0.299 0.964 
rs1889036 SLC44A5 G T 1.11(0.92,1.33) 0.299 0.964 
rs4147779 CHKA G A 0.90(0.75,1.09) 0.300 0.964 
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rs4847362 SLC44A3 A G 0.91(0.76,1.09) 0.301 0.964 
rs6495449 MTHFS A G 0.87(0.66,1.14) 0.301 0.964 
rs6760069 ATIC A G 0.88(0.70,1.12) 0.302 0.964 
rs893363 CHDH C T 1.09(0.92,1.30) 0.302 0.964 
rs11754661 MTHFD1L A G 0.84(0.59,1.18) 0.304 0.964 
rs35592604 SLC44A5 T C 1.12(0.90,1.40) 0.309 0.964 
rs1044988 PCYT1A C T 1.11(0.91,1.36) 0.311 0.964 
rs333214 SLC5A7 C T 1.13(0.89,1.43) 0.311 0.964 
rs668641 MTHFS A G 1.09(0.92,1.28) 0.311 0.964 
rs1405312 SLC44A5 T C 1.13(0.89,1.42) 0.312 0.964 
rs336520 DMGDH A G 1.13(0.89,1.44) 0.315 0.964 
rs2586183 MTHFS T A 0.92(0.78,1.08) 0.316 0.964 
rs3806531 SLC5A7 G A 1.09(0.92,1.29) 0.316 0.964 
rs8065874 SHMT1 T C 0.91(0.75,1.10) 0.318 0.964 
rs4120852 MAT1A C A 0.92(0.77,1.09) 0.319 0.964 
rs2834233 GART G A 1.15(0.87,1.52) 0.320 0.964 
rs4646748 ALDH1L1 T C 1.11(0.90,1.36) 0.320 0.964 
rs234785 CBS G C 0.92(0.77,1.09) 0.323 0.964 
rs1801394 MTRR A G 1.09(0.92,1.29) 0.324 0.964 
rs2077523 ALDH1L1 G T 0.92(0.78,1.09) 0.325 0.964 
rs3797535 DMGDH T C 1.17(0.86,1.60) 0.326 0.964 
rs11849530 MTHFD1 G A 0.91(0.75,1.10) 0.327 0.964 
rs7937515 FOLR3 G A 1.19(0.84,1.69) 0.327 0.964 
rs12209517 SLC22A3 G C 1.14(0.88,1.49) 0.329 0.964 
rs9897362 PEMT A G 0.84(0.60,1.19) 0.329 0.964 
rs2305795 DNMT1 G A 0.92(0.79,1.09) 0.331 0.964 
rs556808 MTHFD2L C T 0.85(0.61,1.18) 0.332 0.964 
rs9383858 MTHFD1L C T 1.09(0.92,1.29) 0.335 0.964 
rs12723350 CTH C T 1.19(0.83,1.70) 0.338 0.964 
rs2236224 MTHFD1 T C 1.09(0.92,1.29) 0.338 0.964 
rs10514154 DMGDH G A 0.90(0.73,1.11) 0.339 0.964 
rs12366105 FOLR3 C T 1.08(0.92,1.28) 0.341 0.964 
rs859101 SLC44A3 A C 1.08(0.92,1.28) 0.342 0.964 
rs9478934 MTHFD1L G A 1.19(0.83,1.69) 0.342 0.964 
rs1109859 PEMT C T 0.90(0.73,1.12) 0.343 0.964 
rs2445887 DMGDH T C 0.92(0.78,1.09) 0.343 0.964 
rs129956 SARDH C T 0.85(0.62,1.19) 0.344 0.964 
rs2286671 PLD2 C T 1.09(0.92,1.29) 0.344 0.964 
rs3744962 TYMS C T 1.15(0.86,1.54) 0.346 0.964 
rs17080689 MTHFD1L C A 0.88(0.67,1.15) 0.347 0.964 
rs3796349 CHDH G A 0.86(0.62,1.18) 0.347 0.964 
rs4744533 SARDH T C 0.92(0.78,1.09) 0.347 0.964 
rs12906758 MTHFS A T 1.11(0.90,1.37) 0.348 0.964 
rs4676168 SLC5A7 T C 0.92(0.77,1.10) 0.348 0.964 
rs11634787 MTHFS A G 0.86(0.63,1.18) 0.349 0.964 
rs131778 CHKB T C 0.93(0.79,1.09) 0.349 0.964 
rs3818239 MTHFD1 G A 0.88(0.68,1.15) 0.349 0.964 
rs17597141 CHKA C G 0.91(0.74,1.12) 0.353 0.964 
rs316025 SLC22A2 A G 1.10(0.90,1.33) 0.353 0.964 
rs6087988 DNMT3B T C 1.09(0.91,1.32) 0.353 0.964 
rs6774437 ALDH1L1 C A 0.93(0.79,1.09) 0.353 0.964 
rs2481030 SLC22A3 G A 0.92(0.77,1.10) 0.355 0.964 
rs12638724 ALDH1L1 A G 0.93(0.79,1.09) 0.359 0.964 
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rs1800779 NOS3 G A 0.93(0.78,1.09) 0.360 0.964 
rs7236459 TYMS G A 1.14(0.86,1.50) 0.360 0.964 
rs9889584 PEMT A G 0.86(0.62,1.19) 0.361 0.964 
rs6669849 SLC44A3 T C 1.20(0.81,1.80) 0.365 0.964 
rs1256146 MTHFD1 A G 1.10(0.90,1.35) 0.366 0.964 
rs17824591 MTHFD1 A G 0.91(0.74,1.12) 0.367 0.964 
rs6910091 MTHFD1L G T 1.09(0.91,1.31) 0.369 0.964 
rs696620 SLC44A3 C T 1.08(0.92,1.27) 0.369 0.964 
rs17080776 MTHFD1L C T 1.08(0.91,1.28) 0.370 0.964 
rs10493570 SLC44A5 T C 1.12(0.87,1.43) 0.374 0.964 
rs859063 SLC44A3 A G 0.93(0.78,1.10) 0.374 0.964 
rs567754 BHMT T C 1.09(0.91,1.30) 0.375 0.964 
rs6792030 ALDH1L1 C T 1.10(0.89,1.36) 0.375 0.964 
rs3774609 CHDH G T 0.93(0.79,1.09) 0.376 0.964 
rs6745054 MTHFD2 C T 0.91(0.73,1.13) 0.376 0.964 
rs11627387 MTHFD1 A G 0.92(0.77,1.10) 0.377 0.964 
rs4920035 CBS A G 0.89(0.68,1.16) 0.377 0.964 
rs9383551 MTHFD1L C T 1.16(0.84,1.60) 0.379 0.964 
rs129940 SARDH G A 0.86(0.61,1.21) 0.382 0.964 
rs316002 SLC22A2 T C 0.90(0.72,1.14) 0.387 0.964 
rs161871 MTRR G A 1.09(0.89,1.34) 0.388 0.964 
rs11755633 MTHFD1L G A 1.11(0.87,1.42) 0.392 0.964 
rs2838951 SLC19A1 G C 1.08(0.91,1.28) 0.394 0.964 
rs131749 CHKB A G 0.93(0.78,1.10) 0.395 0.964 
rs11235451 FOLR3 A T 1.08(0.91,1.28) 0.396 0.964 
rs6919680 MTHFD1L G T 1.13(0.85,1.49) 0.396 0.964 
rs10819309 FPGS A G 0.93(0.79,1.10) 0.398 0.964 
rs3851059 MAT1A A G 0.93(0.77,1.11) 0.400 0.964 
rs957903 SLC44A1 C T 1.09(0.90,1.31) 0.401 0.964 
rs17677908 MAT1A G A 0.90(0.70,1.15) 0.403 0.964 
rs10195701 SLC5A7 C T 1.10(0.88,1.38) 0.404 0.964 
rs3972 CBS T C 1.11(0.87,1.41) 0.405 0.964 
rs7763414 MTHFD1L T A 1.10(0.88,1.38) 0.405 0.964 
rs17232682 MTHFD2L C T 0.90(0.71,1.15) 0.406 0.964 
rs2071010 FOLR1 A G 0.88(0.64,1.20) 0.413 0.964 
rs4702506 MTRR C T 1.09(0.88,1.36) 0.414 0.964 
rs3821466 ALDH1L1 T C 0.93(0.78,1.11) 0.416 0.964 
rs12999687 DNMT3A T G 1.07(0.91,1.26) 0.418 0.964 
rs4244599 PEMT G A 0.93(0.79,1.10) 0.419 0.964 
rs16853723 ATIC C T 0.91(0.71,1.15) 0.420 0.964 
rs9975829 GART G A 1.07(0.90,1.27) 0.420 0.964 
rs12987326 DNMT3A G A 1.07(0.91,1.27) 0.421 0.964 
rs2177268 AMT A T 1.08(0.90,1.30) 0.422 0.964 
rs4817579 GART T C 1.07(0.90,1.28) 0.424 0.964 
rs4819130 SLC19A1 C T 0.93(0.79,1.11) 0.424 0.964 
rs2073643 SLC22A5 T C 0.94(0.79,1.10) 0.425 0.964 
rs2847607 TYMS A G 1.09(0.89,1.32) 0.425 0.964 
rs10874311 SLC44A5 T C 1.08(0.90,1.29) 0.426 0.964 
rs2987981 MTHFD1 C T 0.93(0.76,1.12) 0.428 0.964 
rs487637 MTHFD1L G T 1.08(0.90,1.29) 0.433 0.964 
rs316020 SLC22A2 T C 0.90(0.69,1.17) 0.438 0.964 
rs2510234 SARDH C T 1.07(0.90,1.27) 0.440 0.964 
rs3783731 MTHFD1 T C 1.09(0.88,1.35) 0.440 0.964 
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rs694821 SARDH G A 1.07(0.91,1.25) 0.440 0.964 
rs4902278 MTHFD1 A G 0.87(0.60,1.25) 0.442 0.964 
rs617219 BHMT C A 1.07(0.90,1.27) 0.445 0.964 
rs734693 DNMT3A C T 0.93(0.78,1.12) 0.446 0.964 
rs9322301 MTHFD1L C T 1.07(0.90,1.26) 0.447 0.964 
rs12652027 MAT2B C T 1.16(0.79,1.71) 0.449 0.964 
rs10987742 FPGS T C 0.92(0.75,1.14) 0.451 0.964 
rs2073064 MTHFD1L G A 0.92(0.73,1.15) 0.451 0.964 
rs2163005 MTHFS G A 1.07(0.90,1.26) 0.452 0.964 
rs9397032 MTHFD1L T G 0.94(0.80,1.11) 0.454 0.964 
rs2076828 SLC22A3 G C 0.94(0.80,1.11) 0.457 0.964 
rs9869368 PLD1 G A 1.09(0.87,1.38) 0.457 0.964 
rs17102596 MAT1A C T 0.92(0.75,1.14) 0.459 0.964 
rs17269265 SLC5A7 G A 1.08(0.88,1.33) 0.459 0.964 
rs7544408 SLC44A5 C G 0.94(0.79,1.11) 0.459 0.964 
rs12995245 DNMT3A C T 1.06(0.90,1.25) 0.460 0.964 
rs1476413 MTHFR A G 1.08(0.89,1.31) 0.460 0.964 
rs17823744 DMGDH G A 1.11(0.85,1.44) 0.460 0.964 
rs1045020 SLC22A5 T C 1.10(0.85,1.44) 0.461 0.964 
rs555671 CTH T C 0.88(0.63,1.24) 0.461 0.964 
rs17622208 SLC22A5 A G 1.07(0.90,1.26) 0.464 0.964 
rs1051266 SLC19A1 A G 0.94(0.79,1.11) 0.470 0.964 
rs523230 TYMS C T 1.07(0.89,1.28) 0.470 0.964 
rs1788484 CBS T C 0.94(0.78,1.12) 0.471 0.964 
rs2618372 DHFR A C 1.07(0.89,1.28) 0.471 0.964 
rs17535909 MAT2B A G 0.94(0.79,1.12) 0.472 0.964 
rs4979631 SARDH A G 0.94(0.79,1.12) 0.472 0.964 
rs624249 SLC22A2 A C 0.94(0.79,1.12) 0.472 0.964 
rs7946 PEMT C T 1.07(0.89,1.29) 0.472 0.964 
rs1643638 DHFR C T 1.07(0.89,1.28) 0.473 0.964 
rs9478908 MTHFD1L G A 0.93(0.77,1.13) 0.473 0.964 
rs10494126 CEPT1 A C 1.10(0.85,1.42) 0.474 0.964 
rs273915 SLC22A4 C G 0.94(0.78,1.12) 0.474 0.964 
rs859096 SLC44A3 C A 0.94(0.78,1.12) 0.474 0.964 
rs12344130 SLC44A1 T G 0.90(0.67,1.21) 0.475 0.964 
rs13306567 MTHFR C G 1.15(0.78,1.69) 0.476 0.964 
rs1643650 DHFR C T 1.07(0.89,1.28) 0.476 0.964 
rs1051319 CBS G C 1.10(0.85,1.41) 0.477 0.964 
rs1571511 MTHFD1 G A 0.93(0.76,1.14) 0.477 0.964 
rs10484779 MTHFD1L G T 0.92(0.73,1.16) 0.481 0.964 
rs2072197 TCN2 A C 0.92(0.73,1.16) 0.481 0.964 
rs12743566 SLC44A5 G A 1.11(0.83,1.50) 0.482 0.964 
rs17184211 MTRR T A 0.93(0.76,1.14) 0.483 0.964 
rs538017 MTHFD1L C T 1.07(0.89,1.28) 0.484 0.964 
rs6860806 SLC22A4 A G 0.94(0.80,1.11) 0.484 0.964 
rs3912161 SLC22A2 G A 1.12(0.81,1.56) 0.486 0.964 
rs4629694 MTHFD1L C T 1.19(0.73,1.95) 0.486 0.964 
rs4820887 TCN2 A G 0.91(0.69,1.20) 0.488 0.964 
rs1256142 MTHFD1 C T 1.06(0.90,1.24) 0.493 0.964 
rs647370 FOLH1 A G 0.94(0.77,1.13) 0.493 0.964 
rs10857859 CEPT1 C G 1.06(0.89,1.27) 0.495 0.964 
rs11908960 FTCD C T 0.92(0.73,1.17) 0.496 0.964 
rs3764897 PLD2 T C 1.08(0.86,1.36) 0.496 0.964 
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rs4846052 MTHFR T C 0.94(0.80,1.12) 0.496 0.964 
rs558936 MTHFD1L A G 0.94(0.78,1.13) 0.496 0.964 
rs272894 SLC22A4 G A 0.94(0.80,1.12) 0.499 0.964 
rs3849308 SLC44A3 G A 0.94(0.79,1.12) 0.500 0.964 
rs17096504 SLC44A5 A G 1.13(0.79,1.64) 0.501 0.964 
rs10854479 FTCD C T 0.94(0.78,1.13) 0.502 0.964 
rs16879258 MTRR A C 1.09(0.85,1.39) 0.502 0.964 
rs13161245 DHFR G A 1.06(0.89,1.28) 0.503 0.964 
rs1478834 DHFR A C 1.06(0.89,1.28) 0.503 0.964 
rs711352 PEMT C G 1.07(0.88,1.29) 0.504 0.964 
rs6087983 DNMT3B T G 1.08(0.87,1.33) 0.506 0.964 
rs7638797 PCYT1A C A 1.06(0.90,1.25) 0.506 0.964 
rs11155773 MTHFD1L A G 0.94(0.78,1.13) 0.507 0.964 
rs12121543 MTHFR A C 1.07(0.88,1.30) 0.507 0.964 
rs729352 MAT2B T C 1.06(0.89,1.28) 0.507 0.964 
rs803422 MTHFD1L T C 1.07(0.89,1.28) 0.507 0.964 
rs9432596 SLC44A3 A G 1.07(0.87,1.31) 0.507 0.964 
rs327588 MTRR C G 1.08(0.87,1.34) 0.508 0.964 
rs7830 NOS3 A C 1.06(0.89,1.25) 0.509 0.964 
rs274567 SLC22A5 A G 0.95(0.80,1.12) 0.511 0.964 
rs1548362 SARDH C T 0.94(0.78,1.13) 0.513 0.964 
rs6672579 SLC44A5 A G 1.06(0.90,1.24) 0.514 0.964 
rs9267649 SLC44A4 A G 1.08(0.86,1.35) 0.514 0.964 
rs11235466 FOLR2 C T 0.90(0.65,1.24) 0.516 0.964 
rs13036246 DNMT3A T C 0.95(0.80,1.12) 0.516 0.964 
rs175862 MTHFD1L C T 1.06(0.88,1.28) 0.516 0.964 
rs2847149 TYMS A G 1.06(0.90,1.24) 0.516 0.964 
rs2115540 MTHFS T C 0.95(0.80,1.12) 0.519 0.964 
rs737953 TCN2 G C 0.95(0.80,1.12) 0.520 0.964 
rs11235441 FOLR3 A G 0.87(0.56,1.35) 0.522 0.964 
rs416158 PLD1 A T 0.93(0.75,1.16) 0.522 0.964 
rs582326 SARDH G C 1.06(0.89,1.26) 0.522 0.964 
rs7639712 ALDH1L1 G A 0.93(0.73,1.17) 0.522 0.964 
rs1001761 TYMS T C 1.05(0.90,1.24) 0.523 0.964 
rs1476331 PCYT1A G A 1.06(0.90,1.24) 0.524 0.964 
rs2299648 FOLH1 A G 1.06(0.89,1.26) 0.524 0.964 
rs9644967 SLC44A1 A G 1.06(0.89,1.25) 0.524 0.964 
rs7712332 DHFR G A 1.06(0.89,1.26) 0.525 0.964 
rs11880388 DNMT1 A G 1.05(0.90,1.24) 0.526 0.964 
rs2519154 SARDH G A 1.06(0.89,1.25) 0.526 0.964 
rs162029 MTRR A G 1.07(0.88,1.30) 0.527 0.964 
rs497161 MTHFD1L A G 0.95(0.80,1.12) 0.527 0.964 
rs2277820 FTCD T C 0.94(0.78,1.13) 0.528 0.964 
rs315996 SLC22A2 A G 0.92(0.72,1.18) 0.529 0.964 
rs2241553 CHPT1 C A 0.94(0.79,1.13) 0.530 0.964 
rs2297291 SLC19A1 A G 0.95(0.80,1.12) 0.531 0.964 
rs3789699 SLC44A3 C T 0.92(0.70,1.20) 0.531 0.964 
rs1868138 ALDH1L1 T A 1.06(0.88,1.29) 0.533 0.964 
rs2502741 SARDH G A 0.95(0.81,1.11) 0.533 0.964 
rs3087896 PCYT1A T C 1.08(0.84,1.40) 0.535 0.964 
rs7737937 SLC22A4 A G 0.93(0.74,1.17) 0.535 0.964 
rs3760183 PEMT T G 1.09(0.84,1.40) 0.536 0.964 
rs2073067 MTHFD1L C G 1.06(0.89,1.26) 0.537 0.964 
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rs13306560 MTHFR A G 1.13(0.77,1.66) 0.539 0.964 
rs4646767 ALDH1L1 T C 0.95(0.81,1.12) 0.539 0.964 
rs6502823 PLD2 T C 0.91(0.68,1.23) 0.539 0.964 
rs162031 MTRR T C 1.07(0.86,1.32) 0.540 0.964 
rs2839947 MTHFD1L C T 1.06(0.89,1.25) 0.540 0.964 
rs3816556 DNMT1 C G 0.94(0.79,1.14) 0.541 0.964 
rs12634587 PCYT1A G C 0.94(0.79,1.14) 0.542 0.964 
rs6902496 MTHFD1L T C 0.94(0.77,1.15) 0.545 0.964 
rs2275122 CEPT1 C A 1.09(0.83,1.42) 0.546 0.964 
rs4646398 PEMT G C 1.10(0.80,1.52) 0.546 0.964 
rs2838950 SLC19A1 T C 0.94(0.77,1.15) 0.547 0.964 
rs2516557 CHKB A G 1.10(0.80,1.51) 0.550 0.964 
rs3850181 PLD1 A G 1.10(0.81,1.50) 0.550 0.964 
rs2073191 MTHFD1L G A 0.94(0.78,1.14) 0.551 0.964 
rs17097955 SLC44A5 C T 1.11(0.79,1.56) 0.553 0.964 
rs7173671 MTHFS A G 0.95(0.80,1.13) 0.553 0.964 
rs859106 SLC44A3 C A 0.93(0.73,1.19) 0.553 0.964 
rs3776455 MTRR G A 1.06(0.88,1.26) 0.554 0.964 
rs2236479 SLC19A1 A G 1.05(0.89,1.25) 0.555 0.964 
rs4846049 MTHFR T G 1.06(0.88,1.26) 0.555 0.964 
rs17230459 MTHFD2L T C 1.07(0.86,1.32) 0.556 0.964 
rs2043305 SLC44A2 T C 1.06(0.87,1.30) 0.556 0.964 
rs1563632 SHMT1 C T 0.95(0.79,1.13) 0.558 0.964 
rs96525 DMGDH T C 0.94(0.76,1.16) 0.558 0.964 
rs10518120 MTHFD2L G A 1.07(0.86,1.32) 0.561 0.964 
rs2853532 TYMS T C 1.05(0.89,1.25) 0.562 0.964 
rs653753 SLC22A2 C G 1.07(0.84,1.37) 0.562 0.964 
rs7177659 MTHFS A C 0.95(0.81,1.12) 0.563 0.964 
rs12122907 SLC44A5 A G 1.07(0.86,1.32) 0.564 0.964 
rs13428812 DNMT3A G A 0.95(0.80,1.13) 0.564 0.964 
rs4676169 SLC5A7 G A 0.95(0.81,1.13) 0.564 0.964 
rs3827752 SLC44A3 C A 1.08(0.84,1.38) 0.566 0.964 
rs157572 SLC22A4 C G 1.05(0.88,1.26) 0.567 0.964 
rs9293761 DMGDH A G 0.95(0.80,1.13) 0.568 0.964 
rs10493879 SLC44A3 A C 0.93(0.72,1.20) 0.569 0.964 
rs11667630 DNMT1 A C 1.05(0.89,1.24) 0.570 0.964 
rs10925257 MTR G A 0.94(0.77,1.15) 0.571 0.964 
rs13070856 ALDH1L1 A G 0.95(0.79,1.14) 0.571 0.964 
rs2839116 FTCD C A 1.05(0.88,1.26) 0.571 0.964 
rs1956545 MTHFD1 G A 1.09(0.80,1.50) 0.573 0.964 
rs11724468 MTHFD2L G A 1.06(0.87,1.29) 0.574 0.964 
rs1371795 MTHFD2L G A 0.95(0.80,1.13) 0.574 0.964 
rs2073066 MTHFD1L C T 1.07(0.85,1.33) 0.574 0.964 
rs1805087 MTR G A 0.94(0.77,1.15) 0.576 0.964 
rs406193 DNMT3B T C 0.93(0.73,1.19) 0.577 0.964 
rs10465165 SARDH T G 0.94(0.76,1.17) 0.580 0.964 
rs11612037 SHMT2 T C 1.11(0.77,1.60) 0.580 0.964 
rs859057 SLC44A3 A C 0.94(0.76,1.17) 0.580 0.964 
rs859104 SLC44A3 G C 1.05(0.89,1.24) 0.581 0.964 
rs6676866 MTR T G 1.05(0.89,1.23) 0.582 0.964 
rs6923486 MTHFD1L A G 0.94(0.75,1.18) 0.582 0.964 
rs9325622 CBS G A 0.95(0.80,1.13) 0.586 0.964 
rs817580 CEPT1 A C 1.07(0.85,1.35) 0.587 0.964 
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rs1868128 ALDH1L1 A G 1.05(0.89,1.24) 0.588 0.964 
rs3768139 MTR G C 1.05(0.89,1.24) 0.588 0.964 
rs4659743 MTR A T 1.05(0.89,1.24) 0.588 0.964 
rs11102218 CEPT1 G A 1.05(0.89,1.23) 0.589 0.964 
rs10802569 MTR G C 1.05(0.89,1.24) 0.590 0.964 
rs10932608 ATIC A T 1.06(0.86,1.29) 0.590 0.964 
rs7518629 SLC44A5 T G 0.96(0.81,1.13) 0.592 0.964 
rs859081 SLC44A3 T C 0.95(0.77,1.16) 0.592 0.964 
rs12137650 SLC44A3 T C 0.95(0.80,1.14) 0.593 0.964 
rs13307588 NOS3 A G 0.91(0.63,1.31) 0.593 0.964 
rs471547 FOLR3 G T 1.10(0.79,1.53) 0.593 0.964 
rs1058151 TYMS G A 0.96(0.81,1.13) 0.594 0.964 
rs17349743 MTHFD1L C T 0.95(0.80,1.14) 0.596 0.964 
rs7639752 PCYT1A G A 0.96(0.81,1.13) 0.596 0.964 
rs10491810 SLC44A1 A T 0.91(0.65,1.29) 0.597 0.964 
rs1327873 CTH C G 0.93(0.70,1.23) 0.598 0.964 
rs10887718 MAT1A C T 0.96(0.82,1.13) 0.600 0.964 
rs588885 CEPT1 T A 1.06(0.85,1.33) 0.602 0.964 
rs1013940 SLC5A7 C T 0.93(0.70,1.23) 0.603 0.964 
rs1266164 MTR A G 1.05(0.88,1.24) 0.603 0.964 
rs7631913 PCYT1A T C 0.96(0.81,1.13) 0.603 0.964 
rs12661281 SLC44A4 A T 1.06(0.84,1.34) 0.604 0.964 
rs1575219 MTHFD1L A G 0.95(0.77,1.17) 0.604 0.964 
rs13194204 MTHFD1L A G 1.09(0.79,1.51) 0.606 0.965 
rs2114635 SLC5A7 G A 1.04(0.89,1.23) 0.610 0.967 
rs4924892 PEMT C T 1.06(0.85,1.32) 0.612 0.967 
rs6795005 ALDH1L1 A G 1.05(0.86,1.30) 0.613 0.967 
rs681475 CTH A G 0.96(0.80,1.14) 0.613 0.967 
rs7237413 TYMS T C 1.05(0.87,1.26) 0.613 0.967 
rs1050993 MTR A G 1.05(0.88,1.24) 0.615 0.967 
rs3099820 MTHFD2 T C 1.06(0.85,1.32) 0.615 0.967 
rs1771798 MTHFD1L A G 1.08(0.81,1.44) 0.616 0.967 
rs10179195 MAT2A G A 1.04(0.88,1.23) 0.618 0.967 
rs242542 DNMT3B G A 0.93(0.71,1.23) 0.619 0.967 
rs9842910 ALDH1L1 A G 1.05(0.86,1.30) 0.619 0.967 
rs129934 SARDH T C 0.95(0.77,1.18) 0.625 0.973 
rs2290480 PLD1 A C 1.05(0.86,1.29) 0.627 0.973 
rs2662314 SLC22A4 T C 1.06(0.84,1.34) 0.627 0.973 
rs3737967 MTHFR T C 0.90(0.60,1.36) 0.629 0.973 
rs731991 TCN2 G A 0.96(0.82,1.13) 0.629 0.973 
rs7176987 MTHFS C A 0.95(0.76,1.18) 0.633 0.974 
rs657801 CEPT1 C T 0.96(0.80,1.14) 0.634 0.974 
rs2275566 MTR C T 1.04(0.88,1.23) 0.637 0.974 
rs2839111 FTCD T C 0.95(0.78,1.16) 0.637 0.974 
rs803470 MTHFD1L A G 0.94(0.74,1.20) 0.637 0.974 
rs7636149 PCYT1A A G 1.04(0.88,1.23) 0.639 0.974 
rs2275565 MTR A C 0.96(0.79,1.16) 0.640 0.974 
rs13212656 MTHFD1L G C 0.95(0.74,1.20) 0.642 0.974 
rs1889037 SLC44A5 G C 1.04(0.88,1.23) 0.643 0.974 
rs2853533 TYMS C G 1.05(0.84,1.32) 0.644 0.974 
rs3768142 MTR G T 1.04(0.88,1.23) 0.645 0.974 
rs4073394 FOLR3 G A 1.04(0.88,1.24) 0.645 0.974 
rs7175620 MTHFS C T 1.05(0.87,1.26) 0.647 0.974 
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rs11965547 SLC44A4 A G 1.07(0.81,1.40) 0.648 0.974 
rs4820886 TCN2 G T 0.94(0.73,1.22) 0.648 0.974 
rs11950562 SLC22A4 C A 1.04(0.88,1.23) 0.649 0.974 
rs16853826 ATIC A G 1.06(0.84,1.33) 0.651 0.974 
rs17751556 MTHFD1 C T 0.93(0.68,1.27) 0.651 0.974 
rs5749131 TCN2 A G 1.04(0.88,1.23) 0.652 0.974 
rs17272671 FTCD C T 1.05(0.84,1.31) 0.653 0.974 
rs12483377 SLC19A1 A G 1.07(0.80,1.41) 0.655 0.974 
rs4646754 ALDH1L1 T C 0.96(0.81,1.14) 0.657 0.974 
rs859088 SLC44A3 T C 0.96(0.80,1.15) 0.657 0.974 
rs17579604 SLC44A3 G A 0.95(0.77,1.18) 0.658 0.974 
rs3747003 FTCD T C 0.96(0.80,1.15) 0.658 0.974 
rs13002567 DNMT3A C T 1.04(0.86,1.26) 0.659 0.974 
rs437302 DNMT3B A G 0.94(0.71,1.25) 0.660 0.974 
rs10181373 SLC5A7 A C 0.96(0.80,1.15) 0.663 0.978 
rs2307116 MTRR T C 0.96(0.80,1.15) 0.667 0.981 
rs6940322 MTHFD1L T A 0.96(0.81,1.14) 0.668 0.981 
rs2236222 MTHFD1 C T 0.94(0.70,1.26) 0.669 0.981 
rs466791 CBS T C 0.95(0.75,1.21) 0.673 0.984 
rs1571983 SLC44A5 C T 0.96(0.81,1.15) 0.676 0.984 
rs474244 SLC22A2 T C 1.04(0.86,1.26) 0.677 0.984 
rs1885031 MTHFD1 G A 0.94(0.71,1.25) 0.679 0.984 
rs402894 CBS C T 1.04(0.86,1.25) 0.679 0.984 
rs616827 SLC44A5 G T 1.04(0.87,1.25) 0.679 0.984 
rs11911976 CBS C T 0.96(0.81,1.15) 0.680 0.984 
rs3754255 MTR T C 1.04(0.88,1.22) 0.680 0.984 
rs181715 PLD1 A T 0.97(0.81,1.15) 0.683 0.984 
rs3849303 SLC44A3 T C 0.95(0.75,1.21) 0.683 0.984 
rs1770449 MTR G A 1.04(0.87,1.23) 0.684 0.984 
rs12211869 MTHFD1L T G 0.96(0.81,1.15) 0.688 0.984 
rs6058896 DNMT3B T C 1.08(0.75,1.54) 0.688 0.984 
rs688120 CEPT1 A T 0.97(0.81,1.15) 0.690 0.984 
rs1072389 MTHFD2L A G 0.97(0.81,1.15) 0.692 0.984 
rs1263781 CHPT1 T A 0.97(0.82,1.14) 0.692 0.984 
rs234706 CBS A G 1.04(0.87,1.24) 0.692 0.984 
rs6923669 MTHFD1L G A 1.05(0.83,1.32) 0.695 0.984 
rs3764899 PLD2 T C 0.97(0.81,1.15) 0.697 0.984 
rs13183229 MTRR A G 0.97(0.82,1.15) 0.700 0.984 
rs16961114 SHMT1 C G 0.96(0.80,1.17) 0.701 0.984 
rs162024 MTRR G T 0.97(0.82,1.14) 0.703 0.984 
rs2844458 SLC44A4 T G 1.03(0.87,1.22) 0.704 0.984 
rs10991622 SLC44A1 C T 0.92(0.60,1.42) 0.705 0.984 
rs11235468 FOLR2 G T 1.05(0.82,1.34) 0.705 0.984 
rs1249837 SLC44A5 A G 1.03(0.87,1.22) 0.705 0.984 
rs11155760 MTHFD1L T A 1.04(0.87,1.24) 0.706 0.984 
rs10158990 SLC44A5 G C 0.97(0.82,1.14) 0.707 0.984 
rs328006 SLC44A1 C G 1.05(0.80,1.39) 0.709 0.984 
rs2330183 SLC19A1 C T 0.97(0.82,1.15) 0.710 0.984 
rs9332 MTRR T C 1.05(0.82,1.34) 0.710 0.984 
rs5753220 TCN2 C T 0.97(0.80,1.16) 0.713 0.984 
rs2490334 CEPT1 A G 0.97(0.81,1.15) 0.715 0.984 
rs859074 SLC44A3 T C 1.03(0.87,1.23) 0.716 0.984 
rs9840089 PCYT1A G A 0.97(0.82,1.15) 0.716 0.984 
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rs17226802 BHMT2 C A 1.09(0.68,1.75) 0.717 0.984 
rs2427988 SARDH T C 0.95(0.74,1.23) 0.717 0.984 
rs83615 PLD1 G A 0.96(0.77,1.20) 0.718 0.984 
rs4451422 FPGS C A 1.03(0.87,1.22) 0.719 0.984 
rs316171 SLC22A3 T G 0.97(0.82,1.15) 0.721 0.984 
rs4934027 MAT1A T C 0.97(0.79,1.17) 0.722 0.984 
rs2427995 SARDH T G 0.95(0.71,1.27) 0.723 0.984 
rs3820571 MTR G T 1.03(0.87,1.22) 0.724 0.984 
rs83616 PLD1 G A 1.03(0.87,1.22) 0.724 0.984 
rs7686861 MTHFD2L C T 1.03(0.87,1.22) 0.725 0.984 
rs4573897 MTHFS A G 1.03(0.87,1.22) 0.727 0.984 
rs6799991 ALDH1L1 A G 1.03(0.87,1.21) 0.727 0.984 
rs2619268 SLC22A2 A C 0.97(0.80,1.17) 0.728 0.984 
rs2839127 FTCD A G 1.04(0.84,1.30) 0.728 0.984 
rs9901160 SHMT1 A G 0.96(0.77,1.20) 0.728 0.984 
rs2586167 MTHFS T C 0.97(0.81,1.16) 0.729 0.984 
rs803447 MTHFD1L T C 0.97(0.83,1.14) 0.729 0.984 
rs7552892 SLC44A3 T C 0.96(0.77,1.21) 0.736 0.988 
rs2298444 FOLR2 G A 0.97(0.79,1.18) 0.737 0.988 
rs2073836 SARDH A T 1.03(0.87,1.23) 0.739 0.988 
rs2850146 CBS G C 0.95(0.71,1.28) 0.739 0.988 
rs162899 SLC22A4 G A 0.97(0.81,1.16) 0.743 0.988 
rs3790715 CEPT1 C T 0.96(0.74,1.24) 0.743 0.988 
rs11892646 DNMT3A T C 1.04(0.82,1.33) 0.745 0.988 
rs10515456 SLC22A5 A G 1.05(0.79,1.38) 0.747 0.988 
rs6464119 NOS3 T C 0.97(0.79,1.19) 0.748 0.988 
rs333216 SLC5A7 T C 0.97(0.81,1.17) 0.751 0.988 
rs614549 SLC44A4 C T 1.03(0.87,1.21) 0.752 0.988 
rs7715062 MTRR T G 0.97(0.82,1.15) 0.752 0.988 
rs11656215 PEMT T C 1.03(0.87,1.21) 0.753 0.988 
rs7280485 FTCD A G 1.03(0.86,1.23) 0.753 0.988 
rs2283125 SARDH A C 1.03(0.86,1.23) 0.754 0.988 
rs3772423 ALDH1L1 A C 0.97(0.79,1.18) 0.754 0.988 
rs9371494 MTHFD1L G A 1.03(0.86,1.23) 0.754 0.988 
rs6668344 MTR T C 1.03(0.87,1.21) 0.755 0.988 
rs10026687 MTHFD2L C T 1.03(0.84,1.26) 0.758 0.988 
rs10887721 MAT1A C G 1.04(0.82,1.31) 0.758 0.988 
rs2303629 CHPT1 G C 0.97(0.82,1.16) 0.759 0.988 
rs17004785 SLC19A1 C G 1.04(0.81,1.34) 0.761 0.988 
rs1738575 MTHFD1L G C 0.98(0.83,1.15) 0.762 0.988 
rs2073833 SARDH G C 1.03(0.87,1.21) 0.767 0.988 
rs10874305 SLC44A5 T C 1.03(0.85,1.26) 0.768 0.988 
rs12175302 MTHFD1L C G 1.04(0.79,1.38) 0.768 0.988 
rs6087982 DNMT3B G A 1.03(0.85,1.25) 0.769 0.988 
rs17780078 CHPT1 A G 1.06(0.72,1.55) 0.774 0.988 
rs13089568 ALDH1L1 A G 1.02(0.87,1.20) 0.775 0.988 
rs190024 SLC44A5 C A 1.03(0.84,1.26) 0.775 0.988 
rs4855877 AMT G A 0.98(0.83,1.15) 0.775 0.988 
rs2510257 SARDH A C 1.03(0.85,1.25) 0.776 0.988 
rs11924478 ALDH1L1 T C 1.03(0.85,1.24) 0.777 0.988 
rs706209 CBS T C 0.98(0.83,1.16) 0.777 0.988 
rs16988828 TCN2 G A 0.96(0.74,1.25) 0.778 0.988 
rs3826785 DNMT1 T C 1.04(0.81,1.33) 0.778 0.988 
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rs502396 TYMS C T 1.02(0.87,1.20) 0.779 0.988 
rs7281816 FTCD T C 0.97(0.76,1.23) 0.779 0.988 
rs10196635 DNMT3A T A 1.04(0.79,1.37) 0.780 0.988 
rs2586181 MTHFS T C 1.04(0.80,1.35) 0.780 0.988 
rs4659723 MTR T C 0.97(0.76,1.23) 0.780 0.988 
rs6009931 CHKB G T 0.96(0.69,1.32) 0.780 0.988 
rs4869984 MTHFD1L T C 1.02(0.87,1.21) 0.781 0.988 
rs3819255 CHKA A T 0.98(0.82,1.16) 0.784 0.988 
rs12565150 SLC44A3 A T 0.97(0.79,1.19) 0.785 0.988 
rs2839121 FTCD G C 0.97(0.79,1.20) 0.786 0.988 
rs12661373 MTHFD1L A G 1.03(0.85,1.24) 0.788 0.988 
rs2424898 DNMT3B C T 1.03(0.85,1.24) 0.788 0.988 
rs828863 MTHFD2 A G 1.04(0.77,1.41) 0.788 0.988 
rs2230491 MTHFD1 T C 1.03(0.81,1.32) 0.789 0.988 
rs11751336 MTHFD1L C G 0.95(0.66,1.37) 0.793 0.992 
rs634841 MTHFS T C 1.03(0.83,1.29) 0.795 0.993 
rs11587108 SLC44A3 T C 1.03(0.83,1.27) 0.797 0.994 
rs16837183 ALDH1L1 C T 0.95(0.64,1.41) 0.799 0.995 
rs7560488 DNMT3A C T 1.02(0.87,1.21) 0.800 0.995 
rs1076504 PLD1 G C 1.03(0.84,1.25) 0.801 0.995 
rs8128028 CBS T C 0.98(0.82,1.17) 0.803 0.995 
rs7769613 MTHFD1L A G 0.98(0.80,1.20) 0.805 0.995 
rs7349940 MTHFD1L A T 0.97(0.75,1.25) 0.807 0.995 
rs12202291 MTHFD1L G A 0.98(0.82,1.17) 0.809 0.995 
rs10066017 MTRR G T 1.02(0.85,1.23) 0.812 0.995 
rs11165263 SLC44A3 C T 0.98(0.80,1.20) 0.813 0.995 
rs7700970 BHMT T C 1.02(0.85,1.23) 0.817 0.995 
rs4979632 SARDH T C 1.02(0.84,1.24) 0.818 0.995 
rs12205664 MTHFD1L T C 1.05(0.71,1.55) 0.819 0.995 
rs6271 SARDH T C 1.04(0.75,1.43) 0.820 0.995 
rs6446976 MTHFD2L C G 0.96(0.68,1.36) 0.820 0.995 
rs2057519 SLC44A5 G A 0.98(0.83,1.16) 0.822 0.995 
rs7594432 DNMT3A C T 0.98(0.83,1.16) 0.823 0.995 
rs17567259 SLC44A5 G A 1.04(0.72,1.52) 0.824 0.995 
rs881883 CHDH C T 1.03(0.81,1.29) 0.824 0.995 
rs10483080 SLC19A1 G C 1.03(0.81,1.31) 0.825 0.995 
rs9974320 FTCD A G 1.02(0.85,1.23) 0.826 0.995 
rs175864 MTHFD1L A C 0.97(0.71,1.31) 0.829 0.995 
rs9978174 FTCD C G 0.98(0.83,1.17) 0.831 0.995 
rs2733088 MTHFS A G 0.98(0.83,1.16) 0.833 0.995 
rs6586282 CBS T C 1.03(0.82,1.29) 0.833 0.995 
rs7238 CHKB C T 0.97(0.74,1.27) 0.833 0.995 
rs9606756 TCN2 G A 0.97(0.76,1.24) 0.834 0.995 
rs2342309 PCYT1A T C 0.98(0.82,1.18) 0.835 0.995 
rs316029 SLC22A2 T C 0.97(0.76,1.25) 0.835 0.995 
rs559088 DMGDH C G 1.02(0.86,1.21) 0.836 0.995 
rs575341 FOLR3 A G 0.98(0.76,1.25) 0.839 0.995 
rs6775861 PCYT1A T C 1.04(0.74,1.45) 0.842 0.995 
rs6557111 MTHFD1L A G 1.02(0.85,1.22) 0.845 0.995 
rs77905 SARDH T C 1.02(0.86,1.20) 0.846 0.995 
rs11203172 CBS T G 1.02(0.82,1.28) 0.847 0.995 
rs13194929 MTHFD1L G A 1.02(0.84,1.24) 0.849 0.995 
rs35020344 MTHFD1 G A 1.02(0.86,1.20) 0.850 0.995 
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rs11953102 DMGDH C G 0.98(0.80,1.20) 0.855 0.995 
rs2286670 PLD2 A C 1.02(0.81,1.29) 0.859 0.995 
rs13069815 ALDH1L1 A C 0.98(0.74,1.29) 0.862 0.995 
rs2073063 MTHFD1L C T 1.02(0.86,1.20) 0.863 0.995 
rs1128162 SLC46A1 G T 1.02(0.86,1.20) 0.864 0.995 
rs182411 SLC44A5 A G 0.98(0.81,1.19) 0.864 0.995 
rs2164411 DNMT3A T C 0.98(0.79,1.21) 0.864 0.995 
rs828858 MTHFD2 A T 1.02(0.86,1.20) 0.865 0.995 
rs1541332 SARDH T C 0.99(0.84,1.16) 0.866 0.995 
rs853858 DNMT3B A G 1.01(0.86,1.19) 0.866 0.995 
rs2242665 SLC44A4 G A 0.99(0.84,1.16) 0.867 0.995 
rs4869970 MTHFD1L G A 1.03(0.75,1.40) 0.867 0.995 
rs859072 SLC44A3 G A 0.98(0.80,1.21) 0.870 0.995 
rs2993763 MAT1A A G 0.99(0.83,1.17) 0.871 0.995 
rs6424386 CTH A T 0.98(0.76,1.26) 0.871 0.995 
rs1045075 PCYT1A T C 0.99(0.84,1.17) 0.872 0.995 
rs2073815 SARDH C T 1.01(0.86,1.19) 0.872 0.995 
rs4659724 MTR A G 0.99(0.83,1.17) 0.873 0.995 
rs933683 DMGDH T G 0.99(0.82,1.18) 0.874 0.995 
rs161869 MTRR T C 1.01(0.86,1.20) 0.876 0.995 
rs211688 SLC44A5 A C 0.98(0.81,1.20) 0.877 0.995 
rs7873937 SLC44A1 C G 1.02(0.77,1.35) 0.877 0.995 
rs2070578 FTCD T C 0.99(0.84,1.17) 0.878 0.995 
rs4820874 TCN2 G A 0.98(0.79,1.23) 0.878 0.995 
rs4077829 MTR T G 0.99(0.84,1.17) 0.879 0.995 
rs234709 CBS T C 1.01(0.85,1.20) 0.880 0.995 
rs360402 PLD1 G A 0.99(0.82,1.19) 0.883 0.995 
rs4920037 CBS A G 1.01(0.83,1.25) 0.892 0.995 
rs273909 SLC22A4 C T 1.02(0.78,1.33) 0.893 0.995 
rs7555627 SLC44A5 G A 0.99(0.83,1.18) 0.893 0.995 
rs12614943 ATIC G A 0.99(0.82,1.19) 0.894 0.995 
rs2350631 PEMT T C 0.99(0.84,1.17) 0.894 0.995 
rs4646745 ALDH1L1 T C 0.99(0.81,1.21) 0.896 0.995 
rs1052751 PLD2 A G 1.02(0.81,1.27) 0.897 0.995 
rs12941217 PEMT A G 1.01(0.85,1.20) 0.897 0.995 
rs8118663 DNMT3B G A 0.99(0.82,1.20) 0.899 0.995 
rs11676382 MAT2A G C 1.02(0.76,1.36) 0.900 0.995 
rs2027963 SARDH A C 0.99(0.84,1.17) 0.901 0.995 
rs381870 SLC22A4 T A 1.01(0.83,1.24) 0.902 0.995 
rs3788205 SLC19A1 T C 1.01(0.84,1.22) 0.903 0.995 
rs12626746 FTCD T C 0.99(0.84,1.17) 0.904 0.995 
rs3815743 MTRR G A 1.01(0.82,1.26) 0.904 0.995 
rs4819210 FTCD A G 0.99(0.82,1.20) 0.904 0.995 
rs756682 SARDH G A 0.99(0.84,1.17) 0.904 0.995 
rs12038630 SLC44A3 A G 1.01(0.81,1.28) 0.905 0.995 
rs6780561 PLD1 G A 0.99(0.84,1.17) 0.905 0.995 
rs3805673 SLC22A4 A G 0.98(0.74,1.31) 0.906 0.995 
rs478651 DMGDH G A 0.99(0.84,1.17) 0.906 0.995 
rs10874314 SLC44A5 A G 1.01(0.86,1.19) 0.907 0.995 
rs685487 MTHFS C T 1.01(0.85,1.20) 0.907 0.995 
rs3204635 SHMT2 T C 0.99(0.82,1.19) 0.908 0.995 
rs17112592 SLC44A3 G A 1.01(0.83,1.24) 0.909 0.995 
rs9478847 MTHFD1L C T 1.02(0.70,1.49) 0.909 0.995 
 RR: Risk ratio; CI: Confidence interval 
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rs12209109 MTHFD1L C T 0.99(0.83,1.18) 0.912 0.995 
rs1611123 SARDH A G 0.99(0.84,1.17) 0.912 0.995 
rs1789953 CBS T C 1.01(0.81,1.26) 0.917 0.995 
rs7525338 MTHFR T C 0.94(0.28,3.18) 0.917 0.995 
rs17719944 SLC46A1 G A 1.02(0.75,1.38) 0.918 0.995 
rs579283 MTHFD1L T C 0.99(0.84,1.17) 0.919 0.995 
rs509474 MTHFD1L C G 0.99(0.84,1.17) 0.920 0.995 
rs9322298 MTHFD1L G C 1.02(0.72,1.43) 0.920 0.995 
rs328012 SLC44A1 G T 0.99(0.82,1.20) 0.921 0.995 
rs486416 SLC44A4 C T 0.99(0.82,1.19) 0.921 0.995 
rs506500 BHMT T C 1.01(0.84,1.21) 0.921 0.995 
rs740234 TCN2 C T 1.01(0.82,1.24) 0.922 0.995 
rs1077872 NOS3 C G 0.99(0.84,1.17) 0.923 0.995 
rs7523188 CTH G A 0.99(0.81,1.21) 0.924 0.995 
rs12773664 MAT1A G A 0.99(0.84,1.17) 0.925 0.995 
rs524732 MTHFD1L T C 1.01(0.83,1.22) 0.925 0.995 
rs672413 DMGDH T C 1.01(0.85,1.20) 0.925 0.995 
rs7029443 SLC44A1 A T 1.01(0.80,1.27) 0.925 0.995 
rs162048 MTRR G A 0.99(0.78,1.25) 0.928 0.995 
rs156110 SLC22A4 G C 0.99(0.77,1.28) 0.930 0.995 
rs943199 SLC44A3 G T 0.99(0.83,1.19) 0.930 0.995 
rs2289209 CHDH A G 0.99(0.70,1.38) 0.932 0.995 
rs7757336 SLC22A2 G T 1.01(0.80,1.28) 0.932 0.995 
rs955516 MTR A T 0.99(0.84,1.17) 0.932 0.995 
rs12129440 MTR A G 0.99(0.82,1.20) 0.933 0.995 
rs3849306 SLC44A3 A C 0.99(0.79,1.24) 0.933 0.995 
rs1131603 TCN2 C T 1.02(0.68,1.52) 0.936 0.995 
rs6445607 CHDH G T 0.99(0.84,1.18) 0.936 0.995 
rs10889869 CTH A G 1.01(0.74,1.39) 0.938 0.995 
rs13050660 FTCD T C 0.99(0.83,1.19) 0.939 0.995 
rs1593685 SLC5A7 G C 0.99(0.74,1.32) 0.939 0.995 
rs17407097 SLC44A3 G A 1.01(0.80,1.27) 0.941 0.995 
rs2241933 PLD2 T G 1.01(0.84,1.20) 0.941 0.995 
rs17292141 FTCD G A 1.01(0.75,1.37) 0.942 0.995 
rs494620 SLC44A4 A G 1.01(0.85,1.19) 0.944 0.995 
rs11612551 SHMT2 A G 1.01(0.84,1.21) 0.946 0.995 
rs9874508 ALDH1L1 A G 0.99(0.84,1.17) 0.946 0.995 
rs12060570 MTR C G 1.00(0.84,1.18) 0.951 0.995 
rs17112682 SLC44A3 G A 1.01(0.72,1.43) 0.953 0.995 
rs326123 MTRR G A 1.00(0.84,1.18) 0.953 0.995 
rs316024 SLC22A2 A G 1.01(0.84,1.20) 0.954 0.995 
rs12053233 MTHFD2 T C 1.01(0.84,1.21) 0.956 0.995 
rs5997711 TCN2 T C 1.00(0.84,1.18) 0.957 0.995 
rs529087 MTHFD1L T C 1.01(0.83,1.22) 0.958 0.995 
rs10925252 MTR C T 1.00(0.84,1.18) 0.959 0.995 
rs12185084 MTHFS A G 1.00(0.81,1.22) 0.959 0.995 
rs9804151 CTH C T 0.99(0.80,1.23) 0.959 0.995 
rs12032960 SLC44A3 C T 1.01(0.82,1.23) 0.960 0.995 
rs4328397 MTHFS C T 1.01(0.79,1.28) 0.960 0.995 
rs10493878 SLC44A3 G A 0.99(0.80,1.24) 0.961 0.995 
rs10778137 CHPT1 A G 1.00(0.83,1.19) 0.961 0.995 
rs2075798 SLC44A4 T G 1.01(0.73,1.39) 0.962 0.995 
rs9383552 MTHFD1L G A 1.01(0.72,1.41) 0.962 0.995 
 215 
 
SNP Gene Minor Allele Major Allele RR (95% CI) P-value Q-value 
rs10501409 FOLR1 C A 1.01(0.78,1.31) 0.964 0.995 
rs234784 CBS T C 1.00(0.85,1.19) 0.964 0.995 
rs2612092 TYMS A G 0.99(0.76,1.30) 0.964 0.995 
rs4646750 ALDH1L1 G A 0.99(0.73,1.35) 0.964 0.995 
rs12528219 MTHFD1L C G 1.00(0.78,1.28) 0.966 0.995 
rs1806505 MTR T C 1.00(0.84,1.18) 0.969 0.995 
rs3935460 CHKA G A 1.00(0.85,1.18) 0.971 0.995 
rs803446 MTHFD1L T C 1.00(0.82,1.21) 0.972 0.995 
rs162023 MTRR A G 1.00(0.85,1.17) 0.973 0.995 
rs2293160 PCYT1A C T 1.00(0.84,1.19) 0.974 0.995 
rs2297702 CEPT1 T C 1.00(0.71,1.39) 0.974 0.995 
rs762684 MAT2A T C 1.00(0.83,1.19) 0.974 0.995 
rs17689550 SLC22A5 T C 1.00(0.77,1.30) 0.976 0.995 
rs380691 DHFR C T 1.00(0.84,1.19) 0.976 0.995 
rs9982015 CBS C T 1.00(0.72,1.37) 0.976 0.995 
rs2665355 SLC22A3 C G 1.00(0.85,1.18) 0.977 0.995 
rs1667627 MTHFD2 G A 1.00(0.85,1.18) 0.979 0.995 
rs9966612 TYMS A G 1.00(0.83,1.19) 0.980 0.995 
rs585800 BHMT T A 1.00(0.83,1.21) 0.981 0.995 
rs9478157 MTHFD1L G T 1.00(0.85,1.19) 0.981 0.995 
rs3772431 ALDH1L1 A G 1.00(0.84,1.18) 0.983 0.996 
rs12134663 MTHFR C A 1.00(0.79,1.26) 0.984 0.996 
rs333226 SLC5A7 G A 1.00(0.79,1.27) 0.987 0.997 
rs2502745 SARDH C G 1.00(0.85,1.18) 0.991 0.997 
rs3733075 CHDH T C 1.00(0.85,1.18) 0.991 0.997 
rs1801133 MTHFR T C 1.00(0.84,1.19) 0.992 0.997 
rs698962 SLC44A3 A G 1.00(0.82,1.23) 0.994 0.997 
rs11082 CHPT1 G A 1.00(0.85,1.18) 0.995 0.997 
rs9432593 SLC44A3 G A 1.00(0.83,1.21) 0.995 0.997 
rs13212150 MTHFD1L C T 1.00(0.84,1.19) 0.996 0.997 
rs2851391 CBS T C 1.00(0.85,1.18) 0.996 0.997 
rs16948305 TYMS T C 1.00(0.79,1.27) 0.998 0.998 
rs10918179 RXRG A C 1.00(0.84,1.19) 0.971 0.984 
rs5750041 ISX T C 1.00(0.79,1.26) 0.971 0.984 
rs11264527 CRABP2 C T 1.00(0.84,1.20) 0.973 0.984 
rs1154473 ADH7 T C 1.00(0.85,1.18) 0.976 0.985 
rs2012147 ALDH1A2 T C 1.00(0.70,1.42) 0.982 0.989 
rs7845956 RDH10 A G 1.00(0.68,1.46) 0.99 0.994 
rs1286773 RARB G C 1.00(0.79,1.26) 0.996 0.998 
rs1128977 RXRG T C 1.00(0.84,1.19) >0.999 >0.999 
       
RR: Risk ratio; CI: Confidence interval 
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APPENDIX 5. QQ PLOTS  
A) B)  
C) D)  
A) offspring vitamin A-related SNPs, B) maternal vitamin A-related SNPs, C) offspring folate and 
choline-related SNPs, D) maternal folate and choline-related SNPs 
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